[2016-06-14 11:41:39,150][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:41:39,173][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:41:39,257][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:42:03,708][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:42:05,938][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14.4gb[12.8%], replicas will not be assigned to this node
[2016-06-14 11:42:35,955][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14.3gb[12.6%], replicas will not be assigned to this node
[2016-06-14 11:43:05,970][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14.2gb[12.6%], replicas will not be assigned to this node
[2016-06-14 11:43:24,082][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:43:35,987][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14.1gb[12.5%], replicas will not be assigned to this node
[2016-06-14 11:44:06,010][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14.1gb[12.5%], replicas will not be assigned to this node
[2016-06-14 11:44:36,038][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14gb[12.4%], replicas will not be assigned to this node
[2016-06-14 11:44:39,575][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:06,055][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 14gb[12.3%], replicas will not be assigned to this node
[2016-06-14 11:45:36,072][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.9gb[12.3%], replicas will not be assigned to this node
[2016-06-14 11:45:43,767][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:43,776][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:43,812][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:43,826][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:43,846][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:43,927][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:45:55,451][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:46:02,677][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:46:02,756][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:46:06,089][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.9gb[12.2%], replicas will not be assigned to this node
[2016-06-14 11:46:07,451][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:46:07,485][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:46:13,032][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:46:36,107][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.8gb[12.2%], replicas will not be assigned to this node
[2016-06-14 11:47:06,123][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.7gb[12.1%], replicas will not be assigned to this node
[2016-06-14 11:47:24,204][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:47:24,900][DEBUG][action.bulk              ] ely; the duration and intensity of this effect was dose-dependent (Press release, Novartis, 18 May 1999; Transplantation, 2004, 77, 1424, PMID:15167602).^Preclinical ^In vivo^In Citrobacter rodentium infectious mice model of colitis, treatment with fingolimod hydrochloride 3mg/kg po x6 days pre- infection prevented clearance of bacterial infection in the gastrointestinal tract. Gene expression analysis revealed a deficient host immune response in drug treated mice evidenced by increased expression of IL-17A and IL-1beta and reduced expression of IL-22 (42nd DDW (Chicago), 2011, Abs Sa1776, http:// ddw.apprisor.net/DDW_PRES.cfm?id=6937).^In animal disease models, it reversed established neurological deficits and preserved neuronal functions. It activated S1P receptors on astrocytes, and appeared to play a role in oligodendrocyte survival (Scrip Daily Online, 13 Oct 2006, S00936936).^In rats and mice, fingolimod hydrochloride 0.3mg/kg/day had a significant prophylactic effect on experimental autoimmune encephalomyelitis (EAE), with 0.1-1mg/kg almost completely preventing EAE development. It also had a therapeutic effect on EAE (J Biol Chem, 2002, 277, 21453, PMID:11967257; Cell Mol Immunol, 2005, 2, 439, PMID:16426494).^In a rat model of MS, fingolimod hydrochloride almost completely protected against disease by inhibition of T-cell responses and/ or T-cell migration into the CNS. Transfer of lymphocytes from fingolimod hydrochloride-treated rats into naive recipients reduced disease incidence and severity (J Pharmacol Exp Ther, 2003, 305, 70, PMID:12649354).^In SCID-IBD mice, fingolimod hydrochloride dose-dependently improved body weight, and reduced colon inflammation at 10mg/kg/ day, and 50% of mice given fingolimod hydrochloride survived up to 100 days (6th World Cong Inflamm (Vancouver), 2003).^In vivo, fingolimod hydrochloride po produced a significant decrease in peripheral T-lymphocytes, but not B-lymphocytes (Br J Pharmacol, 2002, 137, 953, PMID:12429567 and 2003, 138, 1303, PMID:12711631).^In primates, fingolimod hydrochloride 0.3mg/kg/day + ciclosporin 40-200ng/ml increased graft survival vs ciclosporin 200-400ng/ml alone (Company Web Page, Novartis, 16 Jan 2001).^In vitro^In leukaemia cells, fingolimod hydrochloride enhanced apoptosis by activation of protein phosphatase 2A or 2A-like phosphatase, and subsequent dephosphorylation of Akt. Sensitivity to fingolimod hydrochloride-induced apoptosis was regulated by Bcl-2 levels (Br J Pharmacol, 2002, 137, 953, PMID:12429567 and 2003, 138, 1303, PMID:12711631).^Licensing^Agreements^________________^Mitsubishi Tanabe Pharma; Novartis; Mitsui Sugar^Japan; Mitsubishi Tanabe retained co-development and co-marketing rights in Japan (Scrip, 1997, 2274, 11). It was also in co- development with Mitsui Sugar, Japan (Company Web Page, Mitsubishi, 29 Jan 2008).^Novartis^Worldwide; Novartis has worldwide rights (Scrip, 1997, 2274, 11; Company Web Page, Novartis, 16 Jan 2001).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140207"],"Document_PK":["Human (5mg/day):t1/2:192:hr","Human (5mg/day):Cmax:18.2:ng/ml","Human (5mg/day):AUC:399:nghr/ml"],"Document_NC":["Yes"],"Document_RB":["14"],"Document_TF":["1901: Receptor > GPCR;","1903: Receptor > GPCR;","8698: Receptor > GPCR;","53637: Receptor > GPCR."],"Document_TG":["1901: sphingosine-1-phosphate receptor 1","1903: sphingosine-1-phosphate receptor 3","8698: sphingosine-1-phosphate receptor 4","53637: sphingosine-1-phosphate receptor 5"],"Document_LCH":["20140201:AD67 : Planned filings for progressive primary multiple sclerosis and chronic inflammatory demyelinating polyneuropathy reported"],"Document_TB":["1901: Receptor > GPCR;","1901: GPCR;","1901: Receptor.","1903: Receptor > GPCR;","1903: GPCR;","1903: Receptor.","8698: Receptor > GPCR;","8698: GPCR;","8698: Receptor.","53637: Receptor > GPCR;","53637: GPCR;","53637: Receptor."],"Document_CASIS-USE_CASIS-MA_PHCD":["S1P1-AG: Sphingosine 1-phosphate 1 receptor agonist: Receptor, Biochemical, Sphingosine phosphate 1 receptor agonist: Edg-1 agonist: R-B-S1P1-AG|S1P5-AG: Sphingosine 1-phosphate 5 receptor agonist: Receptor, Biochemical, Sphingosine phosphate 5 receptor agonist: Edg-8 agonist: R-B-S1P5-AG|IM-AN: Immunosuppressant: Physiological, Hormonal, Immunosuppressant: P-H-IM-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["307.48"],"Document_AL":["3.97"],"Document_CASIS-CO_CO":["Originator: Mitsubishi Tanabe Pharma (JP): Launched","Licensee: Novartis (CH): Launched"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD109571    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"}],"DOCNO":"PH026731","CASIS_COMPOUND":[{"CN":"FTY-726 CCN=FTY726","SRC_DB":"PHPROJ"},{"CN":"Imusera CCN=IMUSERA","SRC_DB":"PHPROJ"},{"CN":"Gilenia CCN=GILENIA","SRC_DB":"PHPROJ"},{"CN":"TDI 132 CCN=TDI132","SRC_DB":"PHPROJ"},{"CN":"fingolimod hydrochloride CCN=FINGOLIMODHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"fingolimod CCN=FINGOLIMOD","SRC_DB":"PHPROJ"},{"CN":"Gilenya CCN=GILENYA","SRC_DB":"PHPROJ"},{"CN":"FTY-720 CCN=FTY720","SRC_DB":"PHPROJ"},{"CN":"FTY720 CCN=FTY720","SRC_DB":"PHPROJ"},{"CN":"TDI-132 CCN=TDI132","SRC_DB":"PHPROJ"},{"CN":"FTY-720A CCN=FTY720A","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-11 15:43:14","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"D","THE_USE":"Transplant rejection, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R8A","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Uveitis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"I5","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N7A","THE_USE":"Multiple sclerosis treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Multiple sclerosis, progressive, primary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Chronic inflammatory demyelinating polyneuropathy","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S1P5-AG","THE_USE":"Sphingosine 1-phosphate 5 receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"IM-AN","THE_USE":"Immunosuppressant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Neuritis, optic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Hypertension, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2B9","THE_USE":"Antihypertensive","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"S1P1-AG","THE_USE":"Sphingosine 1-phosphate 1 receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Multiple sclerosis, relapsing-remitting","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[70, 105, 110, 103, 111, 108, 105, 109, 111, 100, 32, 104, 121, 100, 114, 111, 99, 104, 108, 111, 114, 105, 100, 101, 32, 40, 70, 84, 89, 45]...', original message: bytes can be at most 32766 in length; got 39654
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 39654
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:47:25,234][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 11:47:36,141][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.7gb[12.1%], replicas will not be assigned to this node
[2016-06-14 11:48:04,771][DEBUG][action.bulk              ] release, YM BioSciences, 18 Nov 2004; Company Web Page, YM BioSciences, 10 Sep 2007).^In an open-label Phase I/II trial in 29 adult patients with high- grade glioma, including GBM (15 patients) and anaplastic astrocytoma (9 patients), who underwent debulking surgery or biopsy prior to the trial, nimotuzumab 200mg as 1x/wk x6 infusions + external beam radiation gave 4CRs, 5PRs and 12SDs. In patients with high-grade glioma astrocytic tumours, mean and median survival was 23.7 and 18.1mth, respectively, with a survival rate at 18mth of 53%. There was no evidence of grade 3/4 AEs. One patient had grade 2 dysphasia and sensory alteration (Press release, YM BioSciences, 19 May 2005; 41st ASCO (Orlando), 2005).^A Phase I/II trial in the EU in 18 paediatric patients with astrocytomas or glioblastomas who failed 1st-line therapy and received nimotuzumab iv 1x/wk x6wk was terminated prematurely because of trial success. Of 19 evaluable patients, 6 responded to treatment with 5SDs and 1PR. There was no skin toxicity and no haematological or non-haematological side-effects (Press releases, YM BioSciences, 15 Jun 2004 and 25 Jan 2005).^A US IND was approved for 1 child with advanced glioma. Paediatric expansion of the trial was planned (Press release, YM BioSciences, 16 Mar 2005)^Phase I^A Phase I passive immunotherapy trial in Cuba for epithelial- derived tumours was carried out (Direct communication, CIM, 18 Feb 2000).^In a Cuban Phase I diagnostic trial in 148 patients with suspected cancer of epithelial origin, immunoscintigraphy with murine R3 identified 106/126 cases (confirmed by biopsy), and correctly identified all 22 patients who did not have epithelial cancers. It was in Phase I trials in Canada (12 patients) and Cuba (29 patients) for imaging epithelial-derived tumours (Press release, CIM and York Medical, 9 Jul 1999; Direct communication, CIM, 6 Mar 2001).^A trial with a rhenium-188-labelled version for radioimmunotherapy in glioma was planned (Company brochure, York Medical, Oct 2000; Direct communication, CIM, 6 Mar 2001).^A Phase I pharmacodynamic study in 12-24 patients was completed (BIO 2005 (Philadelphia); Company Web Page, YM BioSciences, 10 Sep 2007).^"],"Document_CASIS-UPD_WE":["20140228"],"Document_PK":["Human (200mg single dose):Cl:23:ml/hr","Human (200mg single dose):Cmax:141:microg/ml","Human (200mg single dose):t1/2:45:hr","Human (200mg single dose):Vd:1.46:l"],"Document_NC":["No"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor"],"Document_LCH":["20140218:AD50 : Ongoing Phase III development for gastric & nsclc and Phase I for oesophageal cancer reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR1-AN: Epidermal growth factor receptor 1 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 1 antagonist: EGFR1 antagonist: HER1 antagonist: ErbB-1 antagonist: R-H-GF-EPR1-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Center of Molecular Immunology (CU): Launched","Licensee: Biocon (IN): Launched","Licensee: Innogene Kalbiotech (SG): Launched","Licensee: Eurofarma (BR): Launched","Licensee: Oncoscience (DE): Pre-registration","Licensee: Kuhnil Pharmaceutical (KR): Phase III Clinical Trial","Licensee: Daiichi Sankyo (JP): Phase III Clinical Trial","Licensee: YM BioSciences (CA): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH028992","CASIS_COMPOUND":[{"CN":"R3 CCN=R3","SRC_DB":"PHPROJ"},{"CN":"L-R3 CCN=LR3","SRC_DB":"PHPROJ"},{"CN":"TheraCIM hR3  CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"OSAG-101 CCN=OSAG101","SRC_DB":"PHPROJ"},{"CN":"BIOMAb CCN=BIOMAB","SRC_DB":"PHPROJ"},{"CN":"CIMAher CCN=CIMAHER","SRC_DB":"PHPROJ"},{"CN":"nimotuzumab CCN=NIMOTUZUMAB","SRC_DB":"PHPROJ"},{"CN":"huR3 CCN=HUR3","SRC_DB":"PHPROJ"},{"CN":"DE-766 CCN=DE766","SRC_DB":"PHPROJ"},{"CN":"DiaCIM CCN=DIACIM","SRC_DB":"PHPROJ"},{"CN":"Theraloc CCN=THERALOC","SRC_DB":"PHPROJ"},{"CN":"YMB-1001 CCN=YMB1001","SRC_DB":"PHPROJ"},{"CN":"TheraCIM CCN=THERACIM","SRC_DB":"PHPROJ"},{"CN":"RadioTheraCIM CCN=RADIOTHERACIM","SRC_DB":"PHPROJ"},{"CN":"anti-EGFr MAb, CIM CCN=ANTIEGFRMABCIM","SRC_DB":"PHPROJ"},{"CN":"TheraCIM-h-R3 CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"BIOMAb-EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"hR3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"Vecthix CCN=VECTHIX","SRC_DB":"PHPROJ"},{"CN":"DiaCIM-h-R3 CCN=DIACIMHR3","SRC_DB":"PHPROJ"},{"CN":"h-R3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"BIOMAb EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-03 11:21:13","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diagnosis, cancer","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, nasopharyngeal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K5A","THE_USE":"Radio-chemosensitizer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"V4A","THE_USE":"Imaging agent","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EPR1-AN","THE_USE":"Epidermal growth factor receptor 1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 105, 109, 111, 116, 117, 122, 117, 109, 97, 98, 32, 40, 82, 51, 41, 32, 105, 115, 32, 97, 110, 32, 73, 103, 71, 49, 32, 104, 117]...', original message: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:48:06,163][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.7gb[12.1%], replicas will not be assigned to this node
[2016-06-14 11:48:13,368][DEBUG][action.bulk              ] release, YM BioSciences, 18 Nov 2004; Company Web Page, YM BioSciences, 10 Sep 2007).^In an open-label Phase I/II trial in 29 adult patients with high- grade glioma, including GBM (15 patients) and anaplastic astrocytoma (9 patients), who underwent debulking surgery or biopsy prior to the trial, nimotuzumab 200mg as 1x/wk x6 infusions + external beam radiation gave 4CRs, 5PRs and 12SDs. In patients with high-grade glioma astrocytic tumours, mean and median survival was 23.7 and 18.1mth, respectively, with a survival rate at 18mth of 53%. There was no evidence of grade 3/4 AEs. One patient had grade 2 dysphasia and sensory alteration (Press release, YM BioSciences, 19 May 2005; 41st ASCO (Orlando), 2005).^A Phase I/II trial in the EU in 18 paediatric patients with astrocytomas or glioblastomas who failed 1st-line therapy and received nimotuzumab iv 1x/wk x6wk was terminated prematurely because of trial success. Of 19 evaluable patients, 6 responded to treatment with 5SDs and 1PR. There was no skin toxicity and no haematological or non-haematological side-effects (Press releases, YM BioSciences, 15 Jun 2004 and 25 Jan 2005).^A US IND was approved for 1 child with advanced glioma. Paediatric expansion of the trial was planned (Press release, YM BioSciences, 16 Mar 2005)^Phase I^A Phase I passive immunotherapy trial in Cuba for epithelial- derived tumours was carried out (Direct communication, CIM, 18 Feb 2000).^In a Cuban Phase I diagnostic trial in 148 patients with suspected cancer of epithelial origin, immunoscintigraphy with murine R3 identified 106/126 cases (confirmed by biopsy), and correctly identified all 22 patients who did not have epithelial cancers. It was in Phase I trials in Canada (12 patients) and Cuba (29 patients) for imaging epithelial-derived tumours (Press release, CIM and York Medical, 9 Jul 1999; Direct communication, CIM, 6 Mar 2001).^A trial with a rhenium-188-labelled version for radioimmunotherapy in glioma was planned (Company brochure, York Medical, Oct 2000; Direct communication, CIM, 6 Mar 2001).^A Phase I pharmacodynamic study in 12-24 patients was completed (BIO 2005 (Philadelphia); Company Web Page, YM BioSciences, 10 Sep 2007).^"],"Document_CASIS-UPD_WE":["20140228"],"Document_PK":["Human (200mg single dose):Cl:23:ml/hr","Human (200mg single dose):Cmax:141:microg/ml","Human (200mg single dose):t1/2:45:hr","Human (200mg single dose):Vd:1.46:l"],"Document_NC":["No"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor"],"Document_LCH":["20140218:AD50 : Ongoing Phase III development for gastric & nsclc and Phase I for oesophageal cancer reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR1-AN: Epidermal growth factor receptor 1 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 1 antagonist: EGFR1 antagonist: HER1 antagonist: ErbB-1 antagonist: R-H-GF-EPR1-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Center of Molecular Immunology (CU): Launched","Licensee: Biocon (IN): Launched","Licensee: Innogene Kalbiotech (SG): Launched","Licensee: Eurofarma (BR): Launched","Licensee: Oncoscience (DE): Pre-registration","Licensee: Kuhnil Pharmaceutical (KR): Phase III Clinical Trial","Licensee: Daiichi Sankyo (JP): Phase III Clinical Trial","Licensee: YM BioSciences (CA): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH028992","CASIS_COMPOUND":[{"CN":"YMB-1001 CCN=YMB1001","SRC_DB":"PHPROJ"},{"CN":"hR3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"OSAG-101 CCN=OSAG101","SRC_DB":"PHPROJ"},{"CN":"anti-EGFr MAb, CIM CCN=ANTIEGFRMABCIM","SRC_DB":"PHPROJ"},{"CN":"huR3 CCN=HUR3","SRC_DB":"PHPROJ"},{"CN":"BIOMAb-EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"BIOMAb EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"nimotuzumab CCN=NIMOTUZUMAB","SRC_DB":"PHPROJ"},{"CN":"BIOMAb CCN=BIOMAB","SRC_DB":"PHPROJ"},{"CN":"CIMAher CCN=CIMAHER","SRC_DB":"PHPROJ"},{"CN":"Vecthix CCN=VECTHIX","SRC_DB":"PHPROJ"},{"CN":"TheraCIM hR3  CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"L-R3 CCN=LR3","SRC_DB":"PHPROJ"},{"CN":"R3 CCN=R3","SRC_DB":"PHPROJ"},{"CN":"RadioTheraCIM CCN=RADIOTHERACIM","SRC_DB":"PHPROJ"},{"CN":"DE-766 CCN=DE766","SRC_DB":"PHPROJ"},{"CN":"DiaCIM CCN=DIACIM","SRC_DB":"PHPROJ"},{"CN":"DiaCIM-h-R3 CCN=DIACIMHR3","SRC_DB":"PHPROJ"},{"CN":"TheraCIM CCN=THERACIM","SRC_DB":"PHPROJ"},{"CN":"Theraloc CCN=THERALOC","SRC_DB":"PHPROJ"},{"CN":"TheraCIM-h-R3 CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"h-R3 CCN=HR3","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-03 11:21:13","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"K5A","THE_USE":"Radio-chemosensitizer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, nasopharyngeal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"V4A","THE_USE":"Imaging agent","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EPR1-AN","THE_USE":"Epidermal growth factor receptor 1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diagnosis, cancer","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 105, 109, 111, 116, 117, 122, 117, 109, 97, 98, 32, 40, 82, 51, 41, 32, 105, 115, 32, 97, 110, 32, 73, 103, 71, 49, 32, 104, 117]...', original message: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:48:31,398][DEBUG][action.bulk              ] ents on the MTD was 9.8mth. Any thrombocytopenia was generally grade 1 and rapidly reversible. There were no signs of neutropenia or leukopenia (43rd ASCO (Chicago), 2007, Abs 1042; Press releases, Genentech, 2 Jun 2007 and ImmunoGen, 3 Jun 2008). At the MTD, it had a t1/2 of 3.5 days (44th ASCO (Chicago) 2008, Abs 1028). In the 1x/wk Phase I trial, 19 patients received 1.2-2.9mg/kg, and the activity and safety were consistent with the 1x/3wk results (Press release, ImmunoGen, 3 Jun 2008).^Preclinical ^In preclinical studies, trastuzumab emtansine was effective than trastuzumab against gastric cancer. Trastuzumab emtansine + pertuzumab showed a 'greater' activity (Press release, ImmunoGen, 28 Apr 2011, http://phx.corporate-ir.net/ phoenix.zhtml?c=97573andp=irol- newsArticleandID=1556544andhighlight=).^In vivo^In athymic nude and beige nude mice with HER2 positive breast cancer, T-DM1 showed antitumour activity (J Pharmacokinet Pharmacodyn, 28 Apr 2010, PMID:20424896, http:// www.ncbi.nlm.nih.gov/pubmed/20424896).^In breast and lung cancer xenograft models, trastuzumab emtansine + pertuzumab showed enhanced in vivo efficacy compared to either agent alone (101st AACR (Washington, DC), 2010 Abs 5607, http:// www.abstractsonline.com/plan/ ViewAbstract.aspx?mID=2521andsKey=0aecf084-8ddf-4688-9383- 4b7dbedb326fandcKey=c055d6d1-817c-404e-b2af- 9078dd4ad172andmKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}).^In normal Sprague-Dawley rats, [3H]-trastuzumab emtansine had a biphasic disposition profile, with no obvious formation of high or low molecule species in the plasma (98th AACR (Los Angeles), 2007, Abs 1543).^It caused complete regression in HER2+ mouse xenograft models. It had increased activity cf trastuzumab alone (1st Qtr Res, ImmunoGen, 2001).^In vivo; In vitro^In in vivo and in vitro trials, trastuzumab emtansine displayed 'superior' efficacy vs trastuzumab conjugated to other maytansinoids through disulphide linkers. In animal models, serum concentrations of T-DM1 remained elevated for longer and it had lower toxicity vs free trastuzumab or trastuzumab conjugated to DM1 via a reducible linker (Cancer Res, 2008, 15, PMID:19010901).^In vitro^In human breast and lung cancer cells that over-express HER2, combination therapy showed synergistic inhibition of cell proliferation. Combination thrapy showed synergistic increase in apoptosis (101st AACR (Washington, DC), 2010 Abs 5607, http:// www.abstractsonline.com/plan/ ViewAbstract.aspx?mID=2521andsKey=0aecf084-8ddf-4688-9383- 4b7dbedb326fandcKey=c055d6d1-817c-404e-b2af- 9078dd4ad172andmKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}).^In a HER2-positive human gastric cancer cell line (NCI-N87), binding of T-DM1 to cell surface HER2 was significantly increased in the presence of pertuzumab. Concomitant treatment with T-DM1 and pertuzumab led to a reduction of phosphorylated (p)EGFR or pHER3 in EGF or heregulin-stimulated cells, respectively, resulting in suppression of downstream pERK or pAkt pathways. Fluorescence microscopy revealed that pertuzumab facilitated the internalization of HER2-bound T-DM1 from the cell surface into the cytoplasm (48th ASCO (Chicago), 2012, Abs e13502, http:// abstract.asco.org/AbstView_114_97582.html).^Licensing^Agreements^________________^ImmunoGen^Genentech and ImmunoGen had a 5yr agreement, in which Genentech was responsible for manufacturing, development and marketing of products (Press release, ImmunoGen, 4 May 2000). In a subsequent agreement with Genentech, ImmunoGen provided access to the maytansinoid technology for use with Genentech's antibodies to non-HER2 targets. Genentech has an exclusive licence to use TAP technology with its antibodies to 5 undisclosed targets in preclinical development. Genentech is responsible for development, manufacturing and marketing of these products (Ann Rep, ImmunoGen, 2006; Press release, ImmunoGen, 8 Dec 2008). Roche exercised an option on a licence for ex-USA development and commercialization (Press release, ImmunoGen, 31 Jan 2008).^"],"Document_CASIS-UPD_WE":["20140307"],"Document_PK":["Human:MTD:3.6:mg/kg","Human:t1/2:84:hr"],"Document_NC":["No"],"Document_TF":["2064: Enzyme > EC number > 2.7.10.1;","2064: Receptor > Cytokine receptor;","2064: Enzyme > Kinase."],"Document_TG":["2064: v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2"],"Document_LCH":["20140225:AD244 : Ongoing development and additional details of Phase III trials for breast and gastric cancer reported"],"Document_TB":["2064: Enzyme > EC number > 2.7.10.1;","2064: EC number > 2.7.10.1;","2064: Enzyme;","2064: 2.7.10.1;","2064: Enzyme > EC number.","2064: Receptor > Cytokine receptor;","2064: Cytokine receptor;","2064: Receptor.","2064: Enzyme > Kinase;","2064: Kinase;","2064: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["MICTUBE-AN: Microtubule inhibitor: Physiological, Biochemical, Microtubule inhibitor: Metaphase inhibitor: Mitosis inhibitor: Antineoplastic e.g. vinca alkaloids, colchicine, podophyllin: P-B-MICTUBE-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Hoffmann-La Roche (CH): Launched","Licensee: ImmunoGen (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH030827","CASIS_COMPOUND":[{"CN":"Herceptin + DM1 CCN=HERCEPTIN+DM1","SRC_DB":"PHPROJ"},{"CN":"RO5304020 CCN=RO5304020","SRC_DB":"PHPROJ"},{"CN":"R-3502 CCN=R3502","SRC_DB":"PHPROJ"},{"CN":"ado-trastuzumab emtansine CCN=ADOTRASTUZUMABEMTANSINE","SRC_DB":"PHPROJ"},{"CN":"Herceptin-DM1 CCN=HERCEPTINDM1","SRC_DB":"PHPROJ"},{"CN":"trastuzumab emtansine CCN=TRASTUZUMABEMTANSINE","SRC_DB":"PHPROJ"},{"CN":"T-DM1 CCN=TDM1","SRC_DB":"PHPROJ"},{"CN":"Kadcyla CCN=KADCYLA","SRC_DB":"PHPROJ"},{"CN":"Pro-132365 CCN=PRO132365","SRC_DB":"PHPROJ"},{"CN":"Pharmaprojects No. 6476 CCN=PHARMAPROJECTSNO.6476","SRC_DB":"PHPROJ"},{"CN":"RG3502 CCN=RG3502","SRC_DB":"PHPROJ"},{"CN":"TDM-1 CCN=TDM1","SRC_DB":"PHPROJ"},{"CN":"RO-5304020 CCN=RO5304020","SRC_DB":"PHPROJ"},{"CN":"trastuzumab-Mcc-DM1 CCN=TRASTUZUMABMCCDM1","SRC_DB":"PHPROJ"},{"CN":"trastuzumab-DM1 CCN=TRASTUZUMABDM1","SRC_DB":"PHPROJ"},{"CN":"R3502 CCN=R3502","SRC_DB":"PHPROJ"},{"CN":"RG-3502 CCN=RG3502","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-07 13:54:50","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"MICTUBE-AN","THE_USE":"Microtubule inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"T3B1","THE_USE":"Immunotoxin","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"K1A","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3B2","THE_USE":"Antibody-drug conjugate","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 114, 97, 115, 116, 117, 122, 117, 109, 97, 98, 32, 101, 109, 116, 97, 110, 115, 105, 110, 101, 32, 40, 116, 114, 97, 115, 116, 117, 122]...', original message: bytes can be at most 32766 in length; got 34040
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34040
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:48:36,180][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.6gb[12%], replicas will not be assigned to this node
[2016-06-14 11:48:42,373][DEBUG][action.bulk              ] e^In a proof-of-concept trial in 4 patients with MWS, canakinumab 10mg/kg iv was well-tolerated, improved symptoms in 2 days and gave clinical remission in 8 days, which lasted a median of 185 days. Canakinumab had a t1/2 of 29 days (7th Eur Cong Rheumatol (Amsterdam), 2006, Abs OP0073).^Preclinical ^Patents^Patent protection for the active ingredient is expected to expire in 2023 in the US and 2024 in Europe (Form 20-F, Novartis, 2009).^Licensing^Agreements^________________^Medarex^It was manufactured using Medarex' (now Bristol-Myers Squibb's (BMS)) UltiMAb technology (Press release, Medarex, 18 Jul 2007).^"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (10mg/kg iv):t1/2:696:hr"],"Document_NC":["No"],"Document_TF":["3553: Cytokine/Growth factor > Cytokine > Interleukin."],"Document_TG":["3553: interleukin 1, beta"],"Document_LCH":["20140310:AD207 : Completion of Phase II trial (CONTROL FMF) for Familial Mediterranean fever reported"],"Document_TB":["3553: Cytokine/Growth factor > Cytokine > Interleukin;","3553: Cytokine > Interleukin;","3553: Cytokine/Growth factor;","3553: Interleukin;","3553: Cytokine/Growth factor > Cytokine."],"Document_CASIS-USE_CASIS-MA_PHCD":["IL-1-B-AN: Interleukin 1b antagonist: Physiological, Hormonal, Interleukin 1b antagonist: IL 1b antagonist: P-H-IL-1-B-AN|IM-AN: Immunosuppressant: Physiological, Hormonal, Immunosuppressant: P-H-IM-AN|"],"Document_ROUT":["P-AC: Parenteral, intra-articular","P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Novartis (CH): Launched"],"Document_MR":["5:Market Rating - Over US$ 10000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH037202","CASIS_COMPOUND":[{"CN":"ACZ885D (SC) CCN=ACZ885D(SC)","SRC_DB":"PHPROJ"},{"CN":"canakinumab (SC) CCN=CANAKINUMAB(SC)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885 CCN=ACZ885","SRC_DB":"PHPROJ"},{"CN":"ACZ-885F (IV) CCN=ACZ885F(IV)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885D (intra-articular) CCN=ACZ885D(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"canakinumab (intra-articular) CCN=CANAKINUMAB(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"ACZ885 (intra-articular) CCN=ACZ885(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885F CCN=ACZ885F","SRC_DB":"PHPROJ"},{"CN":"Ilaris (intra-articular) CCN=ILARIS(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885D (SC) CCN=ACZ885D(SC)","SRC_DB":"PHPROJ"},{"CN":"ACZ885 (SC) CCN=ACZ885(SC)","SRC_DB":"PHPROJ"},{"CN":"Ilaris (SC) CCN=ILARIS(SC)","SRC_DB":"PHPROJ"},{"CN":"ACZ885 (IV) CCN=ACZ885(IV)","SRC_DB":"PHPROJ"},{"CN":"Ilaris CCN=ILARIS","SRC_DB":"PHPROJ"},{"CN":"ACZ885F (IV) CCN=ACZ885F(IV)","SRC_DB":"PHPROJ"},{"CN":"canakinumab CCN=CANAKINUMAB","SRC_DB":"PHPROJ"},{"CN":"ACZ-885D (IV) CCN=ACZ885D(IV)","SRC_DB":"PHPROJ"},{"CN":"ACZ885F CCN=ACZ885F","SRC_DB":"PHPROJ"},{"CN":"ACZ885D (IV) CCN=ACZ885D(IV)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885D CCN=ACZ885D","SRC_DB":"PHPROJ"},{"CN":"ACZ885F (SC) CCN=ACZ885F(SC)","SRC_DB":"PHPROJ"},{"CN":"canakinumab (IV) CCN=CANAKINUMAB(IV)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885F (SC) CCN=ACZ885F(SC)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885 (IV) CCN=ACZ885(IV)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885 (SC) CCN=ACZ885(SC)","SRC_DB":"PHPROJ"},{"CN":"ACZ885D (intra-articular) CCN=ACZ885D(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"Ilaris (IV) CCN=ILARIS(IV)","SRC_DB":"PHPROJ"},{"CN":"ACZ-885F (intra-articular) CCN=ACZ885F(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"ACZ885F (intra-articular) CCN=ACZ885F(INTRAARTICULAR)","SRC_DB":"PHPROJ"},{"CN":"ACZ885D CCN=ACZ885D","SRC_DB":"PHPROJ"},{"CN":"ACZ885 CCN=ACZ885","SRC_DB":"PHPROJ"},{"CN":"ACZ-885 (intra-articular) CCN=ACZ885(INTRAARTICULAR)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Arthritis, osteo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Aneurysm","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Intermittent claudication","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"IL-1-B-AN","THE_USE":"Interleukin 1b antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Chronic obstructive pulmonary disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Atherosclerosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Diabetic complication, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, gouty","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M4A","THE_USE":"Antigout","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Peripheral vascular disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C4A","THE_USE":"Vasodilator","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Xerophthalmia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Neonatal onset multisystem inflammatory disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M1A1","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Polymyalgia rheumatica","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Familial Mediterranean fever","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Familial cold autoinflammatory syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N2Z","THE_USE":"Analgesic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Macular degeneration, age-related, wet","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R4A","THE_USE":"COPD treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"IM-AN","THE_USE":"Immunosuppressant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"R8A","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Muckle-Wells syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"TNF receptor associated periodic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C10","THE_USE":"Hypolipaemic-Antiatherosclerosis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A2","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Hyperuricaemia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[67, 97, 110, 97, 107, 105, 110, 117, 109, 97, 98, 32, 40, 65, 67, 90, 45, 56, 56, 53, 41, 32, 105, 115, 32, 97, 110, 32, 97, 110]...', original message: bytes can be at most 32766 in length; got 48538
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 48538
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:48:42,414][DEBUG][action.bulk              ]  local regulatory approval process, future commercialization, and pharmacovigilance in each of the relevant countries (Press release, UCB, 21 Nov 2012, http:// www.ucb.presscentre.com/News/UCB-and-NewBridge-Pharmaceuticals- Partner-for-Middle-East-and-African-markets-334.aspx).^Orient Europharma^Hong Kong, South East Asia and Taiwan; exclusive marketing rights in Southeast Asia and Taiwan (Press release, Orient, 14 Oct 2010, http://www.oep.com.tw/eng/investor/news_release/newsen101014.pdf; Company Web Page, Orient, 3 Oct 2011, http://www.oep.com.tw/eng/ business/MA-RA-Licensing.aspx).^UCB^Worldwide except Japan; Schwarz acquired worldwide development and marketing rights outside Japan from Harris FRC, the US (Company Web Page, Schwarz, 6 Feb 2001).^Additional Clinical Information^Phase I^A S Korean randomized, double-blind, placebo-controlled, parallel- group, single and repeated dose Phase I trial in healthy male volunteers has been approved. Safety, tolerance and pharmacokinetic properties will be monitored (Pharma Koreana, Oct 2008). (Other source, 2008, Oct, 0).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (400mg po):t1/2:13:hr","Human (400mg po):Cmax:8.7:microg/ml","Human (400mg po):AUC:143:microghr/ml","Human (400mg po):Tmax:1 to 4:hr","Human (600mg po):t1/2:13:hr","Human (600mg po):Cmax:14.3:microg/ml","Human (600mg po):AUC:231:microghr/ml","Human (600mg po):Tmax:1 to 4:hr","Human (800mg po):t1/2:13:hr","Human (800mg po):Cmax:19:microg/ml","Human (800mg po):AUC:302:microghr/ml","Human (800mg po):Tmax:1 to 4:hr"],"Document_NC":["Yes"],"Document_RB":["8"],"Document_TF":["6323: Ion channel > Sodium channel;","6325: Ion channel > Sodium channel;","6328: Ion channel > Sodium channel;","1808: Enzyme > EC number > 3.5.2.2;","1808: Enzyme."],"Document_TG":["6323: sodium channel, voltage-gated, type I, alpha subunit","6325: sodium channel, voltage-gated, type II, alpha 1","6328: sodium channel, voltage-gated, type III, alpha subunit","1808: dihydropyrimidinase-like 2"],"Document_LCH":["20140305:AD113 : Initiation of Phase III trial (EP0034) for partial-onset seizures reported"],"Document_TB":["6323: Ion channel > Sodium channel;","6323: Sodium channel;","6323: Ion channel.","6325: Ion channel > Sodium channel;","6325: Sodium channel;","6325: Ion channel.","6328: Ion channel > Sodium channel;","6328: Sodium channel;","6328: Ion channel.","1808: Enzyme > EC number > 3.5.2.2;","1808: EC number > 3.5.2.2;","1808: Enzyme;","1808: 3.5.2.2;","1808: Enzyme > EC number.","1808: Enzyme;"],"Document_CASIS-USE_CASIS-MA_PHCD":["CHA-NA-V-AN: Voltage-gated sodium channel antagonist: Physiological, Biochemical, Voltagegated sodium channel antagonist: Sodium channel blocker, voltage-gated: Nav channel antagonist: VGSC antagonist: P-B-CHA-NA-V-AN|CRMP-2-AG: Collapsin-response mediator protein 2 stimulant: Physiological, Biochemical, Collapsinresponse mediator protein 2 stimulant: P-B-CRMP-2-AG|CRMP-2-AN: Collapsin-response mediator protein 2 inhibitor: Physiological, Biochemical, Collapsinresponse mediator protein 2 inhibitor: P-B-CRMP-2-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["250.30"],"Document_AL":["-0.06"],"Document_CASIS-CO_CO":["Originator: UCB (BE): Launched","Licensee: Orient Europharma (TW): Registered"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH030238","CASIS_COMPOUND":[{"CN":"SPM 929 (tablet) CCN=SPM929(TABLET)","SRC_DB":"PHPROJ"},{"CN":"SPM-927 CCN=SPM927","SRC_DB":"PHPROJ"},{"CN":"SPM 927 (IV) CCN=SPM927(IV)","SRC_DB":"PHPROJ"},{"CN":"lacosamide (tablet) CCN=LACOSAMIDE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Harkoseride (IV) CCN=HARKOSERIDE(IV)","SRC_DB":"PHPROJ"},{"CN":"SPM 929 (IV) CCN=SPM929(IV)","SRC_DB":"PHPROJ"},{"CN":"SPM-927 (tablet) CCN=SPM927(TABLET)","SRC_DB":"PHPROJ"},{"CN":"SPM 927 (tablet) CCN=SPM927(TABLET)","SRC_DB":"PHPROJ"},{"CN":"SPM 929 CCN=SPM929","SRC_DB":"PHPROJ"},{"CN":"Harkoseride (syrup) CCN=HARKOSERIDE(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"SPM 927 (syrup) CCN=SPM927(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"SPM 927 CCN=SPM927","SRC_DB":"PHPROJ"},{"CN":"Vimpat (tablet) CCN=VIMPAT(TABLET)","SRC_DB":"PHPROJ"},{"CN":"SPM-927 (IV) CCN=SPM927(IV)","SRC_DB":"PHPROJ"},{"CN":"SPM-929 (tablet) CCN=SPM929(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Harkoseride (tablet) CCN=HARKOSERIDE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"lacosamide (syrup) CCN=LACOSAMIDE(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"ADD-234037 (tablet) CCN=ADD234037(TABLET)","SRC_DB":"PHPROJ"},{"CN":"SPM 929 (syrup) CCN=SPM929(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"SPM-927 (syrup) CCN=SPM927(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"ADD-234037 CCN=ADD234037","SRC_DB":"PHPROJ"},{"CN":"SPM-929 (syrup) CCN=SPM929(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"Vimpat (syrup) CCN=VIMPAT(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"lacosamide CCN=LACOSAMIDE","SRC_DB":"PHPROJ"},{"CN":"ADD-234037 (syrup) CCN=ADD234037(SYRUP)","SRC_DB":"PHPROJ"},{"CN":"Vimpat (IV) CCN=VIMPAT(IV)","SRC_DB":"PHPROJ"},{"CN":"Vimpat CCN=VIMPAT","SRC_DB":"PHPROJ"},{"CN":"lacosamide (IV) CCN=LACOSAMIDE(IV)","SRC_DB":"PHPROJ"},{"CN":"SPM-929 (IV) CCN=SPM929(IV)","SRC_DB":"PHPROJ"},{"CN":"ADD-234037 (IV) CCN=ADD234037(IV)","SRC_DB":"PHPROJ"},{"CN":"harkoseride CCN=HARKOSERIDE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Epilepsy, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Epilepsy, partial (focal, local)","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N2Z","THE_USE":"Analgesic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M2Z","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Migraine prophylaxis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N3A","THE_USE":"Antiepileptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N8A","THE_USE":"Antimigraine","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"CHA-NA-V-AN","THE_USE":"Voltage-gated sodium channel antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Arthritis, osteo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"CRMP-2-AG","THE_USE":"Collapsin-response mediator protein 2 stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"CRMP-2-AN","THE_USE":"Collapsin-response mediator protein 2 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Epilepsy, generalized, tonic-clonic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M5Z","THE_USE":"Musculoskeletal","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Pain, neuropathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Neuropathy, diabetic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Fibromyalgia","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 97, 99, 111, 115, 97, 109, 105, 100, 101, 32, 40, 102, 111, 114, 109, 101, 114, 108, 121, 32, 104, 97, 114, 107, 111, 115, 101, 114, 105]...', original message: bytes can be at most 32766 in length; got 34257
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34257
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:48:42,427][DEBUG][action.bulk              ] tuximab + cisplatin survived for 105 days, vs 50 days on control (Press release, Peregrine, 3 Apr 2006).^In murine models of pancreatic cancer, bavituximab controlled the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with gemcitabine hydrochloride (Press release, Peregrine, 11 Jan 2006).^In animals, bavituximab protected against cytomegalovirus and Pichinde viral infections and also bound to human cells infected with influenza A (Press release, Peregrine, 24 Oct 2005).^In human breast cancer models, bavituximab + docetaxel resulted in 93% inhibition of breast cancer growth, cf 68 and 60% on docetaxel or bavituximab alone, respectively. In mouse models of orthotopic human breast cancer, combination therapy decreased tumour burden of liver and lung metastases by 90%, cf 56 and 43% reductions on docetaxel or bavituximab monotherapy, respectively (Press release, Peregrine, 18 May 2004).^In vitro^In vitro studies, bavituximab reversed the inhibitory effects of PS masked on tumour cells as measured by increased phagocytosis, maturation and expression of immunostimulatory molecules (CD40, CD80, CD86 and MHC II), increased production of inflammatory cytokines (TNFalpha, CCL5, IL-1beta and IL-6) and decreased production of anti-inflammatory cytokines (TGFbeta and IL-10) (Press release, Peregrine, 19 Apr 2010).^Patents^US7790860 and US7790159 have been granted (Press release, Peregrine, 7 Sep 2010, http://ir.peregrineinc.com/ releasedetail.cfm?ReleaseID=505041).^US7611704, covering antiviral uses of phosphatidylserine (PS) targeting antibodies including bavituximab, has been granted (Press release, 4 Nov 2009).^US7550141, covering methods for imaging solid tumours using PS- targeting antibodies coupled to a variety of imaging agents, has been granted (Press release, Peregrine, 24 Jun 2009).^US7378386, US7384909 and US7455833 have been granted (Press releases, Perigrine, 16 Jun and 25 Nov 2008).^US6312694 was granted to the University of Texas Southwestern, TX, the US, which assigned it to Arcus (Press release, OXiGENE, 12 Nov 2001).^Licensing^Agreements^________________^Arcus Therapeutics (OXiGENE/Peregrine joint-venture)^Worldwide; it was originally under development by Arcus Therapeutics (OXiGENE/Peregrine joint-venture) using OXiGENE's tubulin binding agents; however, the joint-venture concluded in Feb 2002 and Peregrine reacquired full rights to its VTA technology (Press release, OXiGENE and Peregrine, 28 Feb 2002).^Defense Reduction Agency^USA; Peregrine has a 5yr contract with the Defense Reduction Agency (DTRA) to evaluate bavituximab for the prevention or treatment of viral haemorrhagic fever infections (Press release, Peregrine, 9 Sep 2008).^Qualifying Therapeutic Discovery Project^USA; Peregrine received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) (IRS.gov Web Page, 17 Feb 2011, http://www.irs.gov/businesses/small/article/ 0,,id=229024,00.html).^US Army Medical Research Institute of Infectious Diseases^USA; Peregrine signed a CRADA for material transfer with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential of bavituximab to treat haemorrhagic diseases resulting from Ebola and Marburg viral infections (Press release, Peregrine, 21 Jul 2005).^US NIAID^USA; Peregrine is collaborating with the US NIAID (NIH) to assess bavituximab in preclinical influenza models. Peregrine was also in discussions with other federal officials to evaluate the potential of bavituximab to treat influenza, including avian influenza (Press release, Peregrine, 24 Oct 2005).^US NIAID; University of Texas Southwestern Medical Center^USA; The US NIAID has awarded a 2yr grant to Philip Thorpe, the University of Texas Southwestern Medical Center, the US, to expand studies of anti-PS antibodies for the treatment of viral haemorrhagic fever infections (Press release, Peregrine, 26 Aug 2009).^Availability^________________^Peregrine Pharmaceuticals^Wolrdwide; it is available for licensing worldwide (13th BioPartner Eur (London), 2005; Press release, Peregrine, 20 May 2013, http://pphm.client.shareholder.com/ releasedetail.cfm?ReleaseID=765925).^"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (0.1-3mg/kg iv):Cmax:2 to 56:microg/ml","Human (0.1-3mg/kg iv):t1/2:37.5:hr"],"Document_NC":["No"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140317:PP249 : Enrollment completion in Phase Ib trial reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["PHAT-SE-AN: Phosphatidylserine inhibitor: Physiological, Biochemical, Phosphatidylserine inhibitor: P-B-PHAT-SE-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Peregrine Pharmaceuticals (US): Phase III Clinical Trial","Licensee: AERES Biomedical (GB): Phase III Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"}],"DOCNO":"PH030528","CASIS_COMPOUND":[{"CN":"Tarvacin CCN=TARVACIN","SRC_DB":"PHPROJ"},{"CN":"3G4 CCN=3G4","SRC_DB":"PHPROJ"},{"CN":"anti-phosphatidylserine MAb, Peregrine CCN=ANTIPHOSPHATIDYLSERINEMABPEREGRINE","SRC_DB":"PHPROJ"},{"CN":"bavituximab CCN=BAVITUXIMAB","SRC_DB":"PHPROJ"},{"CN":"anti-PS MAb, Peregrine CCN=ANTIPSMABPEREGRINE","SRC_DB":"PHPROJ"},{"CN":"antiphospholipid ther, Peregrine CCN=ANTIPHOSPHOLIPIDTHERPEREGRINE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PHAT-SE-AN","THE_USE":"Phosphatidylserine inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"T3A4","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Infection, HIV/AIDS","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Infection, haemorrhagic fever","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J7B","THE_USE":"Immunomodulator","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J5Z","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J5A","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[66, 97, 118, 105, 116, 117, 120, 105, 109, 97, 98, 32, 40, 51, 71, 52, 41, 32, 105, 115, 32, 97, 110, 32, 97, 110, 116, 105, 45, 112]...', original message: bytes can be at most 32766 in length; got 36559
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36559
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:49:06,200][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.5gb[12%], replicas will not be assigned to this node
[2016-06-14 11:49:14,640][DEBUG][action.bulk              ] -ranging study sc in 250 patients with MS (ClinicalTrials.gov Web Page, 2 May 2008, NCT00207727). However, development for this indication was discontinued (Direct communication, Centocor, 20 May 2008).^Psoriasis^A 52wk double-blind Phase II trial in 320 patients with moderate- to-severe plaque psoriasis was completed. At 12wk, of the patients on 90mg 4x 1/wk, 45mg 4x 1/wk, single-dose 90mg, or single-dose 45mg ustekinumab, 81, 67, 59 and 52% achieved PASI 75, respectively, 52, 44, 30, and 23% achieved PASI 90, respectively, vs 2% on placebo, and 20, 16, 16 and 5% had PASI 100, respectively, as early as wk2 with further improvements over 24wk. Similar proportions of patients receiving ustekinumab and showing improvement in PASI were assessed as being clear or having an 'excellent' PGA score. At wk12 and wk24, significant proportions on ustekinumab reported that neither their psoriasis nor the treatment had a measurable negative impact on their quality of life. At wk20, 79% on ustekinumab experienced AEs, vs 72% on placebo after an average of 19.7 and 17.9wk, respectively. 43% on ustekinumab experienced an infection, vs 39% on placebo. Rates of AEs and infections were not dose-dependent. SAEs resulting in hospitalization were observed in 4% of patients on ustekinumab, vs 1% on placebo. The most common SAE was myocardial infarction, occurring in 2 on ustekinumab patients. Malignancies were reported in 2% on ustekinumab, vs 2% on placebo (Press release, JandJ, 7 Feb 2007).^Sarcoidosis^A randomized, double-blind, parallel-group, placebo-controlled Phase II trial (CR016405) in 173 subjects with chronic sarcoidosis in Belgium, Denmark, France, Germany, Great Britain, the Netherlands, Norway, Romania, the UK and the US, to evaluate the the safety and efficacy of ustekinumab 180mg sc at wk 0 and 90mg at wk 8, 16 and 24 or golimumab 200mg sc at wk 0 and 100mg at wk 4, 8, 12, 16, 20 and 24, is complete (Company presentation, JandJ, 4 Jun 2009; Company presentation, JandJ, 26 May 2011, Slide 144, http://www.investor.jnj.com/ eventdetail.cfm?eventid=91870;ClinicalTrials.gov, 21 Jan 2012 and 19 Sep 2012, http://www.clinicaltrials.gov/ct2/show/NCT00955279).^Phase I^It is in a Chinese randomized, open-label Phase I trial in 24 healthy male volunteers to assess the safety, tolerability, immune response and pharmacokinetics of ustekinumab (ClinicalTrials.gov, 12 Mar 2010, http://www.clinicaltrials.gov/ ct2/show/NCT01081704).^Multiple sclerosis, general^Phase I trials for MS were completed (Company Web Page, Medarex, 30 Apr 2003; National MS Society Web Page, 30 Apr 2003).^Licensing^Agreements^________________^Centocor (Johnson and Johnson)^USA; Centocor has exclusive US marketing rights (Press releases, Centocor, 17 Jun 2008 and 26 May 2009).^Janssen-Cilag (Johnson and Johnson)^Worldwide except USA; Janssen-Cilag has exclusive rights in all countries outside the US (Press releases, Centocor, 17 Jun 2008 and 26 May 2009).^Janssen-Ortho (Johnson and Johnson)^Canada; marketing (Direct communication, JandJ, 5 Jan 2009).^Medarex (Bristol-Myers Squibb)^Worldwide; Centocor has an agreement to access Medarex' (now Bristol-Myers Squibb's (BMS)) HuMab-Mouse technology for manufacturing (Press release, Medarex, 3 May 2000).^"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["No"],"Document_TF":["3593: Cytokine/Growth factor > Cytokine > Interleukin."],"Document_TG":["3593: interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)"],"Document_LCH":["20140313:PT : Acceptance for use in the Scottish NHS for psoriatic arthritis reported"],"Document_TB":["3593: Cytokine/Growth factor > Cytokine > Interleukin;","3593: Cytokine > Interleukin;","3593: Cytokine/Growth factor;","3593: Interleukin;","3593: Cytokine/Growth factor > Cytokine."],"Document_CASIS-USE_CASIS-MA_PHCD":["IL-12-AN: Interleukin 12 antagonist: Physiological, Hormonal, Interleukin 12 antagonist: IL 12 antagonist: NKSF antagonist: Natural killer cell stimulatory factor antagonist: CLMF antagonist: P-H-IL-12-AN|IL-23-AN: Interleukin 23 antagonist: Physiological, Hormonal, Interleukin 23 antagonist: IL-23 antagonist: P-H-IL-23-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Johnson & Johnson (US): Launched"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"}],"DOCNO":"PH035837","CASIS_COMPOUND":[{"CN":"ustekinumab CCN=USTEKINUMAB","SRC_DB":"PHPROJ"},{"CN":"CNTO-1275 CCN=CNTO1275","SRC_DB":"PHPROJ"},{"CN":"ustekinumab (SC) CCN=USTEKINUMAB(SC)","SRC_DB":"PHPROJ"},{"CN":"Stelara (SC) CCN=STELARA(SC)","SRC_DB":"PHPROJ"},{"CN":"Stelara CCN=STELARA","SRC_DB":"PHPROJ"},{"CN":"CNTO 1275 (IV) CCN=CNTO1275(IV)","SRC_DB":"PHPROJ"},{"CN":"CNTO-1275 (IV) CCN=CNTO1275(IV)","SRC_DB":"PHPROJ"},{"CN":"ustekinumab (IV) CCN=USTEKINUMAB(IV)","SRC_DB":"PHPROJ"},{"CN":"CNTO 1275 (SC) CCN=CNTO1275(SC)","SRC_DB":"PHPROJ"},{"CN":"Stelara (IV) CCN=STELARA(IV)","SRC_DB":"PHPROJ"},{"CN":"CNTO 1275 CCN=CNTO1275","SRC_DB":"PHPROJ"},{"CN":"CNTO-1275 (SC) CCN=CNTO1275(SC)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C3","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cirrhosis, primary biliary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Multiple sclerosis, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Palmoplantar pustulosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A2","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D4A","THE_USE":"Antipruritic-inflamm","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Eczema, atopic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"IL-12-AN","THE_USE":"Interleukin 12 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A5B","THE_USE":"Hepatoprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M1A1","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"IL-23-AN","THE_USE":"Interleukin 23 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N7A","THE_USE":"Multiple sclerosis treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[85, 115, 116, 101, 107, 105, 110, 117, 109, 97, 98, 32, 40, 67, 78, 84, 79, 45, 49, 50, 55, 53, 41, 32, 105, 115, 32, 97, 32, 104]...', original message: bytes can be at most 32766 in length; got 33411
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 33411
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:49:15,712][DEBUG][action.bulk              ] ndpoint) and tolerability in up to 12 patients with relapsed/refractory NHL and at least 1 patient with CLL was completed. Patients received 1 infusion of ofatumumab 300mg followed by 500-1000mg 1x/ wk x7 (Press release, Genmab, 10 Oct 2008; Company Web Page, Genmab, 19 Aug 2009).^Cancer, lymphoma, non-Hodgkin's^GlaxoSmithKline^It is in an open-label, randomized, parallel-assignment, 2-arm Phase I trial (113603) in the US in 70 patients with previously untreated or relapsed indolent B-cell non-Hodgkin's lymphoma, to evaluate the potential drug-drug interactions between ofatumumab and bendamustine. Completion is expected in Apr 2015 (ClinicalTrials.gov, 24 Sep 2013, http://clinicaltrial.gov/show/ NCT01691807).^Preclinical ^In vivo^In SCID mice inoculated with CD20-expressing human Daudi B- lymphoma cells, a single low dose of ofatumumab 8 days after inoculation stopped growth of tumours more effectively vs rituximab or placebo (Press release, Genmab, 8 Dec 2003).^In cynomolgus monkeys, ofatumumab 5-50mg/kg/day x4 days depleted B-cells in blood and lymph nodes for a time period 4x longer than rituximab (Press release, Genmab, 26 Jun 2003).^In vitro^In recombinant CEM tumour cell lines expressing 4500-135000 CD20 molecules/cell, ofatumumab induced significant lysis at the lowest CD20 expression level, whereas these cells were resistant to rituximab, and gave complete lysis at intermediate CD20 expression levels, whereas rituximab did not (Press release, Genmab, 2 Jun 2005).^In vitro, ofatumumab killed up to 50% of patient-derived B-cell CLL tumours vs 5% for rituximab, and killed up to 100% of patient- derived B-cell acute lymphocytic leukaemia cells, vs 10% for rituximab (Press release, Genmab, 7 Feb 2003).^Patents^European and US patent protection expires in 2023 (Ann Rep, GSK, 2009).^Licensing^Agreements^________________^GlaxoSmithKline^Worldwide; it is licensed exclusively to GSK for worldwide co- development. GSK terminated an option to co-promote the drug in the US, but retains other rights (Press releases, Genmab, 19 Dec 2006 and 18 Dec 2008; Scrip Daily Online, 13 May 2009, S01027318). In an amendment to the GSK agreement, GSK will take full responsibility for autoimmune indications, and will jointly develop it with Genmab for oncology indications (Press release, Genmab, 1 Jul 2010, http://www.genmab.com/Press%20Center/ RecentNewsReleases/^^National Comprehensive Cancer Network^Worldwide; GSK awarded a grant to the National Comprehensive Cancer Network (NCCN) to support clinical studies for haematologic malignancies (Press release, NCCN, 27 Jul 2010, http://www.nccn.org/about/news/newsinfo.asp?NewsID=255).^Additional Clinical Information^Phase II^In an open-label, dose-escalating Phase I/II trial in patients with B-CLL, the 1st infusion of 500mg gave an AUC, Cl, Cmax, t1/2 and Vd of 446-117549mg/lhr, 4-1122ml/hr, 42-714mg/l, 4-143hr and 878-7351ml, respectively. After the 4th infusion at 2000mg, AUC, Cl, Cmax, t1/2 and Vd were 62709-1845.398mg/lhr, 1-42ml/hr, 540- 1830mg/l, 55-735hr and 590-9413ml, respectively.^In a 39-patient Phase I/II component of a Phase II active RA trial, 77% (20/26) receiving 2 doses of ofatumumab had an ACR20 at wk24, cf 63% (20/32) including intent-to-treat patients (some of whom had not received both doses), and 0% (0/7) on placebo. On ofatumumab 300, 700 and 100mg x2, ACR20s were obtained in 73, 78 and 78%, ACR50s in 25, 44 and 44%, and ACR70s in 13, 22 and 11%, respectively. The MTD was not reached (Press releases, Genmab, 8 and 21 Mar 2006).^In a 12mth, open-label, dose-escalation Phase I/II trial in 33 relapsed or refractory CLL patients, given ofatumumab 100-300mg, followed by 500-2000mg 1x/wk x3wk, interim results at 19wk showed a response rate of 67% on 2000mg at wk4, and 12/26 evaluable patients (46%) had an >8wk objective response. There were 10CRs over 19wk, and median time-to-progression was >19wk (Press releases, Genmab, 13 Dec 2004 and 12 Dec 2005).^"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (4th infusion 2000mg):AUC:392418:mghr/l","Human (4th infusion 2000mg):Cl:10:ml/hr","Human (4th infusion 2000mg):Cmax:1087:mg/l","Human (4th infusion 2000mg):t1/2:328:hr","Human (4th infusion 2000mg):Vd:3642:ml"],"Document_NC":["No"],"Document_TF":["931: Receptor."],"Document_TG":["931: membrane-spanning 4-domains, subfamily A, member 1"],"Document_LCH":["20140310:AD181 : Ongoing development for pemphigus reported"],"Document_TB":["931: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["CD-20-AN: CD20 antagonist: Receptor, Biochemical, CD20 antagonist: R-B-CD-20-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Genmab (DK): Launched","Licensee: GlaxoSmithKline (GB): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"}],"DOCNO":"PH035024","CASIS_COMPOUND":[{"CN":"GSK-1841157 CCN=GSK1841157","SRC_DB":"PHPROJ"},{"CN":"GSK1841157 (IV) CCN=GSK1841157(IV)","SRC_DB":"PHPROJ"},{"CN":"HuMax-CD20 (IV) CCN=HUMAXCD20(IV)","SRC_DB":"PHPROJ"},{"CN":"HuMax-CD20 (SC) CCN=HUMAXCD20(SC)","SRC_DB":"PHPROJ"},{"CN":"Arzerra CCN=ARZERRA","SRC_DB":"PHPROJ"},{"CN":"GSK1841157 CCN=GSK1841157","SRC_DB":"PHPROJ"},{"CN":"ofatumumab (SC) CCN=OFATUMUMAB(SC)","SRC_DB":"PHPROJ"},{"CN":"HuMax-CD20 CCN=HUMAXCD20","SRC_DB":"PHPROJ"},{"CN":"GSK1841157 (SC) CCN=GSK1841157(SC)","SRC_DB":"PHPROJ"},{"CN":"ofatumumab CCN=OFATUMUMAB","SRC_DB":"PHPROJ"},{"CN":"Arzerra (IV) CCN=ARZERRA(IV)","SRC_DB":"PHPROJ"},{"CN":"ofatumumab (IV) CCN=OFATUMUMAB(IV)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"T3A2","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Pemphigus","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Multiple sclerosis, relapsing-remitting","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D11Z","THE_USE":"Dermatological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"CD-20-AN","THE_USE":"CD20 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Waldenstrom's hypergammaglobulinaemia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N7A","THE_USE":"Multiple sclerosis treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[79, 102, 97, 116, 117, 109, 117, 109, 97, 98, 32, 40, 65, 114, 122, 101, 114, 114, 97, 59, 32, 72, 117, 77, 97, 120, 45, 67, 68, 50]...', original message: bytes can be at most 32766 in length; got 41761
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 41761
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:49:36,219][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.5gb[11.9%], replicas will not be assigned to this node
[2016-06-14 11:49:51,275][DEBUG][action.bulk              ] ey=e23aeab5-75b3-442d-b87d- bce42e349b5aandcKey=ecb0fb97-119f-454a-aa8c- 443f0407c31aandmKey={0C918954-D607-46A7-8073-44F4B537A439}).^Patents^A notice of allowance for a US patent, covering therapeutic combination of tedizolid phosphate + daptomycin has been issued (Press release, Trius, 13 May 2013, http://investor.triusrx.com/ releasedetail.cfm?ReleaseID=764144).^CN908206, covering the composition of matter has been issued. Patent expiry is expected in 2024. It has patent protection in Canada, Europe, Japan and Mexico (Press release, Trius, 16 Feb 2012, http://investor.triusrx.com/ releasedetail.cfm?ReleaseID=649144).^US7816379, covering the composition-of-matter of torezolid phosphate will expire on 23 Feb 2028. Counterpart patents are granted in Australia, India, New Zealand and Russia. Additional counterpart applications are under review in other countries. Patent applications covering other aspects of torezolid phosphate have been filed, which expires on 2030 (Press release, Trius, 25 Oct 2010; Press release, Trius, 11 Apr 2011, http:// investor.triusrx.com/releasedetail.cfm?ReleaseID=568162).^Licensing^Agreements^________________^Qualifying Therapeutic Discovery Project^USA; Trius Therapeutics received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) (IRS.gov Web Page, 19 Jan 2011, http://www.irs.gov/businesses/small/article/ 0,,id=229024,00.html).^Trius Therapeutics (Cubist)^Worldwide except South Korea; Trius Therapeutics has exclusive worldwide rights outside S Korea to develop, manufacture and market oxazolidinone antibacterials (Press release, Dong-A and Trius, 26 Feb 2007).^Bayer; Trius Therapeutics^Worldwide except Canada, EU and USA; exclusive agreement to develop and commercialize torezolid in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding N Korea and S Korea. Bayer will pay Trius upfront fees and will partly bear future development costs required for global approval in ABSSSI and pneumonia. In addition, Trius is eligible to receive payments upon achievement of certain development, regulatory and commercial milestones and will receive double- digit royalties on net sales of torezolid in the licensed territory (Press release, Bayer, 27 Jul 2011, http:// www.investor.bayer.com/en/news/investor-news/investor-news/ showNewsItem/1299/1311760320/5b0b98ca8a/).^Availability^________________^Europe; Trius is evaluating potential strategic alliances for tedizolid in Europe (Scrip Intelligence, 21 Jan 2013, http:// www.scripintelligence.com/business/Pacira-and-Trius-plunge-into- public-markets-in-1.3bn-funding-week-for-US-biotech-339221).^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (200mg):AUC:0.863 to 1.695:microghr/ml","Human (200mg):Cmax:0.849 to 1.408:microg/ml"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140321:PT : Initiation of Phase III study (16121) reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["PRT-50S-AN: Protein 50S ribosomal subunit inhibitor: Physiological, Biochemical, Protein 50S ribosomal subunit inhibitor: Protein 50S ribosomal binding inhibitor: Antimicrobial e.g. chloramphenicol, lincosamides, macrolides: Antimicrobial e.g. erythromycin, clindamycin: P-B-PRT-50S-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_MW":["370.35"],"Document_AL":["1.52"],"Document_CASIS-CO_CO":["Originator: Dong-A (KR): Pre-registration","Licensee: Trius Therapeutics (US): Pre-registration","Licensee: Bayer (DE): Phase III Clinical Trial"],"Document_MR":["5:Market Rating - Over US$ 10000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Pre-registration"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"}],"DOCNO":"PH043887","CASIS_COMPOUND":[{"CN":"BAY 1192631 CCN=BAY1192631","SRC_DB":"PHPROJ"},{"CN":"DA-7218 (oral tablet) CCN=DA7218(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"tedizolid CCN=TEDIZOLID","SRC_DB":"PHPROJ"},{"CN":"DA ? 7218 CCN=DA?7218","SRC_DB":"PHPROJ"},{"CN":"torezolid (IV) CCN=TOREZOLID(IV)","SRC_DB":"PHPROJ"},{"CN":"tedizolid (oral solution) CCN=TEDIZOLID(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"tedizolid phosphate CCN=TEDIZOLIDPHOSPHATE","SRC_DB":"PHPROJ"},{"CN":"TR-700 (SC) CCN=TR700(SC)","SRC_DB":"PHPROJ"},{"CN":"tedizolid (IV) CCN=TEDIZOLID(IV)","SRC_DB":"PHPROJ"},{"CN":"TR-701(IV) CCN=TR701(IV)","SRC_DB":"PHPROJ"},{"CN":"TR701 FA (IV) CCN=TR701FA(IV)","SRC_DB":"PHPROJ"},{"CN":"TR701 FA (oral tablet) CCN=TR701FA(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"TR701 FA CCN=TR701FA","SRC_DB":"PHPROJ"},{"CN":"DA-7218 (oral solution) CCN=DA7218(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"tedizolid (SC) CCN=TEDIZOLID(SC)","SRC_DB":"PHPROJ"},{"CN":"torezolid (oral solution) CCN=TOREZOLID(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"DA ? 7218 (oral solution) CCN=DA?7218(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"TR-701 (oral tablet) CCN=TR701(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"TR701 FA (SC) CCN=TR701FA(SC)","SRC_DB":"PHPROJ"},{"CN":"TR-701 (oral solution) CCN=TR701(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"TR-701 FA CCN=TR701FA","SRC_DB":"PHPROJ"},{"CN":"torezolid (oral tablet) CCN=TOREZOLID(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"DA ? 7218 (oral tablet) CCN=DA?7218(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"DA-7157 (SC) CCN=DA7157(SC)","SRC_DB":"PHPROJ"},{"CN":"BAY-1192631 CCN=BAY1192631","SRC_DB":"PHPROJ"},{"CN":"torezolid phosphate CCN=TOREZOLIDPHOSPHATE","SRC_DB":"PHPROJ"},{"CN":"oxazolidinone, Trius CCN=OXAZOLIDINONETRIUS","SRC_DB":"PHPROJ"},{"CN":"TR-701 CCN=TR701","SRC_DB":"PHPROJ"},{"CN":"tedizolid (oral tablet) CCN=TEDIZOLID(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"TR701 FA (oral solution) CCN=TR701FA(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BAY1192631 CCN=BAY1192631","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"PR","THE_USE":"Infection, skin and skin structure, acute bacterial ","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PRT-50S-AN","THE_USE":"Protein 50S ribosomal subunit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Infection, pneumonia, community-acquired","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Infection, bone","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Infection, MRSA","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Infection, pneumonia, hospital-acquired","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J3Z","THE_USE":"Antibacterial","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Infection, MSSA","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Infection, skin and skin structure, complicated","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Infection, vancomycin-resistant","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Sepsis","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 101, 100, 105, 122, 111, 108, 105, 100, 32, 40, 116, 111, 114, 101, 122, 111, 108, 105, 100, 59, 32, 68, 65, 45, 55, 50, 49, 56, 59]...', original message: bytes can be at most 32766 in length; got 34668
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34668
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:49:51,538][DEBUG][action.bulk              ] release, YM BioSciences, 18 Nov 2004; Company Web Page, YM BioSciences, 10 Sep 2007).^In an open-label Phase I/II trial in 29 adult patients with high- grade glioma, including GBM (15 patients) and anaplastic astrocytoma (9 patients), who underwent debulking surgery or biopsy prior to the trial, nimotuzumab 200mg as 1x/wk x6 infusions + external beam radiation gave 4CRs, 5PRs and 12SDs. In patients with high-grade glioma astrocytic tumours, mean and median survival was 23.7 and 18.1mth, respectively, with a survival rate at 18mth of 53%. There was no evidence of grade 3/4 AEs. One patient had grade 2 dysphasia and sensory alteration (Press release, YM BioSciences, 19 May 2005; 41st ASCO (Orlando), 2005).^A Phase I/II trial in the EU in 18 paediatric patients with astrocytomas or glioblastomas who failed 1st-line therapy and received nimotuzumab iv 1x/wk x6wk was terminated prematurely because of trial success. Of 19 evaluable patients, 6 responded to treatment with 5SDs and 1PR. There was no skin toxicity and no haematological or non-haematological side-effects (Press releases, YM BioSciences, 15 Jun 2004 and 25 Jan 2005).^A US IND was approved for 1 child with advanced glioma. Paediatric expansion of the trial was planned (Press release, YM BioSciences, 16 Mar 2005)^Phase I^A Phase I passive immunotherapy trial in Cuba for epithelial- derived tumours was carried out (Direct communication, CIM, 18 Feb 2000).^In a Cuban Phase I diagnostic trial in 148 patients with suspected cancer of epithelial origin, immunoscintigraphy with murine R3 identified 106/126 cases (confirmed by biopsy), and correctly identified all 22 patients who did not have epithelial cancers. It was in Phase I trials in Canada (12 patients) and Cuba (29 patients) for imaging epithelial-derived tumours (Press release, CIM and York Medical, 9 Jul 1999; Direct communication, CIM, 6 Mar 2001).^A trial with a rhenium-188-labelled version for radioimmunotherapy in glioma was planned (Company brochure, York Medical, Oct 2000; Direct communication, CIM, 6 Mar 2001).^A Phase I pharmacodynamic study in 12-24 patients was completed (BIO 2005 (Philadelphia); Company Web Page, YM BioSciences, 10 Sep 2007).^"],"Document_CASIS-UPD_WE":["20140228"],"Document_PK":["Human (200mg single dose):Cl:23:ml/hr","Human (200mg single dose):Cmax:141:microg/ml","Human (200mg single dose):t1/2:45:hr","Human (200mg single dose):Vd:1.46:l"],"Document_NC":["No"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor"],"Document_LCH":["20140218:AD50 : Ongoing Phase III development for gastric & nsclc and Phase I for oesophageal cancer reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR1-AN: Epidermal growth factor receptor 1 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 1 antagonist: EGFR1 antagonist: HER1 antagonist: ErbB-1 antagonist: R-H-GF-EPR1-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Center of Molecular Immunology (CU): Launched","Licensee: Biocon (IN): Launched","Licensee: Innogene Kalbiotech (SG): Launched","Licensee: Eurofarma (BR): Launched","Licensee: Oncoscience (DE): Pre-registration","Licensee: Kuhnil Pharmaceutical (KR): Phase III Clinical Trial","Licensee: Daiichi Sankyo (JP): Phase III Clinical Trial","Licensee: YM BioSciences (CA): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"}],"DOCNO":"PH028992","CASIS_COMPOUND":[{"CN":"BIOMAb-EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"RadioTheraCIM CCN=RADIOTHERACIM","SRC_DB":"PHPROJ"},{"CN":"hR3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"TheraCIM CCN=THERACIM","SRC_DB":"PHPROJ"},{"CN":"Vecthix CCN=VECTHIX","SRC_DB":"PHPROJ"},{"CN":"BIOMAb EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"TheraCIM-h-R3 CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"TheraCIM hR3  CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"DiaCIM CCN=DIACIM","SRC_DB":"PHPROJ"},{"CN":"CIMAher CCN=CIMAHER","SRC_DB":"PHPROJ"},{"CN":"anti-EGFr MAb, CIM CCN=ANTIEGFRMABCIM","SRC_DB":"PHPROJ"},{"CN":"h-R3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"BIOMAb CCN=BIOMAB","SRC_DB":"PHPROJ"},{"CN":"L-R3 CCN=LR3","SRC_DB":"PHPROJ"},{"CN":"R3 CCN=R3","SRC_DB":"PHPROJ"},{"CN":"YMB-1001 CCN=YMB1001","SRC_DB":"PHPROJ"},{"CN":"DiaCIM-h-R3 CCN=DIACIMHR3","SRC_DB":"PHPROJ"},{"CN":"nimotuzumab CCN=NIMOTUZUMAB","SRC_DB":"PHPROJ"},{"CN":"DE-766 CCN=DE766","SRC_DB":"PHPROJ"},{"CN":"huR3 CCN=HUR3","SRC_DB":"PHPROJ"},{"CN":"Theraloc CCN=THERALOC","SRC_DB":"PHPROJ"},{"CN":"OSAG-101 CCN=OSAG101","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-03 11:21:13","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, nasopharyngeal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K5A","THE_USE":"Radio-chemosensitizer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EPR1-AN","THE_USE":"Epidermal growth factor receptor 1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"V4A","THE_USE":"Imaging agent","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diagnosis, cancer","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 105, 109, 111, 116, 117, 122, 117, 109, 97, 98, 32, 40, 82, 51, 41, 32, 105, 115, 32, 97, 110, 32, 73, 103, 71, 49, 32, 104, 117]...', original message: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:49:52,082][DEBUG][action.bulk              ] herapeutic Discovery Project, USA^USA; Incyte received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) (IRS.gov Web Page, 6 Jan 2011, http://www.irs.gov/businesses/small/article/ 0,,id=229024,00.html).^Availability^________________^Incyte^Worldwide; Incyte is evaluating partnering opportunities for psoriasis (31st Goldman Sachs Ann Global Healthcare Conf (New York), 2010, Slilde 18 of 18, http://phx.corporate-ir.net/^^Additional Clinical Information^Phase II^In a 28-day dose-escalation, proof-of-concept Phase IIa trial in 18 patients with mild-to-moderate psoriasis, topical INCB-18424 0.5, 1.0 and 1.5% once-daily or bid was well tolerated and showed a rapid onset of action and a reduction in mean lesion area, thickness, erythema and scaling. At day 28, the decrease in mean total lesion scores for 1 and 1.5% were 53 and 54%, respectively, cf 32 and 27% with vehicle treatment. The mean total lesion scores for 1.5% bid decreased by 46% cf 40% for calcipotriol (qv) and by 58% cf 44% for Diprolene (JP Morgan 26th Ann Healthcare Conf (San Francisco), 2008; Press releases, Incyte, 14 Feb and 18 Sep 2008).^"],"Document_HA":["4"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (25mg po):t1/2:2.32:hr","Human (po bid):MTD:25:mg"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["3716: Enzyme > EC number > 2.7.10.2;","3716: Enzyme > Kinase;","3717: Enzyme > EC number > 2.7.10.2;","3717: Enzyme > Kinase."],"Document_TG":["3716: Janus kinase 1","3717: Janus kinase 2"],"Document_LCH":["20140321:AD283 : Planned Phase II trial (CINC424A2407) for myelofibrosis reported"],"Document_TB":["3716: Enzyme > EC number > 2.7.10.2;","3716: EC number > 2.7.10.2;","3716: Enzyme;","3716: 2.7.10.2;","3716: Enzyme > EC number.","3716: Enzyme > Kinase;","3716: Kinase;","3716: Enzyme.","3717: Enzyme > EC number > 2.7.10.2;","3717: EC number > 2.7.10.2;","3717: Enzyme;","3717: 2.7.10.2;","3717: Enzyme > EC number.","3717: Enzyme > Kinase;","3717: Kinase;","3717: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-TYJ1-AN: Janus kinase 1 inhibitor: Enzyme, Transferase, Janus kinase 1 inhibitor: JAK1 inhibitor: JAK-1 inhibitor: Janus tyrosine kinase inhibitor: E-TR-KI-TYJ1-AN|KI-TYJ2-AN: Janus kinase 2 inhibitor: Enzyme, Transferase, Janus kinase 2 inhibitor: JAK-2 inhibitor: Janus tyrosine kinase 2 inhibitor: JAK2 inhibitor: E-TR-KI-TYJ2-AN|"],"Document_ROUT":["A-PO: Alimentary, po","T-DM: Topical, skin","T-UN: Topical, general"],"Document_MW":["306.37"],"Document_AL":["2.22"],"Document_CASIS-CO_CO":["Originator: Incyte Corporation (US): Launched","Licensee: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Pre-registration Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"}],"DOCNO":"PH043226","CASIS_COMPOUND":[{"CN":"INCB18424 (topical) CCN=INCB18424(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"INCB-18424 CCN=INCB18424","SRC_DB":"PHPROJ"},{"CN":"INCB018424 CCN=INCB018424","SRC_DB":"PHPROJ"},{"CN":"INC-424 (oral) CCN=INC424(ORAL)","SRC_DB":"PHPROJ"},{"CN":"Jakavi (oral) CCN=JAKAVI(ORAL)","SRC_DB":"PHPROJ"},{"CN":"INCB-18424 (topical) CCN=INCB18424(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"Jakavi CCN=JAKAVI","SRC_DB":"PHPROJ"},{"CN":"INCB-18424 (oral) CCN=INCB18424(ORAL)","SRC_DB":"PHPROJ"},{"CN":"INC424 (SR) CCN=INC424(SR)","SRC_DB":"PHPROJ"},{"CN":"ruxolitinib (oral) CCN=RUXOLITINIB(ORAL)","SRC_DB":"PHPROJ"},{"CN":"Jakafi (oral) CCN=JAKAFI(ORAL)","SRC_DB":"PHPROJ"},{"CN":"INCB018424 (topical) CCN=INCB018424(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"INCB18424 (oral) CCN=INCB18424(ORAL)","SRC_DB":"PHPROJ"},{"CN":"Jakafi CCN=JAKAFI","SRC_DB":"PHPROJ"},{"CN":"Jakafi (topical) CCN=JAKAFI(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"INC-424 (SR) CCN=INC424(SR)","SRC_DB":"PHPROJ"},{"CN":"INCB-018424 CCN=INCB018424","SRC_DB":"PHPROJ"},{"CN":"ruxolitinib phosphate CCN=RUXOLITINIBPHOSPHATE","SRC_DB":"PHPROJ"},{"CN":"Jakafi (SR) CCN=JAKAFI(SR)","SRC_DB":"PHPROJ"},{"CN":"INC-424 CCN=INC424","SRC_DB":"PHPROJ"},{"CN":"Jakavi (topical) CCN=JAKAVI(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"ruxolitinib (SR) CCN=RUXOLITINIB(SR)","SRC_DB":"PHPROJ"},{"CN":"INC424 CCN=INC424","SRC_DB":"PHPROJ"},{"CN":"INCB-018424 (oral) CCN=INCB018424(ORAL)","SRC_DB":"PHPROJ"},{"CN":"INCB-018424 (SR) CCN=INCB018424(SR)","SRC_DB":"PHPROJ"},{"CN":"Jakavi (SR) CCN=JAKAVI(SR)","SRC_DB":"PHPROJ"},{"CN":"INC-424 (topical) CCN=INC424(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"INCB018424 (SR) CCN=INCB018424(SR)","SRC_DB":"PHPROJ"},{"CN":"INC424 (oral) CCN=INC424(ORAL)","SRC_DB":"PHPROJ"},{"CN":"INCB-018424 (topical) CCN=INCB018424(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"ruxolitinib (topical) CCN=RUXOLITINIB(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"ruxolitinib CCN=RUXOLITINIB","SRC_DB":"PHPROJ"},{"CN":"INC424 (topical) CCN=INC424(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"INCB-18424 (SR) CCN=INCB18424(SR)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"P","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M2Z","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Thrombocythaemia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Myelofibrosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lymphoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Polycythaemia vera","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYJ2-AN","THE_USE":"Janus kinase 2 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYJ1-AN","THE_USE":"Janus kinase 1 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M1A1","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"B7Z","THE_USE":"Haematological","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 117, 120, 111, 108, 105, 116, 105, 110, 105, 98, 32, 40, 73, 78, 67, 66, 45, 49, 56, 52, 50, 52, 59, 32, 73, 78, 67, 45, 52]...', original message: bytes can be at most 32766 in length; got 39792
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 39792
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:50:05,912][DEBUG][action.bulk              ] 2 (25th Eur Soc Med Oncol Cong (Hamburg), 2000, Abs 51P).^Cancer, brain^It is in a randomized, open-label Phase I trial in 24 patients with brain metastases from solid tumours receiving concurrent whole brain radiation therapy (ClinicalTrials.gov Web Page, 15 Apr 2009 and 2 Oct 2012, http://clinicaltrials.gov/ct2/show/ NCT00879073).^Cancer, biliary^In a German Phase I trial in 6 patients with unresectable hilar bile duct cancer, bendamustine 140mg/m2 30min iv infusion on day 1 of the 1st course, and 100mg/m2 on days 1 and 2 of the cycle in following courses (maximum 4 courses) resulted in no CRs or PRs. It was well tolerated (Digestive Dis Wk (Orlando), 2003, Abs T- 1790).^Cancer, lymphoma, non-Hodgkin's^An open-label, non-randomized, single group assignment Phase I trial in Japan in 12 patients with aggressive B-cell non- Hodgkin's lymphoma, to assess the safety of bendamustine + rituximab and to explore the recommended dose for the Phase II trial was completed (ClinicalTrials.gov, 25 Nov 2008 and 27 May 2010, http://www.clinicaltrials.gov/show/NCT00794638).^An IND has been filed in China for low-grade NHL (Company pipeline, SymBio, 8 Aug 2011, http://www.symbiopharma.com/en/html/ pipeline_01.html).^In an open-label Phase I trial in Japan in 9 patients with rituximab-refractory indolent B-cell NHL, bendamustine 90 and 120mg/m2/day 60min iv infusion x2 days showed safety and efficacy (Scrip Daily Online, 29 Sep 2006, S00935448; Company Web Page, SymBio, 4 Aug 2008).^Preclinical ^Development of an oral formulation for solid tumours in Japan is planned (Company Web Page, SymBio, 4 Aug 2008).^In vivo^It enhanced the tumour growth inhibition of rituximab in Daudi lymphoma xenografts in SCID mice (46th Meet Am Soc Hematol (San Diego), 2004, Abs 4580).^In vitro^Bendamustine induced >90% ATP depletion following 12hr exposure, cf other nitrogen mustards which required at least 48-72hr. Sustained ATP depletion, measured 48hr after initial exposure to bendamustine, was observed in cells following 30min incubation, cf other nitrogen mustards which had no effect on ATP levels under similar conditions at equitoxic concentrations (96th AACR (Anaheim), 2005, Abs 3336).^Patents^It has US patent exclusivity for non-Hodgkin lymphoma is extended through Apr 2016 (Press release, Teva, 27 Nov 2013, http:// www.tevapharm.com/Media/News/Pages/2013/1880493.aspx).^It has patent exclusivity for chronic lymphocytic leukaemia until 20 Sep 2015 (Press release, Teva, 27 Nov 2013, http:// www.tevapharm.com/Media/News/Pages/2013/1880493.aspx).^Licensing^Agreements^________________^Teva^Canada; exclusive (BIO-Asia (Tokyo), 2004)^China; exclusive sublicense from SymBio (Scrip Daily Online, 9 Apr 2009, S01024916)^Hong Kong; exclusive sublicense from SymBio (Scrip Daily Online, 9 Apr 2009, S01024916)^USA; exclusive (BIO-Asia (Tokyo), 2004)^Eisai^Japan, Singapore and South Korea (Press releases, Eisai, 18 Aug 2008 and 18 May 2009).^Lundbeck^Canada; Lundbeck has the commercial rights in Canada. Lundbeck will register and commercialize on behalf of Cephalon (Press release, Lundbeck, 8 Feb 2011, http://www.lundbeck.com/investor/ releases/ReleaseDetails/Release_1486188_EN.asp).^Mundipharma^EU, Iceland and Norway; exclusive (Press release, Mundipharma, 26 Oct 2006).^SymBio Pharmaceuticals^China, Hong Kong, Japan (with Eisai), Singapore, South Korea and Taiwan; exclusive (Press release, SymBio, 22 Dec 2005; Scrip Daily Online, 7 Dec 2007, S00979694; Company Web Page, SymBio, 4 Aug 2008).^InnoPharmax^Taiwan; SymBio sub-licensed exclusive rights to InnoPharmax, Taiwan (Press release, SymBio, 26 Mar 2008, http:// www.symbiopharma.com/en/news/080326e.pdf).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140131"],"Document_PK":["Human:Cl:700:ml/min","Human:Vd:25:l"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140125:AD244 : Ongoing Phase II trial (2012003) for chronic lymphocytic leukaemia reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["DNA-AN: DNA inhibitor: Physiological, Biochemical, DNA inhibitor: Antineoplastic e.g. actinomycin, bleomycin, anthracyclines: Antineoplastic alkylating agent: Alkylating antineoplastic agent: DNA cross linking agent: P-B-DNA-AN|APOP-AG: Apoptosis stimulant: Physiological, Biochemical, Apoptosis stimulant: General apoptosis stimulant: P-B-APOP-AG|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["344.24"],"Document_AL":["3.90"],"Document_CASIS-CO_CO":["Originator: Astellas (JP): Launched","Licensee: Teva (IL): Launched","Licensee: Mundipharma (CH): Launched","Licensee: SymBio Pharmaceuticals (JP): Launched","Licensee: Eisai (JP): Launched","Licensee: InnoPharmax (TW): Launched","Licensee: Lundbeck (DK): Registered"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD051531    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"}],"DOCNO":"PH020598","CASIS_COMPOUND":[{"CN":"bendamustine CCN=BENDAMUSTINE","SRC_DB":"PHPROJ"},{"CN":"Benda CCN=BENDA","SRC_DB":"PHPROJ"},{"CN":"Ribomustin CCN=RIBOMUSTIN","SRC_DB":"PHPROJ"},{"CN":"Innomustine CCN=INNOMUSTINE","SRC_DB":"PHPROJ"},{"CN":"Treanda CCN=TREANDA","SRC_DB":"PHPROJ"},{"CN":"Ribovact CCN=RIBOVACT","SRC_DB":"PHPROJ"},{"CN":"SyB L-0501 CCN=SYBL0501","SRC_DB":"PHPROJ"},{"CN":"Symbenda CCN=SYMBENDA","SRC_DB":"PHPROJ"},{"CN":"Levact CCN=LEVACT","SRC_DB":"PHPROJ"},{"CN":"P08001 CCN=P08001","SRC_DB":"PHPROJ"},{"CN":"Treakisym CCN=TREAKISYM","SRC_DB":"PHPROJ"},{"CN":"SDX-105 CCN=SDX105","SRC_DB":"PHPROJ"},{"CN":"bendamustine hydrochloride CCN=BENDAMUSTINEHYDROCHLORIDE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-03 16:37:20","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, biliary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K1B","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-AN","THE_USE":"DNA inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"APOP-AG","THE_USE":"Apoptosis stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[66, 101, 110, 100, 97, 109, 117, 115, 116, 105, 110, 101, 32, 105, 115, 32, 97, 32, 98, 101, 110, 122, 105, 109, 105, 100, 97, 122, 111, 108]...', original message: bytes can be at most 32766 in length; got 40819
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40819
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:50:06,255][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.4gb[11.9%], replicas will not be assigned to this node
[2016-06-14 11:50:22,399][DEBUG][action.bulk              ] -15.3%), indicating minimal excretion of metabolite(s) in urine. Total recovery of the radioactive dose was 90.4% in urine and feces (102nd ACCR (Orlando), 2011, Abs 1294, http:// www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=271ac6e9-4b12- 4e9d-afa4-854888e7c268andcKey=be1ad516-359c-4f65-a935- 328e03c8e51aandmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^An open-label, randomized, single-group-assignment, single-arm Phase I trial (E7389-E044-110) in France in 22 patients with advanced solid tumours, to assess whether eribulin mesylate 1.4mg/ m2 iv infusion has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval as well as through a pharmacokinetic-pharmacodynamic (PK/PD) analysis is complete (ClinicalTrials.gov, 2 Apr 2011, http:// www.clinicaltrials.gov/show/NCT01106248).^It is in a Dutch Phase I trial in up to 14 patients with advanced solid tumours in combination with rifampicin (iKCnet Web Page, 12 May 2010, http://www.ikcnet.nl/trials/index.php?id=927).^In a US dose-escalating Phase I trial (101) in 21 patients with refractory non-haematological malignancies, to assess safety and pharmacokinetics of eribulin mesylate 0.25-4mg/m2 21hr infusion q 21 days, SD occurred in 5 patients for at least 6 cycles, with 1 unconfirmed PR. The DLT was neutropenia, and the MTD was 2mg/m2. No non-haematological toxicities were observed; however, 3 patients at 4mg/m2 and 2 at 2.8mg/m2 developed febrile neutropenia. Eribulin mesylate 2mg/m2 had Cmax, AUC, t1/2alpha, t1/2beta, Cl and VD of 0.357ng/ml, 1.845microgramhr/ml, 0.535hr, 4.16hr, 1.11l/hr/m2 and 40.9l/m2, respectively (41st ASCO (Orlando), 2005, Abs 2054).^Preclinical ^In vivo^In mice, eribulin mesylate iv up to 1.75mg/kg (MTD) x2wk showed no decrease in caudal or digital nerve conduction velocity (NCV) and amplitude at any dose tested, whilst paclitaxel showed reduction in caudal NCV and digital nerve amplitude at MTD and 0.75MTD. At MTD and 0.75MTD, eribulin mesylate induced mild pathological changes in dorsal root ganglia (DRG) and sciatic nerve, whilst paclitaxel induced moderate to severe dose- dependent pathological changes in sciatic nerve and DRG at dose of 0.5MTD and higher (101st AACR (Washington, DC), 2010, Abs 4438, http://www.abstractsonline.com/plan/ ViewAbstract.aspx?mID=2521andsKey=9cc5618d-f43d-48c8-8448- 0e32a76562e8andcKey=ff120f92-3ec0-4fda-8e6c- e8cdb0f3251eandmKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}).^Eribulin mesylate was 'highly effective' in MDA-MB-435 breast, COLO 205 colon, LOX melanoma, OVCAR-3 ovary and H522 lung human tumour xenograft models. It was significantly more potent cf paclitaxel and active against paclitaxel-resistant cells (RandD Update, Eisai, 1 Sep 2004).^It inhibited tumour growth in mouse xenografts (94th AACR (Washington, DC), 2003, Abs LB-43).^In vitro^It blocked mitosis and inhibited microtubule assembly in vitro (94th AACR (Washington, DC), 2003, Abs LB-43).^Licensing^Agreements^________________^PharmaSwiss^Bulgaria, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia; Eisai has an agreement with PharmaSwiss to promote and distribute Halaven in Bulgaria, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia (Press release, Eisai, 5 Apr 2012, http://www.eisai.com/news/news201215.html).^NewBridge Pharmaceuticals^The Middle East region; partnership for marketing eribulin in selected countries within the Middle East region (Press release, Eisai, 18 Nov 2013, http://www.biospace.com/News/eisai-inc- announces-partnership-with-newbridge/316055/source=MoreNews).^"],"Document_HA":["13"],"Document_CASIS-UPD_WE":["20140228"],"Document_PK":["Human (iv):t1/2alpha:18.4:hr","Human (iv):t1/2beta:2.5:hr","Human (iv):Vd:42.5:l/m2","Human (2mg/m2 iv):t1/2alpha:0.53:hr","Human (2mg/m2 iv):t1/2beta:4.16:hr","Human (2mg/m2 iv):Vd:40.9:l/m2","Human (2mg/m2 iv):Cmax:0.35:ng/ml","Human (2mg/m2 iv):AUC:1.84:microghr/ml","Human (2mg/m2 iv):Cl:1.11:l/hr/m2","Human (0.25-4mg):MTD:2:mg/m2"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140221:AD151 : Initiation of Phase III trial (E7389-A001-303) for breast cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["TUBE-AN: Tubulin inhibitor: Physiological, Biochemical, Tubulin inhibitor: Tubulin binding agent: Tubulin polymerization inhibitor: P-B-TUBE-AN|MICTUBE-AN: Microtubule inhibitor: Physiological, Biochemical, Microtubule inhibitor: Metaphase inhibitor: Mitosis inhibitor: Antineoplastic e.g. vinca alkaloids, colchicine, podophyllin: P-B-MICTUBE-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["731.89"],"Document_AL":["1.29"],"Document_CASIS-CO_CO":["Originator: Eisai (JP): Launched","Licensee: NewBridge Pharmaceuticals (United Arab Emirates): Preclinical"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD277786    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH034033","CASIS_COMPOUND":[{"CN":"E7389 CCN=E7389","SRC_DB":"PHPROJ"},{"CN":"eribulin CCN=ERIBULIN","SRC_DB":"PHPROJ"},{"CN":"eribulin mesylate CCN=ERIBULINMESYLATE","SRC_DB":"PHPROJ"},{"CN":"BOLD CCN=BOLD","SRC_DB":"PHPROJ"},{"CN":"E-7389 CCN=E7389","SRC_DB":"PHPROJ"},{"CN":"Halaven CCN=HALAVEN","SRC_DB":"PHPROJ"},{"CN":"NSC 707389 CCN=NSC707389","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-03 11:21:14","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, synovial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, leiomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"MICTUBE-AN","THE_USE":"Microtubule inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"TUBE-AN","THE_USE":"Tubulin inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, lipo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[69, 114, 105, 98, 117, 108, 105, 110, 32, 109, 101, 115, 121, 108, 97, 116, 101, 32, 40, 102, 111, 114, 109, 101, 114, 108, 121, 32, 69, 45]...', original message: bytes can be at most 32766 in length; got 34268
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34268
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:50:36,301][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.4gb[11.8%], replicas will not be assigned to this node
[2016-06-14 11:51:06,321][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.3gb[11.7%], replicas will not be assigned to this node
[2016-06-14 11:51:10,518][DEBUG][action.bulk              ]  countries for composition of matter covering abatacept, with expires in 2012 (Form 10-K, BMS, 15 Feb 2013, Page 7, http:// www.sec.gov/Archives/edgar/data/14272/000119312513061678/ d450621d10k.htm).^It is covered by Repligen-owned patents, including US6685941 and a European patent (Ann Rep, Repligen, 2006).^Monoclonal antibodies, soluble fusion proteins and fragments and derivatives of these proteins which are reactive with B7 and CTLA4 are covered in EP682039.^Licensing^Agreements^________________^LFB Biotechnologies^Worldwide; GTC Biotherapeutics (LFB Biotechnologies (formerly Genzyme Transgenics)) previously had an agreement with BMS to develop a humanized version of abatacept in the milk of transgenic goats for the treatment of psoriasis, organ transplant rejection and autoimmune diseases (Direct communication, Genzyme Transgenics, 22 Mar 2000).^Novartis^Worldwide; it was previously under co-development with Novartis, which was developing it for transplant indications, while BMS focused on autoimmune indications; however, the agreement was terminated (Press release, BMS, 18 Oct 2000; Direct communication, Novartis, 15 Mar 2002).^Bristol-Myers Squibb; Ono^Japan; Bristol-Myers Squibb has an agreement with Ono. Under the terms of agreement, Bristol-Myers Squibb and Ono will co-develop and co-commercialize abatacept iv and sc formulation, for rheumatoid arthritis in Japan (Press release, BMS, 20 Sep 2011, http://www.bms.com/news/press_releases/pages/ default.aspx?RSSLink=http://www.businesswire.com/news/bms/ 20110920007303/enandt=634522425593383554; 1st-2nd qtr rep, Ono, 2 Nov 2011, Page 10, http://www.ono.co.jp/eng/investor/pdf/fr/2011/ fi1102.pdf)^Simcere Pharmaceuticals^China; Bristol-Myers Squibb has entered into a co-exclusive collaboration agreement with Simcere Pharmaceuticals for the development and commercialization of abatacept (sc) for the treatment of rheumatoid arthritis. Under the terms of the agreement, Simcere will perform and fund all development and regulatory activities required to obtain market approval, based on a pre-agreed development plan. The companies will share responsibility for commercializing and will share profits and losses related to Orencia SC in China (Press release, Simcere, 14 Jun 2013, http://ir.simcere.com/phoenix.zhtml?c=210451andp=irol- newsArticleandID=1829854andhighlight=; Scrip Intelligence, 21 Jun 2013, http://www.scripintelligence.com/business/Orencia-SC-deal- marks-shift-in-Simceres-BMS-alliance-344260).^Additional Clinical Information^Phase I^It was in Phase I trials for graft-vs-host disease (Scrip, 1996, 2118/9, 9 and 1997, 2271, 10).^"],"Document_CASIS-UPD_WE":["20140214"],"Document_PK":["Human (healthy volunteers; 10mg/kg iv single dose):Cl:0.16 to 0.3:ml/hr/kg","Human (healthy volunteers; 10mg/kg iv single dose):Cmax:175 to 427:microg/ml","Human (healthy volunteers; 10mg/kg iv single dose):Vd:0.06 to 0.13:l/kg","Human (juvenile idiopathic arthritis patients aged 6-17yr):Cl:0.2 to 1.12:ml/hr/kg","Human (RA patients; 10mg/kg iv multiple dose):Cl:0.13 to 0.47:ml/hr/kg","Human (RA patients; 10mg/kg iv multiple dose):Cmax:171 to 398:microg/ml","Human (RA patients; 10mg/kg iv multiple dose):t1/2:314.4:hr","Human (RA patients; 10mg/kg iv multiple dose):Vd:0.02 to 0.13:l/kg"],"Document_NC":["No"],"Document_TG":["941: CD80 molecule","942: CD86 molecule"],"Document_LCH":["20140205:AD207 : Ongoing Phase III development for juvenile idiopathic arthritis and lupus reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["CD-80-AN: CD80 antagonist: Receptor, Biochemical, CD80 antagonist: CD80 binding site antagonist: CD80 receptor antgonist: R-B-CD-80-AN|CD-86-AN: CD86 antagonist: Receptor, Biochemical, CD86 antagonist: B7-2 antagonist: R-B-CD-86-AN|LYM-T-AN: T cell inhibitor: Physiological, Biochemical, T cell inhibitor: General T cells inhibitor: T cells general inhibitor: P-B-LYM-T-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Bristol-Myers Squibb (US): Launched","Licensee: Ono (JP): Launched","Licensee: Simcere Pharmaceuticals (CN): Preclinical","Licensee: LFB Biotechnologies (FR): No Development Reported","Licensee: Novartis (CH): Discontinued"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"}],"DOCNO":"PH019065","CASIS_COMPOUND":[{"CN":"abatacept CCN=ABATACEPT","SRC_DB":"PHPROJ"},{"CN":"BMS-188667 CCN=BMS188667","SRC_DB":"PHPROJ"},{"CN":"CTLA4-Ig, BMS (IV) CCN=CTLA4IGBMS(IV)","SRC_DB":"PHPROJ"},{"CN":"ONO4164 (SC) CCN=ONO4164(SC)","SRC_DB":"PHPROJ"},{"CN":"ONO-4164 CCN=ONO4164","SRC_DB":"PHPROJ"},{"CN":"ONO-4164 (IV) CCN=ONO4164(IV)","SRC_DB":"PHPROJ"},{"CN":"ONO4164 (IV) CCN=ONO4164(IV)","SRC_DB":"PHPROJ"},{"CN":"BMS-188667 (IV) CCN=BMS188667(IV)","SRC_DB":"PHPROJ"},{"CN":"ONO4164 CCN=ONO4164","SRC_DB":"PHPROJ"},{"CN":"abatacept (SC) CCN=ABATACEPT(SC)","SRC_DB":"PHPROJ"},{"CN":"Orencia CCN=ORENCIA","SRC_DB":"PHPROJ"},{"CN":"Orencia (SC) CCN=ORENCIA(SC)","SRC_DB":"PHPROJ"},{"CN":"Orencia (IV) CCN=ORENCIA(IV)","SRC_DB":"PHPROJ"},{"CN":"ONO-4164 (SC) CCN=ONO4164(SC)","SRC_DB":"PHPROJ"},{"CN":"BMS-188667 (SC) CCN=BMS188667(SC)","SRC_DB":"PHPROJ"},{"CN":"CTLA4Ig, BMS CCN=CTLA4IGBMS","SRC_DB":"PHPROJ"},{"CN":"abatacept (IV) CCN=ABATACEPT(IV)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-17 11:55:51","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T2F","THE_USE":"Fusion protein","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"LYM-T-AN","THE_USE":"T cell inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"CD-86-AN","THE_USE":"CD86 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"CD-80-AN","THE_USE":"CD80 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"I5","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Transplant rejection, bone marrow","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"G4Z","THE_USE":"Urological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Nephritis, lupus","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 98, 97, 116, 97, 99, 101, 112, 116, 32, 40, 66, 77, 83, 45, 49, 56, 56, 54, 54, 55, 59, 32, 67, 84, 76, 65, 52, 73, 103]...', original message: bytes can be at most 32766 in length; got 35594
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35594
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:10,532][DEBUG][action.bulk              ] ve features of indeterminate colitis. The response rate to infliximab treatment was similar in both groups (Alimentary Pharmacol Ther, 2003, 18, 741).^In 73 patients with active CD, infliximab 10mg/kg q 8wk maintained median values for CDAI, inflammatory bowel disease questionnaire (a quality of life measurement), and serum CRP concentration at remission levels cf no maintenance with placebo (Gastroenterology, 1999, 117, 761).^In 30 patients with active CD undergoing ileocolonoscopy, infliximab 5, 10 or 20mg/kg iv single infusion 4wk previously resulted in a reduction in the Crohn's Disease Endoscopic Index of Severity without a dose response cf no change with placebo (Gastroenterology, 1999, 116, 1029).^In a double-blind, placebo-controlled trial in 8 patients, repeated infusions of infliximab produced a 70% reduction in the number of active joints and an 85% reduction of CRP. 1 and 10mg/ kg cA2 reduced serum E-selectin levels by 11 and 24%, respectively. Four patients were withdrawn due to adverse effects including urticaria, vasovagal attack, development of SLE- associated antibodies (after 2nd cycle) and chronic sinusitis (after 3rd cycle). Each cycle was given in response to disease relapse (Expert Opin Invest Drugs, 1996, 5, 821).^In trials in 108 patients with CD, infliximab 5-20mg iv x4wk caused significant improvement in disease activity in >65% of patients, cf 17% with placebo. In most patients, benefit was evident after 2wk and persisted for at least 12wk. No side- effects were observed (Scrip, 1996, 2133, 27).^In 73 RA patients, infliximab 1 or 10mg/kg or placebo produced a primary endpoint of a 20% Paulus response in 11/25, 19/24 and 2/ 24, respectively (Scrip, 1994, 1970, 26).^In 10 patients with RA refractory to conventional treatment, 20mg/ kg as 2 or 4 iv infusions over 2wk was well tolerated with no significant adverse effects. Mean serum CRP levels fell from 41 to 9mg/l and 8/9 patients achieved normalization of values. Mean ESR fell from 133 to 14min, pain score from 5.9 to 1.5, Ritchie ind^"],"Document_CASIS-UPD_WE":["20140214"],"Document_PK":["Human (1-20mg/kg iv):Vd:3 to 4.1:l","Human (3-10mg/kg iv):Cmax:77 to 277:microg/ml","Human (3-10mg/kg iv):t1/2beta:210:hr"],"Document_NC":["No"],"Document_TF":["7124: Cytokine/Growth factor > Cytokine > Tumour necrosis factor."],"Document_TG":["7124: tumour necrosis factor"],"Document_LCH":["20140204:AD207 : Ongoing Phase III development for behcet?s, Crohn?s disease, ulcerative colitis and psoriasis confirmed"],"Document_TB":["7124: Cytokine/Growth factor > Cytokine > Tumour necrosis factor;","7124: Cytokine > Tumour necrosis factor;","7124: Cytokine/Growth factor;","7124: Tumour necrosis factor;","7124: Cytokine/Growth factor > Cytokine."],"Document_CASIS-USE_CASIS-MA_PHCD":["TNF-A-AN: Tumour necrosis factor alpha antagonist: Physiological, Hormonal, Tumour necrosis factor alpha antagonist: TNF alpha antagonist: TNF a antagonist: P-H-TNF-A-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Johnson & Johnson (US): Launched","Licensee: Merck & Co (US): Launched","Licensee: Mitsubishi Tanabe Pharma (JP): Launched"],"Document_MR":["1:Market Rating - US$ 0-500 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 1998 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH017218","CASIS_COMPOUND":[{"CN":"SCH 215596 CCN=SCH215596","SRC_DB":"PHPROJ"},{"CN":"infliximab (intravitreal) CCN=INFLIXIMAB(INTRAVITREAL)","SRC_DB":"PHPROJ"},{"CN":"SCH-215596 CCN=SCH215596","SRC_DB":"PHPROJ"},{"CN":"infliximab CCN=INFLIXIMAB","SRC_DB":"PHPROJ"},{"CN":"TA-650 (iv) CCN=TA650(IV)","SRC_DB":"PHPROJ"},{"CN":"cA2 (iv) CCN=CA2(IV)","SRC_DB":"PHPROJ"},{"CN":"Remicade (iv) CCN=REMICADE(IV)","SRC_DB":"PHPROJ"},{"CN":"Avakine CCN=AVAKINE","SRC_DB":"PHPROJ"},{"CN":"infliximab (highly concentrated) CCN=INFLIXIMAB(HIGHLYCONCENTRATED)","SRC_DB":"PHPROJ"},{"CN":"CenTNF CCN=CENTNF","SRC_DB":"PHPROJ"},{"CN":"infliximab (iv) CCN=INFLIXIMAB(IV)","SRC_DB":"PHPROJ"},{"CN":"Remicade CCN=REMICADE","SRC_DB":"PHPROJ"},{"CN":"anti-TNF-alpha MAb, Centocor CCN=ANTITNFALPHAMABCENTOCOR","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-17 11:55:51","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M1A1","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1C1","THE_USE":"Cardiostimulant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Anal fistula","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Chronic obstructive pulmonary disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A4","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Infection, Kawasaki disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T2Z","THE_USE":"Recombinant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M5Z","THE_USE":"Musculoskeletal","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Behcet's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J8Z","THE_USE":"Anti-infective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"TNF-A-AN","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Pain, musculoskeletal, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R4A","THE_USE":"COPD treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Inflammation, vascular","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N2Z","THE_USE":"Analgesic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Heart failure","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D3A","THE_USE":"Vulnerary","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 110, 102, 108, 105, 120, 105, 109, 97, 98, 32, 105, 115, 32, 97, 32, 99, 104, 105, 109, 97, 101, 114, 105, 99, 32, 77, 65, 98, 32]...', original message: bytes can be at most 32766 in length; got 45834
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 45834
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:10,539][DEBUG][action.bulk              ] ________^Amylin; Eli Lilly^Worldwide; it was co-developed with Lilly, which shared US costs and 80% of development costs outside the US (Press releases, Lilly, 8 Nov 2002 and Amylin, 6 Aug 2003). The agreement was subsequently amended, and Lilly was responsible for 53% of shared development and commercialization costs that generate revenue in both the US and outside the US, and 100% of these costs that generate revenue predominantly outside the US (Form 8-K, Amylin, 4 May 2009). The companies entered into an agreement to terminate their alliance for exenatide and resolve the outstanding litigation between the companies. As part of the agreement, the parties will transition full responsibility for the worldwide development and commercialization of exenatide to Amylin, starting in the US on 30 Nov 2011, and progressing to all markets by the end of 2013. Under the terms of the new global agreement, Amylin will make a one-time, upfront payment to Lilly. Amylin will also agree to make future revenue sharing payments to Lilly on global net sales of exenatide products until Amylin has made aggregate payments to Lilly plus accrued interest. If exenatide extended-release for injectable suspension, has not received FDA approval prior to 30 Jun 2014, Amylin's revenue sharing obligations will terminate, and Amylin shall thereafter pay Lilly for global net sales of exenatide products. Amylin will also pay a milestone to Lilly contingent upon FDA approval of a once monthly suspension version of exenatide that is currently in Phase II (Press release, Amylin, 8 Nov 2011, http://phx.corporate- ir.net/phoenix.zhtml?c=101911andp=irol-newsArticleandID=1627459).^AstraZeneca; Bristol-Myers Squibb^Worldwide; Bristol-Myers Squibb has expanded the diabetes alliance with AstraZeneca, for the developement and commercialisation of Amylin's portfolio of products including Byetta and Bydureon, following Bristol-Myers Squibb's acquisition of Amylin; however, AstraZeneca has acquired the intellectual property and global rights for the development, manufacture and commercialization of Byetta (Press release, AstraZeneca and BMS, 30 Jun 2012, http://www.astrazeneca.com/Media/Press-releases/ Article/20120630-Bristol-Myers-Squibb-AstraZeneca-expand-diabetes- alliance; Scrip Intelligence, 16 Apr 2013, http:// www.scripintelligence.com/home/Diabetes-HCV-new-growth-pillars- for-BMS-in-Japan-342158; Press release, AstraZeneca, 3 Feb 2014, http://www.astrazeneca.com/Media/Press-releases/Article/20140203- astrazeneca-acquires-bms-share-of-diabetes-alliance).^Availability^________________^Worldwide except USA; Amylin is seeking for partners outside the US (Press release, Amylin, 9 Jan 2012, http:// investors.amylin.com/phoenix.zhtml?c=101911andp=irol- newsArticleandID=1646276andhighlight=).^"],"Document_CASIS-UPD_WE":["20140214"],"Document_PK":["Human (10microgram sc):AUC:1036:pghr/ml","Human (10microgram sc):Cl:9.1:l/hr","Human (10microgram sc):Cmax:211:pg/ml","Human (10microgram sc):t1/2:2.4:hr","Human (10microgram sc):Vd:28.3:l","Human (Japanese Type II diabetics):t1/2:1.6:hr","Human (Japanese Type II diabetics):Tmax:1.5:hr"],"Document_NC":["No"],"Document_TF":["2740: Receptor > GPCR > Glucagon family."],"Document_TG":["2740: glucagon-like peptide 1 receptor"],"Document_LCH":["20140204:PP236 : Aquisition of Byetta by AstraZeneca reported"],"Document_TB":["2740: Receptor > GPCR > Glucagon family;","2740: GPCR > Glucagon family;","2740: Receptor;","2740: Glucagon family;","2740: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["GLP-1-AG: Glucagon-like peptide 1 agonist: Receptor, Hormonal, Glucagonlike peptide 1 agonist: GLP-1 agonist: R-H-GLP-1-AG|INS-SE-AG: Insulin secretagogue: Physiological, Hormonal, Insulin secretagogue: P-H-INS-SE-AG|INCRE-AG: Incretin mimetic: Physiological, Biochemical, Incretin mimetic: P-B-INCRE-AG|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Amylin (US): Discontinued","Licensee: AstraZeneca (GB): Launched","Licensee: Eli Lilly (US): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing"}],"DOCNO":"PH025105","CASIS_COMPOUND":[{"CN":"AC-2993, Medisorb (IV) CCN=AC2993MEDISORB(IV)","SRC_DB":"PHPROJ"},{"CN":"exenatide CCN=EXENATIDE","SRC_DB":"PHPROJ"},{"CN":"exendin 4 CCN=EXENDIN4","SRC_DB":"PHPROJ"},{"CN":"Medisorb Exendin CCN=MEDISORBEXENDIN","SRC_DB":"PHPROJ"},{"CN":"AC 2993 (IV) CCN=AC2993(IV)","SRC_DB":"PHPROJ"},{"CN":"AC-2993, Medisorb (SC) CCN=AC2993MEDISORB(SC)","SRC_DB":"PHPROJ"},{"CN":"AC-2993 (IV) CCN=AC2993(IV)","SRC_DB":"PHPROJ"},{"CN":"Medisorb Exendin (SC) CCN=MEDISORBEXENDIN(SC)","SRC_DB":"PHPROJ"},{"CN":"Byetta CCN=BYETTA","SRC_DB":"PHPROJ"},{"CN":"AC2993 CCN=AC2993","SRC_DB":"PHPROJ"},{"CN":"AC2993 (SC) CCN=AC2993(SC)","SRC_DB":"PHPROJ"},{"CN":"LY-2148568 CCN=LY2148568","SRC_DB":"PHPROJ"},{"CN":"exendin-4, Amylin (SC) CCN=EXENDIN4AMYLIN(SC)","SRC_DB":"PHPROJ"},{"CN":"exendin 4 (SC) CCN=EXENDIN4(SC)","SRC_DB":"PHPROJ"},{"CN":"AC-2993 CCN=AC2993","SRC_DB":"PHPROJ"},{"CN":"LY2148568 CCN=LY2148568","SRC_DB":"PHPROJ"},{"CN":"exendin-4, Amylin CCN=EXENDIN4AMYLIN","SRC_DB":"PHPROJ"},{"CN":"LY2148568 (IV) CCN=LY2148568(IV)","SRC_DB":"PHPROJ"},{"CN":"LY2148568 (SC) CCN=LY2148568(SC)","SRC_DB":"PHPROJ"},{"CN":"exenatide (SC) CCN=EXENATIDE(SC)","SRC_DB":"PHPROJ"},{"CN":"exendin-4, Amylin (IV) CCN=EXENDIN4AMYLIN(IV)","SRC_DB":"PHPROJ"},{"CN":"Byetta (SC) CCN=BYETTA(SC)","SRC_DB":"PHPROJ"},{"CN":"exenatide (IV) CCN=EXENATIDE(IV)","SRC_DB":"PHPROJ"},{"CN":"LY-2148568 (IV) CCN=LY2148568(IV)","SRC_DB":"PHPROJ"},{"CN":"exendin 4 (IV) CCN=EXENDIN4(IV)","SRC_DB":"PHPROJ"},{"CN":"LY-2148568 (SC) CCN=LY2148568(SC)","SRC_DB":"PHPROJ"},{"CN":"AC-2993, Medisorb CCN=AC2993MEDISORB","SRC_DB":"PHPROJ"},{"CN":"Byetta (IV) CCN=BYETTA(IV)","SRC_DB":"PHPROJ"},{"CN":"AC-2993 (SC) CCN=AC2993(SC)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-17 11:55:52","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"INCRE-AG","THE_USE":"Incretin mimetic","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"INS-SE-AG","THE_USE":"Insulin secretagogue","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"GLP-1-AG","THE_USE":"Glucagon-like peptide 1 agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A8A3","THE_USE":"Anorectic-Antiobesity","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Obesity","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[69, 120, 101, 110, 97, 116, 105, 100, 101, 32, 40, 65, 67, 45, 50, 57, 57, 51, 41, 32, 105, 115, 32, 97, 32, 115, 121, 110, 116, 104]...', original message: bytes can be at most 32766 in length; got 37126
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37126
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:10,581][DEBUG][action.bulk              ] leases, Oncolytics, 4 Feb 2009 and 9 Mar 2010).^Qualifying Therapeutic Discovery Project^USA; Oncolytics Biotech received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) for the development of Reolysin (IRS.gov Web Page, 9 Feb 2011, http:// www.irs.gov/businesses/small/article/0,,id=229024,00.html).^Availability^________________^Worldwide (2nd Ann BioPartner N America (Vancouver), 2004; Press release, Oncolytics, 20 May 2008).^Additional Clinical Information^Phase II^A US open-label, dose-escalation follow-on Phase I/II trial (REO 007) in recurrent malignant glioma patients refractory to standard therapy, to assess Reolysin intratumourally on safety, MTD and DLT (primary endpoints) is complete. Secondary endpoints include immune response, viral replication and antitumour activity (Press release, Oncolytics, 11 Jul 2006; Company Web Page, Oncolytics, 17 Feb 2009; Form 20-F, Oncolytics, 24 Mar 2011, Page 23, http://www.sec.gov/Archives/edgar/data/1129928/ 000091228211000145/oncolytics_20f-12312010.htm). Enrollment is complete in the Phase I portion in 15 patients. Results showed safety, tolerability and the MTD was not established (Press release, Oncolytics, 23 Apr 2010).^Preliminary results from a Canadian Phase II trial (REO 002) in 45 patients with T2 prostate cancer receiving single intratumoural doses of Reolysin showed viral activity in 5/6 patients and apoptotic tumour cell death in 4/6 patients. In 1 patient, PSA levels were reduced by 53% and the prostate gland shrank by 67% prior to surgical removal. No viral activity was seen in healthy prostatic tissue (Press release, Oncolytics, 31 Mar 2003; Company Web Page, Oncolytics, 17 Feb 2009). Further analysis indicated B- and T-cell infiltration in virus-infected tumour and not in adjacent normal tissue (Press release, Oncolytics, 27 Feb 2004).^Phase I^In a Canadian Phase I trial (REO 001) in 18 patients with progressive cancers who failed to respond to conventional therapies, escalating doses of Reolysin sc met the primary endpoint of safety and reached the MTD. It resulted in 32-100% tumour regression and viral activity in 11/18 patients. No serious adverse events were observed (Company Web Page, Oncolytics, 17 Feb 2009).^In a Phase I trial in metastatic nasopharyngeal cancer patients, Reolysin + gemcitabine resulted in improvements in diffuse facial swelling after 8 cycles (Company presentation, Oncolytics, 7 Jan 2009).^In a US dose-escalation Phase I trial (REO 004) in 18 patients with advanced or metastatic cancer, Reolysin iv infusion x1hr q 4wk resulted in SD in 8 patients and PR in 1 breast cancer patient (Press release, Oncolytics, 5 Jun 2007; Company presentation, Oncolytics, 7 Jan 2009; Company Web Page, Oncolytics, 17 Feb 2009).^In an open-label, dose-escalation UK Phase Ia combination trial in 30 advanced cancer patients, Reolysin intratumourally + 2 radiation doses resulted in some PRs. Reolysin was well tolerated and an MTD was not reached (Press releases, Oncolytics, 26 Jul 2005 and 18 Jul 2006).^In a open-label, dose-escalation UK Phase I trial (REO 005) in 33 patients with advanced refractory cancers, Reolysin iv x1hr q 4wk was well tolerated with minimal toxicity. The MTD was not reached. Antitumour activity was observed in a variety of cancer types. 30% had SD, including 2 colorectal cancer patients at 3 and 6mth, 1 endometrial cancer patient at 5mth, 1 metastatic prostate cancer patient, 1 bladder cancer patient, 1 pancreatic cancer patient and 1 nsclc patient at 4mth (Press release, Oncolytics, 26 May 2004; 18th EORTC-NCI-AACR Symp Molec Targ Cancer Ther (Prague), 2006, Abs 348; Company presentation, Oncolytics, 17 Feb 2009).^"],"Document_CASIS-UPD_WE":["20140214"],"Document_NC":["No"],"Document_TG":["99999998: Not applicable"],"Document_LCH":["20140210:AD151 : Ongoing Phase I trial (REO 022) for colorectal cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["NA: Not applicable: Not applicable: NA|"],"Document_ROUT":["P-IP: Parenteral, intraperitoneal","P-IV: Parenteral, intravenous","P-TU: Parenteral, intratumoural","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Oncolytics Biotech (CA): Phase III Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"}],"DOCNO":"PH029356","CASIS_COMPOUND":[{"CN":"Reosyn (IV) CCN=REOSYN(IV)","SRC_DB":"PHPROJ"},{"CN":"Reovirus T3D CCN=REOVIRUST3D","SRC_DB":"PHPROJ"},{"CN":"pelareorep (IP) CCN=PELAREOREP(IP)","SRC_DB":"PHPROJ"},{"CN":"Reolysin CCN=REOLYSIN","SRC_DB":"PHPROJ"},{"CN":"RT3D CCN=RT3D","SRC_DB":"PHPROJ"},{"CN":"Reosyn (intratumoral) CCN=REOSYN(INTRATUMORAL)","SRC_DB":"PHPROJ"},{"CN":"pelareorep (IV) CCN=PELAREOREP(IV)","SRC_DB":"PHPROJ"},{"CN":"pelareorep (intratumoral) CCN=PELAREOREP(INTRATUMORAL)","SRC_DB":"PHPROJ"},{"CN":"Reolysin (intratumoral) CCN=REOLYSIN(INTRATUMORAL)","SRC_DB":"PHPROJ"},{"CN":"Reosyn CCN=REOSYN","SRC_DB":"PHPROJ"},{"CN":"pelareorep CCN=PELAREOREP","SRC_DB":"PHPROJ"},{"CN":"Reovirus T3D (intratumoral) CCN=REOVIRUST3D(INTRATUMORAL)","SRC_DB":"PHPROJ"},{"CN":"Reolysin (IP) CCN=REOLYSIN(IP)","SRC_DB":"PHPROJ"},{"CN":"Reolysin (IV) CCN=REOLYSIN(IV)","SRC_DB":"PHPROJ"},{"CN":"Reovirus T3D (IV) CCN=REOVIRUST3D(IV)","SRC_DB":"PHPROJ"},{"CN":"Reosyn (IP) CCN=REOSYN(IP)","SRC_DB":"PHPROJ"},{"CN":"Reovirus T3D (IP) CCN=REOVIRUST3D(IP)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-17 11:55:52","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, Ewing's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T2D","THE_USE":"Lytic virus","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, nasopharyngeal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"NA","THE_USE":"Not applicable","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, osteo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, leiomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, synovial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[79, 110, 99, 111, 108, 121, 116, 105, 99, 115, 32, 66, 105, 111, 116, 101, 99, 104, 32, 97, 110, 100, 32, 116, 104, 101, 32, 65, 108, 98]...', original message: bytes can be at most 32766 in length; got 33994
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 33994
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:11,499][DEBUG][action.bulk              ] aily produced no dose- dependent increases from baseline in QTcP interval (69th Meet Am Diabetes Assoc (New Orleans), 2009, Abs 2072-PO).^Phase I drug interaction studies with metformin, ketoconazole, moxifloxacin and glyburide were completed. A Phase I trial to compare the relative bioavailability of tablet and capsule formulations was completed (FDA Web Page, 24 Apr 2009).^In Phase I trials in healthy volunteers, the pharmacokinetics and safety profile of saxagliptin were similar in elderly and young volunteers and in male and female volunteers and in volunteers with hepatic impairment. No dose adjustment was required (68th Meet Am Diabetes Assoc (San Francisco), 2008, Abs 551-P and Abs 537-P).^Diabetes, Type 2^Bristol-Myers Squibb^In Phase I trials in 40 Type 2 diabetes patients and 50 healthy volunteers, there were no deaths or serious adverse events (Press release, BMS, 25 Jun 2007).^Preclinical ^In vivo^In monkeys, dogs and rats, the bioavailability was 50-75%, Vd was 1.3-5.2l/kg and t1/2beta was 2.1-4.4hr. Cl was 14.5ml/min/kg in monkeys, 9.3ml/min/kg in dogs and 115ml/min/kg in rats (Drug Metab Dispos, 2009, Jun, 37:1164-71, PMID:19251818).^In Zucker fa/fa rats, saxagliptin 3micromol/kg po decreased glucose levels, with a dose-dependent response in a glucose tolerance test (GTT). In ob/ob mice, saxagliptin 1, 3 and 10micromol/kg po resulted in a dose-dependent decrease in glucose following a GTT (228th ACS (Philadelphia), 2004, MEDI 207).^In normal rats, saxagliptin inhibited DPP-IV and in dogs, the 4hr post-dose ED50 was 0.0125micromol/kg. Saxagliptin and BMS-465980, an early lead, had Kis of 0.45 and 13nM, respectively, with t1/2 and bioavailability of >1hr and >60% in rats, respectively (228th ACS (Philadelphia), 2004, MEDI 207).^In a rat model of insulin resistance, it produced dose-dependent decreases in blood glucose levels (Lehman Bros Rep, 12 Mar 2002).^Licensing^Agreements^________________^AstraZeneca; Bristol-Myers Squibb^Worldwide; it is licensed to AstraZeneca for co-development and co-commercialization worldwide except in Japan; however, AstraZeneca has acquired the intellectual property and global rights for the development, manufacture and commercialization of saxagliptin (Press release, BMS, 11 Jan 2007; Press release, AstraZeneca, 3 Feb 2014, http://www.astrazeneca.com/Media/Press- releases/Article/20140203-astrazeneca-acquires-bms-share-of- diabetes-alliance).^Bristol-Myers Squibb; Otsuka^Japan; it is exclusively licensed to Otsuka for development and commercialization in Japan, with BMS retaining co-promotion rights (Press release, BMS and Otsuka, 27 Dec 2006).^Kyowa Hakko Kirin; Otsuka^Japan; Kyowa Hakko Kirin has an exclusive license agreement with Otsuka. Under the agreement, Kyowa Hakko Kirin will receive exclusive development and marketing rights, whereas Otsuka will receive running royalties after the launch of saxagliptin in proportion to its revenue (Press release, Otsuka, 29 Jun 2012, http://www.otsuka.com/en/hd_release/release/pdf.php?news=572).^Additional Clinical Information^Post-Marketing^It is in a randomized, controlled post-marketing trial, to further characterize the long-term clinical effectiveness and cardiovascular profile of saxagliptin (Press release, AstraZeneca, 2 Apr 2009).^"],"Document_HA":["4"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Dog:Cl:9.3:ml/min/kg","Monkey:Cl:14.5:ml/min/kg","Rat:Cl:115:ml/min/kg"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["1803: Enzyme > EC number > 3.4.14.5;","1803: Enzyme > Protease/peptidase."],"Document_TG":["1803: dipeptidyl-peptidase 4"],"Document_LCH":["20140324:PP183 : Completion of Phase III trial CV181-169 reported"],"Document_TB":["1803: Enzyme > EC number > 3.4.14.5;","1803: EC number > 3.4.14.5;","1803: Enzyme;","1803: 3.4.14.5;","1803: Enzyme > EC number.","1803: Enzyme > Protease/peptidase;","1803: Protease/peptidase;","1803: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PEPT-D4-AN: Dipeptidyl peptidase 4 (DPP IV) inhibitor: Enzyme, Hydrolase, Dipeptidyl peptidase 4 (DPP IV) inhibitor: Dipeptidyl peptidase 4 inhibitor: CD26 inhibitor: DPP IV inhibitor: DPP 4 inhibitor: E-HY-PEPT-D4-AN|INS-SE-AG: Insulin secretagogue: Physiological, Hormonal, Insulin secretagogue: P-H-INS-SE-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["315.42"],"Document_AL":["0.29"],"Document_CASIS-CO_CO":["Originator: Bristol-Myers Squibb (US): Discontinued","Licensee: AstraZeneca (GB): Launched","Licensee: Otsuka (JP): Registered","Licensee: Kyowa Hakko Kirin (JP): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD318831    ","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"}],"DOCNO":"PH033208","CASIS_COMPOUND":[{"CN":"Onglyza CCN=ONGLYZA","SRC_DB":"PHPROJ"},{"CN":"BMS-477118-11 (capsule) CCN=BMS47711811(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"saxagliptin (tablet) CCN=SAXAGLIPTIN(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-465980 CCN=BMS465980","SRC_DB":"PHPROJ"},{"CN":"BMS-47711811 (capsule) CCN=BMS47711811(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Onglyza (solution) CCN=ONGLYZA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BMS-477118 (capsule) CCN=BMS477118(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BMS-477118 (tablet) CCN=BMS477118(TABLET)","SRC_DB":"PHPROJ"},{"CN":"saxagliptin CCN=SAXAGLIPTIN","SRC_DB":"PHPROJ"},{"CN":"OPC-262 (tablet) CCN=OPC262(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-465980 (solution) CCN=BMS465980(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BMS-477118-11 (tablet) CCN=BMS47711811(TABLET)","SRC_DB":"PHPROJ"},{"CN":"OPC-262 CCN=OPC262","SRC_DB":"PHPROJ"},{"CN":"BMS-47711811 (tablet) CCN=BMS47711811(TABLET)","SRC_DB":"PHPROJ"},{"CN":"saxagliptin (capsule) CCN=SAXAGLIPTIN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BMS-477118-11 (solution) CCN=BMS47711811(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"saxagliptin (solution) CCN=SAXAGLIPTIN(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BMS-477118-11 CCN=BMS47711811","SRC_DB":"PHPROJ"},{"CN":"Onglyza (tablet) CCN=ONGLYZA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"OPC-262 (capsule) CCN=OPC262(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BMS-477118 CCN=BMS477118","SRC_DB":"PHPROJ"},{"CN":"BMS-477118 (solution) CCN=BMS477118(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"DPP IV inhibitor, BMS CCN=DPPIVINHIBITORBMS","SRC_DB":"PHPROJ"},{"CN":"Onglyza (capsule) CCN=ONGLYZA(CAPSULE)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"INS-SE-AG","THE_USE":"Insulin secretagogue","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PEPT-D4-AN","THE_USE":"Dipeptidyl peptidase 4 (DPP IV) inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[83, 97, 120, 97, 103, 108, 105, 112, 116, 105, 110, 32, 40, 66, 77, 83, 45, 52, 55, 55, 49, 49, 56, 41, 32, 105, 115, 32, 97, 110]...', original message: bytes can be at most 32766 in length; got 36057
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36057
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:11,632][DEBUG][action.bulk              ] cohort (42nd ASCO (Atlanta), 2006, Abs 3006).^Cancer, head and neck^In a Phase I trial in 12 patients with head and neck cancer, C225 (loading dose of 100-500mg/m2 followed by weekly infusions of 100- 250mg/m2) + radiotherapy produced 1CR and 3PRs. Grade III/IV mucositis occurred in 2 patients, and reversible grade IV anaphylaxis in 1 patient (34th ASCO (Los Angeles), 1998, Abs 1522).^A Phase I study in combination with 5-FU/CP + CET in patients with locally advanced squamous cell anal carcinoma (LAAC) was completed. Seven out of 9 evaluable patients achieved pCR. A DLT of grade 4 neutropenic fever was observed (44th ASCO (Chicago), 2008, Abs 4609).^In a Phase I dose-escalation study in recurrent SCCHN, cetuximab 100-500mg/m2 + cisplatin 100mg/m2 q 3wk produced 1 mixed response, 3PRs and 1CR (35th ASCO (Atlanta), 1999, Abs 1502).^Cancer, lung, non-small cell^It is in a pilot Phase I study (SCRATCH) to assess the safety of cetuximab + sequential and synchronous chemoradiation in 12 patients with stage III nsclc. One patient died mid-treatment from bronchopneumonia, 1 experienced grade 3 lethargy following the 1st dose of cetuximab, and 1 experienced a grade 2 skin reaction following the 3rd dose. In a follow-up analysis, 1 patient experienced manageable grade 3 pneumonitis, and 3 died (2 from disease progression and 1 from thromboembolic disease). Eight patients survived at least 1yr (J Thorac Oncol, 2008, 3, 648).^Preclinical ^Patents^A US patent covering Erbitux in combination with an anti- neoplastic agent expires in 2018 (Form 10-K, BMS, 15 Feb 2013, Page 6, http://www.sec.gov/Archives/edgar/data/14272/ 000119312513061678/d450621d10k.htm).^It is covered by US5770195 (Press release, ImClone, 26 Jan 2005).^Licensing^Agreements^________________^Bristol-Myers Squibb^Canada and USA; it is exclusively licensed to Bristol-Myers Squibb (BMS) for development and co-promotion in Canada and the US (Direct communication, BMS, 19 Sep 2001; Form 10-Q. Lilly, 29 Jul 2011, Page 9, http://sec.gov/Archives/edgar/data/59478/ 000119312511202740/d10q.htm). BMS and ImClone expanded their agreement in order to conduct further trials in tumour types such as brain, breast and prostate cancers (Press release, BMS, 27 Jul 2007).^Bristol-Myers Squibb; ImClone (Eli Lilly); Merck KGaA^Japan; ImClone, BMS and Merck KGaA have co-exclusive rights in Japan (Press release, ImClone, 17 Oct 2007).^Centocor (Johnson and Johnson); Genentech (Roche)^Worldwide; ImClone has agreements with Genentech (Roche) and Centocor (Johnson and Johnson) for the rights to patents covering aspects of the antibody technology and use of EGFR antibodies (Press release, ImClone, 26 Jan 2005).^Merck KGaA^Worldwide except North America; it is licensed exclusively to Merck KGaA for development and marketing outside N America (Press release, Merck KGaA, Dec 1998).^"],"Document_CASIS-UPD_WE":["20140214"],"Document_PK":["Human (400mg/m2 2hr infusion):t1/2:97:hr","Human (400mg/m2 2hr infusion):Cmax:92.32:microg/ml","Mouse (0.04-1.0mg ip):Cmax:16.5 to 407.6:mg/ml","Mouse (0.04-1.0mg ip):AUC:0.53 to 19.21:mghr/ml","Mouse (0.4-1.0mg iv):Vd:0.06 to 0.07:l/kg"],"Document_NC":["No"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor"],"Document_LCH":["20140206:AD151 : Enrollment completion of Phase II trial (EMR 062202-529) for colorectal cancer reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR1-AN: Epidermal growth factor receptor 1 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 1 antagonist: EGFR1 antagonist: HER1 antagonist: ErbB-1 antagonist: R-H-GF-EPR1-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Eli Lilly (US): Launched","Licensee: Merck KGaA (DE): Launched","Licensee: Bristol-Myers Squibb (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["3:Speed Rating - Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"}],"DOCNO":"PH020171","CASIS_COMPOUND":[{"CN":"Erbitux CCN=ERBITUX","SRC_DB":"PHPROJ"},{"CN":"C225 CCN=C225","SRC_DB":"PHPROJ"},{"CN":"anti-EGFR MAbs, ImClone CCN=ANTIEGFRMABSIMCLONE","SRC_DB":"PHPROJ"},{"CN":"LY-2939777  CCN=LY2939777","SRC_DB":"PHPROJ"},{"CN":"MAb C225 CCN=MABC225","SRC_DB":"PHPROJ"},{"CN":"cetuximab CCN=CETUXIMAB","SRC_DB":"PHPROJ"},{"CN":"BMS-564717 CCN=BMS564717","SRC_DB":"PHPROJ"},{"CN":"LY2939777 CCN=LY2939777","SRC_DB":"PHPROJ"},{"CN":"EMR-62202 CCN=EMR62202","SRC_DB":"PHPROJ"},{"CN":"IMC-C225 CCN=IMCC225","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-17 11:55:51","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, biliary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A4","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EPR1-AN","THE_USE":"Epidermal growth factor receptor 1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, thymoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[67, 101, 116, 117, 120, 105, 109, 97, 98, 32, 40, 67, 50, 50, 53, 41, 32, 105, 115, 32, 97, 32, 99, 104, 105, 109, 97, 101, 114, 105]...', original message: bytes can be at most 32766 in length; got 57562
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 57562
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:29,541][DEBUG][action.bulk              ] release, YM BioSciences, 18 Nov 2004; Company Web Page, YM BioSciences, 10 Sep 2007).^In an open-label Phase I/II trial in 29 adult patients with high- grade glioma, including GBM (15 patients) and anaplastic astrocytoma (9 patients), who underwent debulking surgery or biopsy prior to the trial, nimotuzumab 200mg as 1x/wk x6 infusions + external beam radiation gave 4CRs, 5PRs and 12SDs. In patients with high-grade glioma astrocytic tumours, mean and median survival was 23.7 and 18.1mth, respectively, with a survival rate at 18mth of 53%. There was no evidence of grade 3/4 AEs. One patient had grade 2 dysphasia and sensory alteration (Press release, YM BioSciences, 19 May 2005; 41st ASCO (Orlando), 2005).^A Phase I/II trial in the EU in 18 paediatric patients with astrocytomas or glioblastomas who failed 1st-line therapy and received nimotuzumab iv 1x/wk x6wk was terminated prematurely because of trial success. Of 19 evaluable patients, 6 responded to treatment with 5SDs and 1PR. There was no skin toxicity and no haematological or non-haematological side-effects (Press releases, YM BioSciences, 15 Jun 2004 and 25 Jan 2005).^A US IND was approved for 1 child with advanced glioma. Paediatric expansion of the trial was planned (Press release, YM BioSciences, 16 Mar 2005)^Phase I^A Phase I passive immunotherapy trial in Cuba for epithelial- derived tumours was carried out (Direct communication, CIM, 18 Feb 2000).^In a Cuban Phase I diagnostic trial in 148 patients with suspected cancer of epithelial origin, immunoscintigraphy with murine R3 identified 106/126 cases (confirmed by biopsy), and correctly identified all 22 patients who did not have epithelial cancers. It was in Phase I trials in Canada (12 patients) and Cuba (29 patients) for imaging epithelial-derived tumours (Press release, CIM and York Medical, 9 Jul 1999; Direct communication, CIM, 6 Mar 2001).^A trial with a rhenium-188-labelled version for radioimmunotherapy in glioma was planned (Company brochure, York Medical, Oct 2000; Direct communication, CIM, 6 Mar 2001).^A Phase I pharmacodynamic study in 12-24 patients was completed (BIO 2005 (Philadelphia); Company Web Page, YM BioSciences, 10 Sep 2007).^"],"Document_CASIS-UPD_WE":["20140228"],"Document_PK":["Human (200mg single dose):Cl:23:ml/hr","Human (200mg single dose):Cmax:141:microg/ml","Human (200mg single dose):t1/2:45:hr","Human (200mg single dose):Vd:1.46:l"],"Document_NC":["No"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor"],"Document_LCH":["20140218:AD50 : Ongoing Phase III development for gastric & nsclc and Phase I for oesophageal cancer reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR1-AN: Epidermal growth factor receptor 1 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 1 antagonist: EGFR1 antagonist: HER1 antagonist: ErbB-1 antagonist: R-H-GF-EPR1-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Center of Molecular Immunology (CU): Launched","Licensee: Biocon (IN): Launched","Licensee: Innogene Kalbiotech (SG): Launched","Licensee: Eurofarma (BR): Launched","Licensee: Oncoscience (DE): Pre-registration","Licensee: Kuhnil Pharmaceutical (KR): Phase III Clinical Trial","Licensee: Daiichi Sankyo (JP): Phase III Clinical Trial","Licensee: YM BioSciences (CA): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH028992","CASIS_COMPOUND":[{"CN":"hR3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"L-R3 CCN=LR3","SRC_DB":"PHPROJ"},{"CN":"YMB-1001 CCN=YMB1001","SRC_DB":"PHPROJ"},{"CN":"anti-EGFr MAb, CIM CCN=ANTIEGFRMABCIM","SRC_DB":"PHPROJ"},{"CN":"TheraCIM hR3  CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"R3 CCN=R3","SRC_DB":"PHPROJ"},{"CN":"Theraloc CCN=THERALOC","SRC_DB":"PHPROJ"},{"CN":"DiaCIM-h-R3 CCN=DIACIMHR3","SRC_DB":"PHPROJ"},{"CN":"RadioTheraCIM CCN=RADIOTHERACIM","SRC_DB":"PHPROJ"},{"CN":"DE-766 CCN=DE766","SRC_DB":"PHPROJ"},{"CN":"h-R3 CCN=HR3","SRC_DB":"PHPROJ"},{"CN":"huR3 CCN=HUR3","SRC_DB":"PHPROJ"},{"CN":"nimotuzumab CCN=NIMOTUZUMAB","SRC_DB":"PHPROJ"},{"CN":"BIOMAb-EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"OSAG-101 CCN=OSAG101","SRC_DB":"PHPROJ"},{"CN":"BIOMAb EGFR CCN=BIOMABEGFR","SRC_DB":"PHPROJ"},{"CN":"CIMAher CCN=CIMAHER","SRC_DB":"PHPROJ"},{"CN":"Vecthix CCN=VECTHIX","SRC_DB":"PHPROJ"},{"CN":"BIOMAb CCN=BIOMAB","SRC_DB":"PHPROJ"},{"CN":"DiaCIM CCN=DIACIM","SRC_DB":"PHPROJ"},{"CN":"TheraCIM-h-R3 CCN=THERACIMHR3","SRC_DB":"PHPROJ"},{"CN":"TheraCIM CCN=THERACIM","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-03 11:21:13","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"GF-EPR1-AN","THE_USE":"Epidermal growth factor receptor 1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diagnosis, cancer","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, nasopharyngeal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"V4A","THE_USE":"Imaging agent","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K5A","THE_USE":"Radio-chemosensitizer","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 105, 109, 111, 116, 117, 122, 117, 109, 97, 98, 32, 40, 82, 51, 41, 32, 105, 115, 32, 97, 110, 32, 73, 103, 71, 49, 32, 104, 117]...', original message: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40721
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:51:36,340][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.2gb[11.7%], replicas will not be assigned to this node
[2016-06-14 11:51:48,156][DEBUG][action.bulk              ] 2 (25th Eur Soc Med Oncol Cong (Hamburg), 2000, Abs 51P).^Cancer, brain^It is in a randomized, open-label Phase I trial in 24 patients with brain metastases from solid tumours receiving concurrent whole brain radiation therapy (ClinicalTrials.gov Web Page, 15 Apr 2009 and 2 Oct 2012, http://clinicaltrials.gov/ct2/show/ NCT00879073).^Cancer, biliary^In a German Phase I trial in 6 patients with unresectable hilar bile duct cancer, bendamustine 140mg/m2 30min iv infusion on day 1 of the 1st course, and 100mg/m2 on days 1 and 2 of the cycle in following courses (maximum 4 courses) resulted in no CRs or PRs. It was well tolerated (Digestive Dis Wk (Orlando), 2003, Abs T- 1790).^Cancer, lymphoma, non-Hodgkin's^An open-label, non-randomized, single group assignment Phase I trial in Japan in 12 patients with aggressive B-cell non- Hodgkin's lymphoma, to assess the safety of bendamustine + rituximab and to explore the recommended dose for the Phase II trial was completed (ClinicalTrials.gov, 25 Nov 2008 and 27 May 2010, http://www.clinicaltrials.gov/show/NCT00794638).^An IND has been filed in China for low-grade NHL (Company pipeline, SymBio, 8 Aug 2011, http://www.symbiopharma.com/en/html/ pipeline_01.html).^In an open-label Phase I trial in Japan in 9 patients with rituximab-refractory indolent B-cell NHL, bendamustine 90 and 120mg/m2/day 60min iv infusion x2 days showed safety and efficacy (Scrip Daily Online, 29 Sep 2006, S00935448; Company Web Page, SymBio, 4 Aug 2008).^Preclinical ^Development of an oral formulation for solid tumours in Japan is planned (Company Web Page, SymBio, 4 Aug 2008).^In vivo^It enhanced the tumour growth inhibition of rituximab in Daudi lymphoma xenografts in SCID mice (46th Meet Am Soc Hematol (San Diego), 2004, Abs 4580).^In vitro^Bendamustine induced >90% ATP depletion following 12hr exposure, cf other nitrogen mustards which required at least 48-72hr. Sustained ATP depletion, measured 48hr after initial exposure to bendamustine, was observed in cells following 30min incubation, cf other nitrogen mustards which had no effect on ATP levels under similar conditions at equitoxic concentrations (96th AACR (Anaheim), 2005, Abs 3336).^Patents^It has US patent exclusivity for non-Hodgkin lymphoma is extended through Apr 2016 (Press release, Teva, 27 Nov 2013, http:// www.tevapharm.com/Media/News/Pages/2013/1880493.aspx).^It has patent exclusivity for chronic lymphocytic leukaemia until 20 Sep 2015 (Press release, Teva, 27 Nov 2013, http:// www.tevapharm.com/Media/News/Pages/2013/1880493.aspx).^Licensing^Agreements^________________^Teva^Canada; exclusive (BIO-Asia (Tokyo), 2004)^China; exclusive sublicense from SymBio (Scrip Daily Online, 9 Apr 2009, S01024916)^Hong Kong; exclusive sublicense from SymBio (Scrip Daily Online, 9 Apr 2009, S01024916)^USA; exclusive (BIO-Asia (Tokyo), 2004)^Eisai^Japan, Singapore and South Korea (Press releases, Eisai, 18 Aug 2008 and 18 May 2009).^Lundbeck^Canada; Lundbeck has the commercial rights in Canada. Lundbeck will register and commercialize on behalf of Cephalon (Press release, Lundbeck, 8 Feb 2011, http://www.lundbeck.com/investor/ releases/ReleaseDetails/Release_1486188_EN.asp).^Mundipharma^EU, Iceland and Norway; exclusive (Press release, Mundipharma, 26 Oct 2006).^SymBio Pharmaceuticals^China, Hong Kong, Japan (with Eisai), Singapore, South Korea and Taiwan; exclusive (Press release, SymBio, 22 Dec 2005; Scrip Daily Online, 7 Dec 2007, S00979694; Company Web Page, SymBio, 4 Aug 2008).^InnoPharmax^Taiwan; SymBio sub-licensed exclusive rights to InnoPharmax, Taiwan (Press release, SymBio, 26 Mar 2008, http:// www.symbiopharma.com/en/news/080326e.pdf).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140131"],"Document_PK":["Human:Cl:700:ml/min","Human:Vd:25:l"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140125:AD244 : Ongoing Phase II trial (2012003) for chronic lymphocytic leukaemia reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["DNA-AN: DNA inhibitor: Physiological, Biochemical, DNA inhibitor: Antineoplastic e.g. actinomycin, bleomycin, anthracyclines: Antineoplastic alkylating agent: Alkylating antineoplastic agent: DNA cross linking agent: P-B-DNA-AN|APOP-AG: Apoptosis stimulant: Physiological, Biochemical, Apoptosis stimulant: General apoptosis stimulant: P-B-APOP-AG|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["344.24"],"Document_AL":["3.90"],"Document_CASIS-CO_CO":["Originator: Astellas (JP): Launched","Licensee: Teva (IL): Launched","Licensee: Mundipharma (CH): Launched","Licensee: SymBio Pharmaceuticals (JP): Launched","Licensee: Eisai (JP): Launched","Licensee: InnoPharmax (TW): Launched","Licensee: Lundbeck (DK): Registered"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD051531    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH020598","CASIS_COMPOUND":[{"CN":"Innomustine CCN=INNOMUSTINE","SRC_DB":"PHPROJ"},{"CN":"Symbenda CCN=SYMBENDA","SRC_DB":"PHPROJ"},{"CN":"Ribomustin CCN=RIBOMUSTIN","SRC_DB":"PHPROJ"},{"CN":"bendamustine CCN=BENDAMUSTINE","SRC_DB":"PHPROJ"},{"CN":"bendamustine hydrochloride CCN=BENDAMUSTINEHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"SyB L-0501 CCN=SYBL0501","SRC_DB":"PHPROJ"},{"CN":"Treanda CCN=TREANDA","SRC_DB":"PHPROJ"},{"CN":"Treakisym CCN=TREAKISYM","SRC_DB":"PHPROJ"},{"CN":"Benda CCN=BENDA","SRC_DB":"PHPROJ"},{"CN":"P08001 CCN=P08001","SRC_DB":"PHPROJ"},{"CN":"SDX-105 CCN=SDX105","SRC_DB":"PHPROJ"},{"CN":"Levact CCN=LEVACT","SRC_DB":"PHPROJ"},{"CN":"Ribovact CCN=RIBOVACT","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-03 16:37:20","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C1","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, biliary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"APOP-AG","THE_USE":"Apoptosis stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-AN","THE_USE":"DNA inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"K1B","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[66, 101, 110, 100, 97, 109, 117, 115, 116, 105, 110, 101, 32, 105, 115, 32, 97, 32, 98, 101, 110, 122, 105, 109, 105, 100, 97, 122, 111, 108]...', original message: bytes can be at most 32766 in length; got 40819
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40819
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:52:06,359][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.2gb[11.6%], replicas will not be assigned to this node
[2016-06-14 11:52:36,379][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13.1gb[11.6%], replicas will not be assigned to this node
[2016-06-14 11:53:06,412][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13gb[11.5%], replicas will not be assigned to this node
[2016-06-14 11:53:36,431][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 13gb[11.5%], replicas will not be assigned to this node
[2016-06-14 11:54:06,450][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.9gb[11.4%], replicas will not be assigned to this node
[2016-06-14 11:54:36,470][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.9gb[11.4%], replicas will not be assigned to this node
[2016-06-14 11:55:06,490][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.8gb[11.4%], replicas will not be assigned to this node
[2016-06-14 11:55:36,583][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.8gb[11.3%], replicas will not be assigned to this node
[2016-06-14 11:56:06,602][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.7gb[11.3%], replicas will not be assigned to this node
[2016-06-14 11:56:36,637][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.7gb[11.2%], replicas will not be assigned to this node
[2016-06-14 11:57:06,657][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.6gb[11.2%], replicas will not be assigned to this node
[2016-06-14 11:57:36,681][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.5gb[11.1%], replicas will not be assigned to this node
[2016-06-14 11:58:06,719][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.5gb[11.1%], replicas will not be assigned to this node
[2016-06-14 11:58:29,171][DEBUG][action.bulk              ]  2mg/kg q wk) + Arimidex (1mg daily) vs Arimidex alone as a 1st-line therapy (or 2nd-line hormonal therapy) in 208 postmenopausal women with advanced, HER2-positive and hormone receptor-positive breast cancer, patients on trastuzumab had a significant improvement in PFS (Press release, Roche, 29 May 2006).^In 172 patients with advanced metastatic breast cancer, overexpressing HER2, trastuzumab had an overall response rate of 18%. The median duration of response was 9.1mth and median duration of survival was 16.4mth. Trastuzumab + paclitaxel had a response rate of 49%, a median duration of response of 10.9mth, a median time to disease progression of 7.1mth and an increased overall survival time of 25mth cf 17%, 4.6mth, 3mth and 18mth respectively for paclitaxel alone. Adverse events including chills, fever, nausea, vomiting, weakness and headache were reported by 40-50% of patients during 1st infusion and were less frequent with subsequent infusions. Pulmonary events and cardiac dysfunction occurred more frequently when trastuzumab was used in combination therapy (MIMS UK, 2000, Oct, 8).^In the trials in breast cancer mentioned above, the most common adverse events were chills and fever associated with infusion. There was also an increased risk of cardiac dysfunction in women treated with trastuzumab and anthracyclines cf anthracyclines alone. Cardiac dysfunction was reported in a small number of patients on trastuzumab alone and in combination with paclitaxel (Scrip, 1998, 2298, 22).^In a randomized Phase III trial (GBG26) in 156 women with HER2+ locally advanced or metastatic breast cancer, who had previously received trastuzumab, trastuzumab + capecitabine (qv) prolonged survival without disease progression by nearly 3mth, cf chemotherapy alone (8.2 and 5.6mth, respectively). Continuation of trastuzumab therapy increased the percentage of responders from 27 to 48% (Press release, Roche, 30 May 2008).^In an open-label, randomized Phase III trial (NOAH) in 228 patients with locally-advanced HER2+ breast cancer, trastuzumab + chemotherapy prior to surgery improved event-free survival at 3yr, cf 53% for chemotherapy alone. Trastuzumab + chemotherapy completely erradicated tumours in 39%, cf 20% on chemotherapy alone. The overall response rate was 89 cf 77%, respectively (Press release, Roche, 11 Dec 2008).^Phase II^In a Phase II trial in 43 breast cancer patients, trastuzumab 250mg iv followed by 100mg/wk x10wk infusion produced 1CR and 4PRs. The CR patient was disease-free at 23wk and in the PRs, 50% tumour reduction was observed. It was well tolerated, with 11 adverse events (Scrip, 1996, 2112, 23).^Additional References^34th ASCO (Los Angeles) 1998, Abs 376^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (500mg by infusion):t1/2:288:hr","Human (500mg by infusion):Cmax:377:microg/ml","Human (500mg by infusion):Vd:44:ml/kg"],"Document_NC":["No"],"Document_TF":["2064: Enzyme > EC number > 2.7.10.1;","2064: Receptor > Cytokine receptor;","2064: Enzyme > Kinase."],"Document_TG":["2064: v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2"],"Document_LCH":["20140321:AD244 : Planned Phase IIa trial (ML28897) for solid tumours reported"],"Document_TB":["2064: Enzyme > EC number > 2.7.10.1;","2064: EC number > 2.7.10.1;","2064: Enzyme;","2064: 2.7.10.1;","2064: Enzyme > EC number.","2064: Receptor > Cytokine receptor;","2064: Cytokine receptor;","2064: Receptor.","2064: Enzyme > Kinase;","2064: Kinase;","2064: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR2-AN: Epidermal growth factor receptor 2 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 2 antagonist: EGFR2 antagonist: HER2 antagonist: HER2/neu antagonist: ErbB-2 antagonist: R-H-GF-EPR2-AN|"],"Document_ROUT":["P-CR: Parenteral, intracerebral","P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Hoffmann-La Roche (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 1998 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"}],"DOCNO":"PH015922","CASIS_COMPOUND":[{"CN":"R-597 CCN=R597","SRC_DB":"PHPROJ"},{"CN":"RG-597 CCN=RG597","SRC_DB":"PHPROJ"},{"CN":"HER-2 MAb, Roche CCN=HER2MABROCHE","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (SC, unoptimised) CCN=TRASTUZUMAB(SCUNOPTIMISED)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (intracerebral) CCN=TRASTUZUMAB(INTRACEREBRAL)","SRC_DB":"PHPROJ"},{"CN":"Herceptin CCN=HERCEPTIN","SRC_DB":"PHPROJ"},{"CN":"Herceptin (intracerebral) CCN=HERCEPTIN(INTRACEREBRAL)","SRC_DB":"PHPROJ"},{"CN":"RG-597 (IV) CCN=RG597(IV)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (intrathecal) CCN=TRASTUZUMAB(INTRATHECAL)","SRC_DB":"PHPROJ"},{"CN":"R-597 (IV) CCN=R597(IV)","SRC_DB":"PHPROJ"},{"CN":"rhuMAb HER2 CCN=RHUMABHER2","SRC_DB":"PHPROJ"},{"CN":"Ro-45-2317 CCN=RO452317","SRC_DB":"PHPROJ"},{"CN":"Ro-45-2317 (IV) CCN=RO452317(IV)","SRC_DB":"PHPROJ"},{"CN":"anti-HER-2 MAb, Genentech CCN=ANTIHER2MABGENENTECH","SRC_DB":"PHPROJ"},{"CN":"Herceptin (IV) CCN=HERCEPTIN(IV)","SRC_DB":"PHPROJ"},{"CN":"Herceptin (intrathecal) CCN=HERCEPTIN(INTRATHECAL)","SRC_DB":"PHPROJ"},{"CN":"RG597 CCN=RG597","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (IV) CCN=TRASTUZUMAB(IV)","SRC_DB":"PHPROJ"},{"CN":"R597 CCN=R597","SRC_DB":"PHPROJ"},{"CN":"R597 (IV) CCN=R597(IV)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab CCN=TRASTUZUMAB","SRC_DB":"PHPROJ"},{"CN":"anti-HER-2 MAb, Roche CCN=ANTIHER2MABROCHE","SRC_DB":"PHPROJ"},{"CN":"RG597 (IV) CCN=RG597(IV)","SRC_DB":"PHPROJ"},{"CN":"HER-2 MAb, Genentech CCN=HER2MABGENENTECH","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EPR2-AN","THE_USE":"Epidermal growth factor receptor 2 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 114, 97, 115, 116, 117, 122, 117, 109, 97, 98, 32, 105, 115, 32, 97, 32, 104, 117, 109, 97, 110, 105, 122, 101, 100, 32, 77, 65, 98]...', original message: bytes can be at most 32766 in length; got 35788
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35788
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:58:29,259][DEBUG][action.bulk              ] vo^In animal models of venous and arterial thrombosis, it demonstrated antithrombotic efficacy. It inhibited thrombin- induced platelet aggregation. In animal models of atherosclerosis and fibrosis, it showed protective effects on proliferation and promoted plaque stability (242nd ACS (Denver), 2011, MEDI 185).^In experimental models, dabigatran etexilate prevented the progression of tumour cells. In tracheal xenotransplants in mice, dabigatran etexilate x3 and 4wk demonstrated significantly less penetration of MDA-MB-231 breast cancer cells through the tracheal wall. In syngeneic Balb/c mice with primary 4T1 mammary carcinoma, it showed 50% reduction in tumour volume at 4wk and reduced the tumour cells in the blood and liver micrometastases by 50-60%. No weight loss was observed (101st AACR (Washington, DC), 2010 Abs 2271, http://www.abstractsonline.com/plan/ ViewAbstract.aspx?mID=2521andsKey=07c2cd4b-147f-4970-b215- f110442c05ffandcKey=3c4ea4ed-8e76-425f-bc25- 81d766dbd07aandmKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}).^In an in vivo model of arterial thrombosis, dabigatran etexilate po exhibited potent and long-lasting, dose-dependent reduction of thrombus formation. In an in vitro study, dabigatran etexilate concentration-dependently inhibited tissue factor-induced human platelet aggregation (Press release, BI, 9 Dec 2007).^In domestic pigs, dabigatran etexilate 0.3-3mg/kg iv pre-vessel injury dose-dependently inhibited cyclic closure by 84% in the 1st 20min on 1mg/kg, cf 10 closures/interval on placebo. In the final 30min (1.5-2hr post-injury), a 66% reduction in cyclic closures was sustained. In domestic pigs, dabigatran etexilate 0.3-3mg/kg iv post-vessel injury (treatment) dose-dependently decreased cyclic closures, with an 84% reduction in the 1st 20min on 3mg/kg, cf 15 closures/interval on placebo. The reduction in cyclic closures was maintained throughout the 2hr bolus dose and 1.5-2hr post-dosing (48th Meet Am Soc Hematol (Orlando), 2006, Abs 906).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (150mg po):t1/2:28:hr","Human:Tmax:6:hr","Human:bioavailability:6.5:%","Human:t1/2beta:60:hr"],"Document_NC":["Yes"],"Document_RB":["11"],"Document_TF":["2147: Enzyme > EC number > 3.4.21.5;","2147: Enzyme > Protease/peptidase."],"Document_TG":["2147: coagulation factor II (thrombin)"],"Document_LCH":["20140308:PP236 : Approval in Jordan for stroke prevention in atrial fibrillation reported"],"Document_TB":["2147: Enzyme > EC number > 3.4.21.5;","2147: EC number > 3.4.21.5;","2147: Enzyme;","2147: 3.4.21.5;","2147: Enzyme > EC number.","2147: Enzyme > Protease/peptidase;","2147: Protease/peptidase;","2147: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PR-SE-TD-AN: Direct thrombin inhibitor: Enzyme, Hydrolase, Direct thrombin inhibitor: E-HY-PR-SE-TD-AN|PR-SE-AN: Serine protease inhibitor: Enzyme, Hydrolase, Serine protease inhibitor: Serine proteinase unspecified inhibitor: Unspecified serine protease inhibitor: General serine protease inhibitor: General serine proteinase inhibitor: E-HY-PR-SE-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["471.52"],"Document_AL":["2.91"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Launched"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD277193    ","MD294949    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH040208","CASIS_COMPOUND":[{"CN":"Pradaxa (solution) CCN=PRADAXA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate CCN=DABIGATRANETEXILATE","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 (solution) CCN=BIBR1048(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate CCN=DABIGATRANETEXILATEMESYLATE","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate (tablet) CCN=DABIGATRANETEXILATEMESYLATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Pradaxar CCN=PRADAXAR","SRC_DB":"PHPROJ"},{"CN":"Pradaxa (capsule) CCN=PRADAXA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate (tablet) CCN=DABIGATRANETEXILATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Pradax CCN=PRADAX","SRC_DB":"PHPROJ"},{"CN":"BIBR-953ZW CCN=BIBR953ZW","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 (capsule) CCN=BIBR1048(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran (tablet) CCN=DABIGATRAN(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 (capsule) CCN=BIBR1048(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 CCN=BIBR1048","SRC_DB":"PHPROJ"},{"CN":"Prazaxa CCN=PRAZAXA","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 (tablet) CCN=BIBR1048(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Pradaxa (tablet) CCN=PRADAXA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate (capsule) CCN=DABIGATRANETEXILATEMESYLATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 (tablet) CCN=BIBR1048(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 (solution) CCN=BIBR1048(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 CCN=BIBR1048","SRC_DB":"PHPROJ"},{"CN":"dabigatran CCN=DABIGATRAN","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate (solution) CCN=DABIGATRANETEXILATEMESYLATE(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Rendix CCN=RENDIX","SRC_DB":"PHPROJ"},{"CN":"dabigatran (capsule) CCN=DABIGATRAN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran (solution) CCN=DABIGATRAN(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Pradaxa CCN=PRADAXA","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate (capsule) CCN=DABIGATRANETEXILATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate (solution) CCN=DABIGATRANETEXILATE(SOLUTION)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Thrombosis, venous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N7C","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR-SE-TD-AN","THE_USE":"Direct thrombin inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"B1A","THE_USE":"Antithrombotic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Acute coronary syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR-SE-AN","THE_USE":"Serine protease inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Thromboprophylaxis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[68, 97, 98, 105, 103, 97, 116, 114, 97, 110, 32, 101, 116, 101, 120, 105, 108, 97, 116, 101, 32, 40, 66, 73, 66, 82, 45, 49, 48, 52]...', original message: bytes can be at most 32766 in length; got 47571
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47571
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:58:36,738][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.5gb[11%], replicas will not be assigned to this node
[2016-06-14 11:59:06,759][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.4gb[11%], replicas will not be assigned to this node
[2016-06-14 11:59:31,429][DEBUG][action.bulk              ] n/page.php?p=60andq=472).^Handok^South Korea; for multiple myeloma (Press releases, AEterna Zentaris, 2 Dec 2009; BIO 2010 (Chicago), http://www.bio.org/ bfprofiles/pdfs/185863.pdf).^Keryx Biopharmaceuticals^Canada, Mexico and the US ; Keryx Biopharmaceuticals (formerly Access Oncology) previously had development and marketing rights for, including completion of Phase II and III trials; however the agreement was terminated and Aeterna regained all rights including all intellectual property and development data (Press release, Access Oncology, 18 Sep 2002, Press release, Aeterna, 7 May 2012, http://www.aezsinc.com/en/page.php?p=60andq=504).^Meda^It was previously under development by Asta Medica (now Meda; previously Viatris); however, the project was transferred to Zentaris following restructuring of the Degussa group (Direct communication, Zentaris, 24 Sep 2001).^Qualifying Therapeutic Discovery Project^USA; Keryx received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) for the development of perifosine (IRS.gov Web Page, 2 Feb 2011, http://www.irs.gov/ businesses/small/article/0,,id=229024,00.html).^Yakult Honsha^Japan; exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine in Japan. Under the terms of the agreement, Aeterna will receive an initial upfront payment and will be entitled to receive additional payments upon achieving certain pre- established milestones including clinical and regulatory events in Japan. Furthermore, Aeterna will be supplying perifosine to Yakult Honsha on a cost-plus-basis and be entitled to receive double-digit royalties on future net sales of perifosine in Japan (Press release, AEterna Zentaris, 9 Mar 2011, http:// www.aezsinc.com/en/page.php?p=60andq=427).^Availability^________________^Australia, Europe and South America (2nd Ann BioPartner N America (Vancouver), 2004).^Additional Clinical Information^Phase I^"],"Document_HA":["4"],"Document_CASIS-UPD_WE":["20131115"],"Document_PK":["Human (daily):MTD:200:mg/kg","Mouse (40mg/kg po):Vd:11.3:l/kg"],"Document_NC":["Yes"],"Document_RB":["20"],"Document_TF":["207: Enzyme > EC number > 2.7.11.1;","207: Receptor > GPCR;","207: Enzyme > Kinase;","207: Transporter > Porters (uni-, sym- and anti-);","5290: Enzyme > EC number > 2.7.1.137;","5290: Enzyme > Kinase."],"Document_TG":["207: v-akt murine thymoma viral oncogene homologue 1","5290: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha"],"Document_LCH":["20131107:PT : Ongoing development confirmed"],"Document_TB":["207: Enzyme > EC number > 2.7.11.1;","207: EC number > 2.7.11.1;","207: Enzyme;","207: 2.7.11.1;","207: Enzyme > EC number.","207: Receptor > GPCR;","207: GPCR;","207: Receptor.","207: Enzyme > Kinase;","207: Kinase;","207: Enzyme.","207: Transporter > Porters (uni-, sym- and anti-);","207: Porters (uni-, sym- and anti-);","207: Transporter.","5290: Enzyme > EC number > 2.7.1.137;","5290: EC number > 2.7.1.137;","5290: Enzyme;","5290: 2.7.1.137;","5290: Enzyme > EC number.","5290: Enzyme > Kinase;","5290: Kinase;","5290: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-PR-B-AN: Protein kinase B inhibitor: Enzyme, Transferase, Protein kinase B inhibitor: Akt inhibitor: E-TR-KI-PR-B-AN|KI-PR-AN: Protein kinase inhibitor: Enzyme, Transferase, Protein kinase inhibitor: E-TR-KI-PR-AN|KI-PI3-AN: PI3 kinase inhibitor: Enzyme, Transferase, PI3 kinase inhibitor: Phosphoinositol-3-kinase inhibitor: E-TR-KI-PI3-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["461.67"],"Document_AL":["8.20"],"Document_CASIS-CO_CO":["Originator: Meda (SE): Discontinued","Licensee: Yakult Honsha (JP): Phase II Clinical Trial","Licensee: Handok (KR): Preclinical","Licensee: Hikma (GB): Preclinical","Licensee: Nippon Kayaku (JP): Discontinued","Licensee: Keryx Biopharmaceuticals (US): Discontinued","Licensee: AEterna Zentaris (CA): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD104263    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"}],"DOCNO":"PH018604","CASIS_COMPOUND":[{"CN":"YHI 1003 CCN=YHI1003","SRC_DB":"PHPROJ"},{"CN":"D-21805 CCN=D21805","SRC_DB":"PHPROJ"},{"CN":"perifosine CCN=PERIFOSINE","SRC_DB":"PHPROJ"},{"CN":"AEZS104 CCN=AEZS104","SRC_DB":"PHPROJ"},{"CN":"AEZS-104 CCN=AEZS104","SRC_DB":"PHPROJ"},{"CN":"NKA-17 CCN=NKA17","SRC_DB":"PHPROJ"},{"CN":"KRX-0401 CCN=KRX0401","SRC_DB":"PHPROJ"},{"CN":"YHI-1003 CCN=YHI1003","SRC_DB":"PHPROJ"},{"CN":"D-21266 CCN=D21266","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2013-11-18 16:49:31","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-AN","THE_USE":"Protein kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PI3-AN","THE_USE":"PI3 kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Waldenstrom's hypergammaglobulinaemia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-B-AN","THE_USE":"Protein kinase B inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[80, 101, 114, 105, 102, 111, 115, 105, 110, 101, 32, 40, 68, 45, 50, 49, 50, 54, 54, 41, 32, 105, 115, 32, 97, 32, 112, 104, 111, 115]...', original message: bytes can be at most 32766 in length; got 36438
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36438
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:59:36,781][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.4gb[10.9%], replicas will not be assigned to this node
[2016-06-14 11:59:51,581][DEBUG][action.bulk              ] "6714: EC number > 2.7.10.2;","6714: Enzyme;","6714: 2.7.10.2;","6714: Enzyme > EC number.","6714: Enzyme > Kinase;","6714: Kinase;","6714: Enzyme.","3815: Enzyme > Kinase;","3815: Kinase;","3815: Enzyme.","3815: Receptor;","2534: Enzyme > EC number > 2.7.10.2;","2534: EC number > 2.7.10.2;","2534: Enzyme;","2534: 2.7.10.2;","2534: Enzyme > EC number.","2534: Enzyme > Kinase;","2534: Kinase;","2534: Enzyme.","7525: Enzyme > EC number > 2.7.10.2;","7525: EC number > 2.7.10.2;","7525: Enzyme;","7525: 2.7.10.2;","7525: Enzyme > EC number.","7525: Enzyme > Kinase;","7525: Kinase;","7525: Enzyme.","4067: Enzyme > EC number > 2.7.10.2;","4067: EC number > 2.7.10.2;","4067: Enzyme;","4067: 2.7.10.2;","4067: Enzyme > EC number.","4067: Enzyme > Kinase;","4067: Kinase;","4067: Enzyme.","3932: Enzyme > EC number > 2.7.10.1;","3932: EC number > 2.7.10.1;","3932: Enzyme;","3932: 2.7.10.1;","3932: Enzyme > EC number.","3932: Enzyme > Kinase;","3932: Kinase;","3932: Enzyme.","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-BCAB-AN: Bcr-Abl inhibitor: Enzyme, Transferase, BcrAbl inhibitor: Philadelphia chromosome inhibitor: Bcr-Abl kinase inhibitor: E-TR-KI-BCAB-AN|KI-TY-SC-AN: Src inhibitor: Enzyme, Transferase, Src inhibitor: c-Src inhibitor: Src tyrosine kinase inhibitor: E-TR-KI-TY-SC-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|KI-TY-EA-AN: EphA receptor kinase inhibitor: Enzyme, Transferase, EphA receptor kinase inhibitor: EphrinA receptor kinase inhibitor: E-TR-KI-TY-EA-AN|KI-TY-FY-AN: Fyn tyrosine kinase inhibitor: Enzyme, Transferase, Fyn tyrosine kinase inhibitor: Slk tyrosine kinase inhibitor: Syn tyrosine kinase inhibitor: E-TR-KI-TY-FY-AN|KI-TY-YE-AN: Yes tyrosine kinase inhibitor: Enzyme, Transferase, Yes tyrosine kinase inhibitor: E-TR-KI-TY-YE-AN|KI-TY-LN-AN: LYN tyrosine kinase inhibitor: Enzyme, Transferase, LYN tyrosine kinase inhibitor: E-TR-KI-TY-LN-AN|KI-TYRL-AN: Lymphocyte-specific tyrosine kinase inhibitor: Enzyme, Transferase, Lymphocytespecific tyrosine kinase inhibitor: Lck inhibitor: p56lck inhibitor: Lymphocyte tyrosine kinase inhibitor: E-TR-KI-TYRL-AN|KI-GFPLB-AN: Platelet-derived growth factor receptor beta kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor beta kinase inhib: PDGF beta kinase inhibitor: PDGF receptor beta kinase inhibitor: Platelet-derived growth factor beta kinase inhibitor: E-TR-KI-GFPLB-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["488.01"],"Document_AL":["4.19"],"Document_CASIS-CO_CO":["Originator: Bristol-Myers Squibb (US): Launched","Licensee: Otsuka (JP): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing in the Future"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Available for Licensing in the Future"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing in the Future"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"}],"DOCNO":"PH038544","CASIS_COMPOUND":[{"CN":"BMS 354825 (oral suspension) CCN=BMS354825(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"NSC 732517 (oral suspension) CCN=NSC732517(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"Sprycel CCN=SPRYCEL","SRC_DB":"PHPROJ"},{"CN":"Sprycel (tablet) CCN=SPRYCEL(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-354825 (oral suspension) CCN=BMS354825(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"dasatinib (oral suspension) CCN=DASATINIB(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"BMS-354825 (tablet) CCN=BMS354825(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS 354825 (tablet) CCN=BMS354825(TABLET)","SRC_DB":"PHPROJ"},{"CN":"NSC 732517 CCN=NSC732517","SRC_DB":"PHPROJ"},{"CN":"dasatinib CCN=DASATINIB","SRC_DB":"PHPROJ"},{"CN":"NSC 732517 (tablet) CCN=NSC732517(TABLET)","SRC_DB":"PHPROJ"},{"CN":"NSC-732517 CCN=NSC732517","SRC_DB":"PHPROJ"},{"CN":"NSC-732517 (oral suspension) CCN=NSC732517(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"BMS-354825 CCN=BMS354825","SRC_DB":"PHPROJ"},{"CN":"dasatinib (tablet) CCN=DASATINIB(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS 354825 CCN=BMS354825","SRC_DB":"PHPROJ"},{"CN":"NSC-732517 (tablet) CCN=NSC732517(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Sprycel (oral suspension) CCN=SPRYCEL(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"Src/ABL CCN=SRC/ABL","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"KI-TY-EA-AN","THE_USE":"EphA receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-SC-AN","THE_USE":"Src inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-LN-AN","THE_USE":"LYN tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Polycythaemia vera","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-BCAB-AN","THE_USE":"Bcr-Abl inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-YE-AN","THE_USE":"Yes tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Hypereosinophilic syndrome, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-FY-AN","THE_USE":"Fyn tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYRL-AN","THE_USE":"Lymphocyte-specific tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLB-AN","THE_USE":"Platelet-derived growth factor receptor beta kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[68, 97, 115, 97, 116, 105, 110, 105, 98, 32, 40, 66, 77, 83, 45, 51, 53, 52, 56, 50, 53, 41, 32, 105, 115, 32, 97, 110, 32, 111]...', original message: bytes can be at most 32766 in length; got 35629
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35629
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 11:59:51,906][DEBUG][action.bulk              ]  US until 2023, and the EU until 2024, with regulatory exclusivity and patent life until 2012 and 2023, respectively (Company presentation, Shire, 21 Feb 2008).^US7105486 and US7223735 expire on 29 Jun 2023 (Form 10-K, Shire, 2007).^Licensing^Agreements^________________^GlaxoSmithKline^USA; Shire had a 3yr co-promotion agreement with GlaxoSmithKline (GSK); however, Shire terminated the agreement, under the terms of agreement, no termination payment or any other payments were made or are due to GSK since agreed upon sales thresholds were not achieved (Press release, GSK, 31 Mar 2009; Press release, Shire, 29 Oct 2010, http://www.shire.com/shireplc/uploads/press/ Q32010EarningsRelease_29Oct2010.pdf)^New River Pharmaceuticals (Shire)^USA; NRP previously licensed it to Shire for development, manufacturing, marketing and sales in the US (Press release, Shire, 31 Jan 2005; Scrip Daily Online, 31 Jul 2006, S00928872).^Shionogi^Japan; collaboration focused on development and commercialization for ADHD. Shionogi will pay an upfront payment to Shire. Under the terms of the agreement, Shionogi and Shire will jointly pursue development. After launch of, the parties will co-promote and Shionogi will also pay a sales royalty payment on net sales (Press release, Shionogi, 18 Nov 2011, http://www.shionogi.co.jp/ ir_en/news/detail/e_111118.pdf).^Additional Clinical Information^Phase I^In a double-blind, placebo- and active-controlled, single- crossover pharmacodynamic and pharmacokinetic study (A02) to evaluate the safety, tolerability and abuse liability of lisdexamfetamine dimesylate iv in healthy adult volunteers with histories of stimulant abuse, d-amfetamine 20mg iv produced significant responses on measures of amfetamine-like effects, that peaked within 15min, cf lisdexamfetamine dimesylate 50mg iv which produced a lack of significant responses on the same scales. 89% of subjects stated that they would not take lisdexamfetamine dimesylate 50mg again, cf 67% who stated that they would take d-amfetamine 20mg again. On a molar weight basis, the amfetamine free base content of the two drugs was equal, indicating that lisdexamfetamine dimesylate may have little likelihood for abuse by the parenteral route. It was safe and well tolerated (Press release, New River, 20 Jun 2006).^In an open-label, randomized, 4-period crossover Phase I trial in 24 healthy adults, single-dose lisdexamfetamine dimesylate 50mg resulted in median time to maximum plasma d-amfetamine concentration of 3hr, which was unchanged when co-administered with the OTC PPI Prilosec vs a change in maximum plasma concentration of d-amfetamine when Adderall XR was co- administered with Prilosec. Approximately 25% on lisdexamfetamine dimesylate + Prilosec had a shortened time to maximum d- amfetamine plasma concentration of greater than or equal to 1hr (Press release, Shire, 22 May 2009).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TF":["Receptor > GPCR > Adrenoceptor."],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140305:PP183 : Timing of launch for binge eating disorder reported"],"Document_TB":["Receptor > GPCR > Adrenoceptor;","GPCR > Adrenoceptor;","Receptor;","Adrenoceptor;","Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["ADR-AG: Adrenoreceptor agonist: Receptor, Transmitter, Adrenoreceptor agonist: Adrenergic stimulant: Adrenaline agonist: Noradrenaline agonist: Epinephrine agonist: R-T-ADR-AG|ADR-A-AG: Alpha adrenoreceptor agonist: Receptor, Transmitter, Alpha adrenoreceptor agonist: Alpha adrenergic agonist: Alpha adrenoceptor agonist: R-T-ADR-A-AG|DOPAU-AN: Dopamine reuptake inhibitor: Receptor, Transmitter, Dopamine reuptake inhibitor: DA reuptake inhibitor: R-T-DOPAU-AN|ADRU-AN: Adrenergic transmitter uptake inhibitor: Receptor, Transmitter, Adrenergic transmitter uptake inhibitor: Adrenaline uptake inhibitor: Noradrenaline uptake inhibitor: Epinephrine uptake inhibitor: Norepinephrine uptake inhibitor: R-T-ADRU-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["263.39"],"Document_AL":["1.06"],"Document_CASIS-CO_CO":["Originator: Shire (IE): Launched","Licensee: Shionogi (JP): Phase II Clinical Trial","Licensee: GlaxoSmithKline (GB): Discontinued"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD520971    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH038576","CASIS_COMPOUND":[{"CN":"lisdexamfetamine dimesylate CCN=LISDEXAMFETAMINEDIMESYLATE","SRC_DB":"PHPROJ"},{"CN":"Tyvense CCN=TYVENSE","SRC_DB":"PHPROJ"},{"CN":"L-lysine-d-amfetamine CCN=LLYSINEDAMFETAMINE","SRC_DB":"PHPROJ"},{"CN":"amfetamine prodrug, New River CCN=AMFETAMINEPRODRUGNEWRIVER","SRC_DB":"PHPROJ"},{"CN":"Vyvanse CCN=VYVANSE","SRC_DB":"PHPROJ"},{"CN":"Elvanse CCN=ELVANSE","SRC_DB":"PHPROJ"},{"CN":"lisdexamfetamine CCN=LISDEXAMFETAMINE","SRC_DB":"PHPROJ"},{"CN":"Venvanse CCN=VENVANSE","SRC_DB":"PHPROJ"},{"CN":"LDX CCN=LDX","SRC_DB":"PHPROJ"},{"CN":"SPD-489 CCN=SPD489","SRC_DB":"PHPROJ"},{"CN":"NRP-104 CCN=NRP104","SRC_DB":"PHPROJ"},{"CN":"S-877489 CCN=S877489","SRC_DB":"PHPROJ"},{"CN":"S877489 CCN=S877489","SRC_DB":"PHPROJ"},{"CN":"NRP104 CCN=NRP104","SRC_DB":"PHPROJ"},{"CN":"SPD489 CCN=SPD489","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"D","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ADR-AG","THE_USE":"Adrenoreceptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"DOPAU-AN","THE_USE":"Dopamine reuptake inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A8A3","THE_USE":"Anorectic-Antiobesity","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"ADR-A-AG","THE_USE":"Alpha adrenoreceptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Addiction, cocaine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Attention deficit hyperactivity disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Binge eating disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Sleep disorder, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6B","THE_USE":"Psychostimulant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"ADRU-AN","THE_USE":"Adrenergic transmitter uptake inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N9A","THE_USE":"Dependence treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 105, 115, 100, 101, 120, 97, 109, 102, 101, 116, 97, 109, 105, 110, 101, 32, 100, 105, 109, 101, 115, 121, 108, 97, 116, 101, 32, 40, 78]...', original message: bytes can be at most 32766 in length; got 49266
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 49266
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:00:06,803][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.3gb[10.9%], replicas will not be assigned to this node
[2016-06-14 12:00:36,836][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.2gb[10.8%], replicas will not be assigned to this node
[2016-06-14 12:01:06,858][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.2gb[10.8%], replicas will not be assigned to this node
[2016-06-14 12:01:10,140][DEBUG][action.bulk              ]  28, 67 and 86% on 30, 50 and 75mg, respectively, cf 16% on placebo. Platelet count >200000/microl was recorded in 12, 38 and 52% on 30, 50 and 75mg, respectively, cf 4% on placebo. Median platelet counts were 26000, 128000 and 183000/microl, respectively, cf 16000/microl for placebo. Headaches were reported (with no dose-related pattern) in 13, 10 and 21%, respectively, cf 21% on placebo. Bleeding AEs included haemorrhoids, haemorrhagic diarrhoea and conjunctival haemorrhage in 3 placebo patients, epistaxis, gingival bleeding and contusions in 5 patients on 30mg, menorrhagia in 1 patient on 50mg, and contusion in 1 patient on 75mg (11th Cong Eur Hematol Assoc (Amsterdam), 2006, Abs 1022; Press releases, GSK, 19 Jul and 11 Dec 2006).^Phase I^A randomized, double-blind, single-group-assignment UK Phase I trial in 36 healthy volunteers, to evaluate the safety profile and the photoirritant potential of eltrombopag olamine 75mg once- daily, cf ciprofloxacin and placebo, is complete (ClinicalTrials.gov, 24 Aug 2009 and 17 Jan 2013, http:// clinicaltrials.gov/ct2/show/NCT00688272).^In a randomized, single-blind, placebo-controlled, parallel-group Phase I trial in 72 healthy volunteers, eltrombopag olamine 5- 75mg po was well tolerated, with no SAEs. Eltrombopag olamine >30mg x10 days gave a dose-dependent increase in platelet counts, with maximum platelet count on days 14-16 (96th AACR (Anaheim), 2005, Abs 2565).^Thrombocytopenia, unspecified; Hepatic dysfunction, general; Radio/chemotherapy-induced injury, bone marrow, thrombocytopenia^GlaxoSmithKline^It was in Phase I trials in hepatic, renal and chemotherapy- induced thrombocytopenia (Form 10-K, Ligand, 2007; Company Web Page, Ligand, 13 May 2008).^Thrombocytopenia, unspecified^GlaxoSmithKline^Enrollment is complete in an open-label, 3-period, single- sequence, crossover Phase I trial (116010) to evaluate the drug- drug interaction between eltrombopag and boceprevir and between eltrombopag and telaprevir in 56 healthy adult subjects in the US (ClinicalTrials.gov, 7 Aug and 10 Oct 2012, http:// clinicaltrials.gov/ct2/show/NCT01657552).^An open-label, dose-ranging, non-randomized Phase I trial to assess the safety, efficacy and pharmacokinetics of eltrombopag olamine po in 48 sarcoma patients in the US with low platelet count who were receiving adriamycin + ifosfamide was completed (Form 10-Q, Ligand, 8 May 2008; ClinicalTrials.gov, 6 Apr, 24 Aug 2009 and 21 May 2011, http://clinicaltrials.gov/ct2/show/ NCT00358540).^Preclinical ^In vivo^In chimpanzees, eltrombopag olamine 10mg/kg/day po x5 days increased platelet counts 1.3-2.4x (96th AACR (Anaheim), 2005, Abs 4929).^In vitro^In ovarian, lung and breast tumour cell lines, eltrombopag olamine 0.01?100ug/ml induced an inhibition of proliferation on all cell lines tested. The IC50 ranged from 3.7 to 49.7ug/ml. There was no enhancement of proliferation at any concentration of eltrombopag, consistent with the very low or undetectable level of MPL expression. Erythropoietin receptor (EPOR) mRNA was expressed at low-to-moderate levels, while ERBB2 and IGF1R were expressed at higher levels in these cell lines. Microarray analysis showed undetectable MPL mRNA levels in all 118 samples from patients with breast cancer and 52% of the nsclc samples, the remaining nsclc samples expressed low levels of MPL. In contrast, EPOR was expressed in 75?100% of the breast cancer, and NSCLC samples. ERBB2 was expressed in 97?100% of the samples and IGF1R was expressed in 54?100% of the samples (51st Meet Am Soc Hematol (New Orleans), 2009, Abs 2409).^Patents^It is patent protected through 2027 (Company presentation, Ligand, 4 Jun 2012, Page 11, http://investor.ligand.com/Theme/Ligand/ files/doc_presentations/Ligand_Higgins_Foehr_Jefferies_6-4- 12.pdf).^Licensing^Agreements^________________^GlaxoSmithKline^Worldwide; eltrombopag olamine was discovered through a GSK and Ligand collaboration. GSK has exclusive worldwide marketing rights and responsibility for development and registration. Ligand is to receive milestone payments and royalties (Roth Capital Partners Conf (New York), 2004).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["4352: Receptor > Cytokine receptor > Class I."],"Document_TG":["4352: myeloproliferative leukaemia virus oncogene"],"Document_LCH":["20140318:PP183 : Timing of launch for aplastic anaemia reported"],"Document_TB":["4352: Receptor > Cytokine receptor > Class I;","4352: Cytokine receptor > Class I;","4352: Receptor;","4352: Class I;","4352: Receptor > Cytokine receptor."],"Document_CASIS-USE_CASIS-MA_PHCD":["TPO-AG: Thrombopoietin agonist: Physiological, Biochemical, Thrombopoietin agonist: TPO agonist: Platelet regulatory factor agonist: P-B-TPO-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["442.48"],"Document_AL":["6.42"],"Document_CASIS-CO_CO":["Originator: GlaxoSmithKline (GB): Launched","Licensee: Ligand (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD520813    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"}],"DOCNO":"PH035342","CASIS_COMPOUND":[{"CN":"eltrombopag olamine CCN=ELTROMBOPAGOLAMINE","SRC_DB":"PHPROJ"},{"CN":"497115 CCN=497115","SRC_DB":"PHPROJ"},{"CN":"SB-497115 CCN=SB497115","SRC_DB":"PHPROJ"},{"CN":"SB-497115-GR CCN=SB497115GR","SRC_DB":"PHPROJ"},{"CN":"Promacta CCN=PROMACTA","SRC_DB":"PHPROJ"},{"CN":"eltrombopag CCN=ELTROMBOPAG","SRC_DB":"PHPROJ"},{"CN":"SB497115 CCN=SB497115","SRC_DB":"PHPROJ"},{"CN":"Revolade CCN=REVOLADE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"TPO-AG","THE_USE":"Thrombopoietin agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"B7Z","THE_USE":"Haematological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"K5B","THE_USE":"Radio-chemoprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"B3C9","THE_USE":"Antianaemic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Radio/chemotherapy-induced injury, bone marrow, thrombocytopenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Thrombocytopenic purpura, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Hepatic dysfunction, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A5B","THE_USE":"Hepatoprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Anaemia, aplastic, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R","THE_USE":"Thrombocytopenia, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[69, 108, 116, 114, 111, 109, 98, 111, 112, 97, 103, 32, 111, 108, 97, 109, 105, 110, 101, 32, 40, 83, 66, 45, 52, 57, 55, 49, 49, 53]...', original message: bytes can be at most 32766 in length; got 40831
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40831
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:01:10,518][DEBUG][action.bulk              ] assignment, multicenter Phase Ib trial (CR101676) in 30 paediatric subjects with moderately-to-severely active ulcerative colitis in Austria, Belgium, Canada, Denmark, France, Germany, Israel, the Netherlands, Poland and the US, to assess the safety and pharmacokinetics of golimumab sc (ClinicalTrials.gov, 29 Aug 2013, http://www.clinicaltrials.gov/show/NCT01900574).^Infarction, myocardial; Ischaemia, cerebral^Clinical trials to assess the effect of golimumab on cardiovascular event occurrence, including acute myocardial infarction and stroke, in RA patients were planned. Serum markers of cardiovascular risk and carotid artery thickness measurements will be evaluated (Company presentation, JandJ, 7 Jun 2007).^Preclinical ^Preclinical observations suggested potential benefit in reducing cardiovascular events in RA (Company presentation, JandJ, 7 Jun 2007).^In vivo^A single golimumab injection delayed disease progression in a TNF transgenic mouse arthritis model, and reduced histological evidence of joint degradation. In a humanized mouse model of psoriasis, a dose-dependent effect was observed. Mice receiving golimumab 2mg/kg showed significant reductions in epidermal thickness and Ki 67 staining vs control mice (8th Eur Cong Rheumatol (Barcelona), 2007, Abs THU088).^Licensing^Agreements^________________^Janssen-Cilag (Johnson and Johnson)^Hong Kong; Janssen-Cilag (JandJ) has exclusive marketing rights in Hong Kong (Press release, Centocor, 27 Jun 2008).^Medarex^Worldwide; Centocor has an agreement to access Medarex' (now Bristol-Myers Squibb's (BMS)) HuMab-Mouse technology for manufacture (Press release, Medarex, 3 May 2000).^Merck and Co^Europe, Russia and Turkey; As of Jul 2011, Merck transferred exclusive marketing rights to Johnson and Johnson in territories including Canada, Central and S America, the Middle East, Africa and Asia Pacific. Merck retains exclusive marketing rights throughout Europe, Russia and Turkey (Press release, Merck, 29 Jul 2011, http://www.merck.com/newsroom/news-release-archive/ financial/2011_0729.html). Schering-Plough had a co-development and exclusive worldwide marketing rights to golimumab, excluding China, Hong Kong, Indonesia, Japan, Taiwan and the US (Press releases, Schering-Plough, 16 Aug 2005 and 17 Aug 2006). However, on announcement of the merger between S-P and Merck and Co, JandJ filed an arbitration demand to terminate the agreement with S-P, as per the new amended distribution agreement Merck will continue to have exclusive marketing rights in Europe, Russia and Turkey, but will relinquish its exclusive rights in territories including Africa, Asia Pacific, Canada, Central and South America and the Middle East (Press release, JandJ, 27 May 2009; Scrip Intelligence, 18 Apr 2011, http://www.scripintelligence.com/home/ Merck-and-JandJ-settle-Remicade-battle---and--investors-nerves- 314281).^Mitsubishi Tanabe Pharma^Indonesia, Japan and Taiwan; Mitsubishi Tanabe Pharma (Tanabe Seiyaku before the merger) has co-development and marketing rights in Indonesia, Japan and Taiwan (Press release, Tanabe, 7 Aug 2006).^Xian-Janssen (Johnson and Johnson)^China; Xian-Janssen (JandJ) has exclusive marketing rights in China (Press release, Centocor, 27 Jun 2008).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (0.1-10mg/kg iv):t1/2beta:157.44 to 222:hr","Human (0.1-10mg/kg iv):Cl:0.4:l/day","Human (0.1-10mg/kg iv):Vd:3.07:l","Human (0.3-1mg/kg sc):t1/2beta:288 to 624:hr"],"Document_NC":["No"],"Document_TF":["7124: Cytokine/Growth factor > Cytokine > Tumour necrosis factor."],"Document_TG":["7124: tumour necrosis factor"],"Document_LCH":["20140322:AD283 : Additional details of Phase III trial (CR006343) for rheumatoid arthritis reported"],"Document_TB":["7124: Cytokine/Growth factor > Cytokine > Tumour necrosis factor;","7124: Cytokine > Tumour necrosis factor;","7124: Cytokine/Growth factor;","7124: Tumour necrosis factor;","7124: Cytokine/Growth factor > Cytokine."],"Document_CASIS-USE_CASIS-MA_PHCD":["TNF-A-AN: Tumour necrosis factor alpha antagonist: Physiological, Hormonal, Tumour necrosis factor alpha antagonist: TNF alpha antagonist: TNF a antagonist: P-H-TNF-A-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Johnson & Johnson (US): Launched","Licensee: Merck & Co (US): Launched","Licensee: Mitsubishi Tanabe Pharma (JP): Launched"],"Document_MR":["5:Market Rating - Over US$ 10000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"}],"DOCNO":"PH035834","CASIS_COMPOUND":[{"CN":"golimumab CCN=GOLIMUMAB","SRC_DB":"PHPROJ"},{"CN":"golimumab (subcutaneous) CCN=GOLIMUMAB(SUBCUTANEOUS)","SRC_DB":"PHPROJ"},{"CN":"Simponi (subcutaneous) CCN=SIMPONI(SUBCUTANEOUS)","SRC_DB":"PHPROJ"},{"CN":"CNTO-148 (intravenous) CCN=CNTO148(INTRAVENOUS)","SRC_DB":"PHPROJ"},{"CN":"Simponi Aria CCN=SIMPONIARIA","SRC_DB":"PHPROJ"},{"CN":"Simponi CCN=SIMPONI","SRC_DB":"PHPROJ"},{"CN":"CNTO 148 CCN=CNTO148","SRC_DB":"PHPROJ"},{"CN":"CNTO-148 (subcutaneous) CCN=CNTO148(SUBCUTANEOUS)","SRC_DB":"PHPROJ"},{"CN":"CNTO-148 CCN=CNTO148","SRC_DB":"PHPROJ"},{"CN":"golimumab (intravenous) CCN=GOLIMUMAB(INTRAVENOUS)","SRC_DB":"PHPROJ"},{"CN":"Simponi (intravenous) CCN=SIMPONI(INTRAVENOUS)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"TNF-A-AN","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"R8A","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N7C","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M1A1","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A2","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Infarction, myocardial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[71, 111, 108, 105, 109, 117, 109, 97, 98, 32, 40, 67, 78, 84, 79, 45, 49, 52, 56, 41, 32, 105, 115, 32, 97, 32, 104, 117, 109, 97]...', original message: bytes can be at most 32766 in length; got 55910
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 55910
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:01:10,669][DEBUG][action.bulk              ] difying antirheumatic drug: DMARD: P-B-DMARD-AG|IM-AN: Immunosuppressant: Physiological, Hormonal, Immunosuppressant: P-H-IM-AN|KI-TYR-AN: Tyrosine kinase inhibitor (TKI): Enzyme, Transferase, Tyrosine kinase inhibitor (TKI): Protein kinase tyrosine inhibitor: Tyrosylprotein kinase inhibitor: Hydroxyaryl protein kinase inhibitor: TKI: E-TR-KI-TYR-AN|KI-MAP-AN: MAP kinase inhibitor: Enzyme, Transferase, MAP kinase inhibitor: Mitogen-activated protein kinase inhibitor: E-TR-KI-MAP-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-UN: Parenteral, general","T-DM: Topical, skin","T-EY: Topical, eyes","T-ON: Topical, ointment","T-UN: Topical, general"],"Document_MW":["312.38"],"Document_AL":["1.75"],"Document_CASIS-CO_CO":["Originator: Pfizer (US): Launched","Licensee: Takeda (JP): Registered"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH036138","CASIS_COMPOUND":[{"CN":"CP-690550 (ophthalmic) CCN=CP690550(OPHTHALMIC)","SRC_DB":"PHPROJ"},{"CN":"tasocitinib (oral tablet) CCN=TASOCITINIB(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"tofacitinib (ophthalmic) CCN=TOFACITINIB(OPHTHALMIC)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550 (oral tablet) CCN=CP690550(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"CP-690555 CCN=CP690555","SRC_DB":"PHPROJ"},{"CN":"CP-690,555 CCN=CP690555","SRC_DB":"PHPROJ"},{"CN":"CP-690550-10 (oral solution) CCN=CP69055010(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"tofacitinib CCN=TOFACITINIB","SRC_DB":"PHPROJ"},{"CN":"Jaquinus (topical) CCN=JAQUINUS(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"CP-690550 (IV) CCN=CP690550(IV)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550-10 CCN=CP69055010","SRC_DB":"PHPROJ"},{"CN":"tofacitinib citrate CCN=TOFACITINIBCITRATE","SRC_DB":"PHPROJ"},{"CN":"CP-690550-10 (IV) CCN=CP69055010(IV)","SRC_DB":"PHPROJ"},{"CN":"JAK-3 inhibitor (IV), Pfizer CCN=JAK3INHIBITOR(IV)PFIZER","SRC_DB":"PHPROJ"},{"CN":"CP-690,550 (IV) CCN=CP690550(IV)","SRC_DB":"PHPROJ"},{"CN":"CP-690550 CCN=CP690550","SRC_DB":"PHPROJ"},{"CN":"CP-690,550 CCN=CP690550","SRC_DB":"PHPROJ"},{"CN":"Jaquinus (IV) CCN=JAQUINUS(IV)","SRC_DB":"PHPROJ"},{"CN":"CP-690550 (oral solution) CCN=CP690550(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"tofacitinib (oral solution) CCN=TOFACITINIB(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550-10 (oral tablet) CCN=CP69055010(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"JAK-3 inhibitor, Pfizer CCN=JAK3INHIBITORPFIZER","SRC_DB":"PHPROJ"},{"CN":"tofacitinib (topical) CCN=TOFACITINIB(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550 (ophthalmic) CCN=CP690550(OPHTHALMIC)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550-10 (oral solution) CCN=CP69055010(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Xeljanz CCN=XELJANZ","SRC_DB":"PHPROJ"},{"CN":"CP-690,550 (oral solution) CCN=CP690550(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550 (topical) CCN=CP690550(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"CP-690550-10 (oral tablet) CCN=CP69055010(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"tasocitinib citrate CCN=TASOCITINIBCITRATE","SRC_DB":"PHPROJ"},{"CN":"tasocitinib (oral solution) CCN=TASOCITINIB(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"tofacitinib (oral tablet) CCN=TOFACITINIB(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"Jaquinus (oral tablet) CCN=JAQUINUS(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"Jaquinus (ophthalmic) CCN=JAQUINUS(OPHTHALMIC)","SRC_DB":"PHPROJ"},{"CN":"tofacitinib (IV) CCN=TOFACITINIB(IV)","SRC_DB":"PHPROJ"},{"CN":"CP-690550-10 (topical) CCN=CP69055010(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"JAK-3 inhibitor (oral solution), Pfizer CCN=JAK3INHIBITOR(ORALSOLUTION)PFIZER","SRC_DB":"PHPROJ"},{"CN":"Jaquinus CCN=JAQUINUS","SRC_DB":"PHPROJ"},{"CN":"JAK-3 inhibitor (ophthalmic), Pfizer CCN=JAK3INHIBITOR(OPHTHALMIC)PFIZER","SRC_DB":"PHPROJ"},{"CN":"JAK-3 inhibitor (topical), Pfizer CCN=JAK3INHIBITOR(TOPICAL)PFIZER","SRC_DB":"PHPROJ"},{"CN":"CP-690550 (oral tablet) CCN=CP690550(ORALTABLET)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550-10 (IV) CCN=CP69055010(IV)","SRC_DB":"PHPROJ"},{"CN":"tasocitinib (IV) CCN=TASOCITINIB(IV)","SRC_DB":"PHPROJ"},{"CN":"CP-690550 (topical) CCN=CP690550(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"tasocitinib (ophthalmic) CCN=TASOCITINIB(OPHTHALMIC)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550-10 (topical) CCN=CP69055010(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"CP-690550-10 CCN=CP69055010","SRC_DB":"PHPROJ"},{"CN":"tasocitinib CCN=TASOCITINIB","SRC_DB":"PHPROJ"},{"CN":"CP-690550-10 (ophthalmic) CCN=CP69055010(OPHTHALMIC)","SRC_DB":"PHPROJ"},{"CN":"JAK-3 inhibitor (oral tablet), Pfizer CCN=JAK3INHIBITOR(ORALTABLET)PFIZER","SRC_DB":"PHPROJ"},{"CN":"tasocitinib (topical) CCN=TASOCITINIB(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"CP-690,550-10 (ophthalmic) CCN=CP69055010(OPHTHALMIC)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C3","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYJ3-AN","THE_USE":"Janus kinase 3 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Xerophthalmia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Eczema, atopic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYR-AN","THE_USE":"Tyrosine kinase inhibitor (TKI)","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"DMARD-AG","THE_USE":"Disease modifying antirheumatic drug","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"IM-AN","THE_USE":"Immunosuppressant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYJ1-AN","THE_USE":"Janus kinase 1 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Transplant rejection, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"I5","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"R8A","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-MAP-AN","THE_USE":"MAP kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"M2Z","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D4A","THE_USE":"Antipruritic-inflamm","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Inflammatory bowel disease, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 111, 102, 97, 99, 105, 116, 105, 110, 105, 98, 32, 40, 116, 97, 115, 111, 99, 105, 116, 105, 110, 105, 98, 59, 32, 67, 80, 45, 54]...', original message: bytes can be at most 32766 in length; got 56510
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 56510
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:01:31,136][DEBUG][action.bulk              ]  US until 2023, and the EU until 2024, with regulatory exclusivity and patent life until 2012 and 2023, respectively (Company presentation, Shire, 21 Feb 2008).^US7105486 and US7223735 expire on 29 Jun 2023 (Form 10-K, Shire, 2007).^Licensing^Agreements^________________^GlaxoSmithKline^USA; Shire had a 3yr co-promotion agreement with GlaxoSmithKline (GSK); however, Shire terminated the agreement, under the terms of agreement, no termination payment or any other payments were made or are due to GSK since agreed upon sales thresholds were not achieved (Press release, GSK, 31 Mar 2009; Press release, Shire, 29 Oct 2010, http://www.shire.com/shireplc/uploads/press/ Q32010EarningsRelease_29Oct2010.pdf)^New River Pharmaceuticals (Shire)^USA; NRP previously licensed it to Shire for development, manufacturing, marketing and sales in the US (Press release, Shire, 31 Jan 2005; Scrip Daily Online, 31 Jul 2006, S00928872).^Shionogi^Japan; collaboration focused on development and commercialization for ADHD. Shionogi will pay an upfront payment to Shire. Under the terms of the agreement, Shionogi and Shire will jointly pursue development. After launch of, the parties will co-promote and Shionogi will also pay a sales royalty payment on net sales (Press release, Shionogi, 18 Nov 2011, http://www.shionogi.co.jp/ ir_en/news/detail/e_111118.pdf).^Additional Clinical Information^Phase I^In a double-blind, placebo- and active-controlled, single- crossover pharmacodynamic and pharmacokinetic study (A02) to evaluate the safety, tolerability and abuse liability of lisdexamfetamine dimesylate iv in healthy adult volunteers with histories of stimulant abuse, d-amfetamine 20mg iv produced significant responses on measures of amfetamine-like effects, that peaked within 15min, cf lisdexamfetamine dimesylate 50mg iv which produced a lack of significant responses on the same scales. 89% of subjects stated that they would not take lisdexamfetamine dimesylate 50mg again, cf 67% who stated that they would take d-amfetamine 20mg again. On a molar weight basis, the amfetamine free base content of the two drugs was equal, indicating that lisdexamfetamine dimesylate may have little likelihood for abuse by the parenteral route. It was safe and well tolerated (Press release, New River, 20 Jun 2006).^In an open-label, randomized, 4-period crossover Phase I trial in 24 healthy adults, single-dose lisdexamfetamine dimesylate 50mg resulted in median time to maximum plasma d-amfetamine concentration of 3hr, which was unchanged when co-administered with the OTC PPI Prilosec vs a change in maximum plasma concentration of d-amfetamine when Adderall XR was co- administered with Prilosec. Approximately 25% on lisdexamfetamine dimesylate + Prilosec had a shortened time to maximum d- amfetamine plasma concentration of greater than or equal to 1hr (Press release, Shire, 22 May 2009).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TF":["Receptor > GPCR > Adrenoceptor."],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140305:PP183 : Timing of launch for binge eating disorder reported"],"Document_TB":["Receptor > GPCR > Adrenoceptor;","GPCR > Adrenoceptor;","Receptor;","Adrenoceptor;","Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["ADR-AG: Adrenoreceptor agonist: Receptor, Transmitter, Adrenoreceptor agonist: Adrenergic stimulant: Adrenaline agonist: Noradrenaline agonist: Epinephrine agonist: R-T-ADR-AG|ADR-A-AG: Alpha adrenoreceptor agonist: Receptor, Transmitter, Alpha adrenoreceptor agonist: Alpha adrenergic agonist: Alpha adrenoceptor agonist: R-T-ADR-A-AG|DOPAU-AN: Dopamine reuptake inhibitor: Receptor, Transmitter, Dopamine reuptake inhibitor: DA reuptake inhibitor: R-T-DOPAU-AN|ADRU-AN: Adrenergic transmitter uptake inhibitor: Receptor, Transmitter, Adrenergic transmitter uptake inhibitor: Adrenaline uptake inhibitor: Noradrenaline uptake inhibitor: Epinephrine uptake inhibitor: Norepinephrine uptake inhibitor: R-T-ADRU-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["263.39"],"Document_AL":["1.06"],"Document_CASIS-CO_CO":["Originator: Shire (IE): Launched","Licensee: Shionogi (JP): Phase II Clinical Trial","Licensee: GlaxoSmithKline (GB): Discontinued"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD520971    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH038576","CASIS_COMPOUND":[{"CN":"Elvanse CCN=ELVANSE","SRC_DB":"PHPROJ"},{"CN":"LDX CCN=LDX","SRC_DB":"PHPROJ"},{"CN":"SPD-489 CCN=SPD489","SRC_DB":"PHPROJ"},{"CN":"amfetamine prodrug, New River CCN=AMFETAMINEPRODRUGNEWRIVER","SRC_DB":"PHPROJ"},{"CN":"Tyvense CCN=TYVENSE","SRC_DB":"PHPROJ"},{"CN":"lisdexamfetamine dimesylate CCN=LISDEXAMFETAMINEDIMESYLATE","SRC_DB":"PHPROJ"},{"CN":"lisdexamfetamine CCN=LISDEXAMFETAMINE","SRC_DB":"PHPROJ"},{"CN":"NRP104 CCN=NRP104","SRC_DB":"PHPROJ"},{"CN":"S877489 CCN=S877489","SRC_DB":"PHPROJ"},{"CN":"L-lysine-d-amfetamine CCN=LLYSINEDAMFETAMINE","SRC_DB":"PHPROJ"},{"CN":"SPD489 CCN=SPD489","SRC_DB":"PHPROJ"},{"CN":"Venvanse CCN=VENVANSE","SRC_DB":"PHPROJ"},{"CN":"Vyvanse CCN=VYVANSE","SRC_DB":"PHPROJ"},{"CN":"S-877489 CCN=S877489","SRC_DB":"PHPROJ"},{"CN":"NRP-104 CCN=NRP104","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"ADR-AG","THE_USE":"Adrenoreceptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Attention deficit hyperactivity disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6B","THE_USE":"Psychostimulant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Sleep disorder, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Binge eating disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"ADR-A-AG","THE_USE":"Alpha adrenoreceptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A8A3","THE_USE":"Anorectic-Antiobesity","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"ADRU-AN","THE_USE":"Adrenergic transmitter uptake inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N9A","THE_USE":"Dependence treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Addiction, cocaine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DOPAU-AN","THE_USE":"Dopamine reuptake inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 105, 115, 100, 101, 120, 97, 109, 102, 101, 116, 97, 109, 105, 110, 101, 32, 100, 105, 109, 101, 115, 121, 108, 97, 116, 101, 32, 40, 78]...', original message: bytes can be at most 32766 in length; got 49266
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 49266
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:01:31,393][DEBUG][action.bulk              ] n/page.php?p=60andq=472).^Handok^South Korea; for multiple myeloma (Press releases, AEterna Zentaris, 2 Dec 2009; BIO 2010 (Chicago), http://www.bio.org/ bfprofiles/pdfs/185863.pdf).^Keryx Biopharmaceuticals^Canada, Mexico and the US ; Keryx Biopharmaceuticals (formerly Access Oncology) previously had development and marketing rights for, including completion of Phase II and III trials; however the agreement was terminated and Aeterna regained all rights including all intellectual property and development data (Press release, Access Oncology, 18 Sep 2002, Press release, Aeterna, 7 May 2012, http://www.aezsinc.com/en/page.php?p=60andq=504).^Meda^It was previously under development by Asta Medica (now Meda; previously Viatris); however, the project was transferred to Zentaris following restructuring of the Degussa group (Direct communication, Zentaris, 24 Sep 2001).^Qualifying Therapeutic Discovery Project^USA; Keryx received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) for the development of perifosine (IRS.gov Web Page, 2 Feb 2011, http://www.irs.gov/ businesses/small/article/0,,id=229024,00.html).^Yakult Honsha^Japan; exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine in Japan. Under the terms of the agreement, Aeterna will receive an initial upfront payment and will be entitled to receive additional payments upon achieving certain pre- established milestones including clinical and regulatory events in Japan. Furthermore, Aeterna will be supplying perifosine to Yakult Honsha on a cost-plus-basis and be entitled to receive double-digit royalties on future net sales of perifosine in Japan (Press release, AEterna Zentaris, 9 Mar 2011, http:// www.aezsinc.com/en/page.php?p=60andq=427).^Availability^________________^Australia, Europe and South America (2nd Ann BioPartner N America (Vancouver), 2004).^Additional Clinical Information^Phase I^"],"Document_HA":["4"],"Document_CASIS-UPD_WE":["20131115"],"Document_PK":["Human (daily):MTD:200:mg/kg","Mouse (40mg/kg po):Vd:11.3:l/kg"],"Document_NC":["Yes"],"Document_RB":["20"],"Document_TF":["207: Enzyme > EC number > 2.7.11.1;","207: Receptor > GPCR;","207: Enzyme > Kinase;","207: Transporter > Porters (uni-, sym- and anti-);","5290: Enzyme > EC number > 2.7.1.137;","5290: Enzyme > Kinase."],"Document_TG":["207: v-akt murine thymoma viral oncogene homologue 1","5290: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha"],"Document_LCH":["20131107:PT : Ongoing development confirmed"],"Document_TB":["207: Enzyme > EC number > 2.7.11.1;","207: EC number > 2.7.11.1;","207: Enzyme;","207: 2.7.11.1;","207: Enzyme > EC number.","207: Receptor > GPCR;","207: GPCR;","207: Receptor.","207: Enzyme > Kinase;","207: Kinase;","207: Enzyme.","207: Transporter > Porters (uni-, sym- and anti-);","207: Porters (uni-, sym- and anti-);","207: Transporter.","5290: Enzyme > EC number > 2.7.1.137;","5290: EC number > 2.7.1.137;","5290: Enzyme;","5290: 2.7.1.137;","5290: Enzyme > EC number.","5290: Enzyme > Kinase;","5290: Kinase;","5290: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-PR-B-AN: Protein kinase B inhibitor: Enzyme, Transferase, Protein kinase B inhibitor: Akt inhibitor: E-TR-KI-PR-B-AN|KI-PR-AN: Protein kinase inhibitor: Enzyme, Transferase, Protein kinase inhibitor: E-TR-KI-PR-AN|KI-PI3-AN: PI3 kinase inhibitor: Enzyme, Transferase, PI3 kinase inhibitor: Phosphoinositol-3-kinase inhibitor: E-TR-KI-PI3-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["461.67"],"Document_AL":["8.20"],"Document_CASIS-CO_CO":["Originator: Meda (SE): Discontinued","Licensee: Yakult Honsha (JP): Phase II Clinical Trial","Licensee: Handok (KR): Preclinical","Licensee: Hikma (GB): Preclinical","Licensee: Nippon Kayaku (JP): Discontinued","Licensee: Keryx Biopharmaceuticals (US): Discontinued","Licensee: AEterna Zentaris (CA): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD104263    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase II"}],"DOCNO":"PH018604","CASIS_COMPOUND":[{"CN":"KRX-0401 CCN=KRX0401","SRC_DB":"PHPROJ"},{"CN":"D-21266 CCN=D21266","SRC_DB":"PHPROJ"},{"CN":"D-21805 CCN=D21805","SRC_DB":"PHPROJ"},{"CN":"AEZS104 CCN=AEZS104","SRC_DB":"PHPROJ"},{"CN":"AEZS-104 CCN=AEZS104","SRC_DB":"PHPROJ"},{"CN":"perifosine CCN=PERIFOSINE","SRC_DB":"PHPROJ"},{"CN":"NKA-17 CCN=NKA17","SRC_DB":"PHPROJ"},{"CN":"YHI 1003 CCN=YHI1003","SRC_DB":"PHPROJ"},{"CN":"YHI-1003 CCN=YHI1003","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2013-11-18 16:49:31","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Waldenstrom's hypergammaglobulinaemia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-B-AN","THE_USE":"Protein kinase B inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PI3-AN","THE_USE":"PI3 kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-AN","THE_USE":"Protein kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[80, 101, 114, 105, 102, 111, 115, 105, 110, 101, 32, 40, 68, 45, 50, 49, 50, 54, 54, 41, 32, 105, 115, 32, 97, 32, 112, 104, 111, 115]...', original message: bytes can be at most 32766 in length; got 36438
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36438
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:01:32,010][DEBUG][action.bulk              ] "6714: EC number > 2.7.10.2;","6714: Enzyme;","6714: 2.7.10.2;","6714: Enzyme > EC number.","6714: Enzyme > Kinase;","6714: Kinase;","6714: Enzyme.","3815: Enzyme > Kinase;","3815: Kinase;","3815: Enzyme.","3815: Receptor;","2534: Enzyme > EC number > 2.7.10.2;","2534: EC number > 2.7.10.2;","2534: Enzyme;","2534: 2.7.10.2;","2534: Enzyme > EC number.","2534: Enzyme > Kinase;","2534: Kinase;","2534: Enzyme.","7525: Enzyme > EC number > 2.7.10.2;","7525: EC number > 2.7.10.2;","7525: Enzyme;","7525: 2.7.10.2;","7525: Enzyme > EC number.","7525: Enzyme > Kinase;","7525: Kinase;","7525: Enzyme.","4067: Enzyme > EC number > 2.7.10.2;","4067: EC number > 2.7.10.2;","4067: Enzyme;","4067: 2.7.10.2;","4067: Enzyme > EC number.","4067: Enzyme > Kinase;","4067: Kinase;","4067: Enzyme.","3932: Enzyme > EC number > 2.7.10.1;","3932: EC number > 2.7.10.1;","3932: Enzyme;","3932: 2.7.10.1;","3932: Enzyme > EC number.","3932: Enzyme > Kinase;","3932: Kinase;","3932: Enzyme.","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-BCAB-AN: Bcr-Abl inhibitor: Enzyme, Transferase, BcrAbl inhibitor: Philadelphia chromosome inhibitor: Bcr-Abl kinase inhibitor: E-TR-KI-BCAB-AN|KI-TY-SC-AN: Src inhibitor: Enzyme, Transferase, Src inhibitor: c-Src inhibitor: Src tyrosine kinase inhibitor: E-TR-KI-TY-SC-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|KI-TY-EA-AN: EphA receptor kinase inhibitor: Enzyme, Transferase, EphA receptor kinase inhibitor: EphrinA receptor kinase inhibitor: E-TR-KI-TY-EA-AN|KI-TY-FY-AN: Fyn tyrosine kinase inhibitor: Enzyme, Transferase, Fyn tyrosine kinase inhibitor: Slk tyrosine kinase inhibitor: Syn tyrosine kinase inhibitor: E-TR-KI-TY-FY-AN|KI-TY-YE-AN: Yes tyrosine kinase inhibitor: Enzyme, Transferase, Yes tyrosine kinase inhibitor: E-TR-KI-TY-YE-AN|KI-TY-LN-AN: LYN tyrosine kinase inhibitor: Enzyme, Transferase, LYN tyrosine kinase inhibitor: E-TR-KI-TY-LN-AN|KI-TYRL-AN: Lymphocyte-specific tyrosine kinase inhibitor: Enzyme, Transferase, Lymphocytespecific tyrosine kinase inhibitor: Lck inhibitor: p56lck inhibitor: Lymphocyte tyrosine kinase inhibitor: E-TR-KI-TYRL-AN|KI-GFPLB-AN: Platelet-derived growth factor receptor beta kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor beta kinase inhib: PDGF beta kinase inhibitor: PDGF receptor beta kinase inhibitor: Platelet-derived growth factor beta kinase inhibitor: E-TR-KI-GFPLB-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["488.01"],"Document_AL":["4.19"],"Document_CASIS-CO_CO":["Originator: Bristol-Myers Squibb (US): Launched","Licensee: Otsuka (JP): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing in the Future"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Available for Licensing in the Future"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Available for Licensing in the Future"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Available for Licensing in the Future"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Available for Licensing in the Future"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH038544","CASIS_COMPOUND":[{"CN":"dasatinib (tablet) CCN=DASATINIB(TABLET)","SRC_DB":"PHPROJ"},{"CN":"NSC 732517 CCN=NSC732517","SRC_DB":"PHPROJ"},{"CN":"dasatinib CCN=DASATINIB","SRC_DB":"PHPROJ"},{"CN":"BMS-354825 (tablet) CCN=BMS354825(TABLET)","SRC_DB":"PHPROJ"},{"CN":"NSC 732517 (tablet) CCN=NSC732517(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-354825 (oral suspension) CCN=BMS354825(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"BMS 354825 (tablet) CCN=BMS354825(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dasatinib (oral suspension) CCN=DASATINIB(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"NSC-732517 CCN=NSC732517","SRC_DB":"PHPROJ"},{"CN":"Sprycel (tablet) CCN=SPRYCEL(TABLET)","SRC_DB":"PHPROJ"},{"CN":"NSC 732517 (oral suspension) CCN=NSC732517(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"NSC-732517 (tablet) CCN=NSC732517(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-354825 CCN=BMS354825","SRC_DB":"PHPROJ"},{"CN":"Sprycel CCN=SPRYCEL","SRC_DB":"PHPROJ"},{"CN":"BMS 354825 CCN=BMS354825","SRC_DB":"PHPROJ"},{"CN":"NSC-732517 (oral suspension) CCN=NSC732517(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"BMS 354825 (oral suspension) CCN=BMS354825(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"Sprycel (oral suspension) CCN=SPRYCEL(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"Src/ABL CCN=SRC/ABL","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLB-AN","THE_USE":"Platelet-derived growth factor receptor beta kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-LN-AN","THE_USE":"LYN tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-FY-AN","THE_USE":"Fyn tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-YE-AN","THE_USE":"Yes tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TYRL-AN","THE_USE":"Lymphocyte-specific tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-SC-AN","THE_USE":"Src inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Hypereosinophilic syndrome, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Polycythaemia vera","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-EA-AN","THE_USE":"EphA receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-BCAB-AN","THE_USE":"Bcr-Abl inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[68, 97, 115, 97, 116, 105, 110, 105, 98, 32, 40, 66, 77, 83, 45, 51, 53, 52, 56, 50, 53, 41, 32, 105, 115, 32, 97, 110, 32, 111]...', original message: bytes can be at most 32766 in length; got 35629
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35629
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:01:36,878][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.1gb[10.7%], replicas will not be assigned to this node
[2016-06-14 12:02:06,899][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12.1gb[10.7%], replicas will not be assigned to this node
[2016-06-14 12:02:12,327][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,372][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,377][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,390][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,395][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,409][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,433][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,443][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,448][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,464][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,470][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,486][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,492][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,510][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,525][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,530][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,586][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,607][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,643][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,672][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,762][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:12,831][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:13,040][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:13,197][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:13,268][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:13,537][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:20,662][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:20,716][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:20,726][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:20,738][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:20,758][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:20,961][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:21,177][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:21,256][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:02:30,830][DEBUG][action.bulk              ] hieved a mean absolute improvement from baseline compared to placebo of 1.6% through 16wk. Data also showed a mean relative improvement in lung function from baseline compared to placebo of 2% through week 16. A mean reduction in sweat chloride of 2.9mmol/l compared to placebo through 16wk was observed among those treated with ivacaftor. Adverse events were similar between the treatment groups. Adverse events that occurred more frequently in the ivacaftor treatment group compared to placebo were cough, nausea, rash and contact dermatitis. None of these events were serious or led to discontinuation (ClinicalTrials.gov, 27 Aug 2009 and 12 Jan 2010, http://clinicaltrials.gov/ct2/show/NCT00953706; Press release, Vertex, 23 Feb 2011, )http://investors.vrtx.com/ releasedetail.cfm?ReleaseID=551869).^It was in a 96wk, open-label rollover study from the DISCOVER trial. Additional analyses of data was expected in the 1st half of 2011 (Press release, Vertex, 18 Oct 2010, http:// investors.vrtx.com/releasedetail.cfm?ReleaseID=519568).^Phase I^It is in a randomized, placebo and active controlled, double- blind, parallel, factorial-assignment Phase I trial (VX12-809-008) in 200 healthy subjects in the Netherlands and the US, to evaluate the effect of lumacaftor in combination with ivacaftor on cardiac repolarization, as detected by QT/QTc interval corrected for heart rate (ClinicalTrials.gov, 31 Jul 2013, http:// www.clinicaltrials.gov/ct2/show/NCT01910415).^Cystic fibrosis^A randomized, double-blind, placebo-controlled, drug-drug interaction Phase I trial (VX10-809-006) in 48 healthy subjects in the US, to assess the pharmacokinetics and safety of VX-809 capsule once-daily x14days and ivacaftor tablet once q 12hrs x14days alone and in combination x14days is complete (ClinicalTrials.gov, 20 Jan 2012, http://www.clinicaltrials.gov/ ct2/show/NCT01216046).^A non-randomized, open-label, parallel-assignment, uncontrolled Phase I trial (VX10-770-013) in 12 subjects with moderate hepatic impairment and in 12 matched healthy subjects in Czech Republic and Slovakia, to assess the safety and pharmacokinetics of ivacaftor 150mg po tablet, is complete (ClinicalTrials.gov, 14 Jan 2011, http://www.clinicaltrials.gov/ct2/show/NCT01208285).^An open-label, non-randomized, uncontrolled, crossover-assignment Phase I trial (VX10-770-011) in 24 healthy subjects in the US, to evaluate the effect of ivacaftor 150mg po q 12hr on desipramine 50mg, is complete (ClinicalTrials.gov, 11 Dec 2010, http://www.clinicaltrials.gov/ct2/show/NCT01153542).^A non-randomized, open-label, uncontrolled Phase I trial in 24 healthy males receiving a single-dose of ivacaftor 150mg po or rifampin 600mg once-daily x10, was completed (ClinicalTrials.gov, 24 Nov 2009 and 6 May 2010, http://clinicaltrials.gov/ct2/show/ NCT01018368).^A randomized, double-blind, placebo-controlled Phase I trial in 24 healthy subjects receiving VX-809 x14 days, ivacaftor q 12h x14 days or a combination of both, was completed (ClinicalTrials.gov, 8 Feb 2010, http://clinicaltrials.gov/ct2/ show/NCT00966602).^A dose-escalating Phase I trial in up to 50 healthy volunteers and CF patients, to assess safety, tolerability and pharmacokinetics, was completed (Press releases, Vertex, 17 May and 26 Oct 2006).^Preclinical ^In vitro^Treatment of airway cells isolated from multiple patients carrying the most common CFTR mutation (delta-F508) with these compounds increased ion secretion to a level equal to or greater than that achieved with reference compounds, and with lower concentrations. One potentiator increased chloride ion secretion levels 5x above that with genistein at 100x lower concentration (Press release, Vertex, 9 Jun 2004).^Patents^A US patents covering the composition-of-matter of ivacaftor has been issued, with expiry in 2027. It has pending patent application in the EU (Form 10-K, Vertex, 22 Feb 2012, Page 12, http://sec.gov/Archives/edgar/data/875320/000104746912001298/ a2206536z10-k.htm).^Licensing^Agreements^________________^Cystic Fibrosis Foundation Therapeutics^USA; Vertex has an expanded agreement with Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, the US, whereby CFFT will provide funding for Vertex' late-stage CF drug discovery. Vertex retains the right to develop and commercialize any compounds discovered (Press releases, Vertex, 24 May 2004 and 12 Jan 2006; Form 10-K, Vertex, 2004).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140307"],"Document_NC":["Yes"],"Document_RB":["6"],"Document_TF":["1080: Enzyme > EC number > 3.6.3.49;","1080: Enzyme;","1080: Transporter > ABC driven superfamily;","1080: Ion channel > Chloride channel."],"Document_TG":["1080: cystic fibrosis transmembrane conductance regulator (ATP- binding cassette subfamily C, member 7)"],"Document_LCH":["20140303:AD181 : Enrollment completion in Phase IIa trial (VX09- 809-102) for cystic fibrosis reported"],"Document_TB":["1080: Enzyme > EC number > 3.6.3.49;","1080: EC number > 3.6.3.49;","1080: Enzyme;","1080: 3.6.3.49;","1080: Enzyme > EC number.","1080: Enzyme;","1080: Transporter > ABC driven superfamily;","1080: ABC driven superfamily;","1080: Transporter.","1080: Ion channel > Chloride channel;","1080: Chloride channel;","1080: Ion channel."],"Document_CASIS-USE_CASIS-MA_PHCD":["CFTR-AG: CF transmembrane conductance regulator agonist: Physiological, Biochemical, CF transmembrane conductance regulator agonist: Cystic fibrosis chloride channel agonist: CF chloride channel agonist: Cystic fibrosis transmembrane conductance regulator agonist: CFTR agonist: P-B-CFTR-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["392.50"],"Document_AL":["4.69"],"Document_CASIS-CO_CO":["Originator: Vertex Pharmaceuticals (US): Launched"],"Document_MR":["1:Market Rating - US$ 0-500 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"}],"DOCNO":"PH038278","CASIS_COMPOUND":[{"CN":"Kalydeco CCN=KALYDECO","SRC_DB":"PHPROJ"},{"CN":"VX770 CCN=VX770","SRC_DB":"PHPROJ"},{"CN":"cystic fibrosis therapy, Vertex CCN=CYSTICFIBROSISTHERAPYVERTEX","SRC_DB":"PHPROJ"},{"CN":"VX-770 CCN=VX770","SRC_DB":"PHPROJ"},{"CN":"ivacaftor CCN=IVACAFTOR","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-07 13:54:50","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Cystic fibrosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R4B","THE_USE":"Cystic fibrosis treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"CFTR-AG","THE_USE":"CF transmembrane conductance regulator agonist","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 118, 97, 99, 97, 102, 116, 111, 114, 32, 40, 86, 88, 45, 55, 55, 48, 41, 32, 105, 115, 32, 97, 110, 32, 111, 114, 97, 108, 32]...', original message: bytes can be at most 32766 in length; got 36473
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36473
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:02:31,090][DEBUG][action.bulk              ] spx?sKey=b4667ee5-ff60-4b03-86b2- a1f063fedc7aandcKey=71622d95-4536-44ad-a9ed- a9e615bc3ee4andmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^Patents^A Patent covering the composition of matter have been issued in Japan which will expire in Feb 2026 (BIO 2011 (Washington, DC)).^US and international patents covering composition of matter and use are pending (Form 10-K, ArQule, 2007).^Licensing^Agreements^________________^Daiichi Sankyo^Worldwide except China, Hong Kong, Japan, S Korea and Taiwan; Daiichi Sankyo acquired exclusive rights to ARQ-197 for the rest of the world, in return for upfront and milestone payments and royalties. The companies will equally share Phase II and Phase III costs (Press releases, Daiichi Sankyo, 10 Nov 2008 and ArQule, 19 Dec 2008). ArQule retains an option to participate in US commercialization (Form 10-K, ArQule, 2009).^Kyowa Hakko Kirin^China, Hong Kong, Japan, S Korea and Taiwan; Kyowa Hakko Kirin ((KHK) Kyowa Hakko before the merger) has an exclusive licence to develop and commercialize ARQ-197 in China, Hong Kong, Japan, S Korea and Taiwan (Press release, ArQule, 27 Apr 2007).^Qualified Therapeutic Discovery Project^USA; ArQule received a development grant under the Qualified Therapeutic Discovery Project (QTDP) program (Press release, ArQule, 2 Nov 2010, http://investors.arqule.com/ releasedetail.cfm?ReleaseID=526011).^"],"Document_HA":["2"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (360mg bid):AUC:8506:nghr/ml","Human (360mg bid):Cmax:1516:ng/ml"],"Document_NC":["Yes"],"Document_RB":["2"],"Document_TF":["4233: Enzyme > EC number > 2.7.10.1;","4233: Enzyme > Kinase;","4233: Receptor."],"Document_TG":["4233: met proto-oncogene"],"Document_LCH":["20140306:PP236 : Details of Phase III (ARQ 197-009) trial for hepatocellular carcinoma updated"],"Document_TB":["4233: Enzyme > EC number > 2.7.10.1;","4233: EC number > 2.7.10.1;","4233: Enzyme;","4233: 2.7.10.1;","4233: Enzyme > EC number.","4233: Enzyme > Kinase;","4233: Kinase;","4233: Enzyme.","4233: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-TY-MT-AN: MET tyrosine kinase inhibitor: Enzyme, Transferase, MET tyrosine kinase inhibitor: Hepatocyte growth factor receptor tyrosine kinase inhibitor: Met oncogene inhibitor: HGFR tyrosine kinase inhibitor: C-Met receptor tyrosine kinase inhibitor: E-TR-KI-TY-MT-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["369.43"],"Document_AL":["2.55"],"Document_CASIS-CO_CO":["Originator: ArQule (US): Phase III Clinical Trial","Licensee: Daiichi Sankyo (JP): Phase III Clinical Trial","Licensee: Kyowa Hakko Kirin (JP): Phase III Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH036335","CASIS_COMPOUND":[{"CN":"ARQ-707 (powder) CCN=ARQ707(POWDER)","SRC_DB":"PHPROJ"},{"CN":"CSP inhibitors, ArQule CCN=CSPINHIBITORSARQULE","SRC_DB":"PHPROJ"},{"CN":"ARQ197 (powder) CCN=ARQ197(POWDER)","SRC_DB":"PHPROJ"},{"CN":"ARQ-650RP (tablet) CCN=ARQ650RP(TABLET)","SRC_DB":"PHPROJ"},{"CN":"ARQ-197 CCN=ARQ197","SRC_DB":"PHPROJ"},{"CN":"ARQ 197 (capsule) CCN=ARQ197(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"ARQ-650RP (powder) CCN=ARQ650RP(POWDER)","SRC_DB":"PHPROJ"},{"CN":"ARQ 197 (powder) CCN=ARQ197(POWDER)","SRC_DB":"PHPROJ"},{"CN":"650 series, ArQule CCN=650SERIESARQULE","SRC_DB":"PHPROJ"},{"CN":"ARQ-197 (tablet) CCN=ARQ197(TABLET)","SRC_DB":"PHPROJ"},{"CN":"ARQ-197 (powder) CCN=ARQ197(POWDER)","SRC_DB":"PHPROJ"},{"CN":"ARQ-707 CCN=ARQ707","SRC_DB":"PHPROJ"},{"CN":"ARQ-197 (capsule) CCN=ARQ197(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"650 series (capsule), ArQule CCN=650SERIES(CAPSULE)ARQULE","SRC_DB":"PHPROJ"},{"CN":"ARQ 197 CCN=ARQ197","SRC_DB":"PHPROJ"},{"CN":"tivantinib (powder) CCN=TIVANTINIB(POWDER)","SRC_DB":"PHPROJ"},{"CN":"ARQ-707 (capsule) CCN=ARQ707(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"ARQ197 (capsule) CCN=ARQ197(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"650 series (tablet), ArQule CCN=650SERIES(TABLET)ARQULE","SRC_DB":"PHPROJ"},{"CN":"tivantinib CCN=TIVANTINIB","SRC_DB":"PHPROJ"},{"CN":"ARQ-650RP CCN=ARQ650RP","SRC_DB":"PHPROJ"},{"CN":"ARQ197 CCN=ARQ197","SRC_DB":"PHPROJ"},{"CN":"CSP inhibitors (tablet), ArQule CCN=CSPINHIBITORS(TABLET)ARQULE","SRC_DB":"PHPROJ"},{"CN":"ARQ-707 (tablet) CCN=ARQ707(TABLET)","SRC_DB":"PHPROJ"},{"CN":"ARQ 197 (tablet) CCN=ARQ197(TABLET)","SRC_DB":"PHPROJ"},{"CN":"CSP inhibitors (capsule), ArQule CCN=CSPINHIBITORS(CAPSULE)ARQULE","SRC_DB":"PHPROJ"},{"CN":"ARQ197 (tablet) CCN=ARQ197(TABLET)","SRC_DB":"PHPROJ"},{"CN":"tivantinib (capsule) CCN=TIVANTINIB(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"ARQ-650RP (capsule) CCN=ARQ650RP(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"tivantinib (tablet) CCN=TIVANTINIB(TABLET)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, sarcoma, lipo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, Merkel cell carcinoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, biliary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, neuroendocrine, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, testicular","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, oral","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-MT-AN","THE_USE":"MET tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 105, 118, 97, 110, 116, 105, 110, 105, 98, 32, 40, 112, 114, 101, 118, 105, 111, 117, 115, 108, 121, 32, 65, 82, 81, 45, 49, 57, 55]...', original message: bytes can be at most 32766 in length; got 42189
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 42189
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:02:31,172][DEBUG][action.bulk              ] ) was statistically similar to that observed on day 1. No apparent adverse effects, including hypoglycaemia, were reported (Clin Ther, Jan 2006, 55, PMID:16490580).^Preclinical ^In vivo^Sitagliptin phosphate 3mg/kg po had a Cmax of 600nM and exhibited 96% inhibition of DPP-IV, with a 2-3x increase in circulating active GLP-1 (64th Meet Am Diabetes Assoc (Orlando), 2004, Abs 633).^In insulin-resistant mice, 0.3, 3 and 30mg/kg resulted in dose- dependent decreases in glucose excursions following oral glucose administration. The maximum reduction was seen with 3mg/kg, which gave a Cmax of 700nM (64th Meet Am Diabetes Assoc (Orlando), 2004, Abs 633).^Oral bioavailability in mice, rats, dogs and monkeys was 61, 76, 100 and 68%, respectively, and t1/2 ranges from 1-5hr (64th Meet Am Diabetes Assoc (Orlando), 2004, Abs 633).^In mice, 2mg/kg po gave Cl, Vd, t1/2, Cmax and oral bioavailability values of 9.1ml/min/kg, 4.4l/kg, 5.9hr, 1.0microM and 75%, respectively (226th ACS (New York), 2003, MEDI 92-94).^In an oral GTT in lean mice, the lead compound at 3mg/kg + dextrose at 5mg/kg significantly reduced the increase in blood glucose level cf oral administration of dextrose alone at 5mg/kg (226th ACS (New York), 2003, MEDI 92-94).^Patents^US patents covering compound and salt form expires in 2022 and 2026 (Form 10-K, Merck and Co, 28 Feb 2012, Page 12, http:// www.sec.gov/Archives/edgar/data/310158/000119312512084319/ d274705d10k.htm).^Licensing^Agreements^________________^Almirall^Spain; it will be co-marketed with Almirall in Spain (Press release, Almirall, 4 Nov 2008).^Avanir Pharmaceuticals^USA; Merck has an exclusive 3yr agreement with Avanir Pharmaceuticals to co-promote Januvia and the sitagliptin family of products in the long-term care institutional setting in the US (Scrip Intelligence, 13 Aug 2013, http:// www.scripintelligence.com/business/Avanir-to-sell-Mercks-Januvia- in-long-term-care-settings-345843).^Banyu (Merck and Co); Ono^Japan; a 2nd brand is co-marketed by Banyu (Merck and Co) and Ono (Scrip Daily Online, 7 Dec 2009).^Daewoong; Merck and Co^South Korea; co-promoted by Daewoong (Pharma Koreana, Jan 2009).^Additional Clinical Information^Phase I^(66th Meet Am Diabetes Assoc (Washington, DC), 2006, Abs 533-P, 0).^"],"Document_HA":["10"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (healthy male, 25-800mg once-daily):t1/2:13.1:hr","Human (healthy volunteer, 100mg po):Tmax:1 to 4:hr","Rat (1mg/kg iv):Cl:24:ml/min/kg","Human (healthy volunteer, 100mg po):AUC:8.52:microMhr","Rat (1mg/kg iv):Vd:2.5:l/kg","Human (healthy volunteer, 100mg po):Cmax:950:nM","Human (healthy volunteer, 100mg po):bioavailability:87:%","Human (healthy volunteer, 100mg po):Vd:198:l","Mouse (2mg/kg po):Cl:9.1:ml/min/kg","Mouse (2mg/kg po):Vd:4.4:l/kg","Mouse (2mg/kg po):Cmax:1:microM"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["1803: Enzyme > EC number > 3.4.14.5;","1803: Enzyme > Protease/peptidase."],"Document_TG":["1803: dipeptidyl-peptidase 4"],"Document_LCH":["20140315:PP183 : Filing for combination therapy with secretagogues confirmed"],"Document_TB":["1803: Enzyme > EC number > 3.4.14.5;","1803: EC number > 3.4.14.5;","1803: Enzyme;","1803: 3.4.14.5;","1803: Enzyme > EC number.","1803: Enzyme > Protease/peptidase;","1803: Protease/peptidase;","1803: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PEPT-D4-AN: Dipeptidyl peptidase 4 (DPP IV) inhibitor: Enzyme, Hydrolase, Dipeptidyl peptidase 4 (DPP IV) inhibitor: Dipeptidyl peptidase 4 inhibitor: CD26 inhibitor: DPP IV inhibitor: DPP 4 inhibitor: E-HY-PEPT-D4-AN|INS-SE-AG: Insulin secretagogue: Physiological, Hormonal, Insulin secretagogue: P-H-INS-SE-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["407.32"],"Document_AL":["3.81"],"Document_CASIS-CO_CO":["Originator: Merck & Co (US): Launched","Licensee: Daewoong (KR): Launched","Licensee: Ono (JP): Launched","Licensee: Avanir (US): Launched","Licensee: Almirall (ES): Registered"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH036657","CASIS_COMPOUND":[{"CN":"sitagliptin phosphate (capsule) CCN=SITAGLIPTINPHOSPHATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"sitagliptin CCN=SITAGLIPTIN","SRC_DB":"PHPROJ"},{"CN":"Xelevia (tablet) CCN=XELEVIA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Ristaben (capsule) CCN=RISTABEN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Januvia CCN=JANUVIA","SRC_DB":"PHPROJ"},{"CN":"Tesavel CCN=TESAVEL","SRC_DB":"PHPROJ"},{"CN":"Glactiv CCN=GLACTIV","SRC_DB":"PHPROJ"},{"CN":"MK-431 (tablet) CCN=MK431(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Tesavel (tablet) CCN=TESAVEL(TABLET)","SRC_DB":"PHPROJ"},{"CN":"MK-0431 CCN=MK0431","SRC_DB":"PHPROJ"},{"CN":"sitagliptin phosphate CCN=SITAGLIPTINPHOSPHATE","SRC_DB":"PHPROJ"},{"CN":"Januvia (capsule) CCN=JANUVIA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Tesavel (capsule) CCN=TESAVEL(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"sitagliptin (capsule) CCN=SITAGLIPTIN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"MK-431 CCN=MK431","SRC_DB":"PHPROJ"},{"CN":"L-000224715 (tablet) CCN=L000224715(TABLET)","SRC_DB":"PHPROJ"},{"CN":"sitagliptin phosphate (tablet) CCN=SITAGLIPTINPHOSPHATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Ristaben CCN=RISTABEN","SRC_DB":"PHPROJ"},{"CN":"Glactiv (tablet) CCN=GLACTIV(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Glactiv (capsule) CCN=GLACTIV(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Januvia (tablet) CCN=JANUVIA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"MK-0431 (capsule) CCN=MK0431(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"ONO-5435 (tablet) CCN=ONO5435(TABLET)","SRC_DB":"PHPROJ"},{"CN":"L-000224715 CCN=L000224715","SRC_DB":"PHPROJ"},{"CN":"L-000224715 (capsule) CCN=L000224715(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"ONO-5435 CCN=ONO5435","SRC_DB":"PHPROJ"},{"CN":"Xelevia CCN=XELEVIA","SRC_DB":"PHPROJ"},{"CN":"MK-0431 (tablet) CCN=MK0431(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Xelevia (capsule) CCN=XELEVIA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"ONO-5435 (capsule) CCN=ONO5435(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"sitagliptin (tablet) CCN=SITAGLIPTIN(TABLET)","SRC_DB":"PHPROJ"},{"CN":"MK-431 (capsule) CCN=MK431(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Ristaben (tablet) CCN=RISTABEN(TABLET)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PEPT-D4-AN","THE_USE":"Dipeptidyl peptidase 4 (DPP IV) inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"INS-SE-AG","THE_USE":"Insulin secretagogue","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[83, 105, 116, 97, 103, 108, 105, 112, 116, 105, 110, 32, 112, 104, 111, 115, 112, 104, 97, 116, 101, 32, 40, 77, 75, 45, 48, 52, 51, 49]...', original message: bytes can be at most 32766 in length; got 32920
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 32920
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:02:31,490][DEBUG][action.bulk              ] -comparator controlled Phase I trial (ROF-T2D_107; U1111-1128-6945) to evaluate the effect of roflumilast plus alogliptin on postprandial active GLP- 1 level and 24hr glucose level in 40 subjects with Type 2 diabetes who are inadequately controlled on a stable dose of metformin was completed (ClinicalTrials.gov, 8 Dec 2012, http:// clinicaltrials.gov/show/NCT01664624).^In Type 2 diabetic patients receiving alogliptin 25mg, it had a Cmax, Tmax, AUC, Vd, t1/2 and Cl of 153ng/ml, 0.8-4.5hr, 1474nghr/ ml, 299l, 21.1hr and 175ml/min (Clin Ther, 2008, 30, 499, PMID:18405788).^Preclinical ^In preclinical trials, DPP-IV inhibitors po reduced blood glucose and increased insulin response, and showed potential as treatments for obesity, high cholesterol, and other metabolic syndromes (Press release, Syrrx, 22 Jan 2004).^In vivo^In high fat diet/streptozotocin (HFD/STZ) diabetic mice, alogliptin 5, 15 and 45mg/kg po x10wk reduced postprandial and fasting blood glucose levels and blood A1C levels. It increased glucose clearance ability and pancreas insulin content. It significantly restored the beta-cell mass and islet morphology, thus preserving islet function of insulin secretion. In the pancreas, it significantly changed expression of 10 genes including Ins1 and chronic alogliptin treatment completely or partially reversed the abnormalities in gene expression (Diabetes Obes Metab, 2011, 13, 337, PMID:21205126, http:// www.ncbi.nlm.nih.gov/pubmed/21205126).^Absolute oral bioavailability was 45, 86 and 72-88% in rats, dogs and monkeys, respectively (Eur J Pharmacol, 2008, 589, 306, PMID:18538760).^In obese diabetic ob/ob mice treated for 4wk, it decreased glycosylated haemoglobin by 0.4-0.9%, increased plasma insulin by 1.5-2.0x, and decreased plasma glucagon by 23-26% (Eur J Pharmacol, 2008, 588, 325, PMID:18499100).^In monkeys and dogs, it had t1/2 of 5.7 and 2.9hr, respectively (231st ACS (Atlanta), 2006, MEDI 18).^Patents^US8188275, covering dipeptidyl peptidase inhibitors has been issued (Press release, Takeda, 5 Jun 2012, http:// www.therapeuticsdaily.com/news/^^Licensing^Agreements^________________^Furiex Pharmaceuticals; Takeda^Worldwide; the project was exclusively licensed to PPD (now Furiex Pharmaceuticals), which was responsible for development costs through to Phase II; however, Takeda renegotiated the terms of the agreement after the acquisition of Syrrx. Furiex will still receive upfront, milestone and royalty payments; however, all rights to the DPP-IV inhibitor programme now belong to Takeda (Press releases, PPD, 19 Nov 2003 and Takeda, 14 Jul 2005).^Sanofi; Takeda^China; Takeda has a co-promotion agreement with Sanofi for the treatment of Type 2 diabetes. Under the terms of the agreement, Sanofi will have the exclusive rights to co-promote the product in China (Press release, Takeda, 22 Apr 2013, http:// www.tpi.takeda.com/media/news-releases/2013/takeda-and-sanofi- sign-co-promotion-agreement-to-expand-reach-of--alogliptin/).^"],"Document_HA":["4"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (Type II diabetes; 25mg):AUC:1474:nghr/ml","Human (Type II diabetes; 25mg):Cl:175:ml/min","Human (Type II diabetes; 25mg):Cmax:153:ng/ml","Human (Type II diabetes; 25mg):t1/2:21.1:hr","Human (Type II diabetes; 25mg):Tmax:0.8 to 4.5:hr","Human (Type II diabetes; 25mg):Vd:299:l","Human (25-800mg po):t1/2beta:12.4 to 21.4:hr","Human (25-800mg po):Tmax:1 to 2:hr"],"Document_NC":["Yes"],"Document_RB":["4"],"Document_TF":["1803: Enzyme > EC number > 3.4.14.5;","1803: Enzyme > Protease/peptidase."],"Document_TG":["1803: dipeptidyl-peptidase 4"],"Document_LCH":["20140313:PT : Rejection for use in the Scottish NHS for Type 2 diabetes reported"],"Document_TB":["1803: Enzyme > EC number > 3.4.14.5;","1803: EC number > 3.4.14.5;","1803: Enzyme;","1803: 3.4.14.5;","1803: Enzyme > EC number.","1803: Enzyme > Protease/peptidase;","1803: Protease/peptidase;","1803: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PEPT-D4-AN: Dipeptidyl peptidase 4 (DPP IV) inhibitor: Enzyme, Hydrolase, Dipeptidyl peptidase 4 (DPP IV) inhibitor: Dipeptidyl peptidase 4 inhibitor: CD26 inhibitor: DPP IV inhibitor: DPP 4 inhibitor: E-HY-PEPT-D4-AN|INS-SE-AG: Insulin secretagogue: Physiological, Hormonal, Insulin secretagogue: P-H-INS-SE-AG|PR-AN: Protease/peptidase inhibitor: Enzyme, Hydrolase, Protease/peptidase inhibitor: Protease inhibitor: Proteinase inhibitor: E-HY-PR-AN|PEPT-D-HY-AN: Dipeptide hydrolase inhibitor: Enzyme, Hydrolase, PEPTransmitter, DHormonal: Dipeptidase inhibitor: E-HY-PEPT-D-H-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["339.40"],"Document_AL":["1.47"],"Document_CASIS-CO_CO":["Originator: Takeda (JP): Launched","Licensee: Sanofi (FR): Launched","Licensee: Furiex Pharmaceuticals (US): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD520880    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH036723","CASIS_COMPOUND":[{"CN":"SYR-110322 CCN=SYR110322","SRC_DB":"PHPROJ"},{"CN":"SYR-322 CCN=SYR322","SRC_DB":"PHPROJ"},{"CN":"alogliptin benzoate CCN=ALOGLIPTINBENZOATE","SRC_DB":"PHPROJ"},{"CN":"DPP4 inhibitors, Takeda CCN=DPP4INHIBITORSTAKEDA","SRC_DB":"PHPROJ"},{"CN":"alogliptin CCN=ALOGLIPTIN","SRC_DB":"PHPROJ"},{"CN":"SYR 322 CCN=SYR322","SRC_DB":"PHPROJ"},{"CN":"DPP-IV inhibitors, Syrrx-1 CCN=DPPIVINHIBITORSSYRRX1","SRC_DB":"PHPROJ"},{"CN":"Nesina CCN=NESINA","SRC_DB":"PHPROJ"},{"CN":"SYR322 CCN=SYR322","SRC_DB":"PHPROJ"},{"CN":"SYR110322 CCN=SYR110322","SRC_DB":"PHPROJ"},{"CN":"Vipidia CCN=VIPIDIA","SRC_DB":"PHPROJ"},{"CN":"TAK-322 CCN=TAK322","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"PEPT-D4-AN","THE_USE":"Dipeptidyl peptidase 4 (DPP IV) inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"PEPT-D-HY-AN","THE_USE":"Dipeptide hydrolase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Obesity","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C10","THE_USE":"Hypolipaemic-Antiatherosclerosis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A8A3","THE_USE":"Anorectic-Antiobesity","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Hypercholesterolaemia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"INS-SE-AG","THE_USE":"Insulin secretagogue","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"PR-AN","THE_USE":"Protease/peptidase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 108, 111, 103, 108, 105, 112, 116, 105, 110, 32, 98, 101, 110, 122, 111, 97, 116, 101, 32, 40, 83, 89, 82, 45, 51, 50, 50, 59, 32]...', original message: bytes can be at most 32766 in length; got 34881
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34881
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:02:36,925][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12gb[10.6%], replicas will not be assigned to this node
[2016-06-14 12:02:40,186][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:03:06,948][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 12gb[10.6%], replicas will not be assigned to this node
[2016-06-14 12:03:18,467][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:03:36,978][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.8gb[10.5%], replicas will not be assigned to this node
[2016-06-14 12:04:07,000][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.8gb[10.4%], replicas will not be assigned to this node
[2016-06-14 12:04:29,276][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:04:37,045][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.8gb[10.4%], replicas will not be assigned to this node
[2016-06-14 12:05:07,093][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.7gb[10.3%], replicas will not be assigned to this node
[2016-06-14 12:05:25,142][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:05:25,235][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:05:37,170][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.7gb[10.3%], replicas will not be assigned to this node
[2016-06-14 12:06:07,191][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.6gb[10.2%], replicas will not be assigned to this node
[2016-06-14 12:06:37,214][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.5gb[10.2%], replicas will not be assigned to this node
[2016-06-14 12:07:07,236][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.5gb[10.1%], replicas will not be assigned to this node
[2016-06-14 12:07:37,258][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.4gb[10.1%], replicas will not be assigned to this node
[2016-06-14 12:07:39,456][DEBUG][action.bulk              ] 1475; 2011-004584-67; U1111-1124-3136), to assess safety, tolerability, pharmacokinetics and pharmacodynamics of lixisenatide sc in 24 paediatric (10-17yr old) and adult patients with Type 2 diabetes (ClinicalTrials.gov, 10 Apr 2012 and 15 May 2013, http://clinicaltrials.gov/ct2/show/NCT01572649).^In a trial in 15 healthy subjects, it slowed gastric emptying and thus rate of absorption of coadministered drugs (69th Meet Am Diabetes Assoc (New Orleans), 2009, Abs 495-P).^Its PK was unaffected by mild or moderate renal impairment, but drug exposure increased with severe renal impairment ((69th Meet Am Diabetes Assoc (New Orleans), 2009, Abs 557-P).^Preclinical ^In preclinical studies, lixisenatide was more effective in delaying gastric emptying and lowering prandial glucose excursions (change in glucose concentration after a meal) than liraglutide (Press release, Zealand, 24 Jun 2011, http:// ir.zealandpharma.com/releasedetail.cfm?ReleaseID=587248).^In vivo^In isolated Langendorff-perfused rat hearts, lixisenatide 0.3nM starting 10min prior to and during reperfusion significantly reduced myocardial infarct size by 36% compared to 32 and 29% on native GLP-1 0.3nM and liraglutide 0.3nM, respectively. The observed cardioprotective effect was not associated with a significant change in cardiac haemodynamics, particularly coronary flow. However, all GLP-1 receptor agonists stimulated myocardial glucose uptake during recovery from regional ischaemia (71st Scientific Sessions of the American Diabetes Association (ADA) 2011, San Diego, CA, June 24 - 28, 2011, Abs 0968-P, http:// ww2.aievolution.com/ada1101/index.cfm?do=abs.viewAbsandabs=10249).^In an oral glucose tolerance test in dogs, lixisenatide 1microg/ kg sc almost completely abolished blood glucose excursion. In rats, lixisenatide strongly and dose-dependently inhibited gastric emptying with a^significant emptying effect already present at 1microg/kg sc. In mice, after administration of a liquid meal, lixisenatide 3microg/ kg sc was more effective in lowering prandial glucose excursions than liraglutide 200microg/kg. In diabetic mice, lixisenatide 10microg/kg injected sc to improved glucose tolerance at least as effectively as liraglutide 200microg/kg sc (Press release, Sanofi, 24 Jun 2011, http://en.sanofi.com/binaries/ 20110624_LIXISENATIDE_ADA_en_tcm28-32878.pdf).^In an insulinoma cell line stimulated to increase caspase 3 activity and apoptosis, pretreatment with GLP-1, lixisenatide or exendin-4, reduced apoptosis by 50-60%. Approximately 40% reduction in apoptosis was seen after pretreatment with insulin glulisine, insulin lispro and insulin glargine (all qv). Combinations of GLP-1, AVE-0010 or exendin-4 with each insulin analogue was additive, with an 80% reduction in apoptosis on insulin glargine. Akt-phosphorylation occurred in response to GLP- 1, lixisenatide and exendin-4 after 24hr exposure. Lixisenatide + insulin glargine has potential preserving beta-cell mass in Type 2 diabetes (67th Meet Am Diabetes Assoc (Chicago), 2007, Abs 0279OR).^In beagle dogs exposed to glucose 2g/kg, 30min after single doses of lixisenatide 0.15-5microgram/kg sc or saline control, blood glucose in controls rose by approx 5mmol/l. Lixisenatide significantly reduced maximal blood glucose excursion by 49-73% vs placebo, decreased plasma insulin and C-peptide levels in response to oral glucose and demonstrated a trend towards decreased plasma glucagon. Lixisenatide 5microgram/kg without subsequent oral glucose load had no hypoglycaemic effect and did not induce pancreatic insulin release. An oral glucose tolerance test with concomitant acetaminophen 20mg/kg po found lixisenatide 5microg/kg reduced acetaminophen absorption (67th Meet Am Diabetes Assoc (Chicago), 2007, Abs 0486P).^In diabetic animals, the compounds improved glucose tolerance, increased insulin resistance and did not induce hypoglycaemia. In diabetic mice, they decreased glycosylated haemoglobin levels. They are GLP-1 agonists (Company Web Page, Zealand, 6 Aug 2001).^Patents^Compound patents in the EU, Japan and the US expire in 2020 (Form 20-F, Sanofi, 6 Mar 2012, Page 52, http://sec.gov/Archives/edgar/ data/1121404/000119312512098598/d279567d20f.htm#toc279567_9).^WO0104156, covering lixisenatide and other GLP-1 agonists synthesized by Zealand, was filed.^Licensing^Agreements^________________^Sanofi^Worldwide; Sanofi (Aventis before the merger) acquired worldwide rights to lixisenatide. Zealand will receive an upfront payment, milestone and royalty payments (Scrip Daily Online, 25 Jun 2003, S00806168).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (20microgram sc):Cmax:84:pg/ml"],"Document_NC":["No"],"Document_TF":["2740: Receptor > GPCR > Glucagon family."],"Document_TG":["2740: glucagon-like peptide 1 receptor"],"Document_LCH":["20140325:PP183 : Additional launches reported"],"Document_TB":["2740: Receptor > GPCR > Glucagon family;","2740: GPCR > Glucagon family;","2740: Receptor;","2740: Glucagon family;","2740: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["GLP-1-AG: Glucagon-like peptide 1 agonist: Receptor, Hormonal, Glucagonlike peptide 1 agonist: GLP-1 agonist: R-H-GLP-1-AG|INS-SE-AG: Insulin secretagogue: Physiological, Hormonal, Insulin secretagogue: P-H-INS-SE-AG|INCRE-AG: Incretin mimetic: Physiological, Biochemical, Incretin mimetic: P-B-INCRE-AG|"],"Document_ROUT":["P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Zealand Pharmaceuticals (DK): Launched","Licensee: Sanofi (FR): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH032747","CASIS_COMPOUND":[{"CN":"Lyxumia CCN=LYXUMIA","SRC_DB":"PHPROJ"},{"CN":"AVE0010 CCN=AVE0010","SRC_DB":"PHPROJ"},{"CN":"ZS-42-0010 CCN=ZS420010","SRC_DB":"PHPROJ"},{"CN":"lixisenatide CCN=LIXISENATIDE","SRC_DB":"PHPROJ"},{"CN":"ZP10 CCN=ZP10","SRC_DB":"PHPROJ"},{"CN":"ZS42-0010 CCN=ZS420010","SRC_DB":"PHPROJ"},{"CN":"GLP-1 peptide analogues, Zealand CCN=GLP1PEPTIDEANALOGUESZEALAND","SRC_DB":"PHPROJ"},{"CN":"ZP-10 CCN=ZP10","SRC_DB":"PHPROJ"},{"CN":"AVE-0010 CCN=AVE0010","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C1","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GLP-1-AG","THE_USE":"Glucagon-like peptide 1 agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"INS-SE-AG","THE_USE":"Insulin secretagogue","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"INCRE-AG","THE_USE":"Incretin mimetic","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 105, 120, 105, 115, 101, 110, 97, 116, 105, 100, 101, 32, 40, 65, 86, 69, 45, 48, 48, 49, 48, 59, 32, 90, 80, 45, 49, 48, 59]...', original message: bytes can be at most 32766 in length; got 38363
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 38363
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:07:39,461][DEBUG][action.bulk              ] /kg po):Cmax:1674:ng/ml"],"Document_NC":["Yes"],"Document_RB":["9"],"Document_TF":["3791: Enzyme > Kinase;","3791: Receptor;","2321: Enzyme > EC number > 2.7.10.1;","2321: Enzyme > Kinase;","2321: Receptor;","2324: Enzyme > EC number > 2.7.10.1;","2324: Enzyme > Kinase;","2324: Receptor;","5156: Enzyme > Kinase;","5156: Receptor;","4067: Enzyme > EC number > 2.7.10.2;","4067: Enzyme > Kinase."],"Document_TG":["3791: kinase insert domain receptor (a type III receptor tyrosine kinase)","2321: fms-related tyrosine kinase 1","2324: fms-related tyrosine kinase 4","5156: platelet-derived growth factor receptor, alpha polypeptide","4067: v-yes-1 Yamaguchi sarcoma viral related oncogene homologue"],"Document_LCH":["20140325:AD283 : Initiation of Phase III trial (1199.187) for idiopathic pulmonary fibrosis reported"],"Document_TB":["3791: Enzyme > Kinase;","3791: Kinase;","3791: Enzyme.","3791: Receptor;","2321: Enzyme > EC number > 2.7.10.1;","2321: EC number > 2.7.10.1;","2321: Enzyme;","2321: 2.7.10.1;","2321: Enzyme > EC number.","2321: Enzyme > Kinase;","2321: Kinase;","2321: Enzyme.","2321: Receptor;","2324: Enzyme > EC number > 2.7.10.1;","2324: EC number > 2.7.10.1;","2324: Enzyme;","2324: 2.7.10.1;","2324: Enzyme > EC number.","2324: Enzyme > Kinase;","2324: Kinase;","2324: Enzyme.","2324: Receptor;","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;","4067: Enzyme > EC number > 2.7.10.2;","4067: EC number > 2.7.10.2;","4067: Enzyme;","4067: 2.7.10.2;","4067: Enzyme > EC number.","4067: Enzyme > Kinase;","4067: Kinase;","4067: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-GFEN2-AN: VEGFR-2 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 2 tyrosine kinase inhibitor: KDR tyrosine kinase inhibitor: Flk-1 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 2 TK inhibitor: E-TR-KI-GFEN2-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|KI-GFPL-AN: Platelet-derived growth factor receptor kinase inhibitor: Enzyme, Transferase, Plateletderived growth factor receptor kinase inhibitor: Platelet-derived growth factor kinase inhibitor: PDGF receptor kinase inhibitor: PDGF kinase inhibitor: E-TR-KI-GFPL-AN|KI-TY-SC-AN: Src inhibitor: Enzyme, Transferase, Src inhibitor: c-Src inhibitor: Src tyrosine kinase inhibitor: E-TR-KI-TY-SC-AN|KI-TYRL-AN: Lymphocyte-specific tyrosine kinase inhibitor: Enzyme, Transferase, Lymphocytespecific tyrosine kinase inhibitor: Lck inhibitor: p56lck inhibitor: Lymphocyte tyrosine kinase inhibitor: E-TR-KI-TYRL-AN|KI-TY-LN-AN: LYN tyrosine kinase inhibitor: Enzyme, Transferase, LYN tyrosine kinase inhibitor: E-TR-KI-TY-LN-AN|KI-FGFR-AN: FGF receptor tyrosine kinase inhibitor: Enzyme, FGF receptor tyrosine kinase inhibitor: E-KI-FGFR-AN|GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|KI-GFEN-AN: VEGFR tyrosine kinase inhibitor: Enzyme, Transferase, VEGFR tyrosine kinase inhibitor: Vascular endothelial growth factor receptor TK inhibitor: E-TR-KI-GFEN-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["539.64"],"Document_AL":["1.67"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Pre-registration"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Pre-registration"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH033101","CASIS_COMPOUND":[{"CN":"BIBF-1000 CCN=BIBF1000","SRC_DB":"PHPROJ"},{"CN":"nintedanib CCN=NINTEDANIB","SRC_DB":"PHPROJ"},{"CN":"BIBF1120 CCN=BIBF1120","SRC_DB":"PHPROJ"},{"CN":"nintedanib (soft capsule) CCN=NINTEDANIB(SOFTCAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BIBF 1120 CCN=BIBF1120","SRC_DB":"PHPROJ"},{"CN":"BIBF 1120 (soft capsule) CCN=BIBF1120(SOFTCAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BIBF1120 (tablet) CCN=BIBF1120(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBF-1120 (soft capsule) CCN=BIBF1120(SOFTCAPSULE)","SRC_DB":"PHPROJ"},{"CN":"nintedanib (tablet) CCN=NINTEDANIB(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBF-1120 (tablet) CCN=BIBF1120(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Vargatef (soft capsule) CCN=VARGATEF(SOFTCAPSULE)","SRC_DB":"PHPROJ"},{"CN":"intedanib CCN=INTEDANIB","SRC_DB":"PHPROJ"},{"CN":"intedanib (soft capsule) CCN=INTEDANIB(SOFTCAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BIBF 1120 (tablet) CCN=BIBF1120(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBF 1120 ES CCN=BIBF1120ES","SRC_DB":"PHPROJ"},{"CN":"intedanib (tablet) CCN=INTEDANIB(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBF-1120 CCN=BIBF1120","SRC_DB":"PHPROJ"},{"CN":"Vargatef CCN=VARGATEF","SRC_DB":"PHPROJ"},{"CN":"BIBF1120 (soft capsule) CCN=BIBF1120(SOFTCAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Vargatef (tablet) CCN=VARGATEF(TABLET)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"KI-GFPL-AN","THE_USE":"Platelet-derived growth factor receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"R9Z","THE_USE":"Respiratory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-SC-AN","THE_USE":"Src inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-FGFR-AN","THE_USE":"FGF receptor tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYRL-AN","THE_USE":"Lymphocyte-specific tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, gastrointestinal, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Fibrosis, pulmonary, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN-AN","THE_USE":"VEGFR tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN2-AN","THE_USE":"VEGFR-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-LN-AN","THE_USE":"LYN tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 105, 110, 116, 101, 100, 97, 110, 105, 98, 32, 105, 115, 32, 97, 110, 32, 111, 114, 97, 108, 108, 121, 45, 97, 99, 116, 105, 118, 101]...', original message: bytes can be at most 32766 in length; got 33407
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 33407
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:07:39,752][DEBUG][action.bulk              ] ssion in 2 tumours and greater than 80% inhibition in another (102nd ACCR (Orlando), 2011, Abs 1592, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=769c89c8-6c80-4b16-9dfe- f510f41fe44candcKey=798b9884-fc03-435d-adda- 4fe2d85af708andmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^In preclinical studies, it was active against 100% of B-Raf mutant lines and 71% of Ras mutant lines tested. It was also active in multiple B-Raf and K-Ras mutant xenografts (Company presentation, GSK, 19 Jun 2007).^In vitro^In colorectal cancer cell lines, trametinib resulted in growth inhibition accompanied with upregulation of p15INK4b and/or p27KIP1 and COLO205 showed sensitivity to trametinib for inducing apoptosis than HT-29 (102nd ACCR (Orlando), 2011, Abs 3585, http:/ /www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=37bcae41- 860c-44f3-a18f-fe31ecc9581fandcKey=adb8ae4a-340c-45b0-b962- 297d7e2ec056andmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^Licensing^Agreements^________________^GlaxoSmithKline^Worldwide; GlaxoSmithKline (GSK) obtained exclusive, worldwide manufacturing and development rights to trametinib on 18 Apr 2006 (Reuteurs Web Page, 15 Dec 2008; Press release, Japan Tobacco, 31 Mar 2009).^GlaxoSmithKline; Pfizer^Worldwide; Pfizer has entered into an agreement with GlaxoSmithKline to explore the anti-cancer efficacy and the safety of GSK's trametinib combined with Pfizer's palbociclib in a Phase I/II study (Study 200344) in patients with advanced/ metastatic melanoma (Press release, Pfizer, 21 Nov 2013, http:// www.pfizer.com/news/press-release/press-release-detail/^^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["Yes"],"Document_RB":["6"],"Document_TF":["5604: Enzyme > EC number > 2.7.12.2;","5604: Enzyme > Kinase;","5605: Enzyme > EC number > 2.7.12.2;","5605: Enzyme > Kinase."],"Document_TG":["5604: mitogen-activated protein kinase kinase 1","5605: mitogen-activated protein kinase kinase 2"],"Document_LCH":["20140313:AD244 : Ongoing development confirmed"],"Document_TB":["5604: Enzyme > EC number > 2.7.12.2;","5604: EC number > 2.7.12.2;","5604: Enzyme;","5604: 2.7.12.2;","5604: Enzyme > EC number.","5604: Enzyme > Kinase;","5604: Kinase;","5604: Enzyme.","5605: Enzyme > EC number > 2.7.12.2;","5605: EC number > 2.7.12.2;","5605: Enzyme;","5605: 2.7.12.2;","5605: Enzyme > EC number.","5605: Enzyme > Kinase;","5605: Kinase;","5605: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-MEK-AN: MEK inhibitor: Enzyme, Transferase, MEK inhibitor: MAP kinase kinase inhibitor: E-TR-KI-MEK-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["615.41"],"Document_AL":["2.44"],"Document_CASIS-CO_CO":["Originator: Japan Tobacco (JP): Discontinued","Licensee: GlaxoSmithKline (GB): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"}],"DOCNO":"PH044988","CASIS_COMPOUND":[{"CN":"JTP-74057 (oral solution) CCN=JTP74057(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"JTP74057 (capsule) CCN=JTP74057(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"GSK1120212 (oral solution) CCN=GSK1120212(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"GSK212 CCN=GSK212","SRC_DB":"PHPROJ"},{"CN":"GSK1120212 (tablet) CCN=GSK1120212(TABLET)","SRC_DB":"PHPROJ"},{"CN":"JTP-74057 (capsule) CCN=JTP74057(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"trametinib CCN=TRAMETINIB","SRC_DB":"PHPROJ"},{"CN":"trametinib (capsule) CCN=TRAMETINIB(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"GSK-212 CCN=GSK212","SRC_DB":"PHPROJ"},{"CN":"GSK-1120212 CCN=GSK1120212","SRC_DB":"PHPROJ"},{"CN":"1120212 (oral solution) CCN=1120212(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"JTP-74057 (tablet) CCN=JTP74057(TABLET)","SRC_DB":"PHPROJ"},{"CN":"1120212 (capsule) CCN=1120212(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"GSK-1120212 (tablet) CCN=GSK1120212(TABLET)","SRC_DB":"PHPROJ"},{"CN":"GSK1120212 (capsule) CCN=GSK1120212(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"GSK-1120212 (capsule) CCN=GSK1120212(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"GSK-1120212 (oral solution) CCN=GSK1120212(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Mekinist CCN=MEKINIST","SRC_DB":"PHPROJ"},{"CN":"JTP74057 (tablet) CCN=JTP74057(TABLET)","SRC_DB":"PHPROJ"},{"CN":"trametinib (oral solution) CCN=TRAMETINIB(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"trametinib (tablet) CCN=TRAMETINIB(TABLET)","SRC_DB":"PHPROJ"},{"CN":"JTP74057 CCN=JTP74057","SRC_DB":"PHPROJ"},{"CN":"JTP74057 (oral solution) CCN=JTP74057(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"JTP-74057 CCN=JTP74057","SRC_DB":"PHPROJ"},{"CN":"GSK-1120212B CCN=GSK1120212B","SRC_DB":"PHPROJ"},{"CN":"GSK1120212 CCN=GSK1120212","SRC_DB":"PHPROJ"},{"CN":"1120212 CCN=1120212","SRC_DB":"PHPROJ"},{"CN":"GSK1120212B CCN=GSK1120212B","SRC_DB":"PHPROJ"},{"CN":"1120212 (tablet) CCN=1120212(TABLET)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, leukaemia, unspecifed","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, biliary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, leukaemia, hairy cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, testicular","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, lymphoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-MEK-AN","THE_USE":"MEK inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 114, 97, 109, 101, 116, 105, 110, 105, 98, 32, 40, 71, 83, 75, 45, 49, 49, 50, 48, 50, 49, 50, 41, 32, 105, 115, 32, 97, 32]...', original message: bytes can be at most 32766 in length; got 34621
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34621
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:07:39,756][DEBUG][action.bulk              ] N|KI-GFEN3-AN: VEGFR-3 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 3 tyrosine kinase inhibitor: Flt-4 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 3 TK inhibitor: E-TR-KI-GFEN3-AN|KI-GFPL-AN: Platelet-derived growth factor receptor kinase inhibitor: Enzyme, Transferase, Plateletderived growth factor receptor kinase inhibitor: Platelet-derived growth factor kinase inhibitor: PDGF receptor kinase inhibitor: PDGF kinase inhibitor: E-TR-KI-GFPL-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|KI-GFEN-AN: VEGFR tyrosine kinase inhibitor: Enzyme, Transferase, VEGFR tyrosine kinase inhibitor: Vascular endothelial growth factor receptor TK inhibitor: E-TR-KI-GFEN-AN|KI-RAF-B-AN: B-raf kinase inhibitor: Enzyme, Transferase, Biochemical, raf kinase inhibitor: V-raf homologue B1 inhibitor: BRAF inhibitor: RAFB1 inhibitor: Oncogene BRAF inhibitor: E-TR-KI-RAF-B-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-UN: Parenteral, general","T-UN: Topical, general"],"Document_MW":["437.52"],"Document_AL":["2.34"],"Document_CASIS-CO_CO":["Originator: GlaxoSmithKline (GB): Launched"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD520704    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"}],"DOCNO":"PH032117","CASIS_COMPOUND":[{"CN":"GW-2286 CCN=GW2286","SRC_DB":"PHPROJ"},{"CN":"SB-786034 (oral suspension) CCN=SB786034(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"786034 (IV) CCN=786034(IV)","SRC_DB":"PHPROJ"},{"CN":"SB-786034 CCN=SB786034","SRC_DB":"PHPROJ"},{"CN":"GW-786034 CCN=GW786034","SRC_DB":"PHPROJ"},{"CN":"GW-786034 (oral suspension) CCN=GW786034(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"pazopanib CCN=PAZOPANIB","SRC_DB":"PHPROJ"},{"CN":"pazopanib (tablet) CCN=PAZOPANIB(TABLET)","SRC_DB":"PHPROJ"},{"CN":"GW786034 (IV) CCN=GW786034(IV)","SRC_DB":"PHPROJ"},{"CN":"Votrient CCN=VOTRIENT","SRC_DB":"PHPROJ"},{"CN":"GW-786034 (tablet) CCN=GW786034(TABLET)","SRC_DB":"PHPROJ"},{"CN":"GW-786034B CCN=GW786034B","SRC_DB":"PHPROJ"},{"CN":"Armala CCN=ARMALA","SRC_DB":"PHPROJ"},{"CN":"GW786034 (tablet) CCN=GW786034(TABLET)","SRC_DB":"PHPROJ"},{"CN":"pazopanib (oral suspension) CCN=PAZOPANIB(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"SB-786034 (tablet) CCN=SB786034(TABLET)","SRC_DB":"PHPROJ"},{"CN":"pazopanib hydrochloride (IV) CCN=PAZOPANIBHYDROCHLORIDE(IV)","SRC_DB":"PHPROJ"},{"CN":"pazopanib hydrochloride (oral suspension) CCN=PAZOPANIBHYDROCHLORIDE(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"pazopanib hydrochloride (tablet) CCN=PAZOPANIBHYDROCHLORIDE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"786034 (tablet) CCN=786034(TABLET)","SRC_DB":"PHPROJ"},{"CN":"GW786034 (topical) CCN=GW786034(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"GW786034 (oral suspension) CCN=GW786034(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"Patorma CCN=PATORMA","SRC_DB":"PHPROJ"},{"CN":"pazopanib (IV) CCN=PAZOPANIB(IV)","SRC_DB":"PHPROJ"},{"CN":"786034 (topical) CCN=786034(TOPICAL)","SRC_DB":"PHPROJ"},{"CN":"pazopanib hydrochloride CCN=PAZOPANIBHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"786034 CCN=786034","SRC_DB":"PHPROJ"},{"CN":"786034 (oral suspension) CCN=786034(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"pazopanib (topical) CCN=PAZOPANIB(TOPICAL)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C3","THE_USE":"Cancer, sarcoma, leiomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K1C","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, carcinoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN1-AN","THE_USE":"VEGFR-1 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-RAF-B-AN","THE_USE":"B-raf kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, synovial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN2-AN","THE_USE":"VEGFR-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPL-AN","THE_USE":"Platelet-derived growth factor receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN3-AN","THE_USE":"VEGFR-3 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN-AN","THE_USE":"VEGFR tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[80, 97, 122, 111, 112, 97, 110, 105, 98, 32, 40, 86, 111, 116, 114, 105, 101, 110, 116, 41, 32, 105, 115, 32, 97, 32, 109, 117, 108, 116]...', original message: bytes can be at most 32766 in length; got 35573
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35573
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:08:07,281][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.4gb[10.1%], replicas will not be assigned to this node
[2016-06-14 12:08:37,324][INFO ][cluster.routing.allocation.decider] [Pixx] low disk watermark [85%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.3gb[10%], replicas will not be assigned to this node
[2016-06-14 12:09:07,347][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.2gb[9.9%], shards will be relocated away from this node
[2016-06-14 12:09:07,347][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:09:15,297][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:09:15,491][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:09:37,370][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.2gb[9.9%], shards will be relocated away from this node
[2016-06-14 12:09:43,104][DEBUG][action.bulk              ]  2mg/kg q wk) + Arimidex (1mg daily) vs Arimidex alone as a 1st-line therapy (or 2nd-line hormonal therapy) in 208 postmenopausal women with advanced, HER2-positive and hormone receptor-positive breast cancer, patients on trastuzumab had a significant improvement in PFS (Press release, Roche, 29 May 2006).^In 172 patients with advanced metastatic breast cancer, overexpressing HER2, trastuzumab had an overall response rate of 18%. The median duration of response was 9.1mth and median duration of survival was 16.4mth. Trastuzumab + paclitaxel had a response rate of 49%, a median duration of response of 10.9mth, a median time to disease progression of 7.1mth and an increased overall survival time of 25mth cf 17%, 4.6mth, 3mth and 18mth respectively for paclitaxel alone. Adverse events including chills, fever, nausea, vomiting, weakness and headache were reported by 40-50% of patients during 1st infusion and were less frequent with subsequent infusions. Pulmonary events and cardiac dysfunction occurred more frequently when trastuzumab was used in combination therapy (MIMS UK, 2000, Oct, 8).^In the trials in breast cancer mentioned above, the most common adverse events were chills and fever associated with infusion. There was also an increased risk of cardiac dysfunction in women treated with trastuzumab and anthracyclines cf anthracyclines alone. Cardiac dysfunction was reported in a small number of patients on trastuzumab alone and in combination with paclitaxel (Scrip, 1998, 2298, 22).^In a randomized Phase III trial (GBG26) in 156 women with HER2+ locally advanced or metastatic breast cancer, who had previously received trastuzumab, trastuzumab + capecitabine (qv) prolonged survival without disease progression by nearly 3mth, cf chemotherapy alone (8.2 and 5.6mth, respectively). Continuation of trastuzumab therapy increased the percentage of responders from 27 to 48% (Press release, Roche, 30 May 2008).^In an open-label, randomized Phase III trial (NOAH) in 228 patients with locally-advanced HER2+ breast cancer, trastuzumab + chemotherapy prior to surgery improved event-free survival at 3yr, cf 53% for chemotherapy alone. Trastuzumab + chemotherapy completely erradicated tumours in 39%, cf 20% on chemotherapy alone. The overall response rate was 89 cf 77%, respectively (Press release, Roche, 11 Dec 2008).^Phase II^In a Phase II trial in 43 breast cancer patients, trastuzumab 250mg iv followed by 100mg/wk x10wk infusion produced 1CR and 4PRs. The CR patient was disease-free at 23wk and in the PRs, 50% tumour reduction was observed. It was well tolerated, with 11 adverse events (Scrip, 1996, 2112, 23).^Additional References^34th ASCO (Los Angeles) 1998, Abs 376^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (500mg by infusion):t1/2:288:hr","Human (500mg by infusion):Cmax:377:microg/ml","Human (500mg by infusion):Vd:44:ml/kg"],"Document_NC":["No"],"Document_TF":["2064: Enzyme > EC number > 2.7.10.1;","2064: Receptor > Cytokine receptor;","2064: Enzyme > Kinase."],"Document_TG":["2064: v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2"],"Document_LCH":["20140321:AD244 : Planned Phase IIa trial (ML28897) for solid tumours reported"],"Document_TB":["2064: Enzyme > EC number > 2.7.10.1;","2064: EC number > 2.7.10.1;","2064: Enzyme;","2064: 2.7.10.1;","2064: Enzyme > EC number.","2064: Receptor > Cytokine receptor;","2064: Cytokine receptor;","2064: Receptor.","2064: Enzyme > Kinase;","2064: Kinase;","2064: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EPR2-AN: Epidermal growth factor receptor 2 antagonist: Receptor, Hormonal, Epidermal growth factor receptor 2 antagonist: EGFR2 antagonist: HER2 antagonist: HER2/neu antagonist: ErbB-2 antagonist: R-H-GF-EPR2-AN|"],"Document_ROUT":["P-CR: Parenteral, intracerebral","P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Hoffmann-La Roche (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 1998 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"}],"DOCNO":"PH015922","CASIS_COMPOUND":[{"CN":"trastuzumab CCN=TRASTUZUMAB","SRC_DB":"PHPROJ"},{"CN":"R597 (IV) CCN=R597(IV)","SRC_DB":"PHPROJ"},{"CN":"R-597 CCN=R597","SRC_DB":"PHPROJ"},{"CN":"rhuMAb HER2 CCN=RHUMABHER2","SRC_DB":"PHPROJ"},{"CN":"anti-HER-2 MAb, Roche CCN=ANTIHER2MABROCHE","SRC_DB":"PHPROJ"},{"CN":"Ro-45-2317 (IV) CCN=RO452317(IV)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (intracerebral) CCN=TRASTUZUMAB(INTRACEREBRAL)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (intrathecal) CCN=TRASTUZUMAB(INTRATHECAL)","SRC_DB":"PHPROJ"},{"CN":"HER-2 MAb, Roche CCN=HER2MABROCHE","SRC_DB":"PHPROJ"},{"CN":"Herceptin (intrathecal) CCN=HERCEPTIN(INTRATHECAL)","SRC_DB":"PHPROJ"},{"CN":"RG597 (IV) CCN=RG597(IV)","SRC_DB":"PHPROJ"},{"CN":"RG-597 (IV) CCN=RG597(IV)","SRC_DB":"PHPROJ"},{"CN":"Herceptin CCN=HERCEPTIN","SRC_DB":"PHPROJ"},{"CN":"RG-597 CCN=RG597","SRC_DB":"PHPROJ"},{"CN":"Herceptin (intracerebral) CCN=HERCEPTIN(INTRACEREBRAL)","SRC_DB":"PHPROJ"},{"CN":"RG597 CCN=RG597","SRC_DB":"PHPROJ"},{"CN":"Ro-45-2317 CCN=RO452317","SRC_DB":"PHPROJ"},{"CN":"R597 CCN=R597","SRC_DB":"PHPROJ"},{"CN":"anti-HER-2 MAb, Genentech CCN=ANTIHER2MABGENENTECH","SRC_DB":"PHPROJ"},{"CN":"HER-2 MAb, Genentech CCN=HER2MABGENENTECH","SRC_DB":"PHPROJ"},{"CN":"R-597 (IV) CCN=R597(IV)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (SC, unoptimised) CCN=TRASTUZUMAB(SCUNOPTIMISED)","SRC_DB":"PHPROJ"},{"CN":"Herceptin (IV) CCN=HERCEPTIN(IV)","SRC_DB":"PHPROJ"},{"CN":"trastuzumab (IV) CCN=TRASTUZUMAB(IV)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EPR2-AN","THE_USE":"Epidermal growth factor receptor 2 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 114, 97, 115, 116, 117, 122, 117, 109, 97, 98, 32, 105, 115, 32, 97, 32, 104, 117, 109, 97, 110, 105, 122, 101, 100, 32, 77, 65, 98]...', original message: bytes can be at most 32766 in length; got 35788
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35788
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:09:43,602][DEBUG][action.bulk              ] vo^In animal models of venous and arterial thrombosis, it demonstrated antithrombotic efficacy. It inhibited thrombin- induced platelet aggregation. In animal models of atherosclerosis and fibrosis, it showed protective effects on proliferation and promoted plaque stability (242nd ACS (Denver), 2011, MEDI 185).^In experimental models, dabigatran etexilate prevented the progression of tumour cells. In tracheal xenotransplants in mice, dabigatran etexilate x3 and 4wk demonstrated significantly less penetration of MDA-MB-231 breast cancer cells through the tracheal wall. In syngeneic Balb/c mice with primary 4T1 mammary carcinoma, it showed 50% reduction in tumour volume at 4wk and reduced the tumour cells in the blood and liver micrometastases by 50-60%. No weight loss was observed (101st AACR (Washington, DC), 2010 Abs 2271, http://www.abstractsonline.com/plan/ ViewAbstract.aspx?mID=2521andsKey=07c2cd4b-147f-4970-b215- f110442c05ffandcKey=3c4ea4ed-8e76-425f-bc25- 81d766dbd07aandmKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}).^In an in vivo model of arterial thrombosis, dabigatran etexilate po exhibited potent and long-lasting, dose-dependent reduction of thrombus formation. In an in vitro study, dabigatran etexilate concentration-dependently inhibited tissue factor-induced human platelet aggregation (Press release, BI, 9 Dec 2007).^In domestic pigs, dabigatran etexilate 0.3-3mg/kg iv pre-vessel injury dose-dependently inhibited cyclic closure by 84% in the 1st 20min on 1mg/kg, cf 10 closures/interval on placebo. In the final 30min (1.5-2hr post-injury), a 66% reduction in cyclic closures was sustained. In domestic pigs, dabigatran etexilate 0.3-3mg/kg iv post-vessel injury (treatment) dose-dependently decreased cyclic closures, with an 84% reduction in the 1st 20min on 3mg/kg, cf 15 closures/interval on placebo. The reduction in cyclic closures was maintained throughout the 2hr bolus dose and 1.5-2hr post-dosing (48th Meet Am Soc Hematol (Orlando), 2006, Abs 906).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (150mg po):t1/2:28:hr","Human:Tmax:6:hr","Human:bioavailability:6.5:%","Human:t1/2beta:60:hr"],"Document_NC":["Yes"],"Document_RB":["11"],"Document_TF":["2147: Enzyme > EC number > 3.4.21.5;","2147: Enzyme > Protease/peptidase."],"Document_TG":["2147: coagulation factor II (thrombin)"],"Document_LCH":["20140308:PP236 : Approval in Jordan for stroke prevention in atrial fibrillation reported"],"Document_TB":["2147: Enzyme > EC number > 3.4.21.5;","2147: EC number > 3.4.21.5;","2147: Enzyme;","2147: 3.4.21.5;","2147: Enzyme > EC number.","2147: Enzyme > Protease/peptidase;","2147: Protease/peptidase;","2147: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PR-SE-TD-AN: Direct thrombin inhibitor: Enzyme, Hydrolase, Direct thrombin inhibitor: E-HY-PR-SE-TD-AN|PR-SE-AN: Serine protease inhibitor: Enzyme, Hydrolase, Serine protease inhibitor: Serine proteinase unspecified inhibitor: Unspecified serine protease inhibitor: General serine protease inhibitor: General serine proteinase inhibitor: E-HY-PR-SE-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["471.52"],"Document_AL":["2.91"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Launched"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD277193    ","MD294949    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH040208","CASIS_COMPOUND":[{"CN":"dabigatran etexilate mesylate (capsule) CCN=DABIGATRANETEXILATEMESYLATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Pradaxa (capsule) CCN=PRADAXA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 (capsule) CCN=BIBR1048(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Pradaxa (tablet) CCN=PRADAXA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 CCN=BIBR1048","SRC_DB":"PHPROJ"},{"CN":"BIBR-953ZW CCN=BIBR953ZW","SRC_DB":"PHPROJ"},{"CN":"dabigatran (tablet) CCN=DABIGATRAN(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dabigatran (solution) CCN=DABIGATRAN(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate (solution) CCN=DABIGATRANETEXILATEMESYLATE(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"dabigatran CCN=DABIGATRAN","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 (capsule) CCN=BIBR1048(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate CCN=DABIGATRANETEXILATEMESYLATE","SRC_DB":"PHPROJ"},{"CN":"Pradaxa CCN=PRADAXA","SRC_DB":"PHPROJ"},{"CN":"Rendix CCN=RENDIX","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 CCN=BIBR1048","SRC_DB":"PHPROJ"},{"CN":"Prazaxa CCN=PRAZAXA","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 (solution) CCN=BIBR1048(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 (solution) CCN=BIBR1048(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Pradaxar CCN=PRADAXAR","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate (solution) CCN=DABIGATRANETEXILATE(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BIBR-1048 (tablet) CCN=BIBR1048(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate mesylate (tablet) CCN=DABIGATRANETEXILATEMESYLATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BIBR 1048 (tablet) CCN=BIBR1048(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Pradaxa (solution) CCN=PRADAXA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"dabigatran (capsule) CCN=DABIGATRAN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate (tablet) CCN=DABIGATRANETEXILATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate (capsule) CCN=DABIGATRANETEXILATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"dabigatran etexilate CCN=DABIGATRANETEXILATE","SRC_DB":"PHPROJ"},{"CN":"Pradax CCN=PRADAX","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:43","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N7C","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"B1A","THE_USE":"Antithrombotic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR-SE-TD-AN","THE_USE":"Direct thrombin inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Thrombosis, venous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Acute coronary syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR-SE-AN","THE_USE":"Serine protease inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Thromboprophylaxis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[68, 97, 98, 105, 103, 97, 116, 114, 97, 110, 32, 101, 116, 101, 120, 105, 108, 97, 116, 101, 32, 40, 66, 73, 66, 82, 45, 49, 48, 52]...', original message: bytes can be at most 32766 in length; got 47571
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47571
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:10:05,759][DEBUG][action.bulk              ]  28, 67 and 86% on 30, 50 and 75mg, respectively, cf 16% on placebo. Platelet count >200000/microl was recorded in 12, 38 and 52% on 30, 50 and 75mg, respectively, cf 4% on placebo. Median platelet counts were 26000, 128000 and 183000/microl, respectively, cf 16000/microl for placebo. Headaches were reported (with no dose-related pattern) in 13, 10 and 21%, respectively, cf 21% on placebo. Bleeding AEs included haemorrhoids, haemorrhagic diarrhoea and conjunctival haemorrhage in 3 placebo patients, epistaxis, gingival bleeding and contusions in 5 patients on 30mg, menorrhagia in 1 patient on 50mg, and contusion in 1 patient on 75mg (11th Cong Eur Hematol Assoc (Amsterdam), 2006, Abs 1022; Press releases, GSK, 19 Jul and 11 Dec 2006).^Phase I^A randomized, double-blind, single-group-assignment UK Phase I trial in 36 healthy volunteers, to evaluate the safety profile and the photoirritant potential of eltrombopag olamine 75mg once- daily, cf ciprofloxacin and placebo, is complete (ClinicalTrials.gov, 24 Aug 2009 and 17 Jan 2013, http:// clinicaltrials.gov/ct2/show/NCT00688272).^In a randomized, single-blind, placebo-controlled, parallel-group Phase I trial in 72 healthy volunteers, eltrombopag olamine 5- 75mg po was well tolerated, with no SAEs. Eltrombopag olamine >30mg x10 days gave a dose-dependent increase in platelet counts, with maximum platelet count on days 14-16 (96th AACR (Anaheim), 2005, Abs 2565).^Thrombocytopenia, unspecified; Hepatic dysfunction, general; Radio/chemotherapy-induced injury, bone marrow, thrombocytopenia^GlaxoSmithKline^It was in Phase I trials in hepatic, renal and chemotherapy- induced thrombocytopenia (Form 10-K, Ligand, 2007; Company Web Page, Ligand, 13 May 2008).^Thrombocytopenia, unspecified^GlaxoSmithKline^Enrollment is complete in an open-label, 3-period, single- sequence, crossover Phase I trial (116010) to evaluate the drug- drug interaction between eltrombopag and boceprevir and between eltrombopag and telaprevir in 56 healthy adult subjects in the US (ClinicalTrials.gov, 7 Aug and 10 Oct 2012, http:// clinicaltrials.gov/ct2/show/NCT01657552).^An open-label, dose-ranging, non-randomized Phase I trial to assess the safety, efficacy and pharmacokinetics of eltrombopag olamine po in 48 sarcoma patients in the US with low platelet count who were receiving adriamycin + ifosfamide was completed (Form 10-Q, Ligand, 8 May 2008; ClinicalTrials.gov, 6 Apr, 24 Aug 2009 and 21 May 2011, http://clinicaltrials.gov/ct2/show/ NCT00358540).^Preclinical ^In vivo^In chimpanzees, eltrombopag olamine 10mg/kg/day po x5 days increased platelet counts 1.3-2.4x (96th AACR (Anaheim), 2005, Abs 4929).^In vitro^In ovarian, lung and breast tumour cell lines, eltrombopag olamine 0.01?100ug/ml induced an inhibition of proliferation on all cell lines tested. The IC50 ranged from 3.7 to 49.7ug/ml. There was no enhancement of proliferation at any concentration of eltrombopag, consistent with the very low or undetectable level of MPL expression. Erythropoietin receptor (EPOR) mRNA was expressed at low-to-moderate levels, while ERBB2 and IGF1R were expressed at higher levels in these cell lines. Microarray analysis showed undetectable MPL mRNA levels in all 118 samples from patients with breast cancer and 52% of the nsclc samples, the remaining nsclc samples expressed low levels of MPL. In contrast, EPOR was expressed in 75?100% of the breast cancer, and NSCLC samples. ERBB2 was expressed in 97?100% of the samples and IGF1R was expressed in 54?100% of the samples (51st Meet Am Soc Hematol (New Orleans), 2009, Abs 2409).^Patents^It is patent protected through 2027 (Company presentation, Ligand, 4 Jun 2012, Page 11, http://investor.ligand.com/Theme/Ligand/ files/doc_presentations/Ligand_Higgins_Foehr_Jefferies_6-4- 12.pdf).^Licensing^Agreements^________________^GlaxoSmithKline^Worldwide; eltrombopag olamine was discovered through a GSK and Ligand collaboration. GSK has exclusive worldwide marketing rights and responsibility for development and registration. Ligand is to receive milestone payments and royalties (Roth Capital Partners Conf (New York), 2004).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["4352: Receptor > Cytokine receptor > Class I."],"Document_TG":["4352: myeloproliferative leukaemia virus oncogene"],"Document_LCH":["20140318:PP183 : Timing of launch for aplastic anaemia reported"],"Document_TB":["4352: Receptor > Cytokine receptor > Class I;","4352: Cytokine receptor > Class I;","4352: Receptor;","4352: Class I;","4352: Receptor > Cytokine receptor."],"Document_CASIS-USE_CASIS-MA_PHCD":["TPO-AG: Thrombopoietin agonist: Physiological, Biochemical, Thrombopoietin agonist: TPO agonist: Platelet regulatory factor agonist: P-B-TPO-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["442.48"],"Document_AL":["6.42"],"Document_CASIS-CO_CO":["Originator: GlaxoSmithKline (GB): Launched","Licensee: Ligand (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD520813    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"}],"DOCNO":"PH035342","CASIS_COMPOUND":[{"CN":"497115 CCN=497115","SRC_DB":"PHPROJ"},{"CN":"SB-497115 CCN=SB497115","SRC_DB":"PHPROJ"},{"CN":"SB497115 CCN=SB497115","SRC_DB":"PHPROJ"},{"CN":"eltrombopag olamine CCN=ELTROMBOPAGOLAMINE","SRC_DB":"PHPROJ"},{"CN":"eltrombopag CCN=ELTROMBOPAG","SRC_DB":"PHPROJ"},{"CN":"Promacta CCN=PROMACTA","SRC_DB":"PHPROJ"},{"CN":"Revolade CCN=REVOLADE","SRC_DB":"PHPROJ"},{"CN":"SB-497115-GR CCN=SB497115GR","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"TPO-AG","THE_USE":"Thrombopoietin agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"A5B","THE_USE":"Hepatoprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Thrombocytopenic purpura, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R","THE_USE":"Thrombocytopenia, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K5B","THE_USE":"Radio-chemoprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Anaemia, aplastic, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Hepatic dysfunction, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"B7Z","THE_USE":"Haematological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Radio/chemotherapy-induced injury, bone marrow, thrombocytopenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"B3C9","THE_USE":"Antianaemic","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[69, 108, 116, 114, 111, 109, 98, 111, 112, 97, 103, 32, 111, 108, 97, 109, 105, 110, 101, 32, 40, 83, 66, 45, 52, 57, 55, 49, 49, 53]...', original message: bytes can be at most 32766 in length; got 40831
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40831
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:10:05,834][DEBUG][action.bulk              ] assignment, multicenter Phase Ib trial (CR101676) in 30 paediatric subjects with moderately-to-severely active ulcerative colitis in Austria, Belgium, Canada, Denmark, France, Germany, Israel, the Netherlands, Poland and the US, to assess the safety and pharmacokinetics of golimumab sc (ClinicalTrials.gov, 29 Aug 2013, http://www.clinicaltrials.gov/show/NCT01900574).^Infarction, myocardial; Ischaemia, cerebral^Clinical trials to assess the effect of golimumab on cardiovascular event occurrence, including acute myocardial infarction and stroke, in RA patients were planned. Serum markers of cardiovascular risk and carotid artery thickness measurements will be evaluated (Company presentation, JandJ, 7 Jun 2007).^Preclinical ^Preclinical observations suggested potential benefit in reducing cardiovascular events in RA (Company presentation, JandJ, 7 Jun 2007).^In vivo^A single golimumab injection delayed disease progression in a TNF transgenic mouse arthritis model, and reduced histological evidence of joint degradation. In a humanized mouse model of psoriasis, a dose-dependent effect was observed. Mice receiving golimumab 2mg/kg showed significant reductions in epidermal thickness and Ki 67 staining vs control mice (8th Eur Cong Rheumatol (Barcelona), 2007, Abs THU088).^Licensing^Agreements^________________^Janssen-Cilag (Johnson and Johnson)^Hong Kong; Janssen-Cilag (JandJ) has exclusive marketing rights in Hong Kong (Press release, Centocor, 27 Jun 2008).^Medarex^Worldwide; Centocor has an agreement to access Medarex' (now Bristol-Myers Squibb's (BMS)) HuMab-Mouse technology for manufacture (Press release, Medarex, 3 May 2000).^Merck and Co^Europe, Russia and Turkey; As of Jul 2011, Merck transferred exclusive marketing rights to Johnson and Johnson in territories including Canada, Central and S America, the Middle East, Africa and Asia Pacific. Merck retains exclusive marketing rights throughout Europe, Russia and Turkey (Press release, Merck, 29 Jul 2011, http://www.merck.com/newsroom/news-release-archive/ financial/2011_0729.html). Schering-Plough had a co-development and exclusive worldwide marketing rights to golimumab, excluding China, Hong Kong, Indonesia, Japan, Taiwan and the US (Press releases, Schering-Plough, 16 Aug 2005 and 17 Aug 2006). However, on announcement of the merger between S-P and Merck and Co, JandJ filed an arbitration demand to terminate the agreement with S-P, as per the new amended distribution agreement Merck will continue to have exclusive marketing rights in Europe, Russia and Turkey, but will relinquish its exclusive rights in territories including Africa, Asia Pacific, Canada, Central and South America and the Middle East (Press release, JandJ, 27 May 2009; Scrip Intelligence, 18 Apr 2011, http://www.scripintelligence.com/home/ Merck-and-JandJ-settle-Remicade-battle---and--investors-nerves- 314281).^Mitsubishi Tanabe Pharma^Indonesia, Japan and Taiwan; Mitsubishi Tanabe Pharma (Tanabe Seiyaku before the merger) has co-development and marketing rights in Indonesia, Japan and Taiwan (Press release, Tanabe, 7 Aug 2006).^Xian-Janssen (Johnson and Johnson)^China; Xian-Janssen (JandJ) has exclusive marketing rights in China (Press release, Centocor, 27 Jun 2008).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (0.1-10mg/kg iv):t1/2beta:157.44 to 222:hr","Human (0.1-10mg/kg iv):Cl:0.4:l/day","Human (0.1-10mg/kg iv):Vd:3.07:l","Human (0.3-1mg/kg sc):t1/2beta:288 to 624:hr"],"Document_NC":["No"],"Document_TF":["7124: Cytokine/Growth factor > Cytokine > Tumour necrosis factor."],"Document_TG":["7124: tumour necrosis factor"],"Document_LCH":["20140322:AD283 : Additional details of Phase III trial (CR006343) for rheumatoid arthritis reported"],"Document_TB":["7124: Cytokine/Growth factor > Cytokine > Tumour necrosis factor;","7124: Cytokine > Tumour necrosis factor;","7124: Cytokine/Growth factor;","7124: Tumour necrosis factor;","7124: Cytokine/Growth factor > Cytokine."],"Document_CASIS-USE_CASIS-MA_PHCD":["TNF-A-AN: Tumour necrosis factor alpha antagonist: Physiological, Hormonal, Tumour necrosis factor alpha antagonist: TNF alpha antagonist: TNF a antagonist: P-H-TNF-A-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Johnson & Johnson (US): Launched","Licensee: Merck & Co (US): Launched","Licensee: Mitsubishi Tanabe Pharma (JP): Launched"],"Document_MR":["5:Market Rating - Over US$ 10000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"}],"DOCNO":"PH035834","CASIS_COMPOUND":[{"CN":"CNTO 148 CCN=CNTO148","SRC_DB":"PHPROJ"},{"CN":"CNTO-148 (intravenous) CCN=CNTO148(INTRAVENOUS)","SRC_DB":"PHPROJ"},{"CN":"golimumab (intravenous) CCN=GOLIMUMAB(INTRAVENOUS)","SRC_DB":"PHPROJ"},{"CN":"golimumab CCN=GOLIMUMAB","SRC_DB":"PHPROJ"},{"CN":"Simponi (intravenous) CCN=SIMPONI(INTRAVENOUS)","SRC_DB":"PHPROJ"},{"CN":"CNTO-148 (subcutaneous) CCN=CNTO148(SUBCUTANEOUS)","SRC_DB":"PHPROJ"},{"CN":"CNTO-148 CCN=CNTO148","SRC_DB":"PHPROJ"},{"CN":"Simponi (subcutaneous) CCN=SIMPONI(SUBCUTANEOUS)","SRC_DB":"PHPROJ"},{"CN":"Simponi Aria CCN=SIMPONIARIA","SRC_DB":"PHPROJ"},{"CN":"golimumab (subcutaneous) CCN=GOLIMUMAB(SUBCUTANEOUS)","SRC_DB":"PHPROJ"},{"CN":"Simponi CCN=SIMPONI","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"TNF-A-AN","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R8A","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Infarction, myocardial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N7C","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"T3A2","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M1A1","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[71, 111, 108, 105, 109, 117, 109, 97, 98, 32, 40, 67, 78, 84, 79, 45, 49, 52, 56, 41, 32, 105, 115, 32, 97, 32, 104, 117, 109, 97]...', original message: bytes can be at most 32766 in length; got 55910
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 55910
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:10:07,399][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.1gb[9.9%], shards will be relocated away from this node
[2016-06-14 12:10:07,400][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:10:37,423][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11.1gb[9.8%], shards will be relocated away from this node
[2016-06-14 12:11:07,447][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.9gb[9.7%], shards will be relocated away from this node
[2016-06-14 12:11:07,447][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:11:37,470][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.7gb[9.4%], shards will be relocated away from this node
[2016-06-14 12:11:43,030][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:11:43,184][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:11:44,016][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:12:01,009][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:12:01,675][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:12:07,492][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 11gb[9.7%], shards will be relocated away from this node
[2016-06-14 12:12:07,492][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:12:37,515][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.9gb[9.6%], shards will be relocated away from this node
[2016-06-14 12:12:40,255][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:12:40,297][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:12:55,726][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:13:07,538][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.9gb[9.6%], shards will be relocated away from this node
[2016-06-14 12:13:07,538][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:13:37,560][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.8gb[9.6%], shards will be relocated away from this node
[2016-06-14 12:14:07,582][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.8gb[9.5%], shards will be relocated away from this node
[2016-06-14 12:14:07,582][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:14:37,604][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.7gb[9.5%], shards will be relocated away from this node
[2016-06-14 12:15:07,627][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.7gb[9.4%], shards will be relocated away from this node
[2016-06-14 12:15:07,627][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:15:37,655][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.6gb[9.4%], shards will be relocated away from this node
[2016-06-14 12:16:07,678][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.6gb[9.3%], shards will be relocated away from this node
[2016-06-14 12:16:07,678][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:16:37,701][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.4gb[9.2%], shards will be relocated away from this node
[2016-06-14 12:17:07,725][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10gb[8.9%], shards will be relocated away from this node
[2016-06-14 12:17:07,725][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:17:37,747][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.4gb[9.2%], shards will be relocated away from this node
[2016-06-14 12:18:07,770][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.3gb[9.1%], shards will be relocated away from this node
[2016-06-14 12:18:07,770][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:18:37,792][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.3gb[9.1%], shards will be relocated away from this node
[2016-06-14 12:19:07,816][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.2gb[9%], shards will be relocated away from this node
[2016-06-14 12:19:07,816][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:19:37,842][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.2gb[9%], shards will be relocated away from this node
[2016-06-14 12:20:06,180][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:20:06,331][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:20:07,864][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.1gb[8.9%], shards will be relocated away from this node
[2016-06-14 12:20:07,864][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:20:37,890][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.1gb[8.9%], shards will be relocated away from this node
[2016-06-14 12:21:07,912][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10gb[8.8%], shards will be relocated away from this node
[2016-06-14 12:21:07,912][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:21:37,935][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.8gb[8.7%], shards will be relocated away from this node
[2016-06-14 12:22:07,958][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.5gb[8.4%], shards will be relocated away from this node
[2016-06-14 12:22:07,958][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:22:38,033][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.6gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:23:08,056][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.2gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:23:08,056][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:23:38,077][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.3gb[8.2%], shards will be relocated away from this node
[2016-06-14 12:24:08,095][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.7gb[8.6%], shards will be relocated away from this node
[2016-06-14 12:24:08,095][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:24:38,126][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.7gb[8.6%], shards will be relocated away from this node
[2016-06-14 12:25:08,145][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.6gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:25:08,145][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:25:38,182][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.6gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:26:08,202][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.5gb[8.4%], shards will be relocated away from this node
[2016-06-14 12:26:08,202][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:26:38,220][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.5gb[8.4%], shards will be relocated away from this node
[2016-06-14 12:27:08,239][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.4gb[8.3%], shards will be relocated away from this node
[2016-06-14 12:27:08,239][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:27:38,258][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.3gb[8.3%], shards will be relocated away from this node
[2016-06-14 12:28:08,285][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.3gb[8.2%], shards will be relocated away from this node
[2016-06-14 12:28:08,285][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:28:38,303][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.2gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:29:08,335][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.2gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:29:08,335][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:29:38,353][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.2gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:30:00,867][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:30:08,385][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.1gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:30:08,385][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:30:38,404][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.1gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:31:08,436][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.1gb[8%], shards will be relocated away from this node
[2016-06-14 12:31:08,436][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:31:38,454][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.1gb[8%], shards will be relocated away from this node
[2016-06-14 12:32:08,473][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9gb[7.9%], shards will be relocated away from this node
[2016-06-14 12:32:08,473][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:32:38,502][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.9gb[7.9%], shards will be relocated away from this node
[2016-06-14 12:33:08,521][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.9gb[7.8%], shards will be relocated away from this node
[2016-06-14 12:33:08,521][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:33:38,559][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.8gb[7.7%], shards will be relocated away from this node
[2016-06-14 12:34:08,577][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.7gb[7.7%], shards will be relocated away from this node
[2016-06-14 12:34:08,578][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:34:38,617][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.7gb[7.7%], shards will be relocated away from this node
[2016-06-14 12:35:08,664][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.6gb[7.6%], shards will be relocated away from this node
[2016-06-14 12:35:08,664][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:35:38,696][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.6gb[7.6%], shards will be relocated away from this node
[2016-06-14 12:36:08,731][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.5gb[7.5%], shards will be relocated away from this node
[2016-06-14 12:36:08,731][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:36:38,750][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.4gb[7.5%], shards will be relocated away from this node
[2016-06-14 12:37:08,770][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.4gb[7.4%], shards will be relocated away from this node
[2016-06-14 12:37:08,770][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:37:38,795][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.3gb[7.4%], shards will be relocated away from this node
[2016-06-14 12:38:08,815][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.3gb[7.3%], shards will be relocated away from this node
[2016-06-14 12:38:08,816][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:38:38,859][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.3gb[7.3%], shards will be relocated away from this node
[2016-06-14 12:39:08,879][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.2gb[7.3%], shards will be relocated away from this node
[2016-06-14 12:39:08,879][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:39:38,900][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.1gb[7.2%], shards will be relocated away from this node
[2016-06-14 12:40:10,759][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.2gb[7.2%], shards will be relocated away from this node
[2016-06-14 12:40:10,759][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:40:40,797][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.1gb[8.9%], shards will be relocated away from this node
[2016-06-14 12:41:10,862][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.5gb[9.3%], shards will be relocated away from this node
[2016-06-14 12:41:10,863][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:41:40,908][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.3gb[9.1%], shards will be relocated away from this node
[2016-06-14 12:42:10,945][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.3gb[9.1%], shards will be relocated away from this node
[2016-06-14 12:42:10,945][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:42:40,970][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.2gb[9%], shards will be relocated away from this node
[2016-06-14 12:43:10,995][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.2gb[9%], shards will be relocated away from this node
[2016-06-14 12:43:10,995][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:43:41,034][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10.1gb[8.9%], shards will be relocated away from this node
[2016-06-14 12:44:11,165][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 10gb[8.9%], shards will be relocated away from this node
[2016-06-14 12:44:11,165][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:44:41,215][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.9gb[8.7%], shards will be relocated away from this node
[2016-06-14 12:45:11,239][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.9gb[8.8%], shards will be relocated away from this node
[2016-06-14 12:45:11,239][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:45:41,264][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.9gb[8.8%], shards will be relocated away from this node
[2016-06-14 12:45:52,837][DEBUG][action.bulk              ] and 34% of patients on rosiglitazone maleate, metformin and glyburide, respectively, had inadequate glucose control at 5yr. Rosiglitazone maleate was well tolerated. Common Adverse events included oedema, weight gain and hypoglycaemia (Press release, GSK, 14 Jul 2008). Female patients on rosiglitazone maleate were significantly more likely to experience bone fractures at peripheral sites cf those on metformin or glyburide. Fracture rates on rosiglitazone maleate, metformin and glyburide were 2.74, 1.54 and 1.29/100 patient yr, respectively (Press release, GSK, 21 Feb 2007). There has been no increase in spine or hip fractures in patients on rosiglitazone maleate (Press release, GSK, 3 Dec 2007).^In a Phase IV study comparing the incidence of elevated ALT levels in patients receiving rosiglitazone maleate in Phase III trials at the time of the DNA submission to the incidence of elevated ALT in these patients 1yr later, the rate of elevated ALT levels was 0.30 cases/100 patient yr for all patients (Press release, SB, 12 Jun 2000).^In a trial in more than 33000 Type II diabetes patients receiving rosiglitazone maleate, metformin or sulfonylurea, either as a monotherapy or as 2 medicines combined + insulin, results demonstrated that there was no difference in the overall incidence of heart attack and coronary revascularization with rosiglitazone maleate-containing therapies (1.75 cf 1.76 events per 100 person-years on non-rosiglitazone maleate containing theapies). There was no difference in the risk of heart attack or coronary vascularization on rosiglitazone maleate-containing cf non-rosiglitazone maleate containing therapies, and no difference in the risk of composite outcome with rosiglitazone maleate monotherapy cf metformin monotherapy or sulfonylurea monotherapy. There was no risk of composite outcome with rosiglitazone maleate in combination with insulin theapy cf other oral antidiabetic agents + insulin (Press release, GSK, 6 Jun 2007).^Results from the VADT and ACCORD trials showed that rosigliazone maleate did not reduce major cardiovascular events associated with diabetes and was not associated with increased risk of death (Press release, GSK, 6 Jun 2008)^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20131206"],"Document_PK":["Human (2mg po):bioavailability:99:%","Human (2mg po):t1/2:3.78:hr","Human (2mg po):Tmax:3.5:hr","Human (2mg po):Cmax:121:ng/ml","Human (2mg po):AUC:805:mghr/ml","Human (2mg po):Vd:17.6:l","Human (2mg po):Cl:2.89:l/hr"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["5468: Receptor > Nuclear receptor > Peroxisome proliferator."],"Document_TG":["5468: peroxisome proliferative activated receptor, gamma"],"Document_LCH":["20131126:PP259 : FDA decision on the use of rosiglitazone reported"],"Document_TB":["5468: Receptor > Nuclear receptor > Peroxisome proliferator;","5468: Nuclear receptor > Peroxisome proliferator;","5468: Receptor;","5468: Peroxisome proliferator;","5468: Receptor > Nuclear receptor."],"Document_CASIS-USE_CASIS-MA_PHCD":["PPAR-G-AG: Peroxisome proliferator-activated receptor gamma agonist: Receptor, Biochemical, Peroxisome proliferatoractivated receptor gamma agonist: PPAR-gamma agonist: R-B-PPAR-G-AG|INSS-AG: Insulin sensitizer: Receptor, Hormonal, Insulin sensitizer: R-H-INSS-AG|THIAZ-AG: Thiazolidinedione: Physiological, Biochemical, Thiazolidinedione: TZD: P-B-THIAZ-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["357.43"],"Document_AL":["3.13"],"Document_CASIS-CO_CO":["Originator: GlaxoSmithKline (GB): Launched","Licensee: Bristol-Myers Squibb (US): Launched","Licensee: Torrent Pharmaceuticals (IN): Launched","Licensee: Asahi Kasei Pharma (JP): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD243663    ","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"}],"DOCNO":"PH022294","CASIS_COMPOUND":[{"CN":"Avandia CCN=AVANDIA","SRC_DB":"PHPROJ"},{"CN":"BRL-49653 CCN=BRL49653","SRC_DB":"PHPROJ"},{"CN":"BRL 49653C  CCN=BRL49653C","SRC_DB":"PHPROJ"},{"CN":"BRL-49653c CCN=BRL49653C","SRC_DB":"PHPROJ"},{"CN":"Nyracta CCN=NYRACTA","SRC_DB":"PHPROJ"},{"CN":"rosiglitazone CCN=ROSIGLITAZONE","SRC_DB":"PHPROJ"},{"CN":"rosiglitazone maleate CCN=ROSIGLITAZONEMALEATE","SRC_DB":"PHPROJ"},{"CN":"BRL-48482 CCN=BRL48482","SRC_DB":"PHPROJ"},{"CN":"Venvia CCN=VENVIA","SRC_DB":"PHPROJ"},{"CN":"Windia CCN=WINDIA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2013-12-09 13:06:47","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Impaired glucose tolerance","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Atherosclerosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6D","THE_USE":"Cognition enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PPAR-G-AG","THE_USE":"Peroxisome proliferator-activated receptor gamma agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"G1C","THE_USE":"Fertility enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diabetic complication, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cognitive disorder, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Restenosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C10","THE_USE":"Hypolipaemic-Antiatherosclerosis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Polycystic ovarian syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"INSS-AG","THE_USE":"Insulin sensitizer","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"M2Z","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"THIAZ-AG","THE_USE":"Thiazolidinedione","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 111, 115, 105, 103, 108, 105, 116, 97, 122, 111, 110, 101, 32, 109, 97, 108, 101, 97, 116, 101, 32, 40, 66, 82, 76, 45, 52, 57, 54]...', original message: bytes can be at most 32766 in length; got 34136
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34136
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:45:52,942][DEBUG][action.bulk              ] UK open-label, Phase II trial (CRFB002AGB10; 2009-014854-14; REPAIR) in 65 patients with choroidal neovascularization secondary to pathological myopia, to assess the efficacy and safety of ranibizumab 0.5mg x12mth was completed. After 6mth of treatment, mean visual acuity improved by twelve letters. Patients received an average of three ranibizumab injections with 29% requiring no further treatment beyond the first injection. This analysis showed that ranibizumab therapy lead to improvement in visual acuity in patients with this condition. Six month interim results and the full 1yr are planned (ClinicalTrials.gov, 8 Aug 2011 and 20 Sep 2012, http://www.clinicaltrials.gov/ct2/ show/NCT01037348; Press release, Novartis, 5 Sep 2012, http:// www.novartis.com/newsroom/media-releases/en/2012/1638671.shtml). At 12mth, the mean visual acuity gain was 13.8 letters, this was achieved with a low number of injections to month 12 (mean 3.6, median 3) with 21% patients requiring only the one baseline treatment (Press release, Novartis, 8 May 2013, http:// www.novartis.com/newsroom/media-releases/en/2013/1700148.shtml). Myopic CNV patients treated with ranibizumab experienced high overall treatment satisfaction as measured using the Macular Disease Treatment Satisfaction Questionnaire. The overall score increased from 55.0 at month 1 to 64.9 at month 12 (Press release, Novartis, 27 Sep 2013, http://www.novartis.com/newsroom/media- releases/en/2013/1731649.shtml).^Oedema, macular, diabetic^Novartis^A randomized, open-label, laser-controlled Phase II trial (CRFB002DES01) in 85 patients with visual impairment due to diabetic macular oedema in Spain, to assess the efficacy and safety of ranibizumab intravitreally vs laser treatment was completed (ClinicalTrials.gov, 30 Aug 2011 and 23 Jan 2013, http:/ /clinicaltrials.gov/ct2/show/NCT00901186).^Phase I^Macular degeneration, age-related, wet^Genentech (Hoffmann-La Roche)^A Phase I, open label, prospective, observational trial (FVF4150s) in 5 subjects in combination with proton beam irradiation in treating exudative wet AMD in the US was completed (ClinicalTrials.gov, 18 Oct 2012, http://clinicaltrials.gov/show/ NCT00517010).^In an open-label, non-randomized Phase Ia trial in 25 patients with neovascular AMD with best-corrected visual acuity (BCVA) of 20/100, ranibizumab 50-500microg intravitreal injections gave a median BCVA of 20/250. It was well tolerated (Meet Assoc Res Vision Ophthalmol (Fort Lauderdale), 2001, Abs 2807).^Preclinical ^In vivo^In cynomolgus monkeys, ranibizumab 500microg intravitreal injections q 2wk significantly lowered choroidal neovascularization (CNV) vs controls. There were no ocular haemorrhages, and injection-related acute anterior chamber inflammation was resolved within 1wk (Arch Ophthalmol, 2002, 120, 338, PMID:11879138).^In cynomolgus monkeys, 2000microg gave a mean Cl, Vd and t1/2 of 0.85ml/day, 3.0ml and 2.5 days, respectively (Meet Assoc Res Vision Ophthalmol (Fort Lauderdale), 2001, Abs 5000).^Patents^Patent protection in the US expires in 2019 (Company presentation, Roche, 15 Sep 2010, Slide 7, http://www.roche.com/irp100915.pdf).^Patent protection for the active ingredient expires in 2018-22 in Europe and Japan (Form 20-F, Novartis, 2009).^Licensing^Agreements^________________^Alcon; Novartis Ophthalmics (Novartis)^Japan; Alcon has a co-promotion agreement with Novartis for Japan (Scrip Daily Online, 30 Jan 2009, S01018806).^Hoffmann-La Roche^Worldwide; Roche previously had an option to license the product before the acquisition of Genentech (Ann Rep, Roche, 2001).^Novartis Ophthalmics (Novartis)^Worldwide except USA; Novartis Ophthalmics (Novartis) obtained an exclusive licence for development and marketing for eye disease outside N America (Press release, Novartis Ophthalmics, 25 Jun 2003). Novartis Ophthalmics subsequently amended its licence to include Canada (Dow Jones Web Page, 22 Jun 2006).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Cynomolgus monkey (2000microgram):Vd:3:ml","Cynomolgus monkey (2000microgram):Cl:0.85:ml/day"],"Document_NC":["No"],"Document_TF":["7422: Cytokine/Growth factor > Growth factor, non-cytokine."],"Document_TG":["7422: vascular endothelial growth factor A"],"Document_LCH":["20140321:PP249 : Additional launch in Germany and Chinese launch for macular oedema reported"],"Document_TB":["7422: Cytokine/Growth factor > Growth factor, non-cytokine;","7422: Growth factor, non-cytokine;","7422: Cytokine/Growth factor."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|"],"Document_ROUT":["P-UN: Parenteral, general","T-EY: Topical, eyes"],"Document_CASIS-CO_CO":["Originator: Hoffmann-La Roche (CH): Launched","Licensee: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"}],"DOCNO":"PH030035","CASIS_COMPOUND":[{"CN":"RG-3645 CCN=RG3645","SRC_DB":"PHPROJ"},{"CN":"rhuFabV2 CCN=RHUFABV2","SRC_DB":"PHPROJ"},{"CN":"rhuFab V2 CCN=RHUFABV2","SRC_DB":"PHPROJ"},{"CN":"ranibizumab CCN=RANIBIZUMAB","SRC_DB":"PHPROJ"},{"CN":"RG3645 CCN=RG3645","SRC_DB":"PHPROJ"},{"CN":"AMD Fab, Genentech CCN=AMDFABGENENTECH","SRC_DB":"PHPROJ"},{"CN":"RFB002 CCN=RFB002","SRC_DB":"PHPROJ"},{"CN":"Lucentis CCN=LUCENTIS","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"S1G","THE_USE":"Antiglaucoma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Retinal vein occlusion","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Oedema, macular, diabetic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Oedema, macular","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Macular degeneration, age-related, wet","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Myopia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Glaucoma","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 97, 110, 105, 98, 105, 122, 117, 109, 97, 98, 32, 40, 114, 104, 117, 70, 97, 98, 86, 50, 59, 32, 76, 117, 99, 101, 110, 116, 105]...', original message: bytes can be at most 32766 in length; got 43924
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 43924
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:45:53,253][DEBUG][action.bulk              ] onf (New York), 2008).^In human tumour xenograft models, TH-302 in combination with carboplatin, cisplatin, 5-FU or pemetrexed gave greater tumour growth inhibition cf TH-302 or chemotherapy alone (Press release, Threshold, 22 Jul 2008).^In mice, rats, dogs and monkeys, TH-302 had linear pharmacokinetics, 'excellent' oral bioavailability and high clearance (Press release, Threshold, 14 Apr 2008).^In vitro^In in vitro studies, TH-302 activity can be modulated by pharmacological modulators of both reductases and DNA damage and repair pathways and can be inhibited by the flavin reductase inhibitor DPI, while the NQO1 inhibitor dicoumoral can enhance TH- 302 activity. It was not affected by the PARP inhibitor ABT-888 but was potentiated by the HDAC inhibitor VPA. Results supported that HDR and not SSB DNA repair mechanisms is involved in repair of TH-302-induced DNA lesions (102nd ACCR (Orlando), 2011, Abs 2648, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=ea6119bc-2d97-4288-bf2a- 02e27e5c9ad4andcKey=f23f95ed-5896-4cd8-b3b6- 86e24bfbbf60andmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^In in vitro studies, it activated apoptosis with no adverse events (51st Meet Am Soc Hematol (New Orleans), 2009, Abs 3838).^In human prostate cancer cell lines (PC-3, LNCaP, and DU-145), TH- 302 demonstrated hypoxia-selective cytotoxicity (21st AACR-NCI- EORTC Symp Molec Targ Cancer Ther (Boston), 2009, B185).^Preclinical studies showed a >100x difference in cytotoxicity between cells in normal oxygen levels and hypoxic cells (Company Web Page, Threshold, 11 Jul 2005).^Patents^US7550496, covering hypoxia-activated prodrugs of anti-cancer alkylating agents has protection until 2024 (Press release, Threshold, 6 Aug 2009).^Licensing^Agreements^________________^Merck KGaA; Threshold Pharmaceuticals^Worldwide; Threshold has an agreements with Merck KGaA to co- develop and commercialize TH-302. Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the US. In the US, Threshold will have primary responsibility for the development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Subject to FDA approval in the US, Merck KGaA will initially be responsible for commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales. Under the royalty-bearing portion of the agreement, Threshold retains the option to co-promote TH-302 in the US. Additionally, Threshold retains the option to co-commercialize TH-302 allowing the company to participate in up to 50% of the profits in the US based on certain revenue tiers. Outside of the US, Merck KGaA will be solely responsible for the commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales in these territories (Press release, Threshold, 3 Feb 2012, http:/ /investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=645974).^MD Anderson Cancer Center, USA; Threshold Pharmaceuticals^Worldwide; preclinical research collaboration to focus on characterizing the therapeutic efficacy of TH-302 as monotherapy and in combination with conventional chemotherapeutics in both in vitro and in vivo models of leukaemia (Press release, Threshold, 22 Dec 2010, http://investor.thresholdpharm.com/ releasedetail.cfm?ReleaseID=538451).^National Comprehensive Cancer Network (NCCN), USA; Threshold Pharmaceuticals^Worldwide; National Comprehensive Cancer Network (NCCN) has awarded a grant for the clinical development of TH-302 (Press release, Threshold, 6 Jul 2011, http:// investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=589275).^Qualifying Therapeutic Discovery Project, USA; Threshold Pharmaceuticals^USA; Threshold has received a development grant under the Qualified Therapeutic Discovery Project (QTDP) programme (Press release, Threshold, 3 Nov 2010, http:// investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=526715).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (iv):MTD:575:mg/m2"],"Document_NC":["Yes"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140324:AD244 : Ongoing Phase II trial (TH-CR-415) for nsclc reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["DNA-AN: DNA inhibitor: Physiological, Biochemical, DNA inhibitor: Antineoplastic e.g. actinomycin, bleomycin, anthracyclines: Antineoplastic alkylating agent: Alkylating antineoplastic agent: DNA cross linking agent: P-B-DNA-AN|DNA-SYN-AN: DNA synthesis inhibitor: Physiological, Biochemical, DNA synthesis inhibitor: P-B-DNA-SYN-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Threshold Pharmaceuticals (US): Phase III Clinical Trial","Licensee: Merck KGaA (DE): Phase III Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"}],"DOCNO":"PH040674","CASIS_COMPOUND":[{"CN":"TH-302 CCN=TH302","SRC_DB":"PHPROJ"},{"CN":"anticancer prodrug, Threshold CCN=ANTICANCERPRODRUGTHRESHOLD","SRC_DB":"PHPROJ"},{"CN":"TH302 CCN=TH302","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Myelofibrosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-AN","THE_USE":"DNA inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-SYN-AN","THE_USE":"DNA synthesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 72, 45, 51, 48, 50, 32, 105, 115, 32, 97, 32, 99, 121, 116, 111, 116, 111, 120, 105, 99, 32, 112, 114, 111, 100, 114, 117, 103, 44]...', original message: bytes can be at most 32766 in length; got 47408
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47408
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:46:11,289][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.9gb[8.7%], shards will be relocated away from this node
[2016-06-14 12:46:11,289][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:46:30,926][DEBUG][action.bulk              ] was well tolerated. The most common drug-related adverse events included constipation (8%), pruritus (13%), thrombocytopenia (9%) and fatigue (4%). The MTD was 600mg bid, associated with more neutropenia and hyperbilirubinaemia. 60 and 41% of Ph+ CML patients achieved a haematologic and cytogenic response vs 72 and 59% Ph- patients, respectively. 33% of Ph+ ALL patients had a response, vs 0% of patients with no mutation. Steady states were reached by day 8. Cmax and AUC were dose-proportional at 50-400 qid but plateaued at 600-1200 qid. Increased exposure was observed with bid dosing (47th Meet Am Soc Hematol (Atlanta), 2005, Abs 37).^Preclinical ^In vivo^In murine models, nilotinib substantially reduced leukaemic cell accumulation in the bone marrow, nodes, liver and spleen cf vehicle. Nilotinib 75mg/kg/day po x18 days, starting 3 days after injection with leukaemic cells, protected 15/20 mice from developing lethal leukaemia vs development of disease in 19/20 control mice (46th Meet Am Soc Hematol (San Diego), 2004, Abs 551).^In vitro^Nilotinib had higher activity in bcr-abl+ cell lines and in cells from imatinib mesilate-resistant leukaemic patients, had better cellular uptake, and inhibited bcr-abl tyrosine kinase and induction of apoptosis at lower concentrations, cf imatinib mesilate (46th Meet Am Soc Hematol (San Diego), 2004, Abs 762).^Nilotinib was up to 40x more potent vs imatinib mesilate in Ph+ ALL cell lines (46th Meet Am Soc Hematol (San Diego), 2004, Abs 2737).^Patents^US7169791 expires in 2023.^Additional Clinical Information^Phase II^In an open-label, single-dose Phase II trial in imatinib- resistant or -intolerant CML patients in accelerated phase, nilotinib 400mg was safe and well tolerated. Complete haematological response, no evidence of leukaemia, return to chronic phase, SD and disease progression were observed in 15, 8, 15, 6 and 5% of patients, respectively. The median times to 1st haematological response and major cytogenetic response were 1 and 2mth, respectively. The most common adverse events included rash, constipation, pruritus and pyrexia (48th Meet Am Soc Hematol (Orlando), 2006, Abs 2169).^In 119 patients with CML or Ph+ ALL and a bcr-abl mutation before treatment, nilotinib 50-1200mg once-daily or 400-600mg bid produced a haematological and cytogenetic response in 60 and 41%, respectively. In patients with no bcr-abl mutation, responses were higher, with 72 and 59% having a haematological and cytogenetic response, respectively (Scrip Daily Online, 5 Jan 2005, S00906704).^In Phase I/II trials, haematologic responses on nilotinib were 87% in chronic-phase Ph+ CML patients, 83% in accelerated phase, and 54% in myeloid blast crisis. It was well tolerated at <1200mg/ day, with rare liver, skin and bone marrow-related adverse events (Company presentations, Novartis, 10 Nov 2004 and 20 Sep 2005; Press release, Novartis, 3 May 2005).^Phase I^A Phase I trial was conducted in refractory GIST patients (Company presentation, Novartis, 20 Sep 2005).^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (400mg bid po):t1/2:15:hr","Human (po bid):MTD:600:mg"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["613: Enzyme > EC number > 2.7.11.1;","613: Enzyme > Kinase;","25: Enzyme > EC number > 2.7.10.2;","25: Enzyme > Kinase;","3815: Enzyme > Kinase;","3815: Receptor;","5156: Enzyme > Kinase;","5156: Receptor."],"Document_TG":["613: breakpoint cluster region","25: c-abl oncogene 1, non-receptor tyrosine kinase","3815: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue","5156: platelet-derived growth factor receptor, alpha polypeptide"],"Document_LCH":["20140318:AD283 : Ongoing enrollment in Phase III trial (ENESTg1) for GIST reported"],"Document_TB":["613: Enzyme > EC number > 2.7.11.1;","613: EC number > 2.7.11.1;","613: Enzyme;","613: 2.7.11.1;","613: Enzyme > EC number.","613: Enzyme > Kinase;","613: Kinase;","613: Enzyme.","25: Enzyme > EC number > 2.7.10.2;","25: EC number > 2.7.10.2;","25: Enzyme;","25: 2.7.10.2;","25: Enzyme > EC number.","25: Enzyme > Kinase;","25: Kinase;","25: Enzyme.","3815: Enzyme > Kinase;","3815: Kinase;","3815: Enzyme.","3815: Receptor;","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-BCAB-AN: Bcr-Abl inhibitor: Enzyme, Transferase, BcrAbl inhibitor: Philadelphia chromosome inhibitor: Bcr-Abl kinase inhibitor: E-TR-KI-BCAB-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|KI-GFPL-AN: Platelet-derived growth factor receptor kinase inhibitor: Enzyme, Transferase, Plateletderived growth factor receptor kinase inhibitor: Platelet-derived growth factor kinase inhibitor: PDGF receptor kinase inhibitor: PDGF kinase inhibitor: E-TR-KI-GFPL-AN|KI-TY-AB-AN: Abl receptor tyrosine kinase inhibitor: Enzyme, Transferase, Abl receptor tyrosine kinase inhibitor: JTK inhibitor: p150 inhibitor: Abl-1 inhibitor: c-Abl inhibitor: E-TR-KI-TY-AB-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["529.53"],"Document_AL":["4.50"],"Document_CASIS-CO_CO":["Originator: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH039482","CASIS_COMPOUND":[{"CN":"AMN-107 CCN=AMN107","SRC_DB":"PHPROJ"},{"CN":"nilotinib CCN=NILOTINIB","SRC_DB":"PHPROJ"},{"CN":"AMN107 CCN=AMN107","SRC_DB":"PHPROJ"},{"CN":"Tasigna CCN=TASIGNA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2B9","THE_USE":"Antihypertensive","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-AB-AN","THE_USE":"Abl receptor tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-BCAB-AN","THE_USE":"Bcr-Abl inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D4A","THE_USE":"Antipruritic-inflamm","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, unspecifed","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Mastocytosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPL-AN","THE_USE":"Platelet-derived growth factor receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Hypertension, pulmonary","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 105, 108, 111, 116, 105, 110, 105, 98, 32, 40, 65, 77, 78, 45, 49, 48, 55, 41, 32, 105, 115, 32, 97, 32, 115, 105, 103, 110, 97]...', original message: bytes can be at most 32766 in length; got 48347
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 48347
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:46:41,373][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.8gb[8.7%], shards will be relocated away from this node
[2016-06-14 12:47:06,935][DEBUG][action.bulk              ] ","5979: Enzyme > EC number > 2.7.10.1;","5979: EC number > 2.7.10.1;","5979: Enzyme;","5979: 2.7.10.1;","5979: Enzyme > EC number.","5979: Enzyme > Kinase;","5979: Kinase;","5979: Enzyme.","2322: Enzyme > EC number > 2.7.10.1;","2322: EC number > 2.7.10.1;","2322: Enzyme;","2322: 2.7.10.1;","2322: Enzyme > EC number.","2322: Enzyme > Kinase;","2322: Kinase;","2322: Enzyme.","2322: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-RAF-B-AN: B-raf kinase inhibitor: Enzyme, Transferase, Biochemical, raf kinase inhibitor: V-raf homologue B1 inhibitor: BRAF inhibitor: RAFB1 inhibitor: Oncogene BRAF inhibitor: E-TR-KI-RAF-B-AN|KI-GFEN2-AN: VEGFR-2 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 2 tyrosine kinase inhibitor: KDR tyrosine kinase inhibitor: Flk-1 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 2 TK inhibitor: E-TR-KI-GFEN2-AN|KI-GFEN3-AN: VEGFR-3 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 3 tyrosine kinase inhibitor: Flt-4 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 3 TK inhibitor: E-TR-KI-GFEN3-AN|KI-TY-RET-AN: RET tyrosine kinase inhibitor: Enzyme, Transferase, KITYREnzyme: E-TR-KI-TY-RE-AN|KI-FLT3-AN: Flt-3 kinase inhibitor: Enzyme, Transferase, Flt3 kinase inhibitor: E-TR-KI-FLT3-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|KI-GFEN-AN: VEGFR tyrosine kinase inhibitor: Enzyme, Transferase, VEGFR tyrosine kinase inhibitor: Vascular endothelial growth factor receptor TK inhibitor: E-TR-KI-GFEN-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|KI-RAF-AN: Raf kinase inhibitor: Enzyme, Transferase, Raf kinase inhibitor: E-TR-KI-RAF-AN|KI-RAF-C-AN: C-raf kinase inhibitor: Enzyme, Transferase, Craf kinase inhibitor: E-TR-KI-RAF-C-AN|KI-GFPLB-AN: Platelet-derived growth factor receptor beta kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor beta kinase inhib: PDGF beta kinase inhibitor: PDGF receptor beta kinase inhibitor: Platelet-derived growth factor beta kinase inhibitor: E-TR-KI-GFPLB-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["464.83"],"Document_AL":["3.55"],"Document_CASIS-CO_CO":["Originator: Bayer (DE): Launched","Licensee: Onyx Pharmaceuticals (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD272626    ","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH021418","CASIS_COMPOUND":[{"CN":"BAY 54-9085 CCN=BAY549085","SRC_DB":"PHPROJ"},{"CN":"NSC-724772 CCN=NSC724772","SRC_DB":"PHPROJ"},{"CN":"ras inhibitors, Onyx CCN=RASINHIBITORSONYX","SRC_DB":"PHPROJ"},{"CN":"Suranix CCN=SURANIX","SRC_DB":"PHPROJ"},{"CN":"ras inhibitors, Bayer CCN=RASINHIBITORSBAYER","SRC_DB":"PHPROJ"},{"CN":"raf inhibitors, Onyx CCN=RAFINHIBITORSONYX","SRC_DB":"PHPROJ"},{"CN":"sorafenib CCN=SORAFENIB","SRC_DB":"PHPROJ"},{"CN":"Bay-43-9006 CCN=BAY439006","SRC_DB":"PHPROJ"},{"CN":"raf inhibitors, Bayer CCN=RAFINHIBITORSBAYER","SRC_DB":"PHPROJ"},{"CN":"Nexavar CCN=NEXAVAR","SRC_DB":"PHPROJ"},{"CN":"sorafenib tosylate CCN=SORAFENIBTOSYLATE","SRC_DB":"PHPROJ"},{"CN":"Bay 43-9006 CCN=BAY439006","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-RET-AN","THE_USE":"RET tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLB-AN","THE_USE":"Platelet-derived growth factor receptor beta kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN3-AN","THE_USE":"VEGFR-3 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-FLT3-AN","THE_USE":"Flt-3 kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN-AN","THE_USE":"VEGFR tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-RAF-C-AN","THE_USE":"C-raf kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN2-AN","THE_USE":"VEGFR-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-RAF-B-AN","THE_USE":"B-raf kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, neuroendocrine, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-RAF-AN","THE_USE":"Raf kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[83, 111, 114, 97, 102, 101, 110, 105, 98, 32, 116, 111, 115, 121, 108, 97, 116, 101, 32, 40, 66, 97, 121, 45, 52, 51, 45, 57, 48, 48]...', original message: bytes can be at most 32766 in length; got 45567
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 45567
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:07,055][DEBUG][action.bulk              ] .23/LLL63, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=a6f1919c-67b4-4022-8404- eed1cab1de28andcKey=72e13111-af68-4e1f-8dd4- 203c6b02f2deandmKey={E5D5C83F-CE2D-4D71-9DD6-FC7231E090FB}).^In animal models of anxiety disorders and depression, lurasidone showed 'significant' improvement. It showed a preferential effect on the frontal cortex in increasing dopamine turnover. In rats, lurasidone showed antipsychotic activity such as inhibition of methamphetamine (MAP)-induced hyperactivity and apomorphine (APO)- induced stereotyped behavior. In rodent models, lurasidone had weak extrapyramidal effects (J Pharmacol Exp Ther, 19 Apr 2010, PMID:20404009).^In rats, it did not adversely affect prefrontal cognitive functioning (39th Meet Soc Neurosci (Chicago), 2009, Abs 646.24).^It significantly increased punished water licking in the Vogel conflict test (MED = 10mg/kg po). In the Morris water maze and radial-arm maze tests, it reversed MK-801 induced impairment of learning, suggesting use in schizophrenics with cognitive dysfunction (Behav Brain Res, 2008, 186, 197, PMID:17881065).^In vitro^In preclinical studies, lurasidone hydrochloride had a weaker interaction with striatal acetylcholine neurons vs haloperidol, and a preferential action on the mesocortical (vs nigrostriatal) dopaminergic system in terms of increase in dopamine turnover and Fos expression. It had a high affinity for D2 (Ki=1.68nM), 5-HT2 (2.03nM) and 5-HT1A (6.75nM) receptors, but did not interact with 5-HT2C and H1 receptors (31st Meet Soc Neurosci (San Diego), 2001, Abs 664.14).^Licensing^Agreements^________________^Standard Chem. and Pharm, Taiwan^Taiwan; it is licensed to Standard Chem. and Pharm for the exclusive sales of lurasidone (Press Release, SCP, 28 Oct 2013, http://www.standard.com.tw/UserFiles/File/Standard/English/131028- SCP%20Press%20Release%20English.pdf).^Merck and Co^Worldwide excluding China, Japan, South Korea and Taiwan; it was licensed exclusively to Merck and Co for development and marketing, with DSP retaining the option to co-promote it in the US; however, Merck discontinued development and returned rights to DSP (Press release, Dainippon, 13 Dec 2006).^Takeda^EU except the UK, Norway, Russia and Turkey; DSP has a license agreement with Takeda for joint development and exclusive commercialization for the oral formulation. DSP has rights in the UK (Press release, DSP and Takeda, 30 Mar 2011, http://www.ds- pharma.com/pdf_view.php?id=76).^Availability^________________^Dainippon Sumitomo Pharma^EU (Company presentation, Dainippon, 25 Jan 2011, Slide 35, http:/ /www.ds-pharma.com/ir/presentation/img/eir20110125_1.pdf).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3363: 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140321:AD67 : Completion of Phase III study (D1050298) for schizophrenia and bipolar disorder reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3363: GPCR > 5-Hydroxytryptamine;","3363: Receptor;","3363: 5-Hydroxytryptamine;","3363: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AN: Dopamine D2 receptor antagonist: Receptor, Transmitter, Dopamine D2 receptor antagonist: DA D2 receptor antagonist: D2 receptor antagonist: Dopamine DA2 receptor antagonist: DA DA2 receptor antagonist: R-T-DOPA-D2-AN|5HT-7-AN: 5 Hydroxytryptamine 7 receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 7 receptor antagonist: 5HT7 receptor antagonist: Serotonin 7 receptor antagonist: R-H-5HT-7-AN|5HT-1-A-AN: 5 Hydroxytryptamine 1A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor antagonist: 5HT1A receptor antagonist: Serotonin 1A receptor antagonist: R-H-5HT-1-A-AN|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["492.68"],"Document_AL":["4.37"],"Document_CASIS-CO_CO":["Originator: Sunovion Pharmaceuticals (US): Launched","Licensee: Takeda (JP): Launched","Licensee: Merck & Co (US): Discontinued"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD520542    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH023698","CASIS_COMPOUND":[{"CN":"SM-13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"SM13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"SMP13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"MK3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"lurasidone hydrochloride CCN=LURASIDONEHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"Latuda CCN=LATUDA","SRC_DB":"PHPROJ"},{"CN":"SMP-13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"lurasidone CCN=LURASIDONE","SRC_DB":"PHPROJ"},{"CN":"MK-3756 CCN=MK3756","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AN","THE_USE":"5 Hydroxytryptamine 1A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Anxiety, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AN","THE_USE":"Dopamine D2 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"5HT-7-AN","THE_USE":"5 Hydroxytryptamine 7 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 117, 114, 97, 115, 105, 100, 111, 110, 101, 32, 104, 121, 100, 114, 111, 99, 104, 108, 111, 114, 105, 100, 101, 32, 40, 83, 77, 45, 49]...', original message: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:07,296][DEBUG][action.bulk              ] y^A double-blind, randomized, crossover-assignment Phase I trial (GENERATIONS, H7T-MC-TACY) to compare the pharmacokinetics and pharmacodynamics of prasugrel hydrochloride 5 and 10mg po x12 days and clopidogrel 75mg po x12 days in very elderly vs non- elderly aspirin-treated 152 patients with stable coronary artery disease in Ireland, the Netherlands, Sweden and the US, is complete (ClinicalTrials.gov, 22 Nov 2011, http:// clinicaltrials.gov/ct2/show/NCT01107912).^A Phase I trial (H7T-MC-TADI, FEATHER) to compare the pharmacokinetics and pharmacodynamics of prasugrel 5 or 10mg po / day x12 days and clopidogrel in low body weight vs higher body weight aspirin-treated 74 subjects in Ireland, the Netherlands, Sweden and the US with stable coronary artery disease was completed (ClinicalTrials.gov, 3 Aug 2011 and 13 Aug 2011, http:// clinicaltrials.gov/ct2/show/NCT01107925).^Acute coronary syndrome^Daiichi Sankyo; Ube Industries^In a Phase Ib study in 81 ASA-treated patients with stable cardiovascular disease, prasugrel hydrochloride 40 or 60mg resulted in >90% achieving >20% IPA after 6 hr, vs <50% on clopidrogrel hydrogen sulphate 300mg (Press release, Lilly, 14 Mar 2006).^In a randomized Phase I trial in 101 ASA-treated patients with stable atherosclerotic vascular disease, prasugrel 40 and 60mg loading dose resulted in significantly higher levels of IPA, vs a loading dose of clopidogrel hydrogen sulfate 300mg. After 28 days, prasugrel hydrochloride 10 and 15mg maintenance dose resulted in higher levels of platelet inhibition, cf clopidogrel hydrogen sulfate 75mg. There was a trend towards more bruising and minor bleeding on prasugrel hydrochloride 15mg (Press release, Lilly and Sankyo, 9 Mar 2005).^Preclinical ^In vivo^In a rat arterial thrombosis model, prasugrel 0.3-30microM/day po x3 days inhibited ADP-induced platelet aggregation in a dose- dependent manner. In a rat carotid arterial thrombosis model, multiple administrations of prasugrel 0.1-1mg/kg/day x3 days dose- dependently inhibited thrombus formation, with an ED50 of 0.3mg/ kg. In the same model, clopidogrel hydrogen sulfate 1-10mg/kg/day x3 days and ticlopidine 30-300mg/kg/day x3 days were less potent than prasugrel, while having a similar ratio of benefit/bleeding risk (18th Int Cong Thromb Haemos (Paris), 2001).^In rats, 1mg/kg of 1 of the compounds in the series inhibited blood platelet aggregation by 100% (EP542411; Company communications, Ube, Jan 1995 and Sankyo, Feb 1996).^Patents^Effient is protected by a US compound patent that expires in 2017 (Form 10-K, Lilly, 24 Feb 2012, Page 6, http://sec.gov/Archives/ edgar/data/59478/000119312512078393/d266023d10k.htm).^Further cyclic amine derivatives are claimed in WO9808811.^Licensing^Agreements^________________^Ube Industries^Worldwide; development collaboration (Direct communication, Sankyo, Feb 1997; Scrip Daily Online, 1 Sep 2004, S00856132).^Eli Lilly^Worldwide; licensed to Lilly for marketing and development. Lilly and Sankyo are to co-promote the product in Mexico and the US and it will be jointly marketed in the remaining global market except for certain countries where Lilly will receive exclusive sales and marketing rights (Press releases, Lilly, 20 Dec 2000 and Daiichi Sankyo, 10 Feb 2010).^Additional Clinical Information^Phase I^In a Phase Ib study in 81 ASA-treated patients with stable cardiovascular disease, prasugrel 40 or 60mg resulted in >90% achieving >20% IPA after 6 hr, cf <50% on clopidrogrel hydrogen sulphate 300mg (Press release, Lilly, 14 Mar 2006).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["6"],"Document_TF":["64805: Receptor > GPCR > P2Y."],"Document_TG":["64805: purinergic receptor P2Y, G-protein-coupled, 12"],"Document_LCH":["20140325:PP236 : Japanese approval for ischaemic heart disease reported"],"Document_TB":["64805: Receptor > GPCR > P2Y;","64805: GPCR > P2Y;","64805: Receptor;","64805: P2Y;","64805: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["PU-P2-Y12-AN: Purinoreceptor P2Y12 antagonist: Receptor, Biochemical, PUPYY: Platelet ADP receptor antagonist: P2Y12 receptor antagonist: R-B-PU-PY-Y12-AN|PLAT-AD-AN: Platelet aggregation inhibitor: Physiological, Biochemical, Platelet aggregation inhibitor: Platelet adhesion antagonist: Antiplatelet: P-B-PLAT-AD-AN|PU-P2-AN: Purinoreceptor P2 antagonist: Receptor, Biochemical, Purinoreceptor P2 antagonist: ATP P2 receptor antagonist: Nucleotide P2 receptor antagonist: P2 receptor antagonist: R-B-PU-P2-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["373.44"],"Document_AL":["4.15"],"Document_CASIS-CO_CO":["Originator: Daiichi Sankyo (JP): Launched","Licensee: Ube Industries (JP): Launched","Licensee: Eli Lilly (US): Launched"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD093257    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH020275","CASIS_COMPOUND":[{"CN":"Effient CCN=EFFIENT","SRC_DB":"PHPROJ"},{"CN":"LY-640315 CCN=LY640315","SRC_DB":"PHPROJ"},{"CN":"prasugrel hydrochloride, ODT CCN=PRASUGRELHYDROCHLORIDEODT","SRC_DB":"PHPROJ"},{"CN":"Prasita CCN=PRASITA","SRC_DB":"PHPROJ"},{"CN":"prasugrel, ODT CCN=PRASUGRELODT","SRC_DB":"PHPROJ"},{"CN":"Efient CCN=EFIENT","SRC_DB":"PHPROJ"},{"CN":"R99224 CCN=R99224","SRC_DB":"PHPROJ"},{"CN":"prasugrel hydrochloride, oral disintegrating tablet CCN=PRASUGRELHYDROCHLORIDEORALDISINTEGRATINGTABLET","SRC_DB":"PHPROJ"},{"CN":"R-99224 CCN=R99224","SRC_DB":"PHPROJ"},{"CN":"CS-747S  CCN=CS747S","SRC_DB":"PHPROJ"},{"CN":"prasugrel CCN=PRASUGREL","SRC_DB":"PHPROJ"},{"CN":"CS-747 CCN=CS747","SRC_DB":"PHPROJ"},{"CN":"prasugrel hydrochloride CCN=PRASUGRELHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"LY640315 CCN=LY640315","SRC_DB":"PHPROJ"},{"CN":"prasugrel (new formulation) CCN=PRASUGREL(NEWFORMULATION)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"B3C1","THE_USE":"Antisickling","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Infarction, myocardial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PU-P2-AN","THE_USE":"Purinoreceptor P2 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"B1B9","THE_USE":"Antithrombotic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N7C","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PU-P2-Y12-AN","THE_USE":"Purinoreceptor P2Y12 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"PLAT-AD-AN","THE_USE":"Platelet aggregation inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Acute coronary syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Thrombosis, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Anaemia, sickle cell","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[80, 114, 97, 115, 117, 103, 114, 101, 108, 32, 104, 121, 100, 114, 111, 99, 104, 108, 111, 114, 105, 100, 101, 32, 40, 67, 83, 45, 55, 52]...', original message: bytes can be at most 32766 in length; got 33766
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 33766
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:07,693][DEBUG][action.bulk              ]  0.6, 0.3 and 0% on zoledronic acid, respectively. The overall safety profile was consistent with the known Forteo safety profile. The overall incidence of serious adverse events, treatment-emergent adverse events and adverse events leading to discontinuation were similar between the Forteo and zoledronic acid treatment groups (Press release, Lilly, 15 Oct 2012, http://newsroom.lilly.com/ releasedetail.cfm?ReleaseID=713387).^In an international Phase II dose-finding trial in 351 women with PMO, receiving zoledronic acid 0.25-1mg q 3mth, 2mg at onset and 6mth, or a single 4mg dose, BMD values of the spine and femoral neck at 12mth were 4.3-5.1% and 3.1-3.5% higher compared to placebo, respectively (Scrip Daily Online, 4 Mar 2002, S00746328).^Paget's disease^Novartis^In 16 patients with Paget's disease, 1hr infusions of 24- 400microgram zoledronic acid inhibited bone resorption over 2wk. The anti-bone resorbing effect was not associated with clinical or biochemical toxicity (Calcit Tissue Int, 1997, 60, 415).^Phase I^Novartis^In trials, zoledronic acid 2-16mg as single 5 or 15min iv infusions had dose-dependent pharmacokinetics. It was eliminated by a triphasic process, giving t1/2 values of 0.23, 1.75 and 167hr, respectively (MIMS Hong Kong, 2002, 1).^In 32 cancer patients, Cl was 5.61/hr (Company Web Page, Novartis, 7 Oct 2002).^Cancer, breast; Cancer, myeloma^Novartis^An open-label, stratified, single-group-assignment, randomized, multi-center, comparative, 2-arm Phase I trial (CZOL446E2105) in the US in 18 multiple myeloma patients with malignant bone lesions and breast cancer patients with bone metastasis who have received 9-12 doses of zoledronic acid over the prior year, to evaluate the pharmacokinetics, pharmacodynamics and safety of zoledronic acid q 4wk vs q 12wk was completed (ClinicalTrials.gov, 8 Mar 2012, http://clinicaltrials.gov/ct2/show/NCT00424983).^Preclinical ^In vivo^In a mouse model of cervical cancer, zoledronic acid demonstrated 'promising' efficacy against both premalignant lesions and cancers of the cervix (J Clin Inv, 2004, 114, 623, PMID:15343380).^In animals, zoledronic acid had a 100x greater efficacy in increasing mineralized bone tissue cf disodium pamidronate. Zoledronic acid did not lower calcitonin levels, but bone formation was inhibited to a lesser degree than with other antiresorptive agents (Scrip, 1990, 1566, 25).^Patents^US and EU patents are due to expire by 2013 (Scrip Intelligence, 14 Dec 2010, http://www.scripintelligence.com/home/Amgens- denosumab-becomes-first-drug-to-delay-bone-metastases-in-cancer- 307378).^Licensing^Agreements^________________^Asahi Kasei Pharma^Japan; exclusive license to develop and sell zoledronic acid for osteoporosis treatment in Japan (Press release, Asahi Kasei Pharma, 14 Jun 2010, http://www.asahi-kasei.co.jp/asahi/en/news/ 2010/e100614.html).^Nippon Kayaku^Japan; co-promotion (JCN Web Page, 21 Apr 2006).^Additional Clinical Information^Post-Marketing^In an open, prospective, non-randomized trial in 18 patients with bone metastases from prostate cancer, zoledronic acid 4mg iv q 4wk led to a reduction in pain in 12 patients, eradication of pain in 5 patients and 10 patients were able to reduce their daily analgesic intake (28th Cong Eur Assoc Urol (Madrid), 2003, Abs 747, 0).^Additional References^Eur J Cancer 1999, 35 Abs1460^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20131011"],"Document_PK":["Human (volunteers):t1/2beta:1.75:hr","Human (cancer patients):Cl:5.6:l/hr"],"Document_NC":["Yes"],"Document_RB":["9"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20131001:AD151 : Completion of Phase III trial (CZOL446E2352) for bone cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["OSTEOCL-AN: Osteoclast inhibitor: Physiological, Biochemical, Osteoclast inhibitor: P-B-OSTEOCL-AN|BISP-AG: Bisphosphonate: Physiological, Biochemical, Bisphosphonate: Bisphosphonate agonist: P-B-BISP-AG|BONE-R-AN: Bone resorption inhibitor: Physiological, Hormonal, Bone resorption inhibitor: P-H-BONE-R-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["272.10"],"Document_AL":["0.14"],"Document_CASIS-CO_CO":["Originator: Novartis (CH): Launched","Licensee: Nippon Kayaku (JP): Launched","Licensee: Asahi Kasei Pharma (JP): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD054557    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2000 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"}],"DOCNO":"PH016374","CASIS_COMPOUND":[{"CN":"Aclasta CCN=ACLASTA","SRC_DB":"PHPROJ"},{"CN":"CGP-42446 CCN=CGP42446","SRC_DB":"PHPROJ"},{"CN":"Zomera CCN=ZOMERA","SRC_DB":"PHPROJ"},{"CN":"ZOL-446H CCN=ZOL446H","SRC_DB":"PHPROJ"},{"CN":"AK156 CCN=AK156","SRC_DB":"PHPROJ"},{"CN":"Reclast CCN=RECLAST","SRC_DB":"PHPROJ"},{"CN":"ZOL446 CCN=ZOL446","SRC_DB":"PHPROJ"},{"CN":"zoledronic acid CCN=ZOLEDRONICACID","SRC_DB":"PHPROJ"},{"CN":"ZOL446H CCN=ZOL446H","SRC_DB":"PHPROJ"},{"CN":"ZOL-446 CCN=ZOL446","SRC_DB":"PHPROJ"},{"CN":"zoledronate CCN=ZOLEDRONATE","SRC_DB":"PHPROJ"},{"CN":"zoledronate TTS CCN=ZOLEDRONATETTS","SRC_DB":"PHPROJ"},{"CN":"AK-156 CCN=AK156","SRC_DB":"PHPROJ"},{"CN":"CGP42446 CCN=CGP42446","SRC_DB":"PHPROJ"},{"CN":"Osteovan CCN=OSTEOVAN","SRC_DB":"PHPROJ"},{"CN":"Zometa CCN=ZOMETA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2013-10-21 14:05:08","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Hypercalcaemia of malignancy","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M2Z","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Osteoporosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"OSTEOCL-AN","THE_USE":"Osteoclast inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Paget's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"BONE-R-AN","THE_USE":"Bone resorption inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"BISP-AG","THE_USE":"Bisphosphonate","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, bone","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M5A","THE_USE":"Osteoporosis treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[90, 111, 108, 101, 100, 114, 111, 110, 105, 99, 32, 97, 99, 105, 100, 32, 40, 65, 75, 45, 49, 53, 54, 41, 32, 105, 115, 32, 97, 32]...', original message: bytes can be at most 32766 in length; got 35104
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35104
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:11,399][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.8gb[8.7%], shards will be relocated away from this node
[2016-06-14 12:47:11,399][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:47:34,714][DEBUG][action.bulk              ] inetics of afatinib po + gemcitabine (Part A) or docetaxel (Part B). Primary objective includes to establish the MTD based on the occurrence of DLT observed in Cycle 1. Completion is expected in Jun 2013 (ClinicalTrials.gov, 18 Dec 2010 and 29 Jun 2012, http://www.clinicaltrials.gov/show/ NCT01251653). Interim results of 19 patients treated in Part A to date showed that afatinib (A) + gemcitabine (G) was well tolerated, with manageable AEs. AEs observed in most patients were diarrhea (89.5%) and rash (63.2%). DLTs were experienced by 1 patient out of 6 receiving A 30mg and G 1250mg/m2. MTD was exceeded at a dose level of at least A 40mg/day and G 1250mg/m2. An intermediate dose level of A 40mg/day and G 1000mg/m2 is currently under evaluation (48th ASCO (Chicago), 2012, Abs e13009, http://www.asco.org/ASCOv2/Meetings/^^An open-label, non-randomized Phase Ib trial in Belgium in 47 patients with advanced solid tumours, to assess the safety, tolerability, MTD and pharmacokinetics of continuous dosing of afatinib po when combined with cisplatin/paclitaxel or cisplatin/ 5-FU is complete (ClinicalTrials.gov, 27 Nov 2009 and 16 Sep 2010, http://www.clinicaltrials.gov/show/NCT00716417).^A further Phase I trial in France of afatinib in combination with BIBFW-1120 in advanced solid tumours is underway (AFSSAPS Web Page, 14 Oct 2009, EudraCT No: 2009-011321-14; ClinicalTrials.gov Web Page, 11 Dec 2009, http://www.clinicaltrials.gov/show/ NCT00998296).^A Phase I trial in 42 patients with solid tumours in combination with BIBF-1120 ha been completed (ClinicalTrials.gov Web Page, 26 Aug 2009, http://www.clinicaltrials.gov/show/NCT00730821).^It is in a Phase I dose-finding study to determine the maximum tolerated dose (MTD) of 3-day afatinib in combination with docetaxel (qv) once x3wk in 40 patients with advanced solid tumours. Results show the MTD was established at 90mg/day. Objective responses or durable SD of greater than/equal to 6 months was seen in 15 patients. Dose limiting toxicities included grade 4 febrile neutropenia and grade 3 nausea, vomiting and diarrhea (45th ASCO (Orlando), 2009, Abs 3556).^Preclinical ^In vivo^It had IC50s against the wild-type, resistant and dual resistant cell lines H1666, H3255 and NC11875 of 7, 6 and 93nM, respectively, and binding to EGFR/HER2 was irreversible (Company presentation, BI, 8 Nov 2006).^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (10-100mg po):MTD:70:mg"],"Document_NC":["Yes"],"Document_RB":["9"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase;","2064: Enzyme > EC number > 2.7.10.1;","2064: Receptor > Cytokine receptor;","2064: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor","2064: v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2"],"Document_LCH":["20140318:PT : UK NICE recommendation for nsclc reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme.","2064: Enzyme > EC number > 2.7.10.1;","2064: EC number > 2.7.10.1;","2064: Enzyme;","2064: 2.7.10.1;","2064: Enzyme > EC number.","2064: Receptor > Cytokine receptor;","2064: Cytokine receptor;","2064: Receptor.","2064: Enzyme > Kinase;","2064: Kinase;","2064: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-TYE1-AN: ErbB-1 tyrosine kinase inhibitor: Enzyme, Transferase, ErbBiochemical, 1 tyrosine kinase inhibitor: EGFR1 kinase inhibitor: Epidermal growth factor receptor 1 tyrosine kinase inhibitor: HER1 tyrosine kinase inhibitor: E-TR-KI-TYE1-AN|KI-TYE2-AN: ErbB-2 tyrosine kinase inhibitor: Enzyme, Transferase, ErbBiochemical, 2 tyrosine kinase inhibitor: HER2 tyrosine kinase inhibitor: HER2/neu tyrosine kinase inhibitor: Epidermal growth factor receptor 2 tyrosine kinase inhibitor: EGFR2 tyrosine kinase inhibitor: E-TR-KI-TYE2-AN|KI-TYR-AN: Tyrosine kinase inhibitor (TKI): Enzyme, Transferase, Tyrosine kinase inhibitor (TKI): Protein kinase tyrosine inhibitor: Tyrosylprotein kinase inhibitor: Hydroxyaryl protein kinase inhibitor: TKI: E-TR-KI-TYR-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["485.95"],"Document_AL":["2.89"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH042195","CASIS_COMPOUND":[{"CN":"Giotrif CCN=GIOTRIF","SRC_DB":"PHPROJ"},{"CN":"BIBW 2992 CCN=BIBW2992","SRC_DB":"PHPROJ"},{"CN":"Tovok CCN=TOVOK","SRC_DB":"PHPROJ"},{"CN":"Gilotrif CCN=GILOTRIF","SRC_DB":"PHPROJ"},{"CN":"afatinib CCN=AFATINIB","SRC_DB":"PHPROJ"},{"CN":"BIBW-2992 MA2 CCN=BIBW2992MA2","SRC_DB":"PHPROJ"},{"CN":"Tomtovok CCN=TOMTOVOK","SRC_DB":"PHPROJ"},{"CN":"afatinib dimaleate CCN=AFATINIBDIMALEATE","SRC_DB":"PHPROJ"},{"CN":"BIBW-2992 CCN=BIBW2992","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"R4A","THE_USE":"COPD treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-TYE1-AN","THE_USE":"ErbB-1 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Chronic obstructive pulmonary disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYR-AN","THE_USE":"Tyrosine kinase inhibitor (TKI)","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYE2-AN","THE_USE":"ErbB-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 102, 97, 116, 105, 110, 105, 98, 32, 40, 66, 73, 66, 87, 45, 50, 57, 57, 50, 41, 32, 105, 115, 32, 97, 110, 32, 105, 114, 114]...', original message: bytes can be at most 32766 in length; got 44768
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 44768
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:34,799][DEBUG][action.bulk              ] primary endpoint). These patients were also significantly more likely to have 50% reduction in pain from baseline vs placebo (29 cf 13%). Significant improvements in sleep quality and fatigue were seen, and most adverse effects were mild-to-moderate, with dizziness and drowsiness the most common (Scrip Daily Online, 6 Nov 2002, S00777656).^In 276 patients with GAD, pregabalin 150 or 600mg/day reduced scores on the Hamilton Anxiety Rating Scale (HAMA) by 2.42 and 3.43, respectively. In 282 patients with GAD, pregabalin 600mg/ day was more effective vs placebo on the Hamilton Depression Rating Scale (HAMD) (64th Meet Am Diabetes Assoc (Orlando), 2004, Abs 105 and 599).^In 520 fibromyalgia patients, pregabalin 150-450mg resulted in significant improvements and sustained efficacy vs placebo (Analysts' Meet, Pfizer, 30 Nov 2006).^In a randomized study in 287 patients with refractory epilepsy, pregabalin 150 or 600mg/day alongside standard therapy was significantly better at reducing the RRatio (% change in seizure rates) cf placebo. A >50% reduction in seizure frequency was observed in 44% of patients treated with pregabalin 600mg/day, cf 6% on placebo. Common side-effects were drowsiness, dizziness, loss of co-ordination, double vision and weight gain (Scrip Daily Online, 16 Jan 2004, S00829580)^In long-term, open-label, add-on trials, 1480 patients received pregabalin up to 600mg/day bid or tid, and 77.2 and 59.4% of patients received treatment for >24 and 52wk, respectively. The mean number of seizure-free days per 28 days increased by 41.3%, and 8.9 and 5.8% of patients were seizure-free during their last 6mth and 1yr of pregabalin treatment, respectively (56th Meet Am Acad Neurol (San Francisco), 2004, Abs P04.098).^A retrospective pooled analysis of data from 3 randomized clinical trials in >2000 fibromyalgia patients showed that pregabalin 150-600mg resulted in greater pain reduction vs placebo, with pain reductions of 2.08, 2.01, 1.76 and 1.37 on pregabalin 600, 450, 300 and 150mg, respectively, cf 1.25 on placebo. There were reductions in pain regardless of whether patients had symptoms of anxiety or depression. Patients also reported as feeling 'much improved' or 'very much improved' as measured by the Patient Global Impression of Change (Press release, Pfizer, 16 Apr 2008).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (300mg po):bioavailability:89.9:%","Human (300mg po):t1/2:5.6:hr","Human (300mg po):Tmax:0.8:hr","Human (300mg po):Cmax:9.46:microg/ml","Human (300mg po):AUC:66.3:microghr/ml","Human (300mg po):Cl:68:ml/min","Human (50mg po):Tmax:1.2:hr","Human (50mg po):Cmax:1.61:microg/kg","Human (50mg po):AUC:12.2:microghr/ml","Human (50mg po):Cl:61.8:ml/min","Human (po):t1/2beta:6:hr","Human (po):Tmax:0.7 to 1.4:hr"],"Document_NC":["Yes"],"Document_RB":["6"],"Document_TF":["781: Ion channel > Calcium channel."],"Document_TG":["781: calcium channel, voltage-dependent, alpha 2/delta subunit 1"],"Document_LCH":["20140304:AD67 : Additional details reported"],"Document_TB":["781: Ion channel > Calcium channel;","781: Calcium channel;","781: Ion channel."],"Document_CASIS-USE_CASIS-MA_PHCD":["CHA-CA-AN: Calcium channel antagonist: Physiological, Biochemical, Calcium channel antagonist: Calcium channel blocker: Ca++ channel antagonist: Ca2+ channel antagonist: Antiarrhythmic Class IV: P-B-CHA-CA-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["159.23"],"Document_AL":["0.89"],"Document_CASIS-CO_CO":["Originator: Pfizer (US): Launched","Licensee: Eisai (JP): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD093219    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["3:Speed Rating - Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH019883","CASIS_COMPOUND":[{"CN":"CI1008 CCN=CI1008","SRC_DB":"PHPROJ"},{"CN":"Lyrica (solution) CCN=LYRICA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"PD-144723 (solution) CCN=PD144723(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"pregabalin (capsule) CCN=PREGABALIN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CI1008 (solution) CCN=CI1008(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"PD-144550 CCN=PD144550","SRC_DB":"PHPROJ"},{"CN":"PD-144550 (capsule) CCN=PD144550(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CI-1008 CCN=CI1008","SRC_DB":"PHPROJ"},{"CN":"PD144550 CCN=PD144550","SRC_DB":"PHPROJ"},{"CN":"CI1008 (capsule) CCN=CI1008(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"PD144550 (solution) CCN=PD144550(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"CI-1008 (solution) CCN=CI1008(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Lyrica CCN=LYRICA","SRC_DB":"PHPROJ"},{"CN":"PD-144550 (solution) CCN=PD144550(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"PD-144723 (capsule) CCN=PD144723(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"PD144723 (capsule) CCN=PD144723(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Lyrica (capsule) CCN=LYRICA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"PD144550 (capsule) CCN=PD144550(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"PD144723 (solution) CCN=PD144723(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"pregabalin (solution) CCN=PREGABALIN(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"PD-144723 CCN=PD144723","SRC_DB":"PHPROJ"},{"CN":"PD144723 CCN=PD144723","SRC_DB":"PHPROJ"},{"CN":"pregabalin CCN=PREGABALIN","SRC_DB":"PHPROJ"},{"CN":"CI-1008 (capsule) CCN=CI1008(CAPSULE)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:41","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M5Z","THE_USE":"Musculoskeletal","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Neuropathy, diabetic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N2Z","THE_USE":"Analgesic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Social anxiety disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Restless legs syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Epilepsy, partial (focal, local)","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"CHA-CA-AN","THE_USE":"Calcium channel antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Epilepsy, generalized, tonic-clonic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Pain, neuropathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Fibromyalgia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Pain, post-operative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N3A","THE_USE":"Antiepileptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N4A","THE_USE":"Antiparkinsonian","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Pain, post-herpetic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Generalized anxiety disorder","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[80, 114, 101, 103, 97, 98, 97, 108, 105, 110, 32, 40, 80, 68, 45, 49, 52, 52, 55, 50, 51, 41, 32, 105, 115, 32, 97, 32, 103, 97]...', original message: bytes can be at most 32766 in length; got 37345
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37345
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:35,200][DEBUG][action.bulk              ] }).^In paired biopsy specimens from Phase I trial patients, increasing doses of vemurafenib had >80% inhibition of ERK phosphorylation in the tumours of patients and correlated with significant tumour shrinkage and clinical response compared to partial inhibition of RAF activity in the tumour tissue of a subset of patients who received <240mg bid doses (Press release, Plexxikon, 7 Sep 2010, http://www.plexxikon.com/view.cfm/79/Press- Releases).^In nude mice implanted with human melanoma xenografts bearing B- RafV600E, vemurafenib as a monotherapy resulted in complete tumour regression, and antitumour and survival effects were significantly better than temozolomide monotherapy. In vivo combination of vemurafenib and temozolomide did not increase either antitumour activity or survival over that provided by monotherapy of vemurafenib (100th AACR (Denver), 2009, Abs 4420).^Inhibition of melanoma tumour cell growth correlated with inhibition of Erk phosphorylation (Product Fact Sheet, Plexxikon, Nov 2008).^In the HT29 colorectal cancer xenograft model, vemurafenib monotherapy resulted in increased survival levels vs bevacizumab and capecitabine (both qv) monotherapies. Vemurafenib + capecitabine was more effective vs vemurafenib + bevacizumab, whilst vemurafenib + capecitabine + bevacizumab was more effective vs all monotherapies and double therapies (20th EORTC- NCI-AACR Symp Molec Targ Cancer Ther (Geneva), 2008, Abs 252).^In colorectal xenograft models, it dose-dependently inhibited tumour growth (19th EORTC-NCI-AACR Symp Molec Targ Cancer Ther (San Francisco), 2007, Abs 252).^In melanoma and colorectal cancer models, vemurafenib reduced tumour size or slowed the progression of tumours for extended periods, even after treatment was completed (Press release, Plexxikon, 4 Oct 2006).^In mice, vemurafenib 20mg/kg once-daily x14 days resulted in an 80% reduction in tumour growth, with no effect on body weight (232nd ACS (San Francisco), 2006, MEDI 46).^In vitro^In vitro in mammalian cell lines, vemurafenib in combination with temozolomide, DTIC and 17-AAG gave either synergistic or additive effects. Vemurafenib specifically inhibited melanoma cell proliferation and MEK phosphorylation only in melanoma cell lines bearing B-RafV600E but not in cells harbouring wild type B-Raf or non-V600E B-Raf mutations (100th AACR (Denver), 2009, Abs 4420).^In in vitro studies, it had an additive/synergistic effect in combination with 5-FU (19th EORTC-NCI-AACR Symp Molec Targ Cancer Ther (San Francisco), 2007, Abs 252).^Patents^US7863288, covering composition-of-matter expires in 2029 (Press release, Plexxikon, 18 Jan 2011, http://www.plexxikon.com/ view.cfm/86/Press-Releases).^Licensing^Agreements^________________^Bristol-Myers Squibb^Worldwide; Roche has a clinical collaboration agreement with BMS to evaluate the utility of ipilimumab in combination with vemurafenib, in treating patients with a specific type of metastatic melanoma. Under the agreement, the 2 companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination. If appropriate, the companies may conduct further development of the combination (Press release, BMS, 2 Jun 2011, http://www.bms.com/news/press_releases/pages/ default.aspx?RSSLink=http://www.businesswire.com/news/bms/ 20110602005575/enandt=634426293393715140).^Chugai (Hoffmann-La Roche)^Japan; exclusive Japanese development and marketing rights. Chugai will also consider expanding the agreement to other tumour types with BRAF mutations (which include colon and thyroid cancer) in line with Roche's development plans and clinical results (Scrip Intelligence, 15 Aug 2011, http:// www.scripintelligence.com/business/Chugai-takes-on-vemurafenib- for-Japanese-development-and-marketing-319859).^Genentech (Hoffmann-La Roche)^USA; Co-promotion agreement (Press release, Plexxikon, 6 Jan 2011, http://www.plexxikon.com/view.cfm/84/Press-Releases).^Hoffmann-La Roche^Worldwide; Roche has exclusive rights to vemurafenib, with Plexxikon retaining rights to co-promote in the US. Roche will also jointly develop any follow-on compounds from the vemurafenib programme targeting other B-Raf kinase mutations (Press release, Plexxikon, 4 Oct 2006).^"],"Document_HA":["7"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["673: Enzyme > EC number > 2.7.11.1;","673: Enzyme > Kinase."],"Document_TG":["673: v-raf murine sarcoma viral oncogene homologue B"],"Document_LCH":["20140321:AD244 : Planned Phase IIa trial (ML28897) for solid tumours reported"],"Document_TB":["673: Enzyme > EC number > 2.7.11.1;","673: EC number > 2.7.11.1;","673: Enzyme;","673: 2.7.11.1;","673: Enzyme > EC number.","673: Enzyme > Kinase;","673: Kinase;","673: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-RAF-B-AN: B-raf kinase inhibitor: Enzyme, Transferase, Biochemical, raf kinase inhibitor: V-raf homologue B1 inhibitor: BRAF inhibitor: RAFB1 inhibitor: Oncogene BRAF inhibitor: E-TR-KI-RAF-B-AN|KI-PR-AN: Protein kinase inhibitor: Enzyme, Transferase, Protein kinase inhibitor: E-TR-KI-PR-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["489.93"],"Document_AL":["4.19"],"Document_CASIS-CO_CO":["Originator: Daiichi Sankyo (JP): Launched","Licensee: Hoffmann-La Roche (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Preclinical Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase I"}],"DOCNO":"PH042697","CASIS_COMPOUND":[{"CN":"R7204 CCN=R7204","SRC_DB":"PHPROJ"},{"CN":"vemurafenib CCN=VEMURAFENIB","SRC_DB":"PHPROJ"},{"CN":"PLX-4032 CCN=PLX4032","SRC_DB":"PHPROJ"},{"CN":"RG-7204 CCN=RG7204","SRC_DB":"PHPROJ"},{"CN":"RO-5185426 CCN=RO5185426","SRC_DB":"PHPROJ"},{"CN":"R-7204 CCN=R7204","SRC_DB":"PHPROJ"},{"CN":"RG7204 CCN=RG7204","SRC_DB":"PHPROJ"},{"CN":"RO5185426 CCN=RO5185426","SRC_DB":"PHPROJ"},{"CN":"Zelboraf CCN=ZELBORAF","SRC_DB":"PHPROJ"},{"CN":"PLX4032 CCN=PLX4032","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-AN","THE_USE":"Protein kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-RAF-B-AN","THE_USE":"B-raf kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[86, 101, 109, 117, 114, 97, 102, 101, 110, 105, 98, 32, 40, 90, 101, 108, 98, 111, 114, 97, 102, 59, 32, 80, 76, 88, 45, 52, 48, 51]...', original message: bytes can be at most 32766 in length; got 40016
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40016
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:35,267][DEBUG][action.bulk              ] respectively (Form 10-K, BMS, 15 Feb 2013, Page 7, http://www.sec.gov/Archives/edgar/data/14272/ 000119312513061678/d450621d10k.htm).^A US patent covering composition of matter expires in 2020 (Form 10-K, BMS, 18 Feb 2011, Page 9, http://www.sec.gov/Archives/edgar/ data/14272/000119312511040120/d10k.htm).^Licensing^Agreements^________________^Bristol-Myers Squibb^Worldwide; Medarex has a worldwide collaboration with Bristol- Myers Squibb (BMS) for the development and commercialization of ipilimumab and MDX-1379 (a vaccine consisting of 2 gp100 melanoma peptides, in-licensed from the US NCI (NIH)), for use in combination with ipilimumab. BMS and Medarex will share costs of developing ipilimumab and MDX-1379 in Europe and the US, with BMS responsible for all development elsewhere (Press release, BMS and Medarex, 8 Nov 2004).^Gilead Sciences^Worldwide; it was originally under development by Gilead Sciences, but Medarex obtained an exclusive sublicence to the CTLA-4 blockade intellectual property rights owned by the University of California, Berkeley, the US. Medarex used its HuMAb mouse technology to create fully-human, high affinity, anti-CTLA-4 MAbs, and had the option to pursue non-antibody-based methods of blocking CTLA-4 (Press release, Medarex, 1 Sep 1999; Direct communication, Gilead, 22 Jun 2001).^Pfizer^Medarex and Pfizer cross-licensed patents regarding their anti- CTLA-4 antibody programmes. Medarex has rights to patents covering CP-675206 (Scrip Daily Online, 21 Sep 2004, S00858060).^Roche^Worldwide; to evaluate the utility of ipilimumab in combination with Roche's investigational oral BRAF inhibitor PLX-4032 in treating patients with a specific type of metastatic melanoma. Under the agreement, the 2 companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination. If appropriate, the companies may conduct further development of the combination (Press release, BMS, 2 Jun 2011, http://www.bms.com/ news/press_releases/pages/default.aspx?RSSLink=http:// www.businesswire.com/news/bms/20110602005575/ enandt=634426293393715140).^Additional Clinical Information^Phase III^In 29 melanoma patients receiving 3.0mg/kg iv x90min q 3wk, 4/29 had PRs and 2/29 CRs. In 27 patients receiving 3.0mg/kg iv x90min followed by 1.0mg/kg MDX-010 only q 3wk, 3/27 had PRs and 2/27 CRs (Press release, Medarex and BMS, 20 Apr 2005).^Phase II^In a study in 19 patients with advanced resected melanoma, ipilimumab 0.3, 1 or 3mg/kg in combination with gp100/tyrosinase/ MART-1 peptide vaccines (8 doses over 12mth at 1mg/dose/peptide), produced a response in 4/9 and 2/9 patients receiving gp100 and MART-1, respectively. 5/9 patients relapsed (3 alive with disease, 2 in remission following surgery). DLTs were observed at 3mg/kg. (39th ASCO (Chicago), 2003, Abs 2853, 0).^In a trial in 36 patients with metastatic melanoma, ipilimumab 0.1-3.0mg/kg q 3wk + high-dose IL-2 therapy gave 3CRs and 5PRs. Two patients receiving 3.0mg/kg experienced CRs that were ongoing at >13mth, and 1 patient receiving 2.0mg/kg experienced a CR which was ongoing at >16mth (Press release, Medarex, 7 Mar 2005).^Phase I^It was in a dose-escalation, open-label Phase I trial in up to 18 patients with HIV who have an extensive treatment history but whose virus is no longer suppressed by HAART. Patients will receive ipilimumab 2x/mth, and the trial will establish safety and tolerability and preliminarily evaluate clinical efficacy (Press release, Medarex, 11 Jun 2003). Responses were also seen in ovarian cancer, leukaemia and lymphoma (Company presentation, BMS, 12 Dec 2005).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (3mg/kg):t1/2beta:300:hr"],"Document_NC":["No"],"Document_TG":["1493: cytotoxic T-lymphocyte-associated protein 4"],"Document_LCH":["20140320:AD151 : Enrollment completion of Phase II trial (CA184- 162) for gastro-esophageal junction cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["CTLA4-AN: CTLA4 inhibitor: Receptor, Biochemical, CTLA4 inhibitor: R-B-CTLA4-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Gilead Sciences (US): Discontinued","Licensee: Bristol-Myers Squibb (US): Launched","Licensee: Hoffmann-La Roche (CH): Phase II Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH027985","CASIS_COMPOUND":[{"CN":"anti-CTLA-4 MAb, Medarex CCN=ANTICTLA4MABMEDAREX","SRC_DB":"PHPROJ"},{"CN":"Yervoy CCN=YERVOY","SRC_DB":"PHPROJ"},{"CN":"ipilimumab CCN=IPILIMUMAB","SRC_DB":"PHPROJ"},{"CN":"MDX-CTLA-4 CCN=MDXCTLA4","SRC_DB":"PHPROJ"},{"CN":"BMS734016 CCN=BMS734016","SRC_DB":"PHPROJ"},{"CN":"MDX-010 CCN=MDX010","SRC_DB":"PHPROJ"},{"CN":"MDX101 CCN=MDX101","SRC_DB":"PHPROJ"},{"CN":"BMS-734016 CCN=BMS734016","SRC_DB":"PHPROJ"},{"CN":"MDX-101 CCN=MDX101","SRC_DB":"PHPROJ"},{"CN":"MDX010 CCN=MDX010","SRC_DB":"PHPROJ"},{"CN":"anti-CTLA-4 MAb, IDM CCN=ANTICTLA4MABIDM","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, leukaemia, unspecifed","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Infection, HIV/AIDS","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"CTLA4-AN","THE_USE":"CTLA4 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A2","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"K3","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"J5A","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 112, 105, 108, 105, 109, 117, 109, 97, 98, 32, 40, 77, 68, 88, 45, 48, 49, 48, 59, 32, 102, 111, 114, 109, 101, 114, 108, 121, 32]...', original message: bytes can be at most 32766 in length; got 37867
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37867
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:35,275][DEBUG][action.bulk              ]  13/ 606742, covering Sativex formulation of spray device has been issued. Patent is expected to expire in Mar 2021. In addition, a notice of allowance for a US patent application number 13/607897, covering method of sublingual delivery of the Sativex formulation has been issued (Press release, GW, 22 Apr 2013, http:// www.gwpharm.com/SativexPatent.aspx).^An EU patent covering cannabinoid liquid formulations for mucosal administration expires in Aug 2023 (Press release, GW, 22 Nov 2011, http://www.gwpharm.com/uploads/gwprelim2011%5B0%5D.pdf).^A US patent covering method of treating cancer related pain by administering a combination of the cannabinoids cannabidiol and delta-9 tetrahydrocannabinol expires in Apr 2025. It is also protected by a number of other patents related to different aspects of nabiximols (Press release, GW, 20 Apr 2011, http:// www.gwpharm.com/ US%20Patent%20Granted%20for%20Sativex%20in%20Cancer%20Pain.aspx; Press release, GW, 22 Nov 2011, http://www.gwpharm.com/uploads/ gwprelim2011%5B0%5D.pdf).^Licensing^Agreements^________________^Almirall^EU and Mexico; exclusively licensed to Almirall (formerly Almirall-Prodesfarma) for marketing in the EU (excluding the UK), Norway, Switzerland and Turkey (Press release, GW, 12 Dec 2005). The agreement was amended to include rights to market Sativex in Mexico (Scrip Intelligence, 15 Mar 2012, http:// www.scripintelligence.com/business/GW-Pharmaceuticals-to-let- Almirall-sell-cannabis-derived-drug-in-Mexico-328187).^Bayer^Australia, Canada, New Zealand and the UK; exclusive marketing rights (Press release, Bayer, 21 May 2003; Ann Rep, GW, 2003).^Ipsen^Latin America (excluding Mexico and the Islands of the Caribbean); Ipsen and GW Pharmaceuticals entered into an exclusive agreement for Ipsen to promote and distribute Sativex. GW will be responsible for commercial product supply to Ipsen (Press release, Ipsen and GW, 14 Jan 2014, http://www.gwpharm.com/^^Novartis^Africa, Asia (excluding Japan, China and Hong Kong), Australia, Middle East (excluding Israel/Palestine) and New Zealand; Novartis has an exclusive license agreement with GW Pharmaceuticals for the commercialization. Under the terms of the agreement, Novartis will be responsible for regulatory filings and act as Marketing Authorisation holder for Sativex. GW will be responsible for the manufacture and supply of Sativex to Novartis (Press release, GW, 11 Apr 2011, http://www.gwpharm.com/^^Otsuka Pharmaceutical^USA; exclusive development and marketing licence (Press release, GW, 14 Feb 2007).^Availability^________________^GW Pharmaceuticals^The project is available for licensing as shown (Direct communication, GW, 14 Feb 2000).^Additional Clinical Information^Phase III^Four randomized, double-blind trials in 350 patients with MS and neuropathic pain have been completed. Sativex reduced neuropathic pain cf placebo in MS patients and improved other symptoms of MS, such as spasticity and sleep disturbance (Company Web Page, GW, 15 Apr 2003). In the 1st MS Phase III trial, 100 patients received either Sativex as a sublingual spray (maximum dose of 120mg in 24hr) or placebo (Scrip Daily Online, 11 Apr 2001, S00705884; Direct communication, GW, 25 Jan 2002).^"],"Document_HA":["2"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["No"],"Document_RB":["5"],"Document_TF":["1268: Receptor > GPCR > Cannabinoid."],"Document_TG":["1268: cannabinoid receptor 1 (brain)"],"Document_LCH":["20140318:PP241 : Expected timing of Phase III data in cancer pain and revised timing of Phase III trial in multiple sclerosis reported"],"Document_TB":["1268: Receptor > GPCR > Cannabinoid;","1268: GPCR > Cannabinoid;","1268: Receptor;","1268: Cannabinoid;","1268: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["CANN-1-AG: Cannabinoid CB1 receptor agonist: Receptor, Biochemical, Cannabinoid CB1 receptor agonist: CB1 agonist: Cannabinoid receptor 1 agonist: R-B-CANN-1-AG|"],"Document_ROUT":["A-PO: Alimentary, po","A-SL: Alimentary, sublingual"],"Document_MW":["314.47"],"Document_AL":["5.35"],"Document_CASIS-CO_CO":["Originator: GW Pharmaceuticals (GB): Launched","Licensee: Bayer (DE): Launched","Licensee: Almirall (ES): Launched","Licensee: Novartis (CH): Pre-registration","Licensee: Otsuka (JP): Phase III Clinical Trial","Licensee: Ipsen (FR): Preclinical"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD053662    ","MD087412    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"}],"DOCNO":"PH027869","CASIS_COMPOUND":[{"CN":"GW-1000-02 CCN=GW100002","SRC_DB":"PHPROJ"},{"CN":"GWP-42001 CCN=GWP42001","SRC_DB":"PHPROJ"},{"CN":"GWP42001 CCN=GWP42001","SRC_DB":"PHPROJ"},{"CN":"Sativex CCN=SATIVEX","SRC_DB":"PHPROJ"},{"CN":"THC","SRC_DB":"PHPROJ"},{"CN":"tetranabinex/nabidiolex CCN=TETRANABINEX/NABIDIOLEX","SRC_DB":"PHPROJ"},{"CN":"GW-1000 CCN=GW1000","SRC_DB":"PHPROJ"},{"CN":"THC","SRC_DB":"PHPROJ"},{"CN":"nabiximols CCN=NABIXIMOLS","SRC_DB":"PHPROJ"},{"CN":"cannabinoids, GW Pharmaceuticals CCN=CANNABINOIDSGWPHARMACEUTICALS","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"CANN-1-AG","THE_USE":"Cannabinoid CB1 receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Radio/chemotherapy-induced mucositis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Spinal cord injury","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N7C","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N2Z","THE_USE":"Analgesic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Neuropathy, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M3","THE_USE":"Muscle relaxant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Spasticity","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Pain, cancer","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Multiple sclerosis, progressive, secondary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Multiple sclerosis, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Neuropathy, diabetic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Pain, general","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"P","THE_USE":"Cerebral palsy","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N7A","THE_USE":"Multiple sclerosis treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Pain, neuropathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Multiple sclerosis, progressive, primary","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[78, 97, 98, 105, 120, 105, 109, 111, 108, 115, 32, 105, 115, 32, 97, 32, 115, 117, 98, 108, 105, 110, 103, 117, 97, 108, 32, 110, 111, 110]...', original message: bytes can be at most 32766 in length; got 36171
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36171
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:47:41,437][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.7gb[8.6%], shards will be relocated away from this node
[2016-06-14 12:47:49,794][DEBUG][action.bulk              ] .23/LLL63, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=a6f1919c-67b4-4022-8404- eed1cab1de28andcKey=72e13111-af68-4e1f-8dd4- 203c6b02f2deandmKey={E5D5C83F-CE2D-4D71-9DD6-FC7231E090FB}).^In animal models of anxiety disorders and depression, lurasidone showed 'significant' improvement. It showed a preferential effect on the frontal cortex in increasing dopamine turnover. In rats, lurasidone showed antipsychotic activity such as inhibition of methamphetamine (MAP)-induced hyperactivity and apomorphine (APO)- induced stereotyped behavior. In rodent models, lurasidone had weak extrapyramidal effects (J Pharmacol Exp Ther, 19 Apr 2010, PMID:20404009).^In rats, it did not adversely affect prefrontal cognitive functioning (39th Meet Soc Neurosci (Chicago), 2009, Abs 646.24).^It significantly increased punished water licking in the Vogel conflict test (MED = 10mg/kg po). In the Morris water maze and radial-arm maze tests, it reversed MK-801 induced impairment of learning, suggesting use in schizophrenics with cognitive dysfunction (Behav Brain Res, 2008, 186, 197, PMID:17881065).^In vitro^In preclinical studies, lurasidone hydrochloride had a weaker interaction with striatal acetylcholine neurons vs haloperidol, and a preferential action on the mesocortical (vs nigrostriatal) dopaminergic system in terms of increase in dopamine turnover and Fos expression. It had a high affinity for D2 (Ki=1.68nM), 5-HT2 (2.03nM) and 5-HT1A (6.75nM) receptors, but did not interact with 5-HT2C and H1 receptors (31st Meet Soc Neurosci (San Diego), 2001, Abs 664.14).^Licensing^Agreements^________________^Standard Chem. and Pharm, Taiwan^Taiwan; it is licensed to Standard Chem. and Pharm for the exclusive sales of lurasidone (Press Release, SCP, 28 Oct 2013, http://www.standard.com.tw/UserFiles/File/Standard/English/131028- SCP%20Press%20Release%20English.pdf).^Merck and Co^Worldwide excluding China, Japan, South Korea and Taiwan; it was licensed exclusively to Merck and Co for development and marketing, with DSP retaining the option to co-promote it in the US; however, Merck discontinued development and returned rights to DSP (Press release, Dainippon, 13 Dec 2006).^Takeda^EU except the UK, Norway, Russia and Turkey; DSP has a license agreement with Takeda for joint development and exclusive commercialization for the oral formulation. DSP has rights in the UK (Press release, DSP and Takeda, 30 Mar 2011, http://www.ds- pharma.com/pdf_view.php?id=76).^Availability^________________^Dainippon Sumitomo Pharma^EU (Company presentation, Dainippon, 25 Jan 2011, Slide 35, http:/ /www.ds-pharma.com/ir/presentation/img/eir20110125_1.pdf).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3363: 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140321:AD67 : Completion of Phase III study (D1050298) for schizophrenia and bipolar disorder reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3363: GPCR > 5-Hydroxytryptamine;","3363: Receptor;","3363: 5-Hydroxytryptamine;","3363: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AN: Dopamine D2 receptor antagonist: Receptor, Transmitter, Dopamine D2 receptor antagonist: DA D2 receptor antagonist: D2 receptor antagonist: Dopamine DA2 receptor antagonist: DA DA2 receptor antagonist: R-T-DOPA-D2-AN|5HT-7-AN: 5 Hydroxytryptamine 7 receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 7 receptor antagonist: 5HT7 receptor antagonist: Serotonin 7 receptor antagonist: R-H-5HT-7-AN|5HT-1-A-AN: 5 Hydroxytryptamine 1A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor antagonist: 5HT1A receptor antagonist: Serotonin 1A receptor antagonist: R-H-5HT-1-A-AN|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["492.68"],"Document_AL":["4.37"],"Document_CASIS-CO_CO":["Originator: Sunovion Pharmaceuticals (US): Launched","Licensee: Takeda (JP): Launched","Licensee: Merck & Co (US): Discontinued"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD520542    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH023698","CASIS_COMPOUND":[{"CN":"lurasidone hydrochloride CCN=LURASIDONEHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"SMP13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"MK3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"SMP-13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"Latuda CCN=LATUDA","SRC_DB":"PHPROJ"},{"CN":"SM13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"MK-3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"SM-13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"lurasidone CCN=LURASIDONE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Anxiety, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AN","THE_USE":"5 Hydroxytryptamine 1A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AN","THE_USE":"Dopamine D2 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-7-AN","THE_USE":"5 Hydroxytryptamine 7 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 117, 114, 97, 115, 105, 100, 111, 110, 101, 32, 104, 121, 100, 114, 111, 99, 104, 108, 111, 114, 105, 100, 101, 32, 40, 83, 77, 45, 49]...', original message: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:48:00,802][DEBUG][action.bulk              ] onf (New York), 2008).^In human tumour xenograft models, TH-302 in combination with carboplatin, cisplatin, 5-FU or pemetrexed gave greater tumour growth inhibition cf TH-302 or chemotherapy alone (Press release, Threshold, 22 Jul 2008).^In mice, rats, dogs and monkeys, TH-302 had linear pharmacokinetics, 'excellent' oral bioavailability and high clearance (Press release, Threshold, 14 Apr 2008).^In vitro^In in vitro studies, TH-302 activity can be modulated by pharmacological modulators of both reductases and DNA damage and repair pathways and can be inhibited by the flavin reductase inhibitor DPI, while the NQO1 inhibitor dicoumoral can enhance TH- 302 activity. It was not affected by the PARP inhibitor ABT-888 but was potentiated by the HDAC inhibitor VPA. Results supported that HDR and not SSB DNA repair mechanisms is involved in repair of TH-302-induced DNA lesions (102nd ACCR (Orlando), 2011, Abs 2648, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=ea6119bc-2d97-4288-bf2a- 02e27e5c9ad4andcKey=f23f95ed-5896-4cd8-b3b6- 86e24bfbbf60andmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^In in vitro studies, it activated apoptosis with no adverse events (51st Meet Am Soc Hematol (New Orleans), 2009, Abs 3838).^In human prostate cancer cell lines (PC-3, LNCaP, and DU-145), TH- 302 demonstrated hypoxia-selective cytotoxicity (21st AACR-NCI- EORTC Symp Molec Targ Cancer Ther (Boston), 2009, B185).^Preclinical studies showed a >100x difference in cytotoxicity between cells in normal oxygen levels and hypoxic cells (Company Web Page, Threshold, 11 Jul 2005).^Patents^US7550496, covering hypoxia-activated prodrugs of anti-cancer alkylating agents has protection until 2024 (Press release, Threshold, 6 Aug 2009).^Licensing^Agreements^________________^Merck KGaA; Threshold Pharmaceuticals^Worldwide; Threshold has an agreements with Merck KGaA to co- develop and commercialize TH-302. Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the US. In the US, Threshold will have primary responsibility for the development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Subject to FDA approval in the US, Merck KGaA will initially be responsible for commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales. Under the royalty-bearing portion of the agreement, Threshold retains the option to co-promote TH-302 in the US. Additionally, Threshold retains the option to co-commercialize TH-302 allowing the company to participate in up to 50% of the profits in the US based on certain revenue tiers. Outside of the US, Merck KGaA will be solely responsible for the commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales in these territories (Press release, Threshold, 3 Feb 2012, http:/ /investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=645974).^MD Anderson Cancer Center, USA; Threshold Pharmaceuticals^Worldwide; preclinical research collaboration to focus on characterizing the therapeutic efficacy of TH-302 as monotherapy and in combination with conventional chemotherapeutics in both in vitro and in vivo models of leukaemia (Press release, Threshold, 22 Dec 2010, http://investor.thresholdpharm.com/ releasedetail.cfm?ReleaseID=538451).^National Comprehensive Cancer Network (NCCN), USA; Threshold Pharmaceuticals^Worldwide; National Comprehensive Cancer Network (NCCN) has awarded a grant for the clinical development of TH-302 (Press release, Threshold, 6 Jul 2011, http:// investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=589275).^Qualifying Therapeutic Discovery Project, USA; Threshold Pharmaceuticals^USA; Threshold has received a development grant under the Qualified Therapeutic Discovery Project (QTDP) programme (Press release, Threshold, 3 Nov 2010, http:// investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=526715).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (iv):MTD:575:mg/m2"],"Document_NC":["Yes"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140324:AD244 : Ongoing Phase II trial (TH-CR-415) for nsclc reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["DNA-AN: DNA inhibitor: Physiological, Biochemical, DNA inhibitor: Antineoplastic e.g. actinomycin, bleomycin, anthracyclines: Antineoplastic alkylating agent: Alkylating antineoplastic agent: DNA cross linking agent: P-B-DNA-AN|DNA-SYN-AN: DNA synthesis inhibitor: Physiological, Biochemical, DNA synthesis inhibitor: P-B-DNA-SYN-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Threshold Pharmaceuticals (US): Phase III Clinical Trial","Licensee: Merck KGaA (DE): Phase III Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"}],"DOCNO":"PH040674","CASIS_COMPOUND":[{"CN":"TH302 CCN=TH302","SRC_DB":"PHPROJ"},{"CN":"TH-302 CCN=TH302","SRC_DB":"PHPROJ"},{"CN":"anticancer prodrug, Threshold CCN=ANTICANCERPRODRUGTHRESHOLD","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C1","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-SYN-AN","THE_USE":"DNA synthesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-AN","THE_USE":"DNA inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Myelofibrosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 72, 45, 51, 48, 50, 32, 105, 115, 32, 97, 32, 99, 121, 116, 111, 116, 111, 120, 105, 99, 32, 112, 114, 111, 100, 114, 117, 103, 44]...', original message: bytes can be at most 32766 in length; got 47408
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47408
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:48:00,936][DEBUG][action.bulk              ] UK open-label, Phase II trial (CRFB002AGB10; 2009-014854-14; REPAIR) in 65 patients with choroidal neovascularization secondary to pathological myopia, to assess the efficacy and safety of ranibizumab 0.5mg x12mth was completed. After 6mth of treatment, mean visual acuity improved by twelve letters. Patients received an average of three ranibizumab injections with 29% requiring no further treatment beyond the first injection. This analysis showed that ranibizumab therapy lead to improvement in visual acuity in patients with this condition. Six month interim results and the full 1yr are planned (ClinicalTrials.gov, 8 Aug 2011 and 20 Sep 2012, http://www.clinicaltrials.gov/ct2/ show/NCT01037348; Press release, Novartis, 5 Sep 2012, http:// www.novartis.com/newsroom/media-releases/en/2012/1638671.shtml). At 12mth, the mean visual acuity gain was 13.8 letters, this was achieved with a low number of injections to month 12 (mean 3.6, median 3) with 21% patients requiring only the one baseline treatment (Press release, Novartis, 8 May 2013, http:// www.novartis.com/newsroom/media-releases/en/2013/1700148.shtml). Myopic CNV patients treated with ranibizumab experienced high overall treatment satisfaction as measured using the Macular Disease Treatment Satisfaction Questionnaire. The overall score increased from 55.0 at month 1 to 64.9 at month 12 (Press release, Novartis, 27 Sep 2013, http://www.novartis.com/newsroom/media- releases/en/2013/1731649.shtml).^Oedema, macular, diabetic^Novartis^A randomized, open-label, laser-controlled Phase II trial (CRFB002DES01) in 85 patients with visual impairment due to diabetic macular oedema in Spain, to assess the efficacy and safety of ranibizumab intravitreally vs laser treatment was completed (ClinicalTrials.gov, 30 Aug 2011 and 23 Jan 2013, http:/ /clinicaltrials.gov/ct2/show/NCT00901186).^Phase I^Macular degeneration, age-related, wet^Genentech (Hoffmann-La Roche)^A Phase I, open label, prospective, observational trial (FVF4150s) in 5 subjects in combination with proton beam irradiation in treating exudative wet AMD in the US was completed (ClinicalTrials.gov, 18 Oct 2012, http://clinicaltrials.gov/show/ NCT00517010).^In an open-label, non-randomized Phase Ia trial in 25 patients with neovascular AMD with best-corrected visual acuity (BCVA) of 20/100, ranibizumab 50-500microg intravitreal injections gave a median BCVA of 20/250. It was well tolerated (Meet Assoc Res Vision Ophthalmol (Fort Lauderdale), 2001, Abs 2807).^Preclinical ^In vivo^In cynomolgus monkeys, ranibizumab 500microg intravitreal injections q 2wk significantly lowered choroidal neovascularization (CNV) vs controls. There were no ocular haemorrhages, and injection-related acute anterior chamber inflammation was resolved within 1wk (Arch Ophthalmol, 2002, 120, 338, PMID:11879138).^In cynomolgus monkeys, 2000microg gave a mean Cl, Vd and t1/2 of 0.85ml/day, 3.0ml and 2.5 days, respectively (Meet Assoc Res Vision Ophthalmol (Fort Lauderdale), 2001, Abs 5000).^Patents^Patent protection in the US expires in 2019 (Company presentation, Roche, 15 Sep 2010, Slide 7, http://www.roche.com/irp100915.pdf).^Patent protection for the active ingredient expires in 2018-22 in Europe and Japan (Form 20-F, Novartis, 2009).^Licensing^Agreements^________________^Alcon; Novartis Ophthalmics (Novartis)^Japan; Alcon has a co-promotion agreement with Novartis for Japan (Scrip Daily Online, 30 Jan 2009, S01018806).^Hoffmann-La Roche^Worldwide; Roche previously had an option to license the product before the acquisition of Genentech (Ann Rep, Roche, 2001).^Novartis Ophthalmics (Novartis)^Worldwide except USA; Novartis Ophthalmics (Novartis) obtained an exclusive licence for development and marketing for eye disease outside N America (Press release, Novartis Ophthalmics, 25 Jun 2003). Novartis Ophthalmics subsequently amended its licence to include Canada (Dow Jones Web Page, 22 Jun 2006).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Cynomolgus monkey (2000microgram):Vd:3:ml","Cynomolgus monkey (2000microgram):Cl:0.85:ml/day"],"Document_NC":["No"],"Document_TF":["7422: Cytokine/Growth factor > Growth factor, non-cytokine."],"Document_TG":["7422: vascular endothelial growth factor A"],"Document_LCH":["20140321:PP249 : Additional launch in Germany and Chinese launch for macular oedema reported"],"Document_TB":["7422: Cytokine/Growth factor > Growth factor, non-cytokine;","7422: Growth factor, non-cytokine;","7422: Cytokine/Growth factor."],"Document_CASIS-USE_CASIS-MA_PHCD":["GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|"],"Document_ROUT":["P-UN: Parenteral, general","T-EY: Topical, eyes"],"Document_CASIS-CO_CO":["Originator: Hoffmann-La Roche (CH): Launched","Licensee: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"}],"DOCNO":"PH030035","CASIS_COMPOUND":[{"CN":"AMD Fab, Genentech CCN=AMDFABGENENTECH","SRC_DB":"PHPROJ"},{"CN":"RG-3645 CCN=RG3645","SRC_DB":"PHPROJ"},{"CN":"rhuFab V2 CCN=RHUFABV2","SRC_DB":"PHPROJ"},{"CN":"RG3645 CCN=RG3645","SRC_DB":"PHPROJ"},{"CN":"RFB002 CCN=RFB002","SRC_DB":"PHPROJ"},{"CN":"rhuFabV2 CCN=RHUFABV2","SRC_DB":"PHPROJ"},{"CN":"Lucentis CCN=LUCENTIS","SRC_DB":"PHPROJ"},{"CN":"ranibizumab CCN=RANIBIZUMAB","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Macular degeneration, age-related, wet","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Oedema, macular, diabetic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T3A5","THE_USE":"Monoclonal antibody","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"S1Z","THE_USE":"Ophthalmological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Oedema, macular","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"S1G","THE_USE":"Antiglaucoma","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Retinal vein occlusion","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Glaucoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Myopia","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 97, 110, 105, 98, 105, 122, 117, 109, 97, 98, 32, 40, 114, 104, 117, 70, 97, 98, 86, 50, 59, 32, 76, 117, 99, 101, 110, 116, 105]...', original message: bytes can be at most 32766 in length; got 43924
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 43924
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:48:01,541][DEBUG][action.bulk              ] and 34% of patients on rosiglitazone maleate, metformin and glyburide, respectively, had inadequate glucose control at 5yr. Rosiglitazone maleate was well tolerated. Common Adverse events included oedema, weight gain and hypoglycaemia (Press release, GSK, 14 Jul 2008). Female patients on rosiglitazone maleate were significantly more likely to experience bone fractures at peripheral sites cf those on metformin or glyburide. Fracture rates on rosiglitazone maleate, metformin and glyburide were 2.74, 1.54 and 1.29/100 patient yr, respectively (Press release, GSK, 21 Feb 2007). There has been no increase in spine or hip fractures in patients on rosiglitazone maleate (Press release, GSK, 3 Dec 2007).^In a Phase IV study comparing the incidence of elevated ALT levels in patients receiving rosiglitazone maleate in Phase III trials at the time of the DNA submission to the incidence of elevated ALT in these patients 1yr later, the rate of elevated ALT levels was 0.30 cases/100 patient yr for all patients (Press release, SB, 12 Jun 2000).^In a trial in more than 33000 Type II diabetes patients receiving rosiglitazone maleate, metformin or sulfonylurea, either as a monotherapy or as 2 medicines combined + insulin, results demonstrated that there was no difference in the overall incidence of heart attack and coronary revascularization with rosiglitazone maleate-containing therapies (1.75 cf 1.76 events per 100 person-years on non-rosiglitazone maleate containing theapies). There was no difference in the risk of heart attack or coronary vascularization on rosiglitazone maleate-containing cf non-rosiglitazone maleate containing therapies, and no difference in the risk of composite outcome with rosiglitazone maleate monotherapy cf metformin monotherapy or sulfonylurea monotherapy. There was no risk of composite outcome with rosiglitazone maleate in combination with insulin theapy cf other oral antidiabetic agents + insulin (Press release, GSK, 6 Jun 2007).^Results from the VADT and ACCORD trials showed that rosigliazone maleate did not reduce major cardiovascular events associated with diabetes and was not associated with increased risk of death (Press release, GSK, 6 Jun 2008)^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20131206"],"Document_PK":["Human (2mg po):bioavailability:99:%","Human (2mg po):t1/2:3.78:hr","Human (2mg po):Tmax:3.5:hr","Human (2mg po):Cmax:121:ng/ml","Human (2mg po):AUC:805:mghr/ml","Human (2mg po):Vd:17.6:l","Human (2mg po):Cl:2.89:l/hr"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["5468: Receptor > Nuclear receptor > Peroxisome proliferator."],"Document_TG":["5468: peroxisome proliferative activated receptor, gamma"],"Document_LCH":["20131126:PP259 : FDA decision on the use of rosiglitazone reported"],"Document_TB":["5468: Receptor > Nuclear receptor > Peroxisome proliferator;","5468: Nuclear receptor > Peroxisome proliferator;","5468: Receptor;","5468: Peroxisome proliferator;","5468: Receptor > Nuclear receptor."],"Document_CASIS-USE_CASIS-MA_PHCD":["PPAR-G-AG: Peroxisome proliferator-activated receptor gamma agonist: Receptor, Biochemical, Peroxisome proliferatoractivated receptor gamma agonist: PPAR-gamma agonist: R-B-PPAR-G-AG|INSS-AG: Insulin sensitizer: Receptor, Hormonal, Insulin sensitizer: R-H-INSS-AG|THIAZ-AG: Thiazolidinedione: Physiological, Biochemical, Thiazolidinedione: TZD: P-B-THIAZ-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["357.43"],"Document_AL":["3.13"],"Document_CASIS-CO_CO":["Originator: GlaxoSmithKline (GB): Launched","Licensee: Bristol-Myers Squibb (US): Launched","Licensee: Torrent Pharmaceuticals (IN): Launched","Licensee: Asahi Kasei Pharma (JP): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD243663    ","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 1999 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Withdrawn Licensing Availability Unknown"}],"DOCNO":"PH022294","CASIS_COMPOUND":[{"CN":"Windia CCN=WINDIA","SRC_DB":"PHPROJ"},{"CN":"Venvia CCN=VENVIA","SRC_DB":"PHPROJ"},{"CN":"rosiglitazone maleate CCN=ROSIGLITAZONEMALEATE","SRC_DB":"PHPROJ"},{"CN":"BRL 49653C  CCN=BRL49653C","SRC_DB":"PHPROJ"},{"CN":"BRL-49653c CCN=BRL49653C","SRC_DB":"PHPROJ"},{"CN":"Nyracta CCN=NYRACTA","SRC_DB":"PHPROJ"},{"CN":"rosiglitazone CCN=ROSIGLITAZONE","SRC_DB":"PHPROJ"},{"CN":"BRL-48482 CCN=BRL48482","SRC_DB":"PHPROJ"},{"CN":"BRL-49653 CCN=BRL49653","SRC_DB":"PHPROJ"},{"CN":"Avandia CCN=AVANDIA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2013-12-09 13:06:47","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D5A","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Restenosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A16","THE_USE":"GI inflammatory-bowel disorders","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PPAR-G-AG","THE_USE":"Peroxisome proliferator-activated receptor gamma agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diabetic complication, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cognitive disorder, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N6D","THE_USE":"Cognition enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"G1C","THE_USE":"Fertility enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"M2Z","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"THIAZ-AG","THE_USE":"Thiazolidinedione","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C10","THE_USE":"Hypolipaemic-Antiatherosclerosis","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Impaired glucose tolerance","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10C","THE_USE":"Symptomatic antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Polycystic ovarian syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"INSS-AG","THE_USE":"Insulin sensitizer","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Atherosclerosis","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 111, 115, 105, 103, 108, 105, 116, 97, 122, 111, 110, 101, 32, 109, 97, 108, 101, 97, 116, 101, 32, 40, 66, 82, 76, 45, 52, 57, 54]...', original message: bytes can be at most 32766 in length; got 34136
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 34136
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:48:11,467][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.7gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:48:11,467][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:48:27,704][DEBUG][action.bulk              ] onf (New York), 2008).^In human tumour xenograft models, TH-302 in combination with carboplatin, cisplatin, 5-FU or pemetrexed gave greater tumour growth inhibition cf TH-302 or chemotherapy alone (Press release, Threshold, 22 Jul 2008).^In mice, rats, dogs and monkeys, TH-302 had linear pharmacokinetics, 'excellent' oral bioavailability and high clearance (Press release, Threshold, 14 Apr 2008).^In vitro^In in vitro studies, TH-302 activity can be modulated by pharmacological modulators of both reductases and DNA damage and repair pathways and can be inhibited by the flavin reductase inhibitor DPI, while the NQO1 inhibitor dicoumoral can enhance TH- 302 activity. It was not affected by the PARP inhibitor ABT-888 but was potentiated by the HDAC inhibitor VPA. Results supported that HDR and not SSB DNA repair mechanisms is involved in repair of TH-302-induced DNA lesions (102nd ACCR (Orlando), 2011, Abs 2648, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=ea6119bc-2d97-4288-bf2a- 02e27e5c9ad4andcKey=f23f95ed-5896-4cd8-b3b6- 86e24bfbbf60andmKey={507D311A-B6EC-436A-BD67-6D14ED39622C}).^In in vitro studies, it activated apoptosis with no adverse events (51st Meet Am Soc Hematol (New Orleans), 2009, Abs 3838).^In human prostate cancer cell lines (PC-3, LNCaP, and DU-145), TH- 302 demonstrated hypoxia-selective cytotoxicity (21st AACR-NCI- EORTC Symp Molec Targ Cancer Ther (Boston), 2009, B185).^Preclinical studies showed a >100x difference in cytotoxicity between cells in normal oxygen levels and hypoxic cells (Company Web Page, Threshold, 11 Jul 2005).^Patents^US7550496, covering hypoxia-activated prodrugs of anti-cancer alkylating agents has protection until 2024 (Press release, Threshold, 6 Aug 2009).^Licensing^Agreements^________________^Merck KGaA; Threshold Pharmaceuticals^Worldwide; Threshold has an agreements with Merck KGaA to co- develop and commercialize TH-302. Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold an option to co-commercialize the therapeutic in the US. In the US, Threshold will have primary responsibility for the development of TH-302 in the soft tissue sarcoma indication. Threshold and Merck KGaA will jointly develop TH-302 in all other cancer indications being pursued. Subject to FDA approval in the US, Merck KGaA will initially be responsible for commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales. Under the royalty-bearing portion of the agreement, Threshold retains the option to co-promote TH-302 in the US. Additionally, Threshold retains the option to co-commercialize TH-302 allowing the company to participate in up to 50% of the profits in the US based on certain revenue tiers. Outside of the US, Merck KGaA will be solely responsible for the commercialization of TH-302 with Threshold receiving a tiered, double-digit royalty on sales in these territories (Press release, Threshold, 3 Feb 2012, http:/ /investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=645974).^MD Anderson Cancer Center, USA; Threshold Pharmaceuticals^Worldwide; preclinical research collaboration to focus on characterizing the therapeutic efficacy of TH-302 as monotherapy and in combination with conventional chemotherapeutics in both in vitro and in vivo models of leukaemia (Press release, Threshold, 22 Dec 2010, http://investor.thresholdpharm.com/ releasedetail.cfm?ReleaseID=538451).^National Comprehensive Cancer Network (NCCN), USA; Threshold Pharmaceuticals^Worldwide; National Comprehensive Cancer Network (NCCN) has awarded a grant for the clinical development of TH-302 (Press release, Threshold, 6 Jul 2011, http:// investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=589275).^Qualifying Therapeutic Discovery Project, USA; Threshold Pharmaceuticals^USA; Threshold has received a development grant under the Qualified Therapeutic Discovery Project (QTDP) programme (Press release, Threshold, 3 Nov 2010, http:// investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=526715).^"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (iv):MTD:575:mg/m2"],"Document_NC":["Yes"],"Document_TG":["99999999: Unspecified"],"Document_LCH":["20140324:AD244 : Ongoing Phase II trial (TH-CR-415) for nsclc reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["DNA-AN: DNA inhibitor: Physiological, Biochemical, DNA inhibitor: Antineoplastic e.g. actinomycin, bleomycin, anthracyclines: Antineoplastic alkylating agent: Alkylating antineoplastic agent: DNA cross linking agent: P-B-DNA-AN|DNA-SYN-AN: DNA synthesis inhibitor: Physiological, Biochemical, DNA synthesis inhibitor: P-B-DNA-SYN-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Threshold Pharmaceuticals (US): Phase III Clinical Trial","Licensee: Merck KGaA (DE): Phase III Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH040674","CASIS_COMPOUND":[{"CN":"TH302 CCN=TH302","SRC_DB":"PHPROJ"},{"CN":"TH-302 CCN=TH302","SRC_DB":"PHPROJ"},{"CN":"anticancer prodrug, Threshold CCN=ANTICANCERPRODRUGTHRESHOLD","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C1","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-AN","THE_USE":"DNA inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Myelofibrosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-SYN-AN","THE_USE":"DNA synthesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 72, 45, 51, 48, 50, 32, 105, 115, 32, 97, 32, 99, 121, 116, 111, 116, 111, 120, 105, 99, 32, 112, 114, 111, 100, 114, 117, 103, 44]...', original message: bytes can be at most 32766 in length; got 47408
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47408
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:48:41,536][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.6gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:49:11,561][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.6gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:49:11,561][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:49:18,415][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,518][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,529][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,541][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,551][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,566][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,576][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:18,591][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:49:27,490][DEBUG][action.bulk              ] prevented and treated collagen-induced arthritis. It abrogated pathways implicated in RA pathogenesis, including mast cell c-Kit signalling, TNF-alpha release, macrophage c-FMS activation, cytokine production, fibroblast PDGFR signalling amd proliferation (Scrip Daily Online, 29 Sep 2006, S00935424). In mice, imatinib + erythromycin produced greater tumour reductions and better long-term tumour-free survival cf imatinib alone (Cancer Drug News, Nov 2000, 24).^Patents^Patent expiry is expected in 2016 in major EU countries, 2014 in Japan and Jul 2015 (including a paediatric extension) in the US (Form 20-F, Novartis, 2007).^Additional Clinical Information^Phase II^In a trial in 86 patients with GIST, 54% of patients on imatinib 400 or 600mg/day had a partial response and 34% had stable disease at 1-3mth (Scrip Daily Online, 2001, S00709802, 0).^In 7 CML patients and 8 with ALL, all experiencing a lymphoid blast crisis, 9 had a CR, 3 achieved complete blood recovery, and 1 patient was still in remission at 5mth (Scrip Daily Online, 2000, S00670292, 0).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140221"],"Document_PK":["Human (po):bioavailability:98:%","Human (po):t1/2beta:18:hr","Human (po):Tmax:2 to 4:hr","Human (po):Cl:8 to 14:l/hr","Human (100mg x4 capsules):Tmax:2.5:hr","Human (100mg x4 capsules):Cmax:1748:ng/ml","Human (100mg x4 capsules):AUC:27.1:microghr/ml","Human (100mg x4 capsules):t1/2beta:15.8:hr"],"Document_NC":["Yes"],"Document_RB":["8"],"Document_TF":["613: Enzyme > EC number > 2.7.11.1;","613: Enzyme > Kinase;","25: Enzyme > EC number > 2.7.10.2;","25: Enzyme > Kinase;","5156: Enzyme > Kinase;","5156: Receptor;","3815: Enzyme > Kinase;","3815: Receptor."],"Document_TG":["613: breakpoint cluster region","25: c-abl oncogene 1, non-receptor tyrosine kinase","5156: platelet-derived growth factor receptor, alpha polypeptide","3815: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue"],"Document_LCH":["20140212:AD283 : Initiation of Phase III trial (CQTI571AJP01) for pulmonary arterial hypertension reported"],"Document_TB":["613: Enzyme > EC number > 2.7.11.1;","613: EC number > 2.7.11.1;","613: Enzyme;","613: 2.7.11.1;","613: Enzyme > EC number.","613: Enzyme > Kinase;","613: Kinase;","613: Enzyme.","25: Enzyme > EC number > 2.7.10.2;","25: EC number > 2.7.10.2;","25: Enzyme;","25: 2.7.10.2;","25: Enzyme > EC number.","25: Enzyme > Kinase;","25: Kinase;","25: Enzyme.","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;","3815: Enzyme > Kinase;","3815: Kinase;","3815: Enzyme.","3815: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-BCAB-AN: Bcr-Abl inhibitor: Enzyme, Transferase, BcrAbl inhibitor: Philadelphia chromosome inhibitor: Bcr-Abl kinase inhibitor: E-TR-KI-BCAB-AN|KI-GFPL-AN: Platelet-derived growth factor receptor kinase inhibitor: Enzyme, Transferase, Plateletderived growth factor receptor kinase inhibitor: Platelet-derived growth factor kinase inhibitor: PDGF receptor kinase inhibitor: PDGF kinase inhibitor: E-TR-KI-GFPL-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|APOP-AG: Apoptosis stimulant: Physiological, Biochemical, Apoptosis stimulant: General apoptosis stimulant: P-B-APOP-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["493.62"],"Document_AL":["3.30"],"Document_CASIS-CO_CO":["Originator: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH028936","CASIS_COMPOUND":[{"CN":"ST-571 CCN=ST571","SRC_DB":"PHPROJ"},{"CN":"Ruvise CCN=RUVISE","SRC_DB":"PHPROJ"},{"CN":"STI-571A CCN=STI571A","SRC_DB":"PHPROJ"},{"CN":"imatinib mesilate CCN=IMATINIBMESILATE","SRC_DB":"PHPROJ"},{"CN":"QTI571 CCN=QTI571","SRC_DB":"PHPROJ"},{"CN":"imatinib CCN=IMATINIB","SRC_DB":"PHPROJ"},{"CN":"Glivec CCN=GLIVEC","SRC_DB":"PHPROJ"},{"CN":"QTI-571 CCN=QTI571","SRC_DB":"PHPROJ"},{"CN":"CGP-57148B CCN=CGP57148B","SRC_DB":"PHPROJ"},{"CN":"Gleevec CCN=GLEEVEC","SRC_DB":"PHPROJ"},{"CN":"STI-571 CCN=STI571","SRC_DB":"PHPROJ"},{"CN":"imatinib mesylate CCN=IMATINIBMESYLATE","SRC_DB":"PHPROJ"},{"CN":"ST571 CCN=ST571","SRC_DB":"PHPROJ"},{"CN":"STI571 CCN=STI571","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-25 16:28:19","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2B9","THE_USE":"Antihypertensive","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"B7Z","THE_USE":"Haematological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D4A","THE_USE":"Antipruritic-inflamm","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Hypereosinophilic syndrome, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D11Z","THE_USE":"Dermatological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Mastocytosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-BCAB-AN","THE_USE":"Bcr-Abl inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"APOP-AG","THE_USE":"Apoptosis stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Scleroderma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPL-AN","THE_USE":"Platelet-derived growth factor receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Hypertension, pulmonary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 109, 97, 116, 105, 110, 105, 98, 32, 109, 101, 115, 105, 108, 97, 116, 101, 32, 40, 102, 111, 114, 109, 101, 114, 108, 121, 32, 67, 71]...', original message: bytes can be at most 32766 in length; got 42886
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 42886
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:49:27,997][DEBUG][action.bulk              ] .23/LLL63, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=a6f1919c-67b4-4022-8404- eed1cab1de28andcKey=72e13111-af68-4e1f-8dd4- 203c6b02f2deandmKey={E5D5C83F-CE2D-4D71-9DD6-FC7231E090FB}).^In animal models of anxiety disorders and depression, lurasidone showed 'significant' improvement. It showed a preferential effect on the frontal cortex in increasing dopamine turnover. In rats, lurasidone showed antipsychotic activity such as inhibition of methamphetamine (MAP)-induced hyperactivity and apomorphine (APO)- induced stereotyped behavior. In rodent models, lurasidone had weak extrapyramidal effects (J Pharmacol Exp Ther, 19 Apr 2010, PMID:20404009).^In rats, it did not adversely affect prefrontal cognitive functioning (39th Meet Soc Neurosci (Chicago), 2009, Abs 646.24).^It significantly increased punished water licking in the Vogel conflict test (MED = 10mg/kg po). In the Morris water maze and radial-arm maze tests, it reversed MK-801 induced impairment of learning, suggesting use in schizophrenics with cognitive dysfunction (Behav Brain Res, 2008, 186, 197, PMID:17881065).^In vitro^In preclinical studies, lurasidone hydrochloride had a weaker interaction with striatal acetylcholine neurons vs haloperidol, and a preferential action on the mesocortical (vs nigrostriatal) dopaminergic system in terms of increase in dopamine turnover and Fos expression. It had a high affinity for D2 (Ki=1.68nM), 5-HT2 (2.03nM) and 5-HT1A (6.75nM) receptors, but did not interact with 5-HT2C and H1 receptors (31st Meet Soc Neurosci (San Diego), 2001, Abs 664.14).^Licensing^Agreements^________________^Standard Chem. and Pharm, Taiwan^Taiwan; it is licensed to Standard Chem. and Pharm for the exclusive sales of lurasidone (Press Release, SCP, 28 Oct 2013, http://www.standard.com.tw/UserFiles/File/Standard/English/131028- SCP%20Press%20Release%20English.pdf).^Merck and Co^Worldwide excluding China, Japan, South Korea and Taiwan; it was licensed exclusively to Merck and Co for development and marketing, with DSP retaining the option to co-promote it in the US; however, Merck discontinued development and returned rights to DSP (Press release, Dainippon, 13 Dec 2006).^Takeda^EU except the UK, Norway, Russia and Turkey; DSP has a license agreement with Takeda for joint development and exclusive commercialization for the oral formulation. DSP has rights in the UK (Press release, DSP and Takeda, 30 Mar 2011, http://www.ds- pharma.com/pdf_view.php?id=76).^Availability^________________^Dainippon Sumitomo Pharma^EU (Company presentation, Dainippon, 25 Jan 2011, Slide 35, http:/ /www.ds-pharma.com/ir/presentation/img/eir20110125_1.pdf).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3363: 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140321:AD67 : Completion of Phase III study (D1050298) for schizophrenia and bipolar disorder reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3363: GPCR > 5-Hydroxytryptamine;","3363: Receptor;","3363: 5-Hydroxytryptamine;","3363: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AN: Dopamine D2 receptor antagonist: Receptor, Transmitter, Dopamine D2 receptor antagonist: DA D2 receptor antagonist: D2 receptor antagonist: Dopamine DA2 receptor antagonist: DA DA2 receptor antagonist: R-T-DOPA-D2-AN|5HT-7-AN: 5 Hydroxytryptamine 7 receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 7 receptor antagonist: 5HT7 receptor antagonist: Serotonin 7 receptor antagonist: R-H-5HT-7-AN|5HT-1-A-AN: 5 Hydroxytryptamine 1A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor antagonist: 5HT1A receptor antagonist: Serotonin 1A receptor antagonist: R-H-5HT-1-A-AN|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["492.68"],"Document_AL":["4.37"],"Document_CASIS-CO_CO":["Originator: Sunovion Pharmaceuticals (US): Launched","Licensee: Takeda (JP): Launched","Licensee: Merck & Co (US): Discontinued"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD520542    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"}],"DOCNO":"PH023698","CASIS_COMPOUND":[{"CN":"SM13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"MK3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"SMP-13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"lurasidone hydrochloride CCN=LURASIDONEHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"Latuda CCN=LATUDA","SRC_DB":"PHPROJ"},{"CN":"SM-13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"SMP13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"MK-3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"lurasidone CCN=LURASIDONE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-7-AN","THE_USE":"5 Hydroxytryptamine 7 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AN","THE_USE":"5 Hydroxytryptamine 1A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Anxiety, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AN","THE_USE":"Dopamine D2 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 117, 114, 97, 115, 105, 100, 111, 110, 101, 32, 104, 121, 100, 114, 111, 99, 104, 108, 111, 114, 105, 100, 101, 32, 40, 83, 77, 45, 49]...', original message: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:49:41,586][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.6gb[8.5%], shards will be relocated away from this node
[2016-06-14 12:50:04,688][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 12:50:11,611][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.5gb[8.4%], shards will be relocated away from this node
[2016-06-14 12:50:11,612][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:50:21,411][DEBUG][action.bulk              ] .23/LLL63, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=a6f1919c-67b4-4022-8404- eed1cab1de28andcKey=72e13111-af68-4e1f-8dd4- 203c6b02f2deandmKey={E5D5C83F-CE2D-4D71-9DD6-FC7231E090FB}).^In animal models of anxiety disorders and depression, lurasidone showed 'significant' improvement. It showed a preferential effect on the frontal cortex in increasing dopamine turnover. In rats, lurasidone showed antipsychotic activity such as inhibition of methamphetamine (MAP)-induced hyperactivity and apomorphine (APO)- induced stereotyped behavior. In rodent models, lurasidone had weak extrapyramidal effects (J Pharmacol Exp Ther, 19 Apr 2010, PMID:20404009).^In rats, it did not adversely affect prefrontal cognitive functioning (39th Meet Soc Neurosci (Chicago), 2009, Abs 646.24).^It significantly increased punished water licking in the Vogel conflict test (MED = 10mg/kg po). In the Morris water maze and radial-arm maze tests, it reversed MK-801 induced impairment of learning, suggesting use in schizophrenics with cognitive dysfunction (Behav Brain Res, 2008, 186, 197, PMID:17881065).^In vitro^In preclinical studies, lurasidone hydrochloride had a weaker interaction with striatal acetylcholine neurons vs haloperidol, and a preferential action on the mesocortical (vs nigrostriatal) dopaminergic system in terms of increase in dopamine turnover and Fos expression. It had a high affinity for D2 (Ki=1.68nM), 5-HT2 (2.03nM) and 5-HT1A (6.75nM) receptors, but did not interact with 5-HT2C and H1 receptors (31st Meet Soc Neurosci (San Diego), 2001, Abs 664.14).^Licensing^Agreements^________________^Standard Chem. and Pharm, Taiwan^Taiwan; it is licensed to Standard Chem. and Pharm for the exclusive sales of lurasidone (Press Release, SCP, 28 Oct 2013, http://www.standard.com.tw/UserFiles/File/Standard/English/131028- SCP%20Press%20Release%20English.pdf).^Merck and Co^Worldwide excluding China, Japan, South Korea and Taiwan; it was licensed exclusively to Merck and Co for development and marketing, with DSP retaining the option to co-promote it in the US; however, Merck discontinued development and returned rights to DSP (Press release, Dainippon, 13 Dec 2006).^Takeda^EU except the UK, Norway, Russia and Turkey; DSP has a license agreement with Takeda for joint development and exclusive commercialization for the oral formulation. DSP has rights in the UK (Press release, DSP and Takeda, 30 Mar 2011, http://www.ds- pharma.com/pdf_view.php?id=76).^Availability^________________^Dainippon Sumitomo Pharma^EU (Company presentation, Dainippon, 25 Jan 2011, Slide 35, http:/ /www.ds-pharma.com/ir/presentation/img/eir20110125_1.pdf).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140328"],"Document_NC":["Yes"],"Document_RB":["5"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3363: 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140321:AD67 : Completion of Phase III study (D1050298) for schizophrenia and bipolar disorder reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3363: Receptor > GPCR > 5-Hydroxytryptamine;","3363: GPCR > 5-Hydroxytryptamine;","3363: Receptor;","3363: 5-Hydroxytryptamine;","3363: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AN: Dopamine D2 receptor antagonist: Receptor, Transmitter, Dopamine D2 receptor antagonist: DA D2 receptor antagonist: D2 receptor antagonist: Dopamine DA2 receptor antagonist: DA DA2 receptor antagonist: R-T-DOPA-D2-AN|5HT-7-AN: 5 Hydroxytryptamine 7 receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 7 receptor antagonist: 5HT7 receptor antagonist: Serotonin 7 receptor antagonist: R-H-5HT-7-AN|5HT-1-A-AN: 5 Hydroxytryptamine 1A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor antagonist: 5HT1A receptor antagonist: Serotonin 1A receptor antagonist: R-H-5HT-1-A-AN|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["492.68"],"Document_AL":["4.37"],"Document_CASIS-CO_CO":["Originator: Sunovion Pharmaceuticals (US): Launched","Licensee: Takeda (JP): Launched","Licensee: Merck & Co (US): Discontinued"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD520542    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["2:Speed Rating - Slower than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH023698","CASIS_COMPOUND":[{"CN":"lurasidone CCN=LURASIDONE","SRC_DB":"PHPROJ"},{"CN":"Latuda CCN=LATUDA","SRC_DB":"PHPROJ"},{"CN":"lurasidone hydrochloride CCN=LURASIDONEHYDROCHLORIDE","SRC_DB":"PHPROJ"},{"CN":"MK-3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"SM-13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"MK3756 CCN=MK3756","SRC_DB":"PHPROJ"},{"CN":"SM13496 CCN=SM13496","SRC_DB":"PHPROJ"},{"CN":"SMP-13496 CCN=SMP13496","SRC_DB":"PHPROJ"},{"CN":"SMP13496 CCN=SMP13496","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:06","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-7-AN","THE_USE":"5 Hydroxytryptamine 7 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AN","THE_USE":"5 Hydroxytryptamine 1A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Anxiety, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AN","THE_USE":"Dopamine D2 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[76, 117, 114, 97, 115, 105, 100, 111, 110, 101, 32, 104, 121, 100, 114, 111, 99, 104, 108, 111, 114, 105, 100, 101, 32, 40, 83, 77, 45, 49]...', original message: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37774
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:50:21,603][DEBUG][action.bulk              ] prevented and treated collagen-induced arthritis. It abrogated pathways implicated in RA pathogenesis, including mast cell c-Kit signalling, TNF-alpha release, macrophage c-FMS activation, cytokine production, fibroblast PDGFR signalling amd proliferation (Scrip Daily Online, 29 Sep 2006, S00935424). In mice, imatinib + erythromycin produced greater tumour reductions and better long-term tumour-free survival cf imatinib alone (Cancer Drug News, Nov 2000, 24).^Patents^Patent expiry is expected in 2016 in major EU countries, 2014 in Japan and Jul 2015 (including a paediatric extension) in the US (Form 20-F, Novartis, 2007).^Additional Clinical Information^Phase II^In a trial in 86 patients with GIST, 54% of patients on imatinib 400 or 600mg/day had a partial response and 34% had stable disease at 1-3mth (Scrip Daily Online, 2001, S00709802, 0).^In 7 CML patients and 8 with ALL, all experiencing a lymphoid blast crisis, 9 had a CR, 3 achieved complete blood recovery, and 1 patient was still in remission at 5mth (Scrip Daily Online, 2000, S00670292, 0).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140221"],"Document_PK":["Human (po):bioavailability:98:%","Human (po):t1/2beta:18:hr","Human (po):Tmax:2 to 4:hr","Human (po):Cl:8 to 14:l/hr","Human (100mg x4 capsules):Tmax:2.5:hr","Human (100mg x4 capsules):Cmax:1748:ng/ml","Human (100mg x4 capsules):AUC:27.1:microghr/ml","Human (100mg x4 capsules):t1/2beta:15.8:hr"],"Document_NC":["Yes"],"Document_RB":["8"],"Document_TF":["613: Enzyme > EC number > 2.7.11.1;","613: Enzyme > Kinase;","25: Enzyme > EC number > 2.7.10.2;","25: Enzyme > Kinase;","5156: Enzyme > Kinase;","5156: Receptor;","3815: Enzyme > Kinase;","3815: Receptor."],"Document_TG":["613: breakpoint cluster region","25: c-abl oncogene 1, non-receptor tyrosine kinase","5156: platelet-derived growth factor receptor, alpha polypeptide","3815: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue"],"Document_LCH":["20140212:AD283 : Initiation of Phase III trial (CQTI571AJP01) for pulmonary arterial hypertension reported"],"Document_TB":["613: Enzyme > EC number > 2.7.11.1;","613: EC number > 2.7.11.1;","613: Enzyme;","613: 2.7.11.1;","613: Enzyme > EC number.","613: Enzyme > Kinase;","613: Kinase;","613: Enzyme.","25: Enzyme > EC number > 2.7.10.2;","25: EC number > 2.7.10.2;","25: Enzyme;","25: 2.7.10.2;","25: Enzyme > EC number.","25: Enzyme > Kinase;","25: Kinase;","25: Enzyme.","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;","3815: Enzyme > Kinase;","3815: Kinase;","3815: Enzyme.","3815: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-BCAB-AN: Bcr-Abl inhibitor: Enzyme, Transferase, BcrAbl inhibitor: Philadelphia chromosome inhibitor: Bcr-Abl kinase inhibitor: E-TR-KI-BCAB-AN|KI-GFPL-AN: Platelet-derived growth factor receptor kinase inhibitor: Enzyme, Transferase, Plateletderived growth factor receptor kinase inhibitor: Platelet-derived growth factor kinase inhibitor: PDGF receptor kinase inhibitor: PDGF kinase inhibitor: E-TR-KI-GFPL-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|APOP-AG: Apoptosis stimulant: Physiological, Biochemical, Apoptosis stimulant: General apoptosis stimulant: P-B-APOP-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["493.62"],"Document_AL":["3.30"],"Document_CASIS-CO_CO":["Originator: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH028936","CASIS_COMPOUND":[{"CN":"ST571 CCN=ST571","SRC_DB":"PHPROJ"},{"CN":"STI-571 CCN=STI571","SRC_DB":"PHPROJ"},{"CN":"ST-571 CCN=ST571","SRC_DB":"PHPROJ"},{"CN":"Gleevec CCN=GLEEVEC","SRC_DB":"PHPROJ"},{"CN":"STI-571A CCN=STI571A","SRC_DB":"PHPROJ"},{"CN":"imatinib CCN=IMATINIB","SRC_DB":"PHPROJ"},{"CN":"Glivec CCN=GLIVEC","SRC_DB":"PHPROJ"},{"CN":"QTI571 CCN=QTI571","SRC_DB":"PHPROJ"},{"CN":"Ruvise CCN=RUVISE","SRC_DB":"PHPROJ"},{"CN":"imatinib mesilate CCN=IMATINIBMESILATE","SRC_DB":"PHPROJ"},{"CN":"imatinib mesylate CCN=IMATINIBMESYLATE","SRC_DB":"PHPROJ"},{"CN":"STI571 CCN=STI571","SRC_DB":"PHPROJ"},{"CN":"QTI-571 CCN=QTI571","SRC_DB":"PHPROJ"},{"CN":"CGP-57148B CCN=CGP57148B","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-25 16:28:19","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Mastocytosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Scleroderma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2B9","THE_USE":"Antihypertensive","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-BCAB-AN","THE_USE":"Bcr-Abl inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D11Z","THE_USE":"Dermatological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"B7Z","THE_USE":"Haematological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D4A","THE_USE":"Antipruritic-inflamm","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPL-AN","THE_USE":"Platelet-derived growth factor receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Hypereosinophilic syndrome, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"APOP-AG","THE_USE":"Apoptosis stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Hypertension, pulmonary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 109, 97, 116, 105, 110, 105, 98, 32, 109, 101, 115, 105, 108, 97, 116, 101, 32, 40, 102, 111, 114, 109, 101, 114, 108, 121, 32, 67, 71]...', original message: bytes can be at most 32766 in length; got 42886
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 42886
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:50:41,637][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.5gb[8.4%], shards will be relocated away from this node
[2016-06-14 12:50:45,988][DEBUG][action.bulk              ] inetics of afatinib po + gemcitabine (Part A) or docetaxel (Part B). Primary objective includes to establish the MTD based on the occurrence of DLT observed in Cycle 1. Completion is expected in Jun 2013 (ClinicalTrials.gov, 18 Dec 2010 and 29 Jun 2012, http://www.clinicaltrials.gov/show/ NCT01251653). Interim results of 19 patients treated in Part A to date showed that afatinib (A) + gemcitabine (G) was well tolerated, with manageable AEs. AEs observed in most patients were diarrhea (89.5%) and rash (63.2%). DLTs were experienced by 1 patient out of 6 receiving A 30mg and G 1250mg/m2. MTD was exceeded at a dose level of at least A 40mg/day and G 1250mg/m2. An intermediate dose level of A 40mg/day and G 1000mg/m2 is currently under evaluation (48th ASCO (Chicago), 2012, Abs e13009, http://www.asco.org/ASCOv2/Meetings/^^An open-label, non-randomized Phase Ib trial in Belgium in 47 patients with advanced solid tumours, to assess the safety, tolerability, MTD and pharmacokinetics of continuous dosing of afatinib po when combined with cisplatin/paclitaxel or cisplatin/ 5-FU is complete (ClinicalTrials.gov, 27 Nov 2009 and 16 Sep 2010, http://www.clinicaltrials.gov/show/NCT00716417).^A further Phase I trial in France of afatinib in combination with BIBFW-1120 in advanced solid tumours is underway (AFSSAPS Web Page, 14 Oct 2009, EudraCT No: 2009-011321-14; ClinicalTrials.gov Web Page, 11 Dec 2009, http://www.clinicaltrials.gov/show/ NCT00998296).^A Phase I trial in 42 patients with solid tumours in combination with BIBF-1120 ha been completed (ClinicalTrials.gov Web Page, 26 Aug 2009, http://www.clinicaltrials.gov/show/NCT00730821).^It is in a Phase I dose-finding study to determine the maximum tolerated dose (MTD) of 3-day afatinib in combination with docetaxel (qv) once x3wk in 40 patients with advanced solid tumours. Results show the MTD was established at 90mg/day. Objective responses or durable SD of greater than/equal to 6 months was seen in 15 patients. Dose limiting toxicities included grade 4 febrile neutropenia and grade 3 nausea, vomiting and diarrhea (45th ASCO (Orlando), 2009, Abs 3556).^Preclinical ^In vivo^It had IC50s against the wild-type, resistant and dual resistant cell lines H1666, H3255 and NC11875 of 7, 6 and 93nM, respectively, and binding to EGFR/HER2 was irreversible (Company presentation, BI, 8 Nov 2006).^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Human (10-100mg po):MTD:70:mg"],"Document_NC":["Yes"],"Document_RB":["9"],"Document_TF":["1956: Enzyme > EC number > 2.7.10.1;","1956: Receptor > Cytokine receptor;","1956: Enzyme > Kinase;","2064: Enzyme > EC number > 2.7.10.1;","2064: Receptor > Cytokine receptor;","2064: Enzyme > Kinase."],"Document_TG":["1956: epidermal growth factor receptor","2064: v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2"],"Document_LCH":["20140318:PT : UK NICE recommendation for nsclc reported"],"Document_TB":["1956: Enzyme > EC number > 2.7.10.1;","1956: EC number > 2.7.10.1;","1956: Enzyme;","1956: 2.7.10.1;","1956: Enzyme > EC number.","1956: Receptor > Cytokine receptor;","1956: Cytokine receptor;","1956: Receptor.","1956: Enzyme > Kinase;","1956: Kinase;","1956: Enzyme.","2064: Enzyme > EC number > 2.7.10.1;","2064: EC number > 2.7.10.1;","2064: Enzyme;","2064: 2.7.10.1;","2064: Enzyme > EC number.","2064: Receptor > Cytokine receptor;","2064: Cytokine receptor;","2064: Receptor.","2064: Enzyme > Kinase;","2064: Kinase;","2064: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-TYE1-AN: ErbB-1 tyrosine kinase inhibitor: Enzyme, Transferase, ErbBiochemical, 1 tyrosine kinase inhibitor: EGFR1 kinase inhibitor: Epidermal growth factor receptor 1 tyrosine kinase inhibitor: HER1 tyrosine kinase inhibitor: E-TR-KI-TYE1-AN|KI-TYE2-AN: ErbB-2 tyrosine kinase inhibitor: Enzyme, Transferase, ErbBiochemical, 2 tyrosine kinase inhibitor: HER2 tyrosine kinase inhibitor: HER2/neu tyrosine kinase inhibitor: Epidermal growth factor receptor 2 tyrosine kinase inhibitor: EGFR2 tyrosine kinase inhibitor: E-TR-KI-TYE2-AN|KI-TYR-AN: Tyrosine kinase inhibitor (TKI): Enzyme, Transferase, Tyrosine kinase inhibitor (TKI): Protein kinase tyrosine inhibitor: Tyrosylprotein kinase inhibitor: Hydroxyaryl protein kinase inhibitor: TKI: E-TR-KI-TYR-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["485.95"],"Document_AL":["2.89"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH042195","CASIS_COMPOUND":[{"CN":"Tovok CCN=TOVOK","SRC_DB":"PHPROJ"},{"CN":"afatinib CCN=AFATINIB","SRC_DB":"PHPROJ"},{"CN":"BIBW-2992 MA2 CCN=BIBW2992MA2","SRC_DB":"PHPROJ"},{"CN":"afatinib dimaleate CCN=AFATINIBDIMALEATE","SRC_DB":"PHPROJ"},{"CN":"BIBW-2992 CCN=BIBW2992","SRC_DB":"PHPROJ"},{"CN":"Tomtovok CCN=TOMTOVOK","SRC_DB":"PHPROJ"},{"CN":"Giotrif CCN=GIOTRIF","SRC_DB":"PHPROJ"},{"CN":"BIBW 2992 CCN=BIBW2992","SRC_DB":"PHPROJ"},{"CN":"Gilotrif CCN=GILOTRIF","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C1","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYE1-AN","THE_USE":"ErbB-1 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TYE2-AN","THE_USE":"ErbB-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Chronic obstructive pulmonary disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TYR-AN","THE_USE":"Tyrosine kinase inhibitor (TKI)","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"R4A","THE_USE":"COPD treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 102, 97, 116, 105, 110, 105, 98, 32, 40, 66, 73, 66, 87, 45, 50, 57, 57, 50, 41, 32, 105, 115, 32, 97, 110, 32, 105, 114, 114]...', original message: bytes can be at most 32766 in length; got 44768
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 44768
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:51:03,918][DEBUG][action.bulk              ] prevented and treated collagen-induced arthritis. It abrogated pathways implicated in RA pathogenesis, including mast cell c-Kit signalling, TNF-alpha release, macrophage c-FMS activation, cytokine production, fibroblast PDGFR signalling amd proliferation (Scrip Daily Online, 29 Sep 2006, S00935424). In mice, imatinib + erythromycin produced greater tumour reductions and better long-term tumour-free survival cf imatinib alone (Cancer Drug News, Nov 2000, 24).^Patents^Patent expiry is expected in 2016 in major EU countries, 2014 in Japan and Jul 2015 (including a paediatric extension) in the US (Form 20-F, Novartis, 2007).^Additional Clinical Information^Phase II^In a trial in 86 patients with GIST, 54% of patients on imatinib 400 or 600mg/day had a partial response and 34% had stable disease at 1-3mth (Scrip Daily Online, 2001, S00709802, 0).^In 7 CML patients and 8 with ALL, all experiencing a lymphoid blast crisis, 9 had a CR, 3 achieved complete blood recovery, and 1 patient was still in remission at 5mth (Scrip Daily Online, 2000, S00670292, 0).^"],"Document_HA":["6"],"Document_CASIS-UPD_WE":["20140221"],"Document_PK":["Human (po):bioavailability:98:%","Human (po):t1/2beta:18:hr","Human (po):Tmax:2 to 4:hr","Human (po):Cl:8 to 14:l/hr","Human (100mg x4 capsules):Tmax:2.5:hr","Human (100mg x4 capsules):Cmax:1748:ng/ml","Human (100mg x4 capsules):AUC:27.1:microghr/ml","Human (100mg x4 capsules):t1/2beta:15.8:hr"],"Document_NC":["Yes"],"Document_RB":["8"],"Document_TF":["613: Enzyme > EC number > 2.7.11.1;","613: Enzyme > Kinase;","25: Enzyme > EC number > 2.7.10.2;","25: Enzyme > Kinase;","5156: Enzyme > Kinase;","5156: Receptor;","3815: Enzyme > Kinase;","3815: Receptor."],"Document_TG":["613: breakpoint cluster region","25: c-abl oncogene 1, non-receptor tyrosine kinase","5156: platelet-derived growth factor receptor, alpha polypeptide","3815: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue"],"Document_LCH":["20140212:AD283 : Initiation of Phase III trial (CQTI571AJP01) for pulmonary arterial hypertension reported"],"Document_TB":["613: Enzyme > EC number > 2.7.11.1;","613: EC number > 2.7.11.1;","613: Enzyme;","613: 2.7.11.1;","613: Enzyme > EC number.","613: Enzyme > Kinase;","613: Kinase;","613: Enzyme.","25: Enzyme > EC number > 2.7.10.2;","25: EC number > 2.7.10.2;","25: Enzyme;","25: 2.7.10.2;","25: Enzyme > EC number.","25: Enzyme > Kinase;","25: Kinase;","25: Enzyme.","5156: Enzyme > Kinase;","5156: Kinase;","5156: Enzyme.","5156: Receptor;","3815: Enzyme > Kinase;","3815: Kinase;","3815: Enzyme.","3815: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-BCAB-AN: Bcr-Abl inhibitor: Enzyme, Transferase, BcrAbl inhibitor: Philadelphia chromosome inhibitor: Bcr-Abl kinase inhibitor: E-TR-KI-BCAB-AN|KI-GFPL-AN: Platelet-derived growth factor receptor kinase inhibitor: Enzyme, Transferase, Plateletderived growth factor receptor kinase inhibitor: Platelet-derived growth factor kinase inhibitor: PDGF receptor kinase inhibitor: PDGF kinase inhibitor: E-TR-KI-GFPL-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|APOP-AG: Apoptosis stimulant: Physiological, Biochemical, Apoptosis stimulant: General apoptosis stimulant: P-B-APOP-AG|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["493.62"],"Document_AL":["3.30"],"Document_CASIS-CO_CO":["Originator: Novartis (CH): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2001 Licensing Availability Unknown"}],"DOCNO":"PH028936","CASIS_COMPOUND":[{"CN":"QTI-571 CCN=QTI571","SRC_DB":"PHPROJ"},{"CN":"STI-571 CCN=STI571","SRC_DB":"PHPROJ"},{"CN":"imatinib CCN=IMATINIB","SRC_DB":"PHPROJ"},{"CN":"imatinib mesilate CCN=IMATINIBMESILATE","SRC_DB":"PHPROJ"},{"CN":"STI-571A CCN=STI571A","SRC_DB":"PHPROJ"},{"CN":"ST571 CCN=ST571","SRC_DB":"PHPROJ"},{"CN":"CGP-57148B CCN=CGP57148B","SRC_DB":"PHPROJ"},{"CN":"Gleevec CCN=GLEEVEC","SRC_DB":"PHPROJ"},{"CN":"imatinib mesylate CCN=IMATINIBMESYLATE","SRC_DB":"PHPROJ"},{"CN":"Glivec CCN=GLIVEC","SRC_DB":"PHPROJ"},{"CN":"QTI571 CCN=QTI571","SRC_DB":"PHPROJ"},{"CN":"ST-571 CCN=ST571","SRC_DB":"PHPROJ"},{"CN":"STI571 CCN=STI571","SRC_DB":"PHPROJ"},{"CN":"Ruvise CCN=RUVISE","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-25 16:28:19","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"D","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-BCAB-AN","THE_USE":"Bcr-Abl inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2B9","THE_USE":"Antihypertensive","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Hypertension, pulmonary","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Hypereosinophilic syndrome, idiopathic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D4A","THE_USE":"Antipruritic-inflamm","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Mastocytosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"B7Z","THE_USE":"Haematological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"APOP-AG","THE_USE":"Apoptosis stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Scleroderma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D11Z","THE_USE":"Dermatological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPL-AN","THE_USE":"Platelet-derived growth factor receptor kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 109, 97, 116, 105, 110, 105, 98, 32, 109, 101, 115, 105, 108, 97, 116, 101, 32, 40, 102, 111, 114, 109, 101, 114, 108, 121, 32, 67, 71]...', original message: bytes can be at most 32766 in length; got 42886
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 42886
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:51:11,661][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.4gb[8.3%], shards will be relocated away from this node
[2016-06-14 12:51:11,661][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:51:41,727][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.4gb[8.3%], shards will be relocated away from this node
[2016-06-14 12:52:11,751][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.3gb[8.2%], shards will be relocated away from this node
[2016-06-14 12:52:11,751][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:52:41,751][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.3gb[8.2%], shards will be relocated away from this node
[2016-06-14 12:53:11,777][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.3gb[8.2%], shards will be relocated away from this node
[2016-06-14 12:53:11,777][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:53:41,802][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.2gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:54:11,827][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.1gb[8.1%], shards will be relocated away from this node
[2016-06-14 12:54:11,827][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:54:28,187][DEBUG][action.bulk              ] ol-Myers Squibb. Under the terms of agreement, Ono granted Bristol-Myers Squibb exclusive rights to develop and commercialize nivolumab worldwide, except in Japan, S Korea and Taiwan, where Ono will retain all the rights to develop and commercialize nivolumab (Press release, BMS, 20 Sep 2011, http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20110920007303/en&t=634522425593383554).^Celldex Therapeutics^Worldwide; clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab and varlilumab in a Phase I/II study. Under the terms of this agreement, Bristol-Myers Squibb will make a one-time payment to Celldex and the parties will share development costs. Celldex will be responsible for conducting the study (Press release, Celldex, 14 May 2014, http://ir.celldex.com/releasedetail.cfm?ReleaseID=847799).^Kyowa Hakko Kirin^USA; Bristol-Myers Squibb has entered into a clinical collaboration agreement, to conduct a Phase I/II trial of mogamulizumab + nivolumab in patients with advanced or metastatic solid tumours (Press release, KHK, 29 Jul 2015, http://www.kyowa-kirin.com/news_releases/2015/pdf/e20150730_01.pdf).^Kyowa Hakko Kirin^Japan; Ono has a clinical trial collaboration agreement with Kyowa Hakko Kirin, to conduct a Phase I combination study of nivolumab + mogamulizumab in patients with advanced or metastatic solid tumours (Press release, Ono Pharmaceuticals, 10 Dec 2014, http://www.kyowa-kirin.com/news_releases/2014/pdf/e20141210_01.pdf).^Novartis^Worldwide; clinical trial collaboration to evaluate the combination of nivolumab with ceritinib, EGF-816 and INC-280 (Press release, Novartis, 6 Oct 2014, http://hugin.info/134323/R/1860778/652323.pdf).^Seattle Genetics^Worldwide; Bristol-Myers Squibb has entered into a clinical trial collaboration agreement with Seattle Genetics to evaluate the investigational combination of Seattle Genetics'antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab). Under the terms of the agreement, Seattle Genetics will conduct the Hodgkin lymphoma trial and Bristol-Myers Squibb will conduct the non-Hodgkin lymphomas trial (Press release, Seattle, 12 Jan 2015, http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2006751).^University of Texas MD Anderson Cancer Center, the US^Worldwide; BMS has a research collaboration with the University of Texas MD Anderson Cancer Center to evaluate multiple immunotherapies, including nivolumab, ipilimumab and 3 early-stage clinical immuno-oncology assets from BMS, as potential treatment options for acute and chronic leukaemia as well as other haematologic malignancies. Through this approach, BMS and MD Anderson aim to benefit patients by expediting the delivery of new therapies. The collaboration will launch up to 10 Phase I and II trials, conducted by MD Anderson, focused on evaluating investigational immune-based approaches for acute myeloid leukaemia, chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS) and myelofibrosis (MF) (Press release, BMS, 6 Oct 2014, http://news.bms.com/press-release/rd-news/bristol-myers-squibb-and-md-anderson-cancer-center-announce-novel-research-col&t=635481858288520438)."],"Document_LatestChange":["Initiation of Phase III trials for urethral cancer and additional details of Phase III trials (CA209-143 & CA209-214) reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability No"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Preclinical Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"}],"DOCNO":"PD033657","CASIS_COMPOUND":[{"CN":"Opdivo","SRC_DB":"PHP"},{"CN":"BMS-936558","SRC_DB":"PHP"},{"CN":"anti-PD-1 MAb, Medarex","SRC_DB":"PHP"},{"CN":"anti-PD-1 MAb, Ono","SRC_DB":"PHP"},{"CN":"BMS 936558","SRC_DB":"PHP"},{"CN":"NSC 748726","SRC_DB":"PHP"},{"CN":"nivolumab","SRC_DB":"PHP"},{"CN":"MDX-1106","SRC_DB":"PHP"},{"CN":"ONO-4538","SRC_DB":"PHP"},{"CN":"NSC-748726","SRC_DB":"PHP"},{"CN":"ONO 4538","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-23 15:47:31","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Monoclonal antibody, human","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, T-cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, squamous cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anticancer immunotherapy","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"PD-1 antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunomodulator, anti-infective","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anticancer, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, urethral","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseI.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[67, 97, 110, 99, 101, 114, 44, 32, 98, 108, 97, 100, 100, 101, 114, 94, 73, 116, 32, 105, 115, 32, 105, 110, 32, 80, 104, 97, 115, 101]...', original message: bytes can be at most 32766 in length; got 37865
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37865
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:54:41,853][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9.1gb[8%], shards will be relocated away from this node
[2016-06-14 12:55:07,027][DEBUG][action.bulk              ] ed; Licensing Availability: Unknown","ES: Launched 2005; Licensing Availability: Unknown","SE: Launched 2005; Licensing Availability: Unknown","CH: Launched 2005; Licensing Availability: Unknown","TH: Phase III Clinical Trial; Licensing Availability: Unknown","TR: Phase III Clinical Trial; Licensing Availability: Unknown","UK: Launched 2005; Licensing Availability: Unknown","US: Launched 2009; Licensing Availability: Unknown","VE: Phase III Clinical Trial; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Arthritis, rheumatoid::Discontinued","Cancer, brain::Launched","Cancer, breast::Launched","Cancer, carcinoid::Phase III Clinical Trial","Cancer, cervical::Phase I Clinical Trial","Cancer, colorectal::No Development Reported","Cancer, gastrointestinal, neuroendocrine::Pre-registration","Cancer, gastrointestinal, stomach::Phase III Clinical Trial","Cancer, gastrointestinal, stromal::Phase II Clinical Trial","Cancer, leukaemia, chronic lymphocytic::No Development Reported","Cancer, liver::Discontinued","Cancer, lung, neuroendocrine::Pre-registration","Cancer, lung, non-small cell::No Development Reported","Cancer, lung, small cell::No Development Reported","Cancer, lymphoma, B-cell::Phase III Clinical Trial","Cancer, lymphoma, Hodgkin's::Phase II Clinical Trial","Cancer, lymphoma, mantle cell::No Development Reported","Cancer, lymphoma, non-Hodgkin's::Phase III Clinical Trial","Cancer, pancreatic::Phase II Clinical Trial","Cancer, pancreatic, neuroendocrine::Phase I Clinical Trial","Cancer, prostate::No Development Reported","Cancer, renal::Launched","Cancer, sarcoma, osteo::Phase II Clinical Trial","Cancer, sarcoma, soft tissue::Phase II Clinical Trial","Cancer, solid, unspecified::Phase II Clinical Trial","Hepatic dysfunction, unspecified::No Development Reported","Lymphangioleiomyomatosis::Phase III Clinical Trial","Macular degeneration, age-related, unspecified::No Development Reported","Myelodysplastic syndrome::No Development Reported","Neurofibromatosis::Phase II Clinical Trial","Polycystic kidney disease::No Development Reported","Transplant rejection, organ::Launched","Tuberous sclerosis::Launched"],"Document_TargetData_Targets_Target_TargetName":["mechanistic target of rapamycin (serine/threonine kinase)"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_LatestChange":["Regulatory filing details reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched 2012 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Phase II Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"}],"DOCNO":"PD016253","CASIS_COMPOUND":[{"CN":"Certican","SRC_DB":"PHP"},{"CN":"SDZ-RAD","SRC_DB":"PHP"},{"CN":"RAD","SRC_DB":"PHP"},{"CN":"Zortress","SRC_DB":"PHP"},{"CN":"Afinitor Disperz","SRC_DB":"PHP"},{"CN":"Votubia","SRC_DB":"PHP"},{"CN":"RAD001","SRC_DB":"PHP"},{"CN":"Afinitor","SRC_DB":"PHP"},{"CN":"everolimus","SRC_DB":"PHP"},{"CN":"RAD-001","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:45","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Hepatic dysfunction, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cell cycle inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lung, neuroendocrine","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tuberous sclerosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anticancer, antibiotic","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Neurofibromatosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Hepatoprotective","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"mTOR kinase inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunosuppressant","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Protein kinase inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, carcinoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Urological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Polycystic kidney disease","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Lymphangioleiomyomatosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Macular degeneration, age-related, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, gastrointestinal, neuroendocrine","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Transplant rejection, organ","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Respiratory","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ophthalmological, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, sarcoma, osteo","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, mantle cell","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[67, 97, 110, 99, 101, 114, 44, 32, 98, 114, 97, 105, 110, 94, 65, 32, 114, 97, 110, 100, 111, 109, 105, 122, 101, 100, 44, 32, 100, 111]...', original message: bytes can be at most 32766 in length; got 47556
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47556
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:55:11,879][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.9gb[7.9%], shards will be relocated away from this node
[2016-06-14 12:55:11,879][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:55:41,913][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9gb[7.9%], shards will be relocated away from this node
[2016-06-14 12:56:11,946][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.9gb[7.9%], shards will be relocated away from this node
[2016-06-14 12:56:11,946][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:56:41,971][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.9gb[7.8%], shards will be relocated away from this node
[2016-06-14 12:57:12,021][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.8gb[7.8%], shards will be relocated away from this node
[2016-06-14 12:57:12,021][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:57:42,045][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.8gb[7.8%], shards will be relocated away from this node
[2016-06-14 12:58:12,089][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.7gb[7.7%], shards will be relocated away from this node
[2016-06-14 12:58:12,089][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:58:28,588][DEBUG][action.bulk              ] ; Licensing Availability: No","DE: Launched 2009; Licensing Availability: No","GR: Registered; Licensing Availability: No","HK: Not Applicable; Licensing Availability: No","IN: Phase III Clinical Trial; Licensing Availability: Unknown","IE: Launched; Licensing Availability: No","IL: Phase I Clinical Trial; Licensing Availability: Unknown","IT: Registered; Licensing Availability: No","JP: Launched 2011; Licensing Availability: Unknown","LU: Launched 2009; Licensing Availability: No","MY: Phase III Clinical Trial; Licensing Availability: Unknown","MX: Phase III Clinical Trial; Licensing Availability: Unknown","NL: Registered; Licensing Availability: No","NZ: Phase III Clinical Trial; Licensing Availability: Unknown","NO: Phase II Clinical Trial; Licensing Availability: No","PE: Not Applicable; Licensing Availability: Unknown","PH: Phase III Clinical Trial; Licensing Availability: Unknown","PT: Registered; Licensing Availability: No","RU: Phase III Clinical Trial; Licensing Availability: No","ZA: Not Applicable; Licensing Availability: Unknown","KR: Phase III Clinical Trial; Licensing Availability: Unknown","ES: Registered; Licensing Availability: No","SE: Registered; Licensing Availability: No","CH: Phase III Clinical Trial; Licensing Availability: No","TH: Phase III Clinical Trial; Licensing Availability: Unknown","TR: Not Applicable; Licensing Availability: No","UK: Launched 2010; Licensing Availability: No","US: Launched 2010; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Ankylosing spondylitis::Launched","Arthritis, juvenile::Phase III Clinical Trial","Arthritis, psoriatic::Launched","Arthritis, rheumatoid::Launched","Asthma::Phase II Clinical Trial","Colitis, ulcerative::Launched","Infarction, myocardial::No Development Reported","Ischaemia, cerebral::No Development Reported","Sarcoidosis::No Development Reported","Spondyloarthritis, axial::Registered"],"Document_TargetData_Targets_Target_TargetName":["tumour necrosis factor"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Janssen-Cilag (Johnson & Johnson)^Hong Kong; Janssen-Cilag (J&J) has exclusive marketing rights in Hong Kong (Press release, Centocor, 27 Jun 2008).^Medarex^Worldwide; Centocor has an agreement to access Medarex' (now Bristol-Myers Squibb's (BMS)) HuMab-Mouse technology for manufacture (Press release, Medarex, 3 May 2000). ^Merck & Co^Europe, Russia and Turkey; As of Jul 2011, Merck transferred exclusive marketing rights to Johnson & Johnson in territories including Canada, Central and S America, the Middle East, Africa and Asia Pacific. Merck retains exclusive marketing rights throughout Europe, Russia and Turkey (Press release, Merck, 29 Jul 2011, http://www.merck.com/newsroom/news-release-archive/financial/2011_0729.html). Schering-Plough had a co-development and exclusive worldwide marketing rights to golimumab, excluding China, Hong Kong, Indonesia, Japan, Taiwan and the US (Press releases, Schering-Plough, 16 Aug 2005 & 17 Aug 2006). However, on announcement of the merger between S-P and Merck & Co, J&J filed an arbitration demand to terminate the agreement with S-P, as per the new amended distribution agreement Merck will continue to have exclusive marketing rights in Europe, Russia and Turkey, but will relinquish its exclusive rights in territories including Africa, Asia Pacific, Canada, Central and South America and the Middle East (Press release, J&J, 27 May 2009; Scrip Intelligence, 18 Apr 2011, http://www.scripintelligence.com/home/Merck-and-JandJ-settle-Remicade-battle---and--investors-nerves-314281). ^Mitsubishi Tanabe Pharma^Indonesia, Japan and Taiwan; Mitsubishi Tanabe Pharma (Tanabe Seiyaku before the merger) has co-development and marketing rights in Indonesia, Japan and Taiwan (Press release, Tanabe, 7 Aug 2006). ^Xian-Janssen (Johnson & Johnson)^China; Xian-Janssen (J&J) has exclusive marketing rights in China (Press release, Centocor, 27 Jun 2008)."],"Document_LatestChange":["Completion of Phase III trial (CR100937) for ulcerative colitis reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Phase II Clinical Trial Licensing Availability No"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase I Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability Unknown"}],"DOCNO":"PD029448","CASIS_COMPOUND":[{"CN":"Simponi Aria","SRC_DB":"PHP"},{"CN":"CNTO 148 (intravenous)","SRC_DB":"PHP"},{"CN":"golimumab","SRC_DB":"PHP"},{"CN":"golimumab (subcutaneous)","SRC_DB":"PHP"},{"CN":"MK-8259","SRC_DB":"PHP"},{"CN":"MK8259","SRC_DB":"PHP"},{"CN":"CNTO 148","SRC_DB":"PHP"},{"CN":"CNTO 148 (subcutaneous)","SRC_DB":"PHP"},{"CN":"Simponi (subcutaneous)","SRC_DB":"PHP"},{"CN":"MK-8259 (subcutaneous)","SRC_DB":"PHP"},{"CN":"CNTO-148","SRC_DB":"PHP"},{"CN":"MK-8259 (intravenous)","SRC_DB":"PHP"},{"CN":"Simponi","SRC_DB":"PHP"},{"CN":"golimumab (intravenous)","SRC_DB":"PHP"},{"CN":"CNTO-148 (subcutaneous)","SRC_DB":"PHP"},{"CN":"CNTO-148 (intravenous)","SRC_DB":"PHP"},{"CN":"MK8259 (intravenous)","SRC_DB":"PHP"},{"CN":"MK8259 (subcutaneous)","SRC_DB":"PHP"},{"CN":"Simponi (intravenous)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:44","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Monoclonal antibody, human","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Infarction, myocardial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 110, 107, 121, 108, 111, 115, 105, 110, 103, 32, 115, 112, 111, 110, 100, 121, 108, 105, 116, 105, 115, 94, 67, 101, 110, 116, 111, 99, 111]...', original message: bytes can be at most 32766 in length; got 36151
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36151
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:58:36,278][DEBUG][action.bulk              ] ; Licensing Availability: No","DE: Launched 2009; Licensing Availability: No","GR: Registered; Licensing Availability: No","HK: Not Applicable; Licensing Availability: No","IN: Phase III Clinical Trial; Licensing Availability: Unknown","IE: Launched; Licensing Availability: No","IL: Phase I Clinical Trial; Licensing Availability: Unknown","IT: Registered; Licensing Availability: No","JP: Launched 2011; Licensing Availability: Unknown","LU: Launched 2009; Licensing Availability: No","MY: Phase III Clinical Trial; Licensing Availability: Unknown","MX: Phase III Clinical Trial; Licensing Availability: Unknown","NL: Registered; Licensing Availability: No","NZ: Phase III Clinical Trial; Licensing Availability: Unknown","NO: Phase II Clinical Trial; Licensing Availability: No","PE: Not Applicable; Licensing Availability: Unknown","PH: Phase III Clinical Trial; Licensing Availability: Unknown","PT: Registered; Licensing Availability: No","RU: Phase III Clinical Trial; Licensing Availability: No","ZA: Not Applicable; Licensing Availability: Unknown","KR: Phase III Clinical Trial; Licensing Availability: Unknown","ES: Registered; Licensing Availability: No","SE: Registered; Licensing Availability: No","CH: Phase III Clinical Trial; Licensing Availability: No","TH: Phase III Clinical Trial; Licensing Availability: Unknown","TR: Not Applicable; Licensing Availability: No","UK: Launched 2010; Licensing Availability: No","US: Launched 2010; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Ankylosing spondylitis::Launched","Arthritis, juvenile::Phase III Clinical Trial","Arthritis, psoriatic::Launched","Arthritis, rheumatoid::Launched","Asthma::Phase II Clinical Trial","Colitis, ulcerative::Launched","Infarction, myocardial::No Development Reported","Ischaemia, cerebral::No Development Reported","Sarcoidosis::No Development Reported","Spondyloarthritis, axial::Registered"],"Document_TargetData_Targets_Target_TargetName":["tumour necrosis factor"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Janssen-Cilag (Johnson & Johnson)^Hong Kong; Janssen-Cilag (J&J) has exclusive marketing rights in Hong Kong (Press release, Centocor, 27 Jun 2008).^Medarex^Worldwide; Centocor has an agreement to access Medarex' (now Bristol-Myers Squibb's (BMS)) HuMab-Mouse technology for manufacture (Press release, Medarex, 3 May 2000). ^Merck & Co^Europe, Russia and Turkey; As of Jul 2011, Merck transferred exclusive marketing rights to Johnson & Johnson in territories including Canada, Central and S America, the Middle East, Africa and Asia Pacific. Merck retains exclusive marketing rights throughout Europe, Russia and Turkey (Press release, Merck, 29 Jul 2011, http://www.merck.com/newsroom/news-release-archive/financial/2011_0729.html). Schering-Plough had a co-development and exclusive worldwide marketing rights to golimumab, excluding China, Hong Kong, Indonesia, Japan, Taiwan and the US (Press releases, Schering-Plough, 16 Aug 2005 & 17 Aug 2006). However, on announcement of the merger between S-P and Merck & Co, J&J filed an arbitration demand to terminate the agreement with S-P, as per the new amended distribution agreement Merck will continue to have exclusive marketing rights in Europe, Russia and Turkey, but will relinquish its exclusive rights in territories including Africa, Asia Pacific, Canada, Central and South America and the Middle East (Press release, J&J, 27 May 2009; Scrip Intelligence, 18 Apr 2011, http://www.scripintelligence.com/home/Merck-and-JandJ-settle-Remicade-battle---and--investors-nerves-314281). ^Mitsubishi Tanabe Pharma^Indonesia, Japan and Taiwan; Mitsubishi Tanabe Pharma (Tanabe Seiyaku before the merger) has co-development and marketing rights in Indonesia, Japan and Taiwan (Press release, Tanabe, 7 Aug 2006). ^Xian-Janssen (Johnson & Johnson)^China; Xian-Janssen (J&J) has exclusive marketing rights in China (Press release, Centocor, 27 Jun 2008)."],"Document_LatestChange":["Completion of Phase III trial (CR100937) for ulcerative colitis reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Phase II Clinical Trial Licensing Availability No"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase I Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"}],"DOCNO":"PD029448","CASIS_COMPOUND":[{"CN":"golimumab (intravenous)","SRC_DB":"PHP"},{"CN":"Simponi Aria","SRC_DB":"PHP"},{"CN":"MK8259 (subcutaneous)","SRC_DB":"PHP"},{"CN":"CNTO-148","SRC_DB":"PHP"},{"CN":"MK-8259 (subcutaneous)","SRC_DB":"PHP"},{"CN":"Simponi (intravenous)","SRC_DB":"PHP"},{"CN":"MK8259 (intravenous)","SRC_DB":"PHP"},{"CN":"CNTO 148 (intravenous)","SRC_DB":"PHP"},{"CN":"CNTO-148 (intravenous)","SRC_DB":"PHP"},{"CN":"golimumab","SRC_DB":"PHP"},{"CN":"MK8259","SRC_DB":"PHP"},{"CN":"MK-8259","SRC_DB":"PHP"},{"CN":"MK-8259 (intravenous)","SRC_DB":"PHP"},{"CN":"CNTO 148","SRC_DB":"PHP"},{"CN":"Simponi","SRC_DB":"PHP"},{"CN":"CNTO 148 (subcutaneous)","SRC_DB":"PHP"},{"CN":"golimumab (subcutaneous)","SRC_DB":"PHP"},{"CN":"CNTO-148 (subcutaneous)","SRC_DB":"PHP"},{"CN":"Simponi (subcutaneous)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:44","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Monoclonal antibody, human","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Infarction, myocardial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 110, 107, 121, 108, 111, 115, 105, 110, 103, 32, 115, 112, 111, 110, 100, 121, 108, 105, 116, 105, 115, 94, 67, 101, 110, 116, 111, 99, 111]...', original message: bytes can be at most 32766 in length; got 36151
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36151
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:58:42,117][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.5gb[7.6%], shards will be relocated away from this node
[2016-06-14 12:58:58,171][DEBUG][action.bulk              ] ; Licensing Availability: No","DE: Launched 2009; Licensing Availability: No","GR: Registered; Licensing Availability: No","HK: Not Applicable; Licensing Availability: No","IN: Phase III Clinical Trial; Licensing Availability: Unknown","IE: Launched; Licensing Availability: No","IL: Phase I Clinical Trial; Licensing Availability: Unknown","IT: Registered; Licensing Availability: No","JP: Launched 2011; Licensing Availability: Unknown","LU: Launched 2009; Licensing Availability: No","MY: Phase III Clinical Trial; Licensing Availability: Unknown","MX: Phase III Clinical Trial; Licensing Availability: Unknown","NL: Registered; Licensing Availability: No","NZ: Phase III Clinical Trial; Licensing Availability: Unknown","NO: Phase II Clinical Trial; Licensing Availability: No","PE: Not Applicable; Licensing Availability: Unknown","PH: Phase III Clinical Trial; Licensing Availability: Unknown","PT: Registered; Licensing Availability: No","RU: Phase III Clinical Trial; Licensing Availability: No","ZA: Not Applicable; Licensing Availability: Unknown","KR: Phase III Clinical Trial; Licensing Availability: Unknown","ES: Registered; Licensing Availability: No","SE: Registered; Licensing Availability: No","CH: Phase III Clinical Trial; Licensing Availability: No","TH: Phase III Clinical Trial; Licensing Availability: Unknown","TR: Not Applicable; Licensing Availability: No","UK: Launched 2010; Licensing Availability: No","US: Launched 2010; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Ankylosing spondylitis::Launched","Arthritis, juvenile::Phase III Clinical Trial","Arthritis, psoriatic::Launched","Arthritis, rheumatoid::Launched","Asthma::Phase II Clinical Trial","Colitis, ulcerative::Launched","Infarction, myocardial::No Development Reported","Ischaemia, cerebral::No Development Reported","Sarcoidosis::No Development Reported","Spondyloarthritis, axial::Registered"],"Document_TargetData_Targets_Target_TargetName":["tumour necrosis factor"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Janssen-Cilag (Johnson & Johnson)^Hong Kong; Janssen-Cilag (J&J) has exclusive marketing rights in Hong Kong (Press release, Centocor, 27 Jun 2008).^Medarex^Worldwide; Centocor has an agreement to access Medarex' (now Bristol-Myers Squibb's (BMS)) HuMab-Mouse technology for manufacture (Press release, Medarex, 3 May 2000). ^Merck & Co^Europe, Russia and Turkey; As of Jul 2011, Merck transferred exclusive marketing rights to Johnson & Johnson in territories including Canada, Central and S America, the Middle East, Africa and Asia Pacific. Merck retains exclusive marketing rights throughout Europe, Russia and Turkey (Press release, Merck, 29 Jul 2011, http://www.merck.com/newsroom/news-release-archive/financial/2011_0729.html). Schering-Plough had a co-development and exclusive worldwide marketing rights to golimumab, excluding China, Hong Kong, Indonesia, Japan, Taiwan and the US (Press releases, Schering-Plough, 16 Aug 2005 & 17 Aug 2006). However, on announcement of the merger between S-P and Merck & Co, J&J filed an arbitration demand to terminate the agreement with S-P, as per the new amended distribution agreement Merck will continue to have exclusive marketing rights in Europe, Russia and Turkey, but will relinquish its exclusive rights in territories including Africa, Asia Pacific, Canada, Central and South America and the Middle East (Press release, J&J, 27 May 2009; Scrip Intelligence, 18 Apr 2011, http://www.scripintelligence.com/home/Merck-and-JandJ-settle-Remicade-battle---and--investors-nerves-314281). ^Mitsubishi Tanabe Pharma^Indonesia, Japan and Taiwan; Mitsubishi Tanabe Pharma (Tanabe Seiyaku before the merger) has co-development and marketing rights in Indonesia, Japan and Taiwan (Press release, Tanabe, 7 Aug 2006). ^Xian-Janssen (Johnson & Johnson)^China; Xian-Janssen (J&J) has exclusive marketing rights in China (Press release, Centocor, 27 Jun 2008)."],"Document_LatestChange":["Completion of Phase III trial (CR100937) for ulcerative colitis reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase I Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Phase II Clinical Trial Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"}],"DOCNO":"PD029448","CASIS_COMPOUND":[{"CN":"CNTO 148","SRC_DB":"PHP"},{"CN":"Simponi (intravenous)","SRC_DB":"PHP"},{"CN":"CNTO 148 (intravenous)","SRC_DB":"PHP"},{"CN":"golimumab (intravenous)","SRC_DB":"PHP"},{"CN":"golimumab (subcutaneous)","SRC_DB":"PHP"},{"CN":"Simponi (subcutaneous)","SRC_DB":"PHP"},{"CN":"Simponi Aria","SRC_DB":"PHP"},{"CN":"Simponi","SRC_DB":"PHP"},{"CN":"CNTO-148 (subcutaneous)","SRC_DB":"PHP"},{"CN":"MK-8259 (subcutaneous)","SRC_DB":"PHP"},{"CN":"golimumab","SRC_DB":"PHP"},{"CN":"CNTO-148","SRC_DB":"PHP"},{"CN":"CNTO 148 (subcutaneous)","SRC_DB":"PHP"},{"CN":"MK-8259","SRC_DB":"PHP"},{"CN":"MK8259 (subcutaneous)","SRC_DB":"PHP"},{"CN":"MK-8259 (intravenous)","SRC_DB":"PHP"},{"CN":"MK8259","SRC_DB":"PHP"},{"CN":"CNTO-148 (intravenous)","SRC_DB":"PHP"},{"CN":"MK8259 (intravenous)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:44","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Monoclonal antibody, human","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Infarction, myocardial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ischaemia, cerebral","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Neuroprotective","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 110, 107, 121, 108, 111, 115, 105, 110, 103, 32, 115, 112, 111, 110, 100, 121, 108, 105, 116, 105, 115, 94, 67, 101, 110, 116, 111, 99, 111]...', original message: bytes can be at most 32766 in length; got 36151
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36151
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 12:59:12,141][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.7gb[7.7%], shards will be relocated away from this node
[2016-06-14 12:59:12,141][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 12:59:42,167][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.6gb[7.6%], shards will be relocated away from this node
[2016-06-14 13:00:07,936][DEBUG][action.bulk              ] ), nausea (40%), fatigue (38%), pyrexia (34%) and diarrhoea (29%). Common grade 3 or 4 AEs occurring in 5% of patients were neutropenia (21%), peripheral neuropathy (17%), thrombocytopaenia (14%), anaemia (7%) and recurrent ALCL (5%) (Press release, Seattle, 7 Dec 2014, http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1995484).^Lupus erythematosus, systemic^It is in a randomized, double-blind, parallel assignment, placebo-controlled, dose-escalation Phase II trial (SGN35-022) in the US in 40 adult patients with systemic lupus erythematosus (SLE), to evaluate the safety, tolerability and activity of brentuximab vedotin x3wk. The primary objective is evaluation of the safety of brentuximab vedotin in adults with active lupus. In addition, the trial will evaluate the activity and pharmacokinetics of brentuximab vedotin in lupus (Press release, Seattle Genetics, 30 Apr 2015, http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2042566&highlight=; Press release, Seattle Genetics, 9 Jul 2015, http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2066461&highlight=; ClinicalTrials.gov, 4 Sep 2015, https://clinicaltrials.gov/ct2/show/NCT02533570)."],"Document_CASIS-RN_CASNumber":["914088-09-8"],"Document_CASIS-UPD":["20160223"],"Document_CASIS-LN_LN":["Antibody-drug conjugate:Launched","Anticancer, immunological:Launched","Immunosuppressant:Phase II Clinical Trial","Immunotoxin:Launched"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_CASIS-USE_CASIS-MA_MA":["Tubulin inhibitor"],"Document_CASIS-DSTA_Country":["World: Launched","AR: Pre-registration; Licensing Availability: No","AU: Launched 2014; Licensing Availability: No","AT: Registered; Licensing Availability: No","BE: Registered; Licensing Availability: No","BR: Registered; Licensing Availability: No","CA: Launched; Licensing Availability: No","CL: Not Applicable; Licensing Availability: No","CN: Pre-registration; Licensing Availability: No","CO: Pre-registration; Licensing Availability: No","DK: Registered; Licensing Availability: No","SF: Registered; Licensing Availability: No","FR: Registered; Licensing Availability: No","DE: Registered; Licensing Availability: No","GR: Registered; Licensing Availability: No","HK: Pre-registration; Licensing Availability: No","IN: Not Applicable; Licensing Availability: No","IE: Registered; Licensing Availability: No","IL: Registered; Licensing Availability: No","IT: Registered; Licensing Availability: No","JP: Launched; Licensing Availability: No","LU: Registered; Licensing Availability: No","MY: Not Applicable; Licensing Availability: No","MX: Launched 2014; Licensing Availability: No","NL: Registered; Licensing Availability: No","NZ: Not Applicable; Licensing Availability: No","NO: Launched; Licensing Availability: No","PE: Not Applicable; Licensing Availability: No","PH: Not Applicable; Licensing Availability: No","PT: Registered; Licensing Availability: No","RU: Phase III Clinical Trial; Licensing Availability: No","ZA: Pre-registration; Licensing Availability: No","KR: Launched 2014; Licensing Availability: No","ES: Registered; Licensing Availability: No","SE: Registered; Licensing Availability: No","CH: Launched; Licensing Availability: No","TH: Pre-registration; Licensing Availability: No","TR: Not Applicable; Licensing Availability: No","UK: Launched 2013; Licensing Availability: No","US: Launched 2011; Licensing Availability: No","VE: Pre-registration; Licensing Availability: No"],"Document_CASIS-USE_CASIS-IND_IND":["Cancer, haematological, unspecified::Phase I Clinical Trial","Cancer, leukaemia, unspecifed::Phase II Clinical Trial","Cancer, lymphoma, anaplastic large cell::Launched","Cancer, lymphoma, B-cell::Phase II Clinical Trial","Cancer, lymphoma, Hodgkin's::Launched","Cancer, lymphoma, non-Hodgkin's::Phase II Clinical Trial","Cancer, lymphoma, T-cell::Phase III Clinical Trial","Cancer, myeloma::Phase II Clinical Trial","Cancer, solid, unspecified::Phase II Clinical Trial","Lupus erythematosus, systemic::Phase II Clinical Trial"],"Document_TargetData_Targets_Target_TargetName":["tumour necrosis factor receptor superfamily, member 8"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Bristol-Myers Squibb^Worldwide; Seattle Genetics has entered into a clinical trial collaboration agreement with Bristol-Myers Squibb to evaluate the investigational combination of Seattle Genetics'antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab). Under the terms of the agreement, Seattle Genetics will conduct the Hodgkin lymphoma trial and Bristol-Myers Squibb will conduct the non-Hodgkin lymphomas trial (Press release, Seattle, 12 Jan 2015, http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2006751).^Millennium (Takeda)^Worldwide excluding Canada and USA; it is licensed to Millennium (Takeda) for commercialization worldwide except Canada and the US (Press release, Seattle & Millennium, 15 Dec 2009)."],"Document_LatestChange":["Details of Phase III trial (C25003; ECHELON-1; U1111-1161-4937; 12/LO/1950; JapicCTI-142491) reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability No"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2011 Licensing Availability No"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"}],"DOCNO":"PD028702","CASIS_COMPOUND":[{"CN":"SGN35","SRC_DB":"PHP"},{"CN":"Adcetris","SRC_DB":"PHP"},{"CN":"brentuximab vedotin","SRC_DB":"PHP"},{"CN":"SGN-35","SRC_DB":"PHP"},{"CN":"b-vedotin","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-23 15:47:27","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Tubulin inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, haematological, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, leukaemia, unspecifed","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antibody-drug conjugate","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anticancer, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, T-cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunotoxin","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Lupus erythematosus, systemic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, anaplastic large cell","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[67, 97, 110, 99, 101, 114, 44, 32, 108, 121, 109, 112, 104, 111, 109, 97, 44, 32, 66, 45, 99, 101, 108, 108, 94, 83, 101, 97, 116, 116]...', original message: bytes can be at most 32766 in length; got 37828
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37828
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:00:12,192][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.6gb[7.6%], shards will be relocated away from this node
[2016-06-14 13:00:12,192][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:00:32,666][DEBUG][action.bulk              ] ctively and decreased total body weight (secondary endpoints) in -2.7, -2.5, -2.7, -3.4 and -3.4% of patients, respectively. Common adverse events included nausea, urinary tract infection, headache and diarrhea (Press release, BMS, 27 Mar 2009). The % of patients who achieved an HbA1c decrease of 0.5% or more was 65.2% and 65.2% for dapagliflozin 10 and 20mg, respectively, cf 15.8% with placebo. Changes in baseline FPG were for the 3 groups were +2.4, -9.6 and +17.8mg/dl, respectively (Press release, BMS & AZ, 6 Jun 2009).^Diabetes, Type 2^Bristol-Myers Squibb^In a 14-day Phase IIa study in 47 patients with Type 2 diabetes, either drug-naive or stable on metformin, 5, 25 and 100mg/day doses produced decreases in fasting serum glucose of 14.5, 17.3 and 21.9%, respectively. There were no serious adverse events. Adverse events included 2 cases of hypoglycaemia and 2 of vulvovaginal infection (Press release, BMS, 25 Jun 2007; Scrip Daily Online, 5 Jul 2007, S00963130)."],"Document_CASIS-RN_CASNumber":["461432-26-8"],"Document_MW":["408.87"],"Document_CASIS-UPD":["20160223"],"Document_CASIS-LN_LN":["Antidiabetic:Launched"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_CASIS-USE_CASIS-MA_MA":["Sodium/glucose cotransporter 2 inhibitor"],"Document_CASIS-DSTA_Country":["World: Launched","AR: Registered; Licensing Availability: Unknown","AU: Registered; Licensing Availability: Unknown","AT: Launched 2014; Licensing Availability: Unknown","BE: Launched 2014; Licensing Availability: Unknown","BR: Registered; Licensing Availability: Unknown","CA: Registered; Licensing Availability: Unknown","CL: Phase III Clinical Trial; Licensing Availability: Unknown","CN: Pre-registration; Licensing Availability: Unknown","CO: Phase III Clinical Trial; Licensing Availability: Unknown","DK: Launched 2013; Licensing Availability: Unknown","SF: Launched 2014; Licensing Availability: Unknown","FR: Launched 2014; Licensing Availability: Unknown","DE: Launched 2013; Licensing Availability: Unknown","GR: Launched 2014; Licensing Availability: Unknown","HK: Not Applicable; Licensing Availability: Unknown","IN: Launched 2015; Licensing Availability: Unknown","IE: Launched 2014; Licensing Availability: Unknown","IL: Phase III Clinical Trial; Licensing Availability: Unknown","IT: Launched 2014; Licensing Availability: Unknown","JP: Launched 2014; Licensing Availability: No","LU: Launched 2014; Licensing Availability: Unknown","MY: Not Applicable; Licensing Availability: Unknown","MX: Launched 2013; Licensing Availability: Unknown","NL: Launched 2014; Licensing Availability: Unknown","NZ: Registered; Licensing Availability: Unknown","NO: Launched 2014; Licensing Availability: Unknown","PE: Phase III Clinical Trial; Licensing Availability: Unknown","PH: Phase III Clinical Trial; Licensing Availability: Unknown","PT: Launched 2014; Licensing Availability: Unknown","RU: Pre-registration; Licensing Availability: Unknown","ZA: Phase III Clinical Trial; Licensing Availability: Unknown","KR: Phase III Clinical Trial; Licensing Availability: Unknown","ES: Launched 2014; Licensing Availability: Unknown","SE: Launched 2014; Licensing Availability: Unknown","CH: Phase III Clinical Trial; Licensing Availability: Unknown","TH: Not Applicable; Licensing Availability: Unknown","TR: Not Applicable; Licensing Availability: Unknown","UK: Launched 2013; Licensing Availability: Unknown","US: Launched 2014; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Diabetes, Type 1::Phase III Clinical Trial","Diabetes, Type 2::Launched"],"Document_TargetData_Targets_Target_TargetName":["solute carrier family 5 (sodium/glucose cotransporter), member 2"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^AstraZeneca; Bristol-Myers Squibb^Worldwide; a licensing agreement with AstraZeneca (excluding Japan) for co-development was extended to include Japan; however, AstraZeneca has acquired the intellectual property and global rights for the development, manufacture and commercialization of dapagliflozin (Press release, AstraZeneca, 8 Dec 2008; Press release, AstraZeneca, 3 Feb 2014, http://www.astrazeneca.com/Media/Press-releases/Article/20140203-astrazeneca-acquires-bms-share-of-diabetes-alliance).^Ono^AstraZeneca and Ono has an agreement to co-promote dapagliflozin for an once-daily oral therapy to treat Type 2 diabetes mellitus in Japan. AstraZeneca simultaneously entered into an agreement with BMS granting AstraZeneca exclusive rights to commercialize dapagliflozin in Japan once approved. Under the terms of the agreement, Ono will make an up-front payment and further payments relating to the launch and sales-related milestones, which will be shared by BMS and AstraZeneca. Bristol-Myers Squibb and AstraZeneca will supply dapagliflozin and Ono will be responsible for its distribution. AstraZeneca and Ono will jointly detail dapagliflozin to healthcare professionals in Japan (Press release, Ono, 3 Dec 2013, http://www.ono.co.jp/eng/news/pdf/sm_cn131203.pdf)."],"Document_LatestChange":["Phase IIIb trial (CV181-369; 2015-001702-33) details and planned Phase III trial (D1683C00005) reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PD032764","CASIS_COMPOUND":[{"CN":"dapagliflozin","SRC_DB":"PHP"},{"CN":"BMS-512148","SRC_DB":"PHP"},{"CN":"BMS-512148 (IV)","SRC_DB":"PHP"},{"CN":"dapagliflozin (oral solution)","SRC_DB":"PHP"},{"CN":"Forxiga (oral solution)","SRC_DB":"PHP"},{"CN":"dapagliflozin (tablet)","SRC_DB":"PHP"},{"CN":"Forxiga (IV)","SRC_DB":"PHP"},{"CN":"BMS-512148 (tablet)","SRC_DB":"PHP"},{"CN":"Forxiga","SRC_DB":"PHP"},{"CN":"dapagliflozin (IV)","SRC_DB":"PHP"},{"CN":"Farxiga","SRC_DB":"PHP"},{"CN":"BMS-512148 (oral solution)","SRC_DB":"PHP"},{"CN":"dapagliflozin (capsule)","SRC_DB":"PHP"},{"CN":"Farxiga (tablet)","SRC_DB":"PHP"},{"CN":"Forxiga (capsule)","SRC_DB":"PHP"},{"CN":"Edistride","SRC_DB":"PHP"},{"CN":"BMS-512148 (capsule)","SRC_DB":"PHP"},{"CN":"Forxiga (tablet)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-23 15:47:25","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Sodium/glucose cotransporter 2 inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[68, 105, 97, 98, 101, 116, 101, 115, 44, 32, 84, 121, 112, 101, 32, 49, 94, 73, 116, 32, 105, 115, 32, 105, 110, 32, 97, 32, 114, 97]...', original message: bytes can be at most 32766 in length; got 46291
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 46291
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:00:42,257][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.5gb[7.5%], shards will be relocated away from this node
[2016-06-14 13:01:12,287][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.5gb[7.5%], shards will be relocated away from this node
[2016-06-14 13:01:12,288][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:01:42,314][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.4gb[7.4%], shards will be relocated away from this node
[2016-06-14 13:02:12,375][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.2gb[7.3%], shards will be relocated away from this node
[2016-06-14 13:02:12,375][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:02:25,502][DEBUG][action.bulk              ] ty: Unknown","NO: Launched 2010; Licensing Availability: Unknown","PE: Not Applicable; Licensing Availability: Unknown","PH: Not Applicable; Licensing Availability: Unknown","PT: Registered; Licensing Availability: No","RU: Launched; Licensing Availability: Unknown","ZA: Phase III Clinical Trial; Licensing Availability: Unknown","KR: Phase III Clinical Trial; Licensing Availability: Unknown","ES: Launched 2010; Licensing Availability: No","SE: Launched 2010; Licensing Availability: No","CH: Launched 2008; Licensing Availability: Unknown","TH: Not Applicable; Licensing Availability: Unknown","TR: Phase III Clinical Trial; Licensing Availability: Unknown","UK: Launched 2009; Licensing Availability: No","US: Launched 2008; Licensing Availability: No","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Ankylosing spondylitis::Launched","Arthritis, juvenile::Phase III Clinical Trial","Arthritis, psoriatic::Launched","Arthritis, rheumatoid::Launched","Crohn's disease::Launched","Psoriasis::Phase III Clinical Trial","Spondyloarthritis, axial::Launched"],"Document_TargetData_Targets_Target_TargetName":["tumour necrosis factor"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Astellas^Japan; UCB has entered into an agreement with Astellas to jointly develop and commercialize certolizumab pegol for the treatment of rheumatoid arthritis (RA). Under the agreement, UCB will manufacture and supply the product for commercialization. Astellas will manage the distribution exclusively, and both Astellas and UCB will co-develop and co-commercialise certolizumab pegol in Japan (Press release, Astellas, 1 Feb 2012, http://www.astellas.com/en/corporate/news/detail/ucb-and-astellas-announce-agre.html).^Dermira^Canada, EU and the US; UCB has an agreement with Dermira for the development and future commercialization of Cimzia in dermatology. Under the terms of the agreement, UCB grants Dermira an exclusive license to develop certolizumab pegol in psoriasis in the US, Canada and the EU. Dermira will be responsible for Phase 3 development costs. Subject to regulatory approval of Cimzia in psoriasis, Dermira is granted an exclusive commercial license to market Cimzia to dermatologists in the US and Canada (Press release, UCB, 3 Jul 2014, http://www.dermira.com/ucb-and-dermira-enter-into-strategic-collaboration-in-dermatology-to-broaden-patient-access-to-cimzia-certolizumab-pegol/).^NewBridge^Middle East and African countries; UCB has an exclusive partnership agreement with NewBridge Pharmaceuticals, UAE to make Cimzia available in several Middle East and African countries. Under the agreement, NewBridge acquired the rights to Cimzia from UCB in the region. UCB will supply NewBridge with the product on exclusive basis. NewBridge will also be responsible for managing the local regulatory approval process, future commercialization, and pharmacovigilance in each of the relevant countries (Press release, UCB, UCB, 21 Nov 2012, http://www.ucb.presscentre.com/News/UCB-and-NewBridge-Pharmaceuticals-Partner-for-Middle-East-and-African-markets-334.aspx).^Otsuka^Japan; UCB had a licensing agreement with Otsuka for co-development and co-promotion; however, UCB discontinued the co-development and co-promotion agreement with Otsuka in Japan followed by an agreed upon transition period (Press release, UCB, 10 Jun 2008; Press release, UCB, 13 Jan 2012, http://www.ucb.presscentre.com/News/Otsuka-Pharmaceutical-and-UCB-focus-collaboration-in-the-area-of-Central-Nervous-System-CNS-disorders-291.aspx).^AstraZeneca^Brazil; which will register the drug for RA and be its exclusive distributor, with UCB retaining copromotion rights (Press release, UCB, 28 Sep 2009).^Nektar Therapeutics^Worldwide; Nektar Therapeutics (formerly Inhale Therapeutic Systems) has a licence to provide proprietary pegylation technology for certolizumab pegol. This technology is derived from Nektar and Enzon's strategic alliance, and both companies will split milestone payments, royalties and PEG manufacturing revenues (Press release, Inhale, 26 Feb 2002; Analysts' Rep, Cowen & Co, Mar 2006).^Pfizer^Worldwide; a previous worldwide licence to Pfizer (Pharmacia before the merger) for all indications excluding CD was discontinued (Press release, Celltech, 1 Dec 2003; Scrip Daily Online, 23 Feb 2004, S00834054). ^Availability^________________^UCB^USA; UCB is planning to partner the compound in the US for RA (Scrip Daily Online, 23 Feb 2004, S00834054)."],"Document_LatestChange":["Completion of Phase III trial (C-EARLY; RA0055A) for rheumatoid arthritis reported"],"Document_DeliveryData_DeliveryTechnologyData_DeliveryTechnology":["Pegylated"]},"CASIS_DEVSTATUS":[{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2009 Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2008 Licensing Availability No"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"}],"DOCNO":"PD003334","CASIS_COMPOUND":[{"CN":"certolizumab pegol (SC)","SRC_DB":"PHP"},{"CN":"CDP-870 (IV)","SRC_DB":"PHP"},{"CN":"CDP-870","SRC_DB":"PHP"},{"CN":"CDP870 (IV)","SRC_DB":"PHP"},{"CN":"Cimzia (SC)","SRC_DB":"PHP"},{"CN":"CDP-870 (SC)","SRC_DB":"PHP"},{"CN":"CDP870","SRC_DB":"PHP"},{"CN":"certolizumab","SRC_DB":"PHP"},{"CN":"CDP870 (SC)","SRC_DB":"PHP"},{"CN":"certolizumab (IV)","SRC_DB":"PHP"},{"CN":"certolizumab pegol","SRC_DB":"PHP"},{"CN":"PHA-738144 (SC)","SRC_DB":"PHP"},{"CN":"certolizumab (SC)","SRC_DB":"PHP"},{"CN":"PHA-738144 (IV)","SRC_DB":"PHP"},{"CN":"PHA-738144","SRC_DB":"PHP"},{"CN":"Perstymab","SRC_DB":"PHP"},{"CN":"certolizumab pegol (IV)","SRC_DB":"PHP"},{"CN":"Cimzia","SRC_DB":"PHP"},{"CN":"Cimzia (IV)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:51","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Monoclonal antibody, humanized","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 110, 107, 121, 108, 111, 115, 105, 110, 103, 32, 115, 112, 111, 110, 100, 121, 108, 108, 105, 116, 105, 115, 59, 32, 83, 112, 111, 110, 100]...', original message: bytes can be at most 32766 in length; got 51371
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 51371
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:02:42,448][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.3gb[7.3%], shards will be relocated away from this node
[2016-06-14 13:03:12,473][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.3gb[7.3%], shards will be relocated away from this node
[2016-06-14 13:03:12,473][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:03:42,500][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.2gb[7.3%], shards will be relocated away from this node
[2016-06-14 13:04:12,550][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.1gb[7.1%], shards will be relocated away from this node
[2016-06-14 13:04:12,550][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:04:13,305][DEBUG][action.bulk              ] l:Launched","GI inflammatory/bowel disorders:Launched","Monoclonal antibody, human:Launched","Musculoskeletal:Phase III Clinical Trial","Ophthalmological, other:Phase III Clinical Trial","Septic shock treatment:Discontinued"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_CASIS-USE_CASIS-MA_MA":["Immunosuppressant","Tumour necrosis factor alpha antagonist"],"Document_CASIS-DSTA_Country":["World: Launched","AR: Launched; Licensing Availability: No","AU: Launched; Licensing Availability: No","AT: Launched; Licensing Availability: No","BE: Launched 2004; Licensing Availability: No","BR: Launched; Licensing Availability: No","CA: Launched; Licensing Availability: No","CL: Launched; Licensing Availability: No","CN: Launched; Licensing Availability: No","CO: Launched; Licensing Availability: No","DK: Launched 2005; Licensing Availability: No","SF: Launched 2005; Licensing Availability: No","FR: Launched; Licensing Availability: No","DE: Launched 2003; Licensing Availability: No","GR: Launched; Licensing Availability: No","HK: Launched 2004; Licensing Availability: No","IN: Not Applicable; Licensing Availability: No","IE: Launched 2003; Licensing Availability: No","IL: Launched; Licensing Availability: No","IT: Launched; Licensing Availability: No","JP: Launched 2008; Licensing Availability: No","LU: Registered; Licensing Availability: No","MY: Launched; Licensing Availability: No","MX: Launched; Licensing Availability: No","NL: Launched; Licensing Availability: No","NZ: Launched 2006; Licensing Availability: No","NO: Launched; Licensing Availability: No","PE: Not Applicable; Licensing Availability: No","PH: Not Applicable; Licensing Availability: No","PT: Launched; Licensing Availability: No","RU: Launched; Licensing Availability: No","ZA: Not Applicable; Licensing Availability: No","KR: Launched 2007; Licensing Availability: No","ES: Launched 2004; Licensing Availability: No","SE: Launched; Licensing Availability: No","CH: Launched 2004; Licensing Availability: No","TH: Not Applicable; Licensing Availability: No","TR: Launched; Licensing Availability: No","UK: Launched 2003; Licensing Availability: No","US: Launched 2003; Licensing Availability: No","VE: Launched; Licensing Availability: No"],"Document_CASIS-USE_CASIS-IND_IND":["Ankylosing spondylitis::Launched","Arthritis, juvenile::Launched","Arthritis, psoriatic::Launched","Arthritis, rheumatoid::Launched","Arthritis, unspecified::Phase III Clinical Trial","Asthma::No Development Reported","Behcet's disease::Launched","Colitis, ulcerative::Launched","Crohn's disease::Launched","Hidradenitis suppurativa::Launched","Inflammatory bowel disease, unspecified::Discontinued","Psoriasis::Launched","Sepsis::Discontinued","Spondyloarthritis, axial::Launched","Spondyloarthritis, peripheral::Phase III Clinical Trial","Uveitis::Phase III Clinical Trial"],"Document_TargetData_Targets_Target_TargetName":["tumour necrosis factor"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Abbott; AstraZeneca^Worldwide; it was discovered using CAT?s technology and commercialized by Abbott (Press release, CAT, 6 Jan 2003).^Abbott; Eisai^Japan, South Korea and Taiwan; Abbott and Eisai will co-develop and co-market it as Humira (previously Raheara) in S Korea and Taiwan, as well as in Japan (Press releases, Eisai, 1 Mar 2007 & 17 Jun 2008). ^Abbott; Royalty Pharma^Worldwide; Royalty Pharma, NY, the US, has completed the purchase of royalty rights for adalimumab from CAT, and will receive the revenue from Abbott previously paid to CAT (Press release, Royalty Pharma, 26 Oct 2006)."],"Document_LatestChange":["Health Canada approval for hidradenitis suppurativa reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched 2004 Licensing Availability No"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2003 Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2004 Licensing Availability No"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Launched 2004 Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Launched 2007 Licensing Availability No"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2003 Licensing Availability No"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability No"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2008 Licensing Availability No"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched 2003 Licensing Availability No"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2003 Licensing Availability No"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Launched 2006 Licensing Availability No"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Launched 2004 Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Launched Licensing Availability No"}],"DOCNO":"PD005044","CASIS_COMPOUND":[{"CN":"Trudexa","SRC_DB":"PHP"},{"CN":"LU-200134 (intravitreal)","SRC_DB":"PHP"},{"CN":"D2E7 (SC)","SRC_DB":"PHP"},{"CN":"LU 200134","SRC_DB":"PHP"},{"CN":"ABT-D2E7","SRC_DB":"PHP"},{"CN":"adalimumab (IV)","SRC_DB":"PHP"},{"CN":"LU 200134 (SC)","SRC_DB":"PHP"},{"CN":"ABT-D2E7 (IV)","SRC_DB":"PHP"},{"CN":"LU-200134 (SC)","SRC_DB":"PHP"},{"CN":"D2E7 (intravitreal)","SRC_DB":"PHP"},{"CN":"ABT-D2E7 (intravitreal)","SRC_DB":"PHP"},{"CN":"adalimumab (intravitreal)","SRC_DB":"PHP"},{"CN":"D2E7","SRC_DB":"PHP"},{"CN":"LU-200134","SRC_DB":"PHP"},{"CN":"ABT-D2E7 (SC)","SRC_DB":"PHP"},{"CN":"LU-200134 (IV)","SRC_DB":"PHP"},{"CN":"D2E7 (IV)","SRC_DB":"PHP"},{"CN":"Humira","SRC_DB":"PHP"},{"CN":"Raheara","SRC_DB":"PHP"},{"CN":"LU 200134 (IV)","SRC_DB":"PHP"},{"CN":"adalimumab","SRC_DB":"PHP"},{"CN":"adalimumab (SC)","SRC_DB":"PHP"},{"CN":"LU 200134 (intravitreal)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-23 15:47:33","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Musculoskeletal","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Behcet's disease","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Septic shock treatment","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, immunological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ophthalmological, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, juvenile","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Monoclonal antibody, human","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Spondyloarthritis, axial","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Uveitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Inflammatory bowel disease, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Sepsis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Spondyloarthritis, peripheral","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunosuppressant","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Hidradenitis suppurativa","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Dermatological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[69, 105, 115, 97, 105, 94, 73, 116, 32, 105, 115, 32, 105, 110, 32, 80, 104, 97, 115, 101, 32, 73, 73, 73, 32, 116, 114, 105, 97, 108]...', original message: bytes can be at most 32766 in length; got 46694
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 46694
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:04:42,576][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8gb[7.1%], shards will be relocated away from this node
[2016-06-14 13:04:51,504][DEBUG][action.bulk              ] 229"],"Document_CASIS-LN_LN":["Anti-inflammatory:Pre-registration","Antiarthritic, other:Launched","Antiasthma:No Development Reported","Antipruritic/inflamm, allergic:No Development Reported","Antipsoriasis:Launched","Dermatological:Phase II Clinical Trial","GI inflammatory/bowel disorders:Phase II Clinical Trial","Immunosuppressant:No Development Reported"],"Document_CASIS-MDNUMBER":["MD304143    "],"Document_CASIS-USE_CASIS-MA_MA":["Phosphodiesterase 4 inhibitor","Tumour necrosis factor alpha antagonist"],"Document_CASIS-DSTA_Country":["World: Launched","AR: Not Applicable; Licensing Availability: Unknown","AU: Registered; Licensing Availability: Unknown","AT: Launched 2015; Licensing Availability: Unknown","BE: Registered; Licensing Availability: Unknown","BR: Not Applicable; Licensing Availability: Unknown","CA: Launched; Licensing Availability: Unknown","CL: Not Applicable; Licensing Availability: Unknown","CN: Not Applicable; Licensing Availability: Unknown","CO: Not Applicable; Licensing Availability: Unknown","DK: Launched 2015; Licensing Availability: Unknown","SF: Registered; Licensing Availability: Unknown","FR: Registered; Licensing Availability: Unknown","DE: Launched 2015; Licensing Availability: Unknown","GR: Registered; Licensing Availability: Unknown","HK: Not Applicable; Licensing Availability: Unknown","IN: Not Applicable; Licensing Availability: Unknown","IE: Registered; Licensing Availability: Unknown","IL: Phase II Clinical Trial; Licensing Availability: Unknown","IT: Registered; Licensing Availability: Unknown","JP: Phase III Clinical Trial; Licensing Availability: Unknown","LU: Registered; Licensing Availability: Unknown","MY: Not Applicable; Licensing Availability: Unknown","MX: Not Applicable; Licensing Availability: Unknown","NL: Launched 2015; Licensing Availability: Unknown","NZ: Phase III Clinical Trial; Licensing Availability: Unknown","NO: Not Applicable; Licensing Availability: Unknown","PE: Not Applicable; Licensing Availability: Unknown","PH: Not Applicable; Licensing Availability: Unknown","PT: Registered; Licensing Availability: Unknown","RU: Phase III Clinical Trial; Licensing Availability: Unknown","ZA: Phase III Clinical Trial; Licensing Availability: Unknown","KR: Phase III Clinical Trial; Licensing Availability: Unknown","ES: Registered; Licensing Availability: Unknown","SE: Launched 2015; Licensing Availability: Unknown","CH: Launched 2015; Licensing Availability: Unknown","TH: Not Applicable; Licensing Availability: Unknown","TR: Pre-registration; Licensing Availability: Unknown","UK: Registered; Licensing Availability: Unknown","US: Launched 2014; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Ankylosing spondylitis::Phase III Clinical Trial","Arthritis, osteo::Phase II Clinical Trial","Arthritis, psoriatic::Launched","Arthritis, rheumatoid::Phase II Clinical Trial","Asthma::No Development Reported","Behcet's disease::Pre-registration","Colitis, ulcerative::Phase II Clinical Trial","Crohn's disease::Preclinical","Eczema, atopic::Phase II Clinical Trial","Lupus erythematosus, cutaneous::No Development Reported","Pruritus::No Development Reported","Psoriasis::Launched","Sarcoidosis::No Development Reported"],"Document_TargetData_Targets_Target_TargetName":["phosphodiesterase 4A, cAMP-specific","phosphodiesterase 4B, cAMP-specific","phosphodiesterase 4C, cAMP-specific","phosphodiesterase 4D, cAMP-specific","tumour necrosis factor receptor superfamily, member 1A"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_LatestChange":["Completion of Phase IIb trial (CC-10004-PSOR-011) for psoriasis reported"],"Document_DeliveryData_DeliveryTechnologyData_DeliveryTechnology":["Immediate-release","Modified-release"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase II Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"}],"DOCNO":"PD031098","CASIS_COMPOUND":[{"CN":"Otezla (capsule)","SRC_DB":"PHP"},{"CN":"Otezla (tablet)","SRC_DB":"PHP"},{"CN":"apremilast (capsule)","SRC_DB":"PHP"},{"CN":"apremilast","SRC_DB":"PHP"},{"CN":"apremilast (modified-release)","SRC_DB":"PHP"},{"CN":"CC 10004 (tablet)","SRC_DB":"PHP"},{"CN":"CC10004 (tablet)","SRC_DB":"PHP"},{"CN":"CC10004 (modified-release)","SRC_DB":"PHP"},{"CN":"CC-10004 (modified-release)","SRC_DB":"PHP"},{"CN":"CC-10004 (tablet)","SRC_DB":"PHP"},{"CN":"Otezla","SRC_DB":"PHP"},{"CN":"CC 10004 (capsule)","SRC_DB":"PHP"},{"CN":"CC10004","SRC_DB":"PHP"},{"CN":"CC10004 (capsule)","SRC_DB":"PHP"},{"CN":"CC 10004 (modified-release)","SRC_DB":"PHP"},{"CN":"CC-10004","SRC_DB":"PHP"},{"CN":"apremilast (tablet)","SRC_DB":"PHP"},{"CN":"CC-10004 (capsule)","SRC_DB":"PHP"},{"CN":"CC 10004","SRC_DB":"PHP"},{"CN":"Otezla (modified-release)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:47","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Antipsoriasis","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, osteo","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Asthma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Behcet's disease","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anti-inflammatory","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Sarcoidosis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Dermatological","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, psoriatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Colitis, ulcerative","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Psoriasis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Eczema, atopic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Lupus erythematosus, cutaneous","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiasthma","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Phosphodiesterase 4 inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Ankylosing spondylitis","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Pruritus","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antipruritic/inflamm, allergic","SOURCE":"ACT","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 110, 107, 121, 108, 111, 115, 105, 110, 103, 32, 115, 112, 111, 110, 100, 121, 108, 105, 116, 105, 115, 94, 65, 32, 114, 97, 110, 100, 111]...', original message: bytes can be at most 32766 in length; got 37807
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 37807
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:04:51,516][DEBUG][action.bulk              ] nched"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_CASIS-USE_CASIS-MA_MA":["HCV nonstructural protein 3 inhibitor","Serine protease inhibitor"],"Document_CASIS-DSTA_Country":["World: Launched","AR: Phase III Clinical Trial; Licensing Availability: No","AU: Launched 2014; Licensing Availability: No","AT: Launched 2014; Licensing Availability: No","BE: Launched 2014; Licensing Availability: No","BR: Phase III Clinical Trial; Licensing Availability: No","CA: Launched 2013; Licensing Availability: No","CL: Not Applicable; Licensing Availability: No","CN: Phase III Clinical Trial; Licensing Availability: No","CO: Not Applicable; Licensing Availability: No","DK: Launched 2014; Licensing Availability: No","SF: Launched 2014; Licensing Availability: No","FR: Launched 2014; Licensing Availability: No","DE: Launched 2014; Licensing Availability: No","GR: Launched 2014; Licensing Availability: No","HK: Not Applicable; Licensing Availability: No","IN: Not Applicable; Licensing Availability: No","IE: Launched 2014; Licensing Availability: No","IL: Phase III Clinical Trial; Licensing Availability: No","IT: Launched 2014; Licensing Availability: No","JP: Launched 2013; Licensing Availability: No","LU: Launched 2014; Licensing Availability: No","MY: Not Applicable; Licensing Availability: No","MX: Launched 2014; Licensing Availability: No","NL: Launched 2014; Licensing Availability: No","NZ: Phase III Clinical Trial; Licensing Availability: No","NO: Launched 2014; Licensing Availability: No","PE: Not Applicable; Licensing Availability: No","PH: Not Applicable; Licensing Availability: No","PT: Launched 2014; Licensing Availability: No","RU: Launched 2014; Licensing Availability: No","ZA: Not Applicable; Licensing Availability: No","KR: Phase III Clinical Trial; Licensing Availability: No","ES: Launched 2014; Licensing Availability: No","SE: Launched 2014; Licensing Availability: No","CH: Phase III Clinical Trial; Licensing Availability: No","TH: Phase II Clinical Trial; Licensing Availability: No","TR: Phase III Clinical Trial; Licensing Availability: No","UK: Launched 2014; Licensing Availability: No","US: Launched 2013; Licensing Availability: No","VE: Not Applicable; Licensing Availability: No"],"Document_CASIS-USE_CASIS-IND_IND":["Infection, hepatitis-C virus::Launched"],"Document_TargetData_Targets_Target_TargetName":["polyprotein, hepatitis-C virus"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_CASIS-TX_Licensing":["Agreements^________________^Bristol-Myers Squibb^Worldwide; Tibotec has a clinical collaboration agreement with Bristol-Myers Squibb to evaluate the utility of daclatasvir in combination with simeprevir for the treatment of HCV infection (Press release, BMS, 2 Dec 2011, http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20111202005035/en&t=634584648256497534). The collaboration agreement has been expanded to to conduct a drug-drug interaction study with TMC-435 and BMS-986094 (Press release, Medivir, 18 Apr 2012, http://www.medivir.se/v4/en/ir_media/pressrelease.cfm?year=2012&releaseid=659101).^Pharmasset^Worldwide; Tibotec has a clinical collaboration agreement with Pharmasset to combine PSI-7977 and Tibotec's simeprevir, a protease inhibitor (Press release, Pharmasset, 25 Jul 2011, http://investor.pharmasset.com/releasedetail.cfm?ReleaseID=593884).^Tibotec (Johnson & Johnson)^Worldwide except Nordic countries; Tibotec (Johnson & Johnson) has exclusive worldwide rights, excluding the Nordic countries, where Medivir will be responsible for commercialization (Scrip Daily Online, 2 Dec 2004, S00865904). A non-exclusive collaborative agreement was concluded between Janssen and Idenix for Phase II combination trials of simeprevir, TMC-647055 and IDX-719. The collaboration intends to evaluate a fully oral, interferon-free, antiviral combination therapy for the treatment of hepatitis C (Press release, Medivir, 22 Feb 2013, http://www.medivir.se/v4/en/ir_media/pressrelease.cfm?year=2013&releaseid=745936)."],"Document_LatestChange":["Expected timing of filing for combination regimen reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability No"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability No"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability No"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability No"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability No"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability No"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Phase II Clinical Trial Licensing Availability No"}],"DOCNO":"PD032069","CASIS_COMPOUND":[{"CN":"TMC435 (tablet)","SRC_DB":"PHP"},{"CN":"JNJ-38733214-AAA (tablet)","SRC_DB":"PHP"},{"CN":"R-494617 (tablet)","SRC_DB":"PHP"},{"CN":"TMC-435350 (tablet)","SRC_DB":"PHP"},{"CN":"Sovriad (tablet)","SRC_DB":"PHP"},{"CN":"Galexos","SRC_DB":"PHP"},{"CN":"Sovriad (capsule)","SRC_DB":"PHP"},{"CN":"TMC 435 (iv)","SRC_DB":"PHP"},{"CN":"R494617 (capsule)","SRC_DB":"PHP"},{"CN":"simeprevir (tablet)","SRC_DB":"PHP"},{"CN":"simeprevir","SRC_DB":"PHP"},{"CN":"HCV-PI, Medivir","SRC_DB":"PHP"},{"CN":"TMC435350 (capsule)","SRC_DB":"PHP"},{"CN":"TMC-435350 (capsule)","SRC_DB":"PHP"},{"CN":"simeprevir (oral solution)","SRC_DB":"PHP"},{"CN":"TMC435 (capsule)","SRC_DB":"PHP"},{"CN":"TMC-435 (oral solution)","SRC_DB":"PHP"},{"CN":"TMC435350","SRC_DB":"PHP"},{"CN":"JNJ-38733214-AAA","SRC_DB":"PHP"},{"CN":"Olysio (tablet)","SRC_DB":"PHP"},{"CN":"TMC435350 (tablet)","SRC_DB":"PHP"},{"CN":"simeprevir (iv)","SRC_DB":"PHP"},{"CN":"TMC-435 (iv)","SRC_DB":"PHP"},{"CN":"G-008","SRC_DB":"PHP"},{"CN":"TMC435 (iv)","SRC_DB":"PHP"},{"CN":"JNJ-38733214-AAA (capsule)","SRC_DB":"PHP"},{"CN":"HCV NS3/4A protease inhibitor, Medivir","SRC_DB":"PHP"},{"CN":"JNJ-38733214-AAA (oral solution)","SRC_DB":"PHP"},{"CN":"Olysio (iv)","SRC_DB":"PHP"},{"CN":"Olysio (capsule)","SRC_DB":"PHP"},{"CN":"R494617 (oral solution)","SRC_DB":"PHP"},{"CN":"Olysio","SRC_DB":"PHP"},{"CN":"R-494617 (oral solution)","SRC_DB":"PHP"},{"CN":"TMC-435350 (oral solution)","SRC_DB":"PHP"},{"CN":"TMC 435","SRC_DB":"PHP"},{"CN":"Sovriad (oral solution)","SRC_DB":"PHP"},{"CN":"R-494617 (capsule)","SRC_DB":"PHP"},{"CN":"TMC-435","SRC_DB":"PHP"},{"CN":"HCV protease inhib, Medivir","SRC_DB":"PHP"},{"CN":"Sovriad (iv)","SRC_DB":"PHP"},{"CN":"TMC-435 (tablet)","SRC_DB":"PHP"},{"CN":"TMC-435 (capsule)","SRC_DB":"PHP"},{"CN":"TMC435","SRC_DB":"PHP"},{"CN":"TMC-435350","SRC_DB":"PHP"},{"CN":"R494617 (tablet)","SRC_DB":"PHP"},{"CN":"simeprevir (capsule)","SRC_DB":"PHP"},{"CN":"R-494617","SRC_DB":"PHP"},{"CN":"G008","SRC_DB":"PHP"},{"CN":"Sovriad","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-23 15:47:32","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiviral, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Serine protease inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"HCV nonstructural protein 3 inhibitor","SOURCE":"MA","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 110, 102, 101, 99, 116, 105, 111, 110, 44, 32, 104, 101, 112, 97, 116, 105, 116, 105, 115, 45, 67, 32, 118, 105, 114, 117, 115, 94, 66]...', original message: bytes can be at most 32766 in length; got 33725
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 33725
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:04:51,531][DEBUG][action.bulk              ] ensing Availability: Unknown","DE: Launched; Licensing Availability: Unknown","GR: Launched; Licensing Availability: Unknown","HK: Launched; Licensing Availability: Unknown","IN: Not Applicable; Licensing Availability: Unknown","IE: Launched 2008; Licensing Availability: Unknown","IL: Registered; Licensing Availability: Unknown","IT: Launched; Licensing Availability: Unknown","JP: Launched 2010; Licensing Availability: Unknown","LU: Registered; Licensing Availability: Unknown","MY: Launched; Licensing Availability: Unknown","MX: Registered; Licensing Availability: Unknown","NL: Launched 2015; Licensing Availability: Unknown","NZ: Registered; Licensing Availability: Unknown","NO: Launched 2015; Licensing Availability: Unknown","PE: Registered; Licensing Availability: Unknown","PH: Registered; Licensing Availability: Unknown","PT: Registered; Licensing Availability: Unknown","RU: Registered; Licensing Availability: Unknown","ZA: Phase III Clinical Trial; Licensing Availability: Unknown","KR: Registered; Licensing Availability: Unknown","ES: Launched 2015; Licensing Availability: Unknown","SE: Launched 2015; Licensing Availability: Unknown","CH: Launched 2008; Licensing Availability: Unknown","TH: Launched; Licensing Availability: Unknown","TR: Registered; Licensing Availability: Unknown","UK: Registered; Licensing Availability: Unknown","US: Launched 2005; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Anaemia, unspecified::Launched","Arthritis, rheumatoid::No Development Reported","Cancer, breast::No Development Reported","Cancer, carcinoid::No Development Reported","Cancer, CNS::No Development Reported","Cancer, colorectal::No Development Reported","Cancer, gastrointestinal, stromal::No Development Reported","Cancer, leukaemia, acute myelogenous::Phase II Clinical Trial","Cancer, leukaemia, chronic lymphocytic::Phase III Clinical Trial","Cancer, lung, non-small cell::No Development Reported","Cancer, lymphoma, B-cell::Phase III Clinical Trial","Cancer, lymphoma, B-cell, marginal zone::Phase III Clinical Trial","Cancer, lymphoma, mantle cell::Launched","Cancer, lymphoma, non-Hodgkin's::Phase III Clinical Trial","Cancer, lymphoma, T-cell, peripheral::Phase II Clinical Trial","Cancer, melanoma::Discontinued","Cancer, myeloma::Launched","Cancer, ovarian::No Development Reported","Cancer, pancreatic::No Development Reported","Cancer, peritoneal::No Development Reported","Cancer, prostate::No Development Reported","Cancer, renal::No Development Reported","Crohn's disease::No Development Reported","Diabetes, undisclosed Type::No Development Reported","Heart failure::No Development Reported","Myelodysplastic syndrome::Launched","Pain, complex regional::No Development Reported","Pain, neuropathic, general::No Development Reported","Waldenstrom's hypergammaglobulinaemia::No Development Reported"],"Document_TargetData_Targets_Target_TargetName":["Unspecified"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_LatestChange":["Planned Phase I/II trial (MEDI4736-MM-002) for multiple myeloma reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Launched Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"}],"DOCNO":"PD008874","CASIS_COMPOUND":[{"CN":"CDC 501","SRC_DB":"PHP"},{"CN":"CC 5053","SRC_DB":"PHP"},{"CN":"CC 5013","SRC_DB":"PHP"},{"CN":"IMiDs, class I, Celgene","SRC_DB":"PHP"},{"CN":"Revlimid","SRC_DB":"PHP"},{"CN":"CC-5053","SRC_DB":"PHP"},{"CN":"CDC-5013","SRC_DB":"PHP"},{"CN":"CDC-501","SRC_DB":"PHP"},{"CN":"CC-5013","SRC_DB":"PHP"},{"CN":"CDC 5013","SRC_DB":"PHP"},{"CN":"lenalidomide","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:48","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Crohn's disease","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, mantle cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antianaemic","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Pain, complex regional","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, carcinoid","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Diabetes, undisclosed Type","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antiarthritic, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Pain, neuropathic, general","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Heart failure","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"GI inflammatory/bowel disorders","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, T-cell, peripheral","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, CNS","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anticancer, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Analgesic, other","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, lymphoma, B-cell, marginal zone","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Tumour necrosis factor alpha antagonist","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Anaemia, unspecified","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cardiostimulant","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Waldenstrom's hypergammaglobulinaemia","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[67, 97, 110, 99, 101, 114, 44, 32, 108, 101, 117, 107, 97, 101, 109, 105, 97, 44, 32, 99, 104, 114, 111, 110, 105, 99, 32, 108, 121, 109]...', original message: bytes can be at most 32766 in length; got 39371
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 39371
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:04:51,557][DEBUG][action.bulk              ] duction from baseline and final mean value were -1.3, -1.5 and -1.5% and 7.4, 7.3 and 7.2%, respectively. The final mean FPG was 113, 116 and 115mg/dl on insulin degludec once-daily, 3x/wk and insulin glargine, respectively. The mean reductions from baseline were -65, -75 and -61mg/dl for the dose groups. Rates of confirmed hypoglycaemia were low and only one severe event was reported on insulin degludec 3x/wk. The rate of confirmed hypoglycaemia was 0.6, 2.3 and 1.1 events/ patient year on insulin degludec once-daily, 3x/wk and insulin glargine, respectively. The proportion of subjects with adverse events was similar across treatment arms, with no specific patterns or clustering. The majority of AEs were mild or moderate in severity. Insulin degludec 3x/wk or once-daily was safe, well tolerated and provided similar glycaemic control to insulin glargine (Reference: 70th Meet Am Diabetes Assoc (Orlando), 2010, Abs 40-OR, http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=78988).^A randomized, open-label, safety/efficacy Phase II trial (NN1250-1836) conducted in Africa, Asia and N America in 236 Type 2 diabetes patients receiving 1 of 2 insulin degludec formulations or insulin glargine, all in combination with metformin, was completed (Company presentation, Novo Nordisk, 31 Jan 2008; Company Web Page, Novo Nordisk, 15 Feb 2008).^A randomized, open-label, safety/efficacy Phase II trial (NN1250-1835) with 2 formulations of insulin degludec in 177 Type 2 diabetics, conducted in Australia, Europe (as shown) and the US, was completed. Patients received insulin degludec + insulin Aspart or insulin glargine + insulin Aspart x16wk (Company presentation, Novo Nordisk, 31 Jan 2008; Company Web Page, Novo Nordisk, 15 Feb 2008)."],"Document_CASIS-RN_CASNumber":["844439-96-9"],"Document_CASIS-UPD":["20160229"],"Document_CASIS-LN_LN":["Antidiabetic:Launched","Insulin:Launched","Recombinant hormone:Launched"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_CASIS-USE_CASIS-MA_MA":["Long-acting insulin"],"Document_CASIS-DSTA_Country":["World: Launched","AR: Launched 2014; Licensing Availability: Unknown","AU: Pre-registration; Licensing Availability: Unknown","AT: Registered; Licensing Availability: Unknown","BE: Registered; Licensing Availability: Unknown","BR: Launched 2014; Licensing Availability: Unknown","CA: Pre-registration; Licensing Availability: Unknown","CL: Launched 2014; Licensing Availability: Unknown","CN: Phase III Clinical Trial; Licensing Availability: Unknown","CO: Launched 2015; Licensing Availability: Unknown","DK: Launched 2013; Licensing Availability: Unknown","SF: Launched 2015; Licensing Availability: Unknown","FR: Registered; Licensing Availability: Unknown","DE: Launched 2014; Licensing Availability: Unknown","GR: Registered; Licensing Availability: Unknown","HK: Phase III Clinical Trial; Licensing Availability: Unknown","IN: Launched 2013; Licensing Availability: Unknown","IE: Registered; Licensing Availability: Unknown","IL: Launched 2014; Licensing Availability: Unknown","IT: Launched 2015; Licensing Availability: Unknown","JP: Launched 2013; Licensing Availability: Unknown","LU: Registered; Licensing Availability: Unknown","MY: Pre-registration; Licensing Availability: Unknown","MX: Launched 2013; Licensing Availability: Unknown","NL: Launched 2014; Licensing Availability: Unknown","NZ: Not Applicable; Licensing Availability: Unknown","NO: Registered; Licensing Availability: Unknown","PE: Not Applicable; Licensing Availability: Unknown","PH: Pre-registration; Licensing Availability: Unknown","PT: Registered; Licensing Availability: Unknown","RU: Launched 2014; Licensing Availability: Unknown","ZA: Pre-registration; Licensing Availability: Unknown","KR: Registered; Licensing Availability: Unknown","ES: Launched 2016; Licensing Availability: Unknown","SE: Launched 2013; Licensing Availability: Unknown","CH: Launched 2013; Licensing Availability: Unknown","TH: Pre-registration; Licensing Availability: Unknown","TR: Phase III Clinical Trial; Licensing Availability: Unknown","UK: Launched 2013; Licensing Availability: Unknown","US: Launched 2016; Licensing Availability: Unknown","VE: Not Applicable; Licensing Availability: Unknown"],"Document_CASIS-USE_CASIS-IND_IND":["Diabetes, Type 1::Launched","Diabetes, Type 2::Launched"],"Document_TargetData_Targets_Target_TargetName":["insulin receptor"],"Document_SO":["T&F Informa UK Ltd, London"],"Document_LatestChange":["Results of Phase III trials (SWITCH 1 & SWITCH 2) reported"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CA","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"SF","SRC_DB":"PHP","DSTA":"Launched 2015 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHP","DSTA":"Launched"},{"COUNTRY":"VE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"UK","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHP","DSTA":"Launched 2014 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHP","DSTA":"Phase III Clinical Trial Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHP","DSTA":"Not Applicable Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHP","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHP","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHP","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHP","DSTA":"Launched 2016 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHP","DSTA":"Launched 2016 Licensing Availability Unknown"}],"DOCNO":"PD039993","CASIS_COMPOUND":[{"CN":"insulin 454","SRC_DB":"PHP"},{"CN":"NNC 0100-0454","SRC_DB":"PHP"},{"CN":"NNC-0100-0454 (SC)","SRC_DB":"PHP"},{"CN":"NN-1250 (IM)","SRC_DB":"PHP"},{"CN":"NNC-0100-0454","SRC_DB":"PHP"},{"CN":"Degludec (IM)","SRC_DB":"PHP"},{"CN":"NNC-0100-0454 (IM)","SRC_DB":"PHP"},{"CN":"SIBA, Novo Nordisk","SRC_DB":"PHP"},{"CN":"Tresiba","SRC_DB":"PHP"},{"CN":"insulin degludec (SC)","SRC_DB":"PHP"},{"CN":"NNC 0100-0454 (IV)","SRC_DB":"PHP"},{"CN":"Tresiba (IV)","SRC_DB":"PHP"},{"CN":"SIBA, Novo Nordisk (SC)","SRC_DB":"PHP"},{"CN":"Tresiba (IM)","SRC_DB":"PHP"},{"CN":"insulin degludec (IV)","SRC_DB":"PHP"},{"CN":"NNC 0100-0454 (IM)","SRC_DB":"PHP"},{"CN":"NN-1250 (IV)","SRC_DB":"PHP"},{"CN":"SIBA, Novo Nordisk (IM)","SRC_DB":"PHP"},{"CN":"Tresiba (SC)","SRC_DB":"PHP"},{"CN":"SIBA, Novo Nordisk (IV)","SRC_DB":"PHP"},{"CN":"NN1250 (IM)","SRC_DB":"PHP"},{"CN":"Degludec","SRC_DB":"PHP"},{"CN":"IDeg (IV)","SRC_DB":"PHP"},{"CN":"NNC 0100-0454 (SC)","SRC_DB":"PHP"},{"CN":"Degludec (IV)","SRC_DB":"PHP"},{"CN":"NNC-0100-0454 (IV)","SRC_DB":"PHP"},{"CN":"NN-1250","SRC_DB":"PHP"},{"CN":"NN1250 (IV)","SRC_DB":"PHP"},{"CN":"NN1250 (SC)","SRC_DB":"PHP"},{"CN":"insulin degludec","SRC_DB":"PHP"},{"CN":"IDeg","SRC_DB":"PHP"},{"CN":"NN-1250 (SC)","SRC_DB":"PHP"},{"CN":"IDeg (SC)","SRC_DB":"PHP"},{"CN":"NN1250","SRC_DB":"PHP"},{"CN":"insulin degludec (IM)","SRC_DB":"PHP"},{"CN":"Degludec (SC)","SRC_DB":"PHP"}],"DATEINSERTED":"2016-02-29 15:27:48","SRC_DB":"PHP","CASIS_USE":[{"CODE":"","THE_USE":"Recombinant hormone","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Insulin","SOURCE":"ACT","SRC_DB":"PHP"},{"CODE":"","THE_USE":"Long-acting insulin","SOURCE":"MA","SRC_DB":"PHP"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_KeyClinicalInformation_PhaseIII.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 32, 71, 101, 114, 109, 97, 110, 32, 114, 97, 110, 100, 111, 109, 105, 122, 101, 100, 44, 32, 99, 114, 111, 115, 115, 111, 118, 101, 114]...', original message: bytes can be at most 32766 in length; got 35676
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35676
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:05:12,655][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.1gb[7.2%], shards will be relocated away from this node
[2016-06-14 13:05:12,658][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:05:42,756][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8gb[7.1%], shards will be relocated away from this node
[2016-06-14 13:06:12,788][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8gb[7.1%], shards will be relocated away from this node
[2016-06-14 13:06:12,788][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:06:42,814][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8gb[7.1%], shards will be relocated away from this node
[2016-06-14 13:07:12,859][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.9gb[7%], shards will be relocated away from this node
[2016-06-14 13:07:12,859][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:07:42,906][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.9gb[7%], shards will be relocated away from this node
[2016-06-14 13:08:12,932][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.9gb[7%], shards will be relocated away from this node
[2016-06-14 13:08:12,932][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:08:42,957][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.8gb[6.9%], shards will be relocated away from this node
[2016-06-14 13:09:12,982][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.8gb[6.9%], shards will be relocated away from this node
[2016-06-14 13:09:12,983][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:09:43,029][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.8gb[6.9%], shards will be relocated away from this node
[2016-06-14 13:10:13,054][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.7gb[6.8%], shards will be relocated away from this node
[2016-06-14 13:10:13,054][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:10:41,079][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 13:10:43,099][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.8gb[7.8%], shards will be relocated away from this node
[2016-06-14 13:11:13,141][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9gb[8%], shards will be relocated away from this node
[2016-06-14 13:11:13,141][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:11:21,948][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 13:11:43,183][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 9gb[7.9%], shards will be relocated away from this node
[2016-06-14 13:12:13,184][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.9gb[7.8%], shards will be relocated away from this node
[2016-06-14 13:12:13,184][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:12:43,208][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.8gb[7.8%], shards will be relocated away from this node
[2016-06-14 13:13:13,233][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.7gb[7.7%], shards will be relocated away from this node
[2016-06-14 13:13:13,233][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:13:43,257][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.7gb[7.7%], shards will be relocated away from this node
[2016-06-14 13:14:13,287][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.6gb[7.6%], shards will be relocated away from this node
[2016-06-14 13:14:13,293][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:14:43,419][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.5gb[7.5%], shards will be relocated away from this node
[2016-06-14 13:15:12,783][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 13:15:13,475][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.5gb[7.5%], shards will be relocated away from this node
[2016-06-14 13:15:13,475][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:15:43,502][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.3gb[7.4%], shards will be relocated away from this node
[2016-06-14 13:16:13,528][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.4gb[7.4%], shards will be relocated away from this node
[2016-06-14 13:16:13,528][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:16:43,586][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8.1gb[7.2%], shards will be relocated away from this node
[2016-06-14 13:17:13,613][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 8gb[7.1%], shards will be relocated away from this node
[2016-06-14 13:17:13,613][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:17:43,686][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.7gb[6.8%], shards will be relocated away from this node
[2016-06-14 13:18:13,736][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.7gb[6.8%], shards will be relocated away from this node
[2016-06-14 13:18:13,736][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:18:43,827][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.5gb[6.6%], shards will be relocated away from this node
[2016-06-14 13:19:13,868][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.5gb[6.6%], shards will be relocated away from this node
[2016-06-14 13:19:13,868][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:19:43,915][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.4gb[6.6%], shards will be relocated away from this node
[2016-06-14 13:20:13,941][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.3gb[6.4%], shards will be relocated away from this node
[2016-06-14 13:20:13,946][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:20:43,972][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.3gb[6.5%], shards will be relocated away from this node
[2016-06-14 13:21:13,999][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.3gb[6.5%], shards will be relocated away from this node
[2016-06-14 13:21:13,999][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:21:44,054][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.2gb[6.3%], shards will be relocated away from this node
[2016-06-14 13:22:14,087][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7gb[6.2%], shards will be relocated away from this node
[2016-06-14 13:22:14,087][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:22:44,119][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.8gb[6%], shards will be relocated away from this node
[2016-06-14 13:22:51,904][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 13:22:51,991][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 13:23:14,202][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.7gb[5.9%], shards will be relocated away from this node
[2016-06-14 13:23:14,202][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:23:44,228][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.5gb[5.7%], shards will be relocated away from this node
[2016-06-14 13:24:14,255][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.5gb[5.7%], shards will be relocated away from this node
[2016-06-14 13:24:14,255][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:24:44,308][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.5gb[5.7%], shards will be relocated away from this node
[2016-06-14 13:25:14,335][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.3gb[5.6%], shards will be relocated away from this node
[2016-06-14 13:25:14,335][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:25:44,362][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.4gb[5.7%], shards will be relocated away from this node
[2016-06-14 13:26:14,411][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.4gb[5.6%], shards will be relocated away from this node
[2016-06-14 13:26:14,411][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:26:44,437][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.3gb[5.6%], shards will be relocated away from this node
[2016-06-14 13:27:14,465][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.3gb[5.6%], shards will be relocated away from this node
[2016-06-14 13:27:14,465][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:27:44,556][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.2gb[5.5%], shards will be relocated away from this node
[2016-06-14 13:28:14,584][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.1gb[5.4%], shards will be relocated away from this node
[2016-06-14 13:28:14,584][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:28:44,614][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6gb[5.3%], shards will be relocated away from this node
[2016-06-14 13:29:14,642][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.8gb[5.1%], shards will be relocated away from this node
[2016-06-14 13:29:14,642][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:29:44,675][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.9%], shards will be relocated away from this node
[2016-06-14 13:30:14,699][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:30:14,699][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:30:44,726][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:31:14,757][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:31:14,757][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:31:44,786][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:32:14,815][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.4gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:32:14,825][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:32:44,939][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.4gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:33:14,967][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.3gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:33:14,967][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:33:44,997][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.3gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:34:15,025][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.2gb[4.6%], shards will be relocated away from this node
[2016-06-14 13:34:15,025][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:34:45,102][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.2gb[4.6%], shards will be relocated away from this node
[2016-06-14 13:35:15,130][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.1gb[4.5%], shards will be relocated away from this node
[2016-06-14 13:35:15,130][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:35:45,251][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.1gb[4.5%], shards will be relocated away from this node
[2016-06-14 13:36:15,283][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.1gb[4.5%], shards will be relocated away from this node
[2016-06-14 13:36:15,283][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:36:45,310][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5gb[4.4%], shards will be relocated away from this node
[2016-06-14 13:37:15,338][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5gb[4.4%], shards will be relocated away from this node
[2016-06-14 13:37:15,338][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:37:45,365][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5gb[4.4%], shards will be relocated away from this node
[2016-06-14 13:37:49,680][DEBUG][action.bulk              ] cs of venlafaxine in 38 healthy subjects was completed (ClinicalTrials.gov, 24 Sep 2011, http://clinicaltrials.gov/ct2/show/NCT00362271).^Preclinical ^Development for acute agitation was planned (Scrip Daily Online, 22 Nov 2004, S00864506).^In vivo^In chloral hydrate-anaesthetized rats, aripiprazole inhibited the antidromic spike of dopaminergic neurones in the ventral segmental area (5th Conf Clin Pharmacol Ther (Yokohama), 1992, Abs O-15-05 and P-102-17; Company communication, Otsuka, Feb 1995).^Patents^Exclusivity in the US is expected to expire in Apr 2015 (Press release, BMS, 6 Apr 2009).^Patent expirations are expected in 2014 (Scrip Daily Online, 11 Oct 2005, S00898476).^Licensing^Agreements^________________^Bristol-Myers Squibb^Worldwide excluding Japan and select Asian and Middle Eastern countries; it is licensed to BMS for co-marketing in the EU and the US, and for exclusive marketing elsewhere except Japan and some Asian and Middle Eastern countries (Press release, BMS, 21 Sep 1999). The US portion of the development and commercialization agreement with BMS has been extended from Nov 2012 to Apr 2015, when exclusivity in the US is expected to expire (Press release, BMS, 6 Apr 2009).^Ligand^Worldwide (Company Pipeline, Ligand, 6 Oct 2011, http:// www.ligand.com/pipeline).^Lundbeck^EU; Lundbeck gained rights for the promotion of product (Scrip Intelligence, 11 Mar 2013, http://www.scripintelligence.com/home/ Otsuka-and-Lundbeck-tout-alliance-benefits-as-they-mull-future- CNS-strategy-340991).^Additional Clinical Information^Additional References^23rd CINP (Montreal) 2002, AbsP4E031.^23rd CINP (Montreal) 2002, AbsP4E026.^10th Biennial Winter Workshop Schizophrenia (Davos) 2000, 1.^CNS Drug Rev 1997, 3, 24^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140117"],"Document_PK":["Human (po):bioavailability:87:%","Human (po):t1/2beta:75:hr","Human (po):Tmax:3 to 5:hr","Human (iv):Vd:404:l"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140113:AD67 : Completion of Phase III study (CN138-112) for schizophrenia reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AG: Dopamine D2 receptor agonist: Receptor, Transmitter, Dopamine D2 receptor agonist: DA D2 receptor agonist: D2 receptor agonist: Dopamine DA2 receptor agonist: DA DA2 receptor agonist: R-T-DOPA-D2-AG|5HT-1-A-AG: 5 Hydroxytryptamine 1A receptor agonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor agonist: 5HT1A receptor agonist: Serotonin 1A receptor agonist: R-H-5HT-1-A-AG|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IM: Parenteral, intramuscular","P-UN: Parenteral, general"],"Document_MW":["448.40"],"Document_AL":["4.31"],"Document_CASIS-CO_CO":["Originator: Otsuka (JP): Launched","Licensee: Bristol-Myers Squibb (US): Launched","Licensee: Ligand (US): Launched","Licensee: Lundbeck (DK): Launched"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD021321    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"}],"DOCNO":"PH018937","CASIS_COMPOUND":[{"CN":"OPC-14597 (tablet) CCN=OPC14597(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilify IM CCN=ABILIFYIM","SRC_DB":"PHPROJ"},{"CN":"aripiprazole CCN=ARIPIPRAZOLE","SRC_DB":"PHPROJ"},{"CN":"BMS-337039 (tablet) CCN=BMS337039(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilitat (tablet) CCN=ABILITAT(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilify CCN=ABILIFY","SRC_DB":"PHPROJ"},{"CN":"aripiprazole (tablet) CCN=ARIPIPRAZOLE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilify (solution) CCN=ABILIFY(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole (solution) CCN=ARIPIPRAZOLE(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole IM CCN=ARIPIPRAZOLEIM","SRC_DB":"PHPROJ"},{"CN":"Abilify (tablet) CCN=ABILIFY(TABLET)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-01-20 09:32:51","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C3","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AG","THE_USE":"5 Hydroxytryptamine 1A receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5D","THE_USE":"Antineurotic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Attention deficit hyperactivity disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Post-traumatic stress disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Tourette's syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N9A","THE_USE":"Dependence treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Addiction, alcohol","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AG","THE_USE":"Dopamine D2 receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N6B","THE_USE":"Psychostimulant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Alzheimer's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6D","THE_USE":"Cognition enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 114, 105, 112, 105, 112, 114, 97, 122, 111, 108, 101, 32, 105, 115, 32, 97, 32, 113, 117, 105, 110, 111, 108, 105, 110, 111, 110, 101, 32]...', original message: bytes can be at most 32766 in length; got 36451
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36451
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:38:15,401][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.8gb[4.3%], shards will be relocated away from this node
[2016-06-14 13:38:15,401][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:38:45,439][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.6gb[4.1%], shards will be relocated away from this node
[2016-06-14 13:39:15,483][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.3gb[3.8%], shards will be relocated away from this node
[2016-06-14 13:39:15,483][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:39:45,510][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.4gb[3.8%], shards will be relocated away from this node
[2016-06-14 13:40:15,605][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.1gb[3.7%], shards will be relocated away from this node
[2016-06-14 13:40:15,605][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:40:45,628][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.8gb[6%], shards will be relocated away from this node
[2016-06-14 13:41:15,653][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.3gb[6.5%], shards will be relocated away from this node
[2016-06-14 13:41:15,653][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:41:45,678][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.2gb[6.4%], shards will be relocated away from this node
[2016-06-14 13:42:15,753][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.2gb[6.3%], shards will be relocated away from this node
[2016-06-14 13:42:15,753][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:42:45,777][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.1gb[6.3%], shards will be relocated away from this node
[2016-06-14 13:43:15,860][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7.1gb[6.3%], shards will be relocated away from this node
[2016-06-14 13:43:15,860][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:43:45,883][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7gb[6.2%], shards will be relocated away from this node
[2016-06-14 13:44:15,922][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7gb[6.2%], shards will be relocated away from this node
[2016-06-14 13:44:15,922][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:44:42,523][DEBUG][action.bulk              ] cs of venlafaxine in 38 healthy subjects was completed (ClinicalTrials.gov, 24 Sep 2011, http://clinicaltrials.gov/ct2/show/NCT00362271).^Preclinical ^Development for acute agitation was planned (Scrip Daily Online, 22 Nov 2004, S00864506).^In vivo^In chloral hydrate-anaesthetized rats, aripiprazole inhibited the antidromic spike of dopaminergic neurones in the ventral segmental area (5th Conf Clin Pharmacol Ther (Yokohama), 1992, Abs O-15-05 and P-102-17; Company communication, Otsuka, Feb 1995).^Patents^Exclusivity in the US is expected to expire in Apr 2015 (Press release, BMS, 6 Apr 2009).^Patent expirations are expected in 2014 (Scrip Daily Online, 11 Oct 2005, S00898476).^Licensing^Agreements^________________^Bristol-Myers Squibb^Worldwide excluding Japan and select Asian and Middle Eastern countries; it is licensed to BMS for co-marketing in the EU and the US, and for exclusive marketing elsewhere except Japan and some Asian and Middle Eastern countries (Press release, BMS, 21 Sep 1999). The US portion of the development and commercialization agreement with BMS has been extended from Nov 2012 to Apr 2015, when exclusivity in the US is expected to expire (Press release, BMS, 6 Apr 2009).^Ligand^Worldwide (Company Pipeline, Ligand, 6 Oct 2011, http:// www.ligand.com/pipeline).^Lundbeck^EU; Lundbeck gained rights for the promotion of product (Scrip Intelligence, 11 Mar 2013, http://www.scripintelligence.com/home/ Otsuka-and-Lundbeck-tout-alliance-benefits-as-they-mull-future- CNS-strategy-340991).^Additional Clinical Information^Additional References^23rd CINP (Montreal) 2002, AbsP4E031.^23rd CINP (Montreal) 2002, AbsP4E026.^10th Biennial Winter Workshop Schizophrenia (Davos) 2000, 1.^CNS Drug Rev 1997, 3, 24^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140117"],"Document_PK":["Human (po):bioavailability:87:%","Human (po):t1/2beta:75:hr","Human (po):Tmax:3 to 5:hr","Human (iv):Vd:404:l"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140113:AD67 : Completion of Phase III study (CN138-112) for schizophrenia reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AG: Dopamine D2 receptor agonist: Receptor, Transmitter, Dopamine D2 receptor agonist: DA D2 receptor agonist: D2 receptor agonist: Dopamine DA2 receptor agonist: DA DA2 receptor agonist: R-T-DOPA-D2-AG|5HT-1-A-AG: 5 Hydroxytryptamine 1A receptor agonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor agonist: 5HT1A receptor agonist: Serotonin 1A receptor agonist: R-H-5HT-1-A-AG|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IM: Parenteral, intramuscular","P-UN: Parenteral, general"],"Document_MW":["448.40"],"Document_AL":["4.31"],"Document_CASIS-CO_CO":["Originator: Otsuka (JP): Launched","Licensee: Bristol-Myers Squibb (US): Launched","Licensee: Ligand (US): Launched","Licensee: Lundbeck (DK): Launched"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD021321    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"}],"DOCNO":"PH018937","CASIS_COMPOUND":[{"CN":"aripiprazole (solution) CCN=ARIPIPRAZOLE(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Abilify CCN=ABILIFY","SRC_DB":"PHPROJ"},{"CN":"Abilify (tablet) CCN=ABILIFY(TABLET)","SRC_DB":"PHPROJ"},{"CN":"OPC-14597 (tablet) CCN=OPC14597(TABLET)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole CCN=ARIPIPRAZOLE","SRC_DB":"PHPROJ"},{"CN":"Abilify (solution) CCN=ABILIFY(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole (tablet) CCN=ARIPIPRAZOLE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-337039 (tablet) CCN=BMS337039(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilitat (tablet) CCN=ABILITAT(TABLET)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole IM CCN=ARIPIPRAZOLEIM","SRC_DB":"PHPROJ"},{"CN":"Abilify IM CCN=ABILIFYIM","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-01-20 09:32:51","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Attention deficit hyperactivity disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6D","THE_USE":"Cognition enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5D","THE_USE":"Antineurotic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Addiction, alcohol","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AG","THE_USE":"Dopamine D2 receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Post-traumatic stress disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AG","THE_USE":"5 Hydroxytryptamine 1A receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6B","THE_USE":"Psychostimulant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N9A","THE_USE":"Dependence treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Alzheimer's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Tourette's syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 114, 105, 112, 105, 112, 114, 97, 122, 111, 108, 101, 32, 105, 115, 32, 97, 32, 113, 117, 105, 110, 111, 108, 105, 110, 111, 110, 101, 32]...', original message: bytes can be at most 32766 in length; got 36451
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36451
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:44:45,947][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 7gb[6.2%], shards will be relocated away from this node
[2016-06-14 13:45:15,971][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.9gb[6.1%], shards will be relocated away from this node
[2016-06-14 13:45:15,971][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:45:45,997][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.9gb[6.1%], shards will be relocated away from this node
[2016-06-14 13:46:16,022][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.9gb[6.1%], shards will be relocated away from this node
[2016-06-14 13:46:16,022][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:46:46,047][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.8gb[6%], shards will be relocated away from this node
[2016-06-14 13:46:58,379][DEBUG][action.bulk              ] te was well tolerated at doses >500mg/day, and no DLTs were observed. Of the 6 patients who completed the initial 28-day treatment cycle, all experienced a decline in PSA, and 5/6 patients (83%) experienced a >50% decline in PSA (Press release, BTG, 27 Feb 2007).^In a Phase I trial in 14 chemotherapy-naive CRPC patients, despite treatment with LHRH analogues, antiandrogens, diethylstilboestrol and dexamethasone, abiraterone acetate once- daily was well-tolerated at doses up to 2000mg, with no DLTs observed. In 13 patients evaluable for antitumour activity, 9 had a decline in PSA levels of >50% and 6 had a decline of >90%. PR (measured by RECIST) was observed in 5/8 evaluable patients. Individual patients treated with abiraterone acetate experienced radiographic regression of bone metastases and pain reduction. 16/ 18 patients continued treatment, with some receiving abiraterone acetate for >11mth (Press releases, Cougar, 8 Oct and 8 Dec 2006).^In a UK Phase I trial in patients with HRPC, abiraterone acetate was safe and well tolerated and inhibited testosterone generation (Press release, Cougar, 14 Dec 2005).^Preclinical ^In vivo^In male WHT mice, abiraterone acetate 5mmol/kg was rapidly converted to CB-7598, with <5% of prodrug being detected. Dosing ip showed a depot effect with CB-7598 levels of 140ng/ml at 8 and 24hr post-dosing, whereas po dosing gave peak plasma levels of 1512.5ng/ml at 1hr with rapid clearance (terminal t1/2 <3hr). In male Wistar rats, 0.5mmol/kg po was rapidly and almost fully converted to CB-7598, with plasma testosterone reduced to undetectable levels (<0.2nM) within 2hr of dosing and for up to 24hr, and LH levels increased up to 8x within 24hr (85th AACR (San Francisco), 1994, Abs 2507).^Patents^US5604213 and US5618807 have been granted until 2014, and other patent applications have been filed worldwide (Company Web Page, BTG, 1 Aug 2001).^Licensing^Agreements^________________^Boehringer Ingelheim^Worldwide; A licence to Boehringer Ingelheim for development and marketing was discontinued (Direct communication, BTG, 10 Feb 1999).^Johnson and Johnson^Worldwide; it is exclusively licensed to Cougar Biotechnology (Johnson and Johnson) for development and commercialization worldwide (Press release, BTG and Cougar, 20 Apr 2004, http:// www.cougarbiotechnology.com/News/pr_042004.htm).^AstraZeneca; Johnson and Johnson^Japan; co-promotion agreement for the treatment of patients with prostate cancer (Press release, AstraZeneca, 11 Oct 2013, http:// www.astrazeneca.com/Media/Press-releases/Article/20131010- astrazeneca-enters-copromotion-agreement-with-janssen).^Additional Clinical Information^Phase I^In 3 open-label Phase I trials, abiraterone acetate was administered in single or multiple doses of 10-800mg. In a pooled analysis of the 3 trials, AUC, Cmax, Tmax, t1/2alpha and t1/2beta were 0.09-11.66microM/hr, 0.001-1.19microM, 0.16-4hr, 0.05-6.5hr and 12-87hr, respectively. (Br J Cancer, 2004, 90, 2317).^In 2 single-dose clinical studies, castrated and non-castrated prostate cancer patients received abiraterone acetate 10-500mg. 6/ 6 castrated patients had suppression of testosterone to <0.14nM at 500mg. In a multiple-dose study in 6 treatment-experienced prostate cancer patients, abiraterone acetate 500 or 800mg once- daily x12 days suppressed testosterone to castrate levels (<2.0nM). 2/3 patients on 800mg/day had testosterone suppression to levels seen with LHRH agonists (<0.7nM). Treatment was well tolerated with no biochemical or haematological effects (Press releases, Cougar, 25 Oct 2004 and 21 Feb 2005).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140221"],"Document_PK":["Human (10-800mg/m2):AUC:0.09 to 11.66:microMhr","Human (10-800mg/m2):Cmax:0.001 to 1.19:microM","Human (10-800mg/m2):t1/2alpha:0.05 to 6.5:hr","Human (10-800mg/m2):t1/2beta:12 to 87:hr","Human (10-800mg/m2):Tmax:0.16 to 4:hr"],"Document_NC":["Yes"],"Document_RB":["3"],"Document_TF":["1586: Enzyme > EC number > 1.14.99.9;","1586: Enzyme > Hydroxylase;","1586: Enzyme > Oxygenase."],"Document_TG":["1586: cytochrome P450, family 17, subfamily A, polypeptide 1"],"Document_LCH":["20140217:AD151 : Ongoing development of Phase III trial for prostate cancer reported"],"Document_TB":["1586: Enzyme > EC number > 1.14.99.9;","1586: EC number > 1.14.99.9;","1586: Enzyme;","1586: 1.14.99.9;","1586: Enzyme > EC number.","1586: Enzyme > Hydroxylase;","1586: Hydroxylase;","1586: Enzyme.","1586: Enzyme > Oxygenase;","1586: Oxygenase;","1586: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["LY-1720-AN: 17,20 lyase inhibitor: Enzyme, 17,20 lyase inhibitor: Steroid 17alpha-monooxygenase inhibitor: 17alpha hydroxylase inhibitor: 17,20 desmolase inhibitor: CYP17A1 inhibitor: E-LY-1720-AN|SY-STER-AN: Steroid synthesis inhibitor: Physiological, Biochemical, Steroid synthesis inhibitor: P-B-SY-STER-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["391.56"],"Document_AL":["4.13"],"Document_CASIS-CO_CO":["Originator: BTG (GB): Launched","Licensee: Johnson & Johnson (US): Launched","Licensee: AstraZeneca (GB): Pre-registration","Licensee: Boehringer Ingelheim (DE): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD093356    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"}],"DOCNO":"PH021287","CASIS_COMPOUND":[{"CN":"Zytiga CCN=ZYTIGA","SRC_DB":"PHPROJ"},{"CN":"CB-7630 (capsule) CCN=CB7630(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate (tablet) CCN=ABIRATERONEACETATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"abiraterone (capsule) CCN=ABIRATERONE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"abiraterone (tablet) CCN=ABIRATERONE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate (capsule) CCN=ABIRATERONEACETATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CB7630 (capsule) CCN=CB7630(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CB7630 CCN=CB7630","SRC_DB":"PHPROJ"},{"CN":"CB-7630 (tablet) CCN=CB7630(TABLET)","SRC_DB":"PHPROJ"},{"CN":"JNJ 212082 CCN=JNJ212082","SRC_DB":"PHPROJ"},{"CN":"JNJ-212082 CCN=JNJ212082","SRC_DB":"PHPROJ"},{"CN":"CB7630 (tablet) CCN=CB7630(TABLET)","SRC_DB":"PHPROJ"},{"CN":"abiraterone (oral suspension) CCN=ABIRATERONE(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate (oral suspension) CCN=ABIRATERONEACETATE(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"CB-7630 CCN=CB7630","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate CCN=ABIRATERONEACETATE","SRC_DB":"PHPROJ"},{"CN":"abiraterone CCN=ABIRATERONE","SRC_DB":"PHPROJ"},{"CN":"CB-7598 CCN=CB7598","SRC_DB":"PHPROJ"},{"CN":"JNJ-589485 CCN=JNJ589485","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-25 16:28:19","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C3","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"LY-1720-AN","THE_USE":"17,20 lyase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K2","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"SY-STER-AN","THE_USE":"Steroid synthesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 98, 105, 114, 97, 116, 101, 114, 111, 110, 101, 32, 97, 99, 101, 116, 97, 116, 101, 32, 40, 67, 66, 45, 55, 54, 51, 48, 41, 32]...', original message: bytes can be at most 32766 in length; got 43245
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 43245
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:46:58,971][DEBUG][action.bulk              ] virenz 50mg and the multiple dose efavirenz 600mg on Cyp 3A4 and the pharmacokinetics of faldaprevir (ClinicalTrials.gov, 26 Aug 2011, http://clinicaltrials.gov/show/ NCT01371006).^Enrollment is complete in an open-label, non-randomized, single- group assignment US Phase I drug interaction trial (1220.50) in 16 healthy male and female volunteers to assess the effect of multiple dosing with faldaprevir 240mg bid on the steady state pharmacokinetics of tenofovir 300mg once-daily pharmacokinetics (ClinicalTrials.gov, 20 Jun 2011, http://clinicaltrials.gov/show/ NCT01340196).^Infection, hepatitis-C virus^Enrollment is complete in a multicentre, randomized, open-label, parallel-group Phase I trial (1241.27) in Canada, Germany and the US, in 102 treatment-naive patients and treatment relapsed patients with HCV genotype 1 infection, to evaluate the pharmacokinetic interactions between BI-207127 600mg tid and faldaprevir 120mg once-daily in combination with ribavirin x24wk, and their combined effect on the pharmacokinetics of tenofovir, caffeine, tolbutamide and midazolam (ClinicalTrials.gov, 18 Feb and 7 May 2012 and 24 Jan 2014, http://clinicaltrials.gov/show/ NCT01525628). Preliminary bioanalytical results from an addition of deleobuvir increased faldaprevir plasma concentrations and addition of faldaprevir increased deleobuvir plasma concentrations. After 8wk of combined treatment, faldaprevir concentrations approximated to those observed prior to deleobuvir dosing, while DBV concentrations remained elevated. Pharmacokinetic analysis of CYP probe data is limited to CYP2C9 and CYP3A4, and suggests weak induction of CYP2C9 (64th AASLD (Washington), 2013, Abs 1083, http:// aasld2013.abstractcentral.com/s1agxt/com.scholarone.s1agxt.s1agxt/^^A 2-part Phase I trial in 264 patients with chronic genotype 1 HCV, to investigate safety, efficacy and pharmacokinetics has been completed. The 1st part was a double-blind, randomized trial, in which treatment-naive patients received multiple escalating doses of faldaprevir po x14 days followed by faldaprevir + Pegasys (PEG-interferon alpha-2a, Roche; qv) x14 days. The 2nd part was an open-label trial in which treatment-experienced patients received faldaprevir + Pegasys + ribavirin x28 days. Results are expected in Apr 2011 (ClinicalTrials.gov Web Page, 11 Jan 2010, NCT00793793).^A 24wk trial in naive patients with Type 1 HCV to assess the efficacy, safety and pharmacoepidemiology has been approved by the S Korean FDA (Pharma Koreana, 16 Jan 2009).^In a completed Phase I trial in patients receiving 40-240mg once- daily x12-28 days, it was well tolerated and had a steady-state t1/2 of 22.3-30.9hr.^Preclinical ^In vivo^In rat, monkey and dog models, it showed a good ADME profile. In rats, it showed favorable drug distribution to the target organ (Antimicrob Agents Chemother, Nov 2010, 54, 4611, PMID:20823284, http://www.ncbi.nlm.nih.gov/pubmed/20823284).^In vitro^In vitro, BI-201335 showed a good ADME profile and had good permeability in Caco-2 cell assays, with an EC50 of 6.5 and 3.1nM in genotype 1a and 1b replicon assays (Antimicrob Agents Chemother, Nov 2010, 54, 4611, PMID:20823284, http:// www.ncbi.nlm.nih.gov/pubmed/20823284).^Licensing^Agreements^________________^Presidio^Worldwide; Presidio has a non-exclusive collaboration with Boehringer Ingelheim for a Phase IIa trial of an oral interferon- free, direct-acting antiviral (DAA) combination treatment for patients with chronic HCV infection. The trial will evaluate PPI- 668 in combination with faldaprevir and BI-207127 (Press release, Presidio, 12 Mar 2013, http://presidiopharma.files.wordpress.com/ 2013/03/presidio-pharmaceuticals-announces-collaboration-with- boehringer-ingelheim-press-release-march-12-2013.pdf).^"],"Document_HA":["12"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (20-240mg/day):t1/2:26.6:hr"],"Document_NC":["Yes"],"Document_RB":["20"],"Document_TF":["951475: Enzyme > Polymerase;","951475: Enzyme > Protease/peptidase."],"Document_TG":["951475: polyprotein, hepatitis-C virus"],"Document_LCH":["20140310:PT : Addtional results of Phase III trial (STARTVerso 4), enrollment completion in Phase II trial (1241.30) and acceptance of US NDA filing reported"],"Document_TB":["951475: Enzyme > Polymerase;","951475: Polymerase;","951475: Enzyme.","951475: Enzyme > Protease/peptidase;","951475: Protease/peptidase;","951475: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PR-NS3-AN: HCV NS3 protease inhibitor: Enzyme, Hydrolase, HCV NS3 protease inhibitor: NS3-4A protease inhibitor: Protease inhibitor, NS3: HCV NS3 serine protease inhibitor: E-HY-PR-NS3-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["870.85"],"Document_AL":["5.12"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Pre-registration"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Pre-registration"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH047429","CASIS_COMPOUND":[{"CN":"BI 1335 CCN=BI1335","SRC_DB":"PHPROJ"},{"CN":"BI 201335 (solution) CCN=BI201335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"faldaprevir  CCN=FALDAPREVIR","SRC_DB":"PHPROJ"},{"CN":"BI-201335 NA (solution) CCN=BI201335NA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI 1335 (solution) CCN=BI1335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 NA (capsule) CCN=BI201335NA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-1335 (capsule) CCN=BI1335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 (capsule) CCN=BI201335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 NA (capsule) CCN=BI201335NA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"faldaprevir CCN=FALDAPREVIR","SRC_DB":"PHPROJ"},{"CN":"BI 201335 (capsule) CCN=BI201335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"faldaprevir (capsule) CCN=FALDAPREVIR(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-1335 CCN=BI1335","SRC_DB":"PHPROJ"},{"CN":"BI-1335 (solution) CCN=BI1335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI201335 CCN=BI201335","SRC_DB":"PHPROJ"},{"CN":"BI-201335 NA CCN=BI201335NA","SRC_DB":"PHPROJ"},{"CN":"BI-201335 (solution) CCN=BI201335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 CCN=BI201335","SRC_DB":"PHPROJ"},{"CN":"BI201335 (solution) CCN=BI201335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI201335 (capsule) CCN=BI201335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 CCN=BI201335","SRC_DB":"PHPROJ"},{"CN":"BI 201335 NA CCN=BI201335NA","SRC_DB":"PHPROJ"},{"CN":"BI 1335 (capsule) CCN=BI1335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 NA (solution) CCN=BI201335NA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"faldaprevir (solution) CCN=FALDAPREVIR(SOLUTION)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:44","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"PR","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J5Z","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"PR-NS3-AN","THE_USE":"HCV NS3 protease inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[70, 97, 108, 100, 97, 112, 114, 101, 118, 105, 114, 32, 40, 66, 73, 45, 50, 48, 49, 51, 51, 53, 41, 32, 105, 115, 32, 97, 32, 115]...', original message: bytes can be at most 32766 in length; got 40744
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40744
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:47:16,100][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.8gb[6%], shards will be relocated away from this node
[2016-06-14 13:47:16,117][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:47:46,144][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.5gb[5.8%], shards will be relocated away from this node
[2016-06-14 13:48:16,170][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.6gb[5.9%], shards will be relocated away from this node
[2016-06-14 13:48:16,170][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:48:46,195][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.6gb[5.8%], shards will be relocated away from this node
[2016-06-14 13:49:16,223][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.6gb[5.8%], shards will be relocated away from this node
[2016-06-14 13:49:16,223][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:49:46,248][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.5gb[5.8%], shards will be relocated away from this node
[2016-06-14 13:50:16,274][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.5gb[5.8%], shards will be relocated away from this node
[2016-06-14 13:50:16,274][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:50:46,372][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.4gb[5.7%], shards will be relocated away from this node
[2016-06-14 13:51:16,472][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6.2gb[5.5%], shards will be relocated away from this node
[2016-06-14 13:51:16,472][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:51:46,502][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6gb[5.3%], shards will be relocated away from this node
[2016-06-14 13:52:16,540][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6gb[5.3%], shards will be relocated away from this node
[2016-06-14 13:52:16,549][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:52:27,928][DEBUG][action.bulk              ] PP, 15 Nov 2005).^Additional Clinical Information^Phase II^In a US Phase I/II trial in 41 chemotherapy-naive advanced nsclc patients to determine the MTD and DLTs and evaluate safety and antitumour activity of iv 1x/wk administration, preliminary results showed 1CR, 7 confirmed PRs and 4PRs awaiting confirmation. The study was to be expanded into a Phase II efficacy study (Press releases, APP, 25 Feb 2004 and 3 Nov 2005).^In 2 open-label Phase II trials in metastatic breast cancer patients without steroid pretreatment, ABI-007 175 and 300mg/m2 iv q 21 days gave overall response rates of 51 and 61%, respectively. It was well tolerated (38th ASCO (Orlando), 2002, Abs 209).^In a Phase II trial in 106 patients with progressive metastatic breast cancer whose disease had progressed on standard paclitaxel or docetaxel, ABI-007 1x/wk gave a 15% overall response rate. Probability of survival at 12mth was 38%. The proportion of patients free of disease progression was 40 and 30% at 4 and 6mth, respectively. Response rates were 24 and 16% in patients who had failed on paclitaxel and docetaxel alone, respectively (Scrip's Target Daily Online, 7 Jun 2004, W00846222).^It is in an open-label, non-randomized Phase II trial in 70 patients with locally-advanced or metastatic breast cancer, receiving ABI-007 125mg/m2 30min iv infusion q wk x3 in 4wk cycles in combination with trastuzumab (qv). The primary endpoint is response rate and secondary endpoints are TTP, overall survival and toxicities (Press release, APP, 4 Apr 2005).^In an open-label Phase II trial in early-stage breast cancer patients, ABI-007 260mg/m2 q 2wk x4, administered as adjuvant therapy following doxorubicin + cyclophosphamide, was well tolerated (Press releases, APP, 3 May and 9 Dec 2005).^Phase I^In a randomized Phase I trial in 23 patients with de novo lesions in native coronary arteries, ABI-007 10-100mg/m2 iv following stenting resulted in some trends in efficacy, and there were no significant AEs in patients receiving <70mg/m2. Further trials to determine efficacy in coronary restenosis were conducted (Press release, APP, 5 Apr 2005).^"],"Document_HA":["14"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (260mg/m2):Cl:15:l/hr/m2","Human (260mg/m2):Vd:632:l/m2","Human (80-375mg/m2):t1/2:27:hr","Animal (20mg/kg):Cmax:328:ng/ml","Animal (20mg/kg):AUC:656:nCi/hr/ml"],"Document_NC":["No"],"Document_RB":["18"],"Document_TG":["203068: tubulin, beta class I"],"Document_LCH":["20140314:AD283 : Initiation of Phase II trial (PANC-001) for pancreatic cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["TAX-AG: Taxane: Physiological, Biochemical, Taxane: Taxane anticancer drug: Paclitaxel-type anticancer: P-B-TAX-AG|TUBE-B-AN: Beta tubulin antagonist: Physiological, Biochemical, Beta tubulin antagonist: Beta tubulin binding agent: P-B-TUBE-B-AN|MICTUBE-AG: Microtubule stimulant: Physiological, Biochemical, Microtubule stimulant: Antineoplastic e.g. taxol: P-B-MICTUBE-AG|"],"Document_ROUT":["P-IP: Parenteral, intraperitoneal","P-IV: Parenteral, intravenous","P-UN: Parenteral, general","P-VE: Parenteral, intravesical"],"Document_MW":["853.93"],"Document_AL":["3.96"],"Document_CASIS-CO_CO":["Originator: Celgene (US): Launched","Licensee: Biocon (IN): Launched","Licensee: Taiho (JP): Launched","Licensee: Specialised Therapeutics (AU): Launched","Licensee: Green Cross (KR): Registered","Licensee: AstraZeneca (GB): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD087473    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["3:Speed Rating - Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH033757","CASIS_COMPOUND":[{"CN":"ABI-007 (IV) CCN=ABI007(IV)","SRC_DB":"PHPROJ"},{"CN":"Abraxane (Intraperitoneal) CCN=ABRAXANE(INTRAPERITONEAL)","SRC_DB":"PHPROJ"},{"CN":"albumin-bound paclitaxel (IV) CCN=ALBUMINBOUNDPACLITAXEL(IV)","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel (IV) CCN=NABPACLITAXEL(IV)","SRC_DB":"PHPROJ"},{"CN":"Coroxane CCN=COROXANE","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel (Intraperitoneal) CCN=NABPACLITAXEL(INTRAPERITONEAL)","SRC_DB":"PHPROJ"},{"CN":"paclitaxel, American BioScience (IV) CCN=PACLITAXELAMERICANBIOSCIENCE(IV)","SRC_DB":"PHPROJ"},{"CN":"Abraxane (intravesical) CCN=ABRAXANE(INTRAVESICAL)","SRC_DB":"PHPROJ"},{"CN":"Abraxane (IV) CCN=ABRAXANE(IV)","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel CCN=NABPACLITAXEL","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel (intravesical) CCN=NABPACLITAXEL(INTRAVESICAL)","SRC_DB":"PHPROJ"},{"CN":"Abraxane CCN=ABRAXANE","SRC_DB":"PHPROJ"},{"CN":"Capxol CCN=CAPXOL","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Restenosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K5A","THE_USE":"Radio-chemosensitizer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, neuroblastoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"TAX-AG","THE_USE":"Taxane","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"TUBE-B-AN","THE_USE":"Beta tubulin antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"MICTUBE-AG","THE_USE":"Microtubule stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, sarcoma, rhabdomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"F3A2","THE_USE":"Reformulation","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 66, 73, 45, 48, 48, 55, 32, 40, 65, 98, 114, 97, 120, 97, 110, 101, 41, 32, 105, 115, 32, 97, 110, 32, 97, 108, 98, 117, 109]...', original message: bytes can be at most 32766 in length; got 38457
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 38457
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:52:28,095][DEBUG][action.bulk              ] nconova, 8 Jul 2011, http://www.onconova.com/pdfs/ pressreleases/20110708_Onconova_SymBio%20PressRelease.pdf).^The Leukemia and Lymphoma Society (LLS)^USA; Onconova is collaborating to advance clinical development of ON-01910.Na for MDS (Press release, Onconova, 1 Jun 2010, http:// www.onconova.com/pdfs/pressreleases/ 20100601_LLS_Onconova_PressRelease.pdf)^Availability^________________^Worldwide; Onconova will seek partners after Phase II trials (Company Web Page, Onconova, 2 Jan 2009).^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Rat (10microgram/ml):AUC:290:microgmin/ml","Rat (10microgram/ml):Cl:2.91:ml/min","Rat (10microgram/ml):Cmax:11.3:microg/ml","Rat (100microgram/ml):AUC:4010:microgmin/ml","Rat (100microgram/ml):Cl:2.08:ml/min","Rat (100microgram/ml):Cmax:106:microg/ml","Rat (250microgram/ml):AUC:21100:microgmin/ml","Rat (250microgram/ml):Cl:0.959:ml/min","Rat (250microgram/ml):Cmax:257:microg/ml","Rat (50microgram/ml):AUC:1480:microgmin/ml","Rat (50microgram/ml):Cl:2.71:ml/min","Rat (50microgram/ml):Cmax:56.1:microg/ml","Human (80-4370mg):Vd:58:l","Human (80-4370mg):t1/2:20:hr","Human (80-4370mg):Cl:13:l/hr","Human (80-4370mg):t1/2beta:27:hr","Human (800-1800mg/m2/day):t1/2:1.3:hr"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TF":["5347: Enzyme > EC number > 2.7.11.21;","5347: Enzyme > Kinase."],"Document_TG":["5347: polo-like kinase 1","4170: myeloid cell leukaemia sequence 1 (BCL2-related)"],"Document_LCH":["20140312:PP236 : Pivotal trial plans and details of Phase I/II (09-08) trial for myelodysplastic syndrome reported"],"Document_TB":["5347: Enzyme > EC number > 2.7.11.21;","5347: EC number > 2.7.11.21;","5347: Enzyme;","5347: 2.7.11.21;","5347: Enzyme > EC number.","5347: Enzyme > Kinase;","5347: Kinase;","5347: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-PLK-1-AN: Polo-like kinase 1 inhibitor: Enzyme, Transferase, Pololike kinase 1 inhibitor: PLK1 inhibitor: E-TR-KI-PLK-1-AN|CELL-CY-AN: Cell cycle inhibitor: Physiological, Biochemical, Cell cycle inhibitor: P-B-CELL-CY-AN|KI-PR-AN: Protein kinase inhibitor: Enzyme, Transferase, Protein kinase inhibitor: E-TR-KI-PR-AN|MCL-1-AN: Mcl-1 antagonist: Physiological, Biochemical, M: P-B-MCL1-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["450.49"],"Document_AL":["2.72"],"Document_CASIS-CO_CO":["Originator: Onconova (US): Phase III Clinical Trial","Licensee: Baxter International (US): Phase III Clinical Trial","Licensee: SymBio Pharmaceuticals (JP): Phase I Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["3:Speed Rating - Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Preclinical Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"}],"DOCNO":"PH034170","CASIS_COMPOUND":[{"CN":"ESTYBON CCN=ESTYBON","SRC_DB":"PHPROJ"},{"CN":"ON 01910 (IV) CCN=ON01910(IV)","SRC_DB":"PHPROJ"},{"CN":"SyB 1101 CCN=SYB1101","SRC_DB":"PHPROJ"},{"CN":"rigosertib sodium CCN=RIGOSERTIBSODIUM","SRC_DB":"PHPROJ"},{"CN":"Novonex (oral) CCN=NOVONEX(ORAL)","SRC_DB":"PHPROJ"},{"CN":"rigosertib (oral) CCN=RIGOSERTIB(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON-01910 (IV) CCN=ON01910(IV)","SRC_DB":"PHPROJ"},{"CN":"ON-01910.Na (IV) CCN=ON01910.NA(IV)","SRC_DB":"PHPROJ"},{"CN":"SyB C-1101 CCN=SYBC1101","SRC_DB":"PHPROJ"},{"CN":"ON-01910 CCN=ON01910","SRC_DB":"PHPROJ"},{"CN":"Novonex (IV) CCN=NOVONEX(IV)","SRC_DB":"PHPROJ"},{"CN":"ON-01910.NA (oral) CCN=ON01910.NA(ORAL)","SRC_DB":"PHPROJ"},{"CN":"SyB L-1101 CCN=SYBL1101","SRC_DB":"PHPROJ"},{"CN":"SyB 1101 (IV) CCN=SYB1101(IV)","SRC_DB":"PHPROJ"},{"CN":"Product A, Onconova CCN=PRODUCTAONCONOVA","SRC_DB":"PHPROJ"},{"CN":"ON-01910 (oral) CCN=ON01910(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON 01910.Na (IV) CCN=ON01910.NA(IV)","SRC_DB":"PHPROJ"},{"CN":"rigosertib CCN=RIGOSERTIB","SRC_DB":"PHPROJ"},{"CN":"ON-01910.Na CCN=ON01910.NA","SRC_DB":"PHPROJ"},{"CN":"SyB 1101 (oral) CCN=SYB1101(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON 01910 (oral) CCN=ON01910(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON 01910.Na (oral) CCN=ON01910.NA(ORAL)","SRC_DB":"PHPROJ"},{"CN":"rigosertib (IV) CCN=RIGOSERTIB(IV)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, anal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, sarcoma, leiomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, haematological, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, lymphoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"MCL-1-AN","THE_USE":"Mcl-1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, skin, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PLK-1-AN","THE_USE":"Polo-like kinase 1 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"CELL-CY-AN","THE_USE":"Cell cycle inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-AN","THE_USE":"Protein kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 105, 103, 111, 115, 101, 114, 116, 105, 98, 32, 40, 79, 78, 45, 48, 49, 57, 49, 48, 59, 32, 69, 83, 84, 89, 66, 79, 78, 41]...', original message: bytes can be at most 32766 in length; got 36383
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36383
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:52:28,490][DEBUG][action.bulk              ] 321: Enzyme > Kinase;","2321: Kinase;","2321: Enzyme.","2321: Receptor;","3791: Enzyme > Kinase;","3791: Kinase;","3791: Enzyme.","3791: Receptor;","2324: Enzyme > EC number > 2.7.10.1;","2324: EC number > 2.7.10.1;","2324: Enzyme;","2324: 2.7.10.1;","2324: Enzyme > EC number.","2324: Enzyme > Kinase;","2324: Kinase;","2324: Enzyme.","2324: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-GFEN-AN: VEGFR tyrosine kinase inhibitor: Enzyme, Transferase, VEGFR tyrosine kinase inhibitor: Vascular endothelial growth factor receptor TK inhibitor: E-TR-KI-GFEN-AN|KI-FLT3-AN: Flt-3 kinase inhibitor: Enzyme, Transferase, Flt3 kinase inhibitor: E-TR-KI-FLT3-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|COLSF-R1-AN: Colony stimulating factor 1 receptor antagonist: Physiological, Hormonal, Colony stimulating factor 1 receptor antagonist: macrophage colony-stimulating factor receptor antagonist: c-FMS antagonist: CSF-1R antagonist: P-H-COLSF-R1-AN|GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|KI-TY-RET-AN: RET tyrosine kinase inhibitor: Enzyme, Transferase, KITYREnzyme: E-TR-KI-TY-RE-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|KI-GFEN1-AN: VEGFR-1 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 1 tyrosine kinase inhibitor: Flt-1 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 1 TK inhibitor: E-TR-KI-GFEN1-AN|KI-GFEN2-AN: VEGFR-2 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 2 tyrosine kinase inhibitor: KDR tyrosine kinase inhibitor: Flk-1 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 2 TK inhibitor: E-TR-KI-GFEN2-AN|KI-GFEN3-AN: VEGFR-3 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 3 tyrosine kinase inhibitor: Flt-4 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 3 TK inhibitor: E-TR-KI-GFEN3-AN|KI-GFPLB-AN: Platelet-derived growth factor receptor beta kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor beta kinase inhib: PDGF beta kinase inhibitor: PDGF receptor beta kinase inhibitor: Platelet-derived growth factor beta kinase inhibitor: E-TR-KI-GFPLB-AN|KI-GFPLA-AN: Platelet-derived growth factor receptor alpha kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor alpha kinase inhib: PDGF alpha kinase inhibitor: PDGF receptor alpha kinase inhibitor: Platelet-derived growth factor alpha kinase inhibitor: E-TR-KI-GFPLA-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["398.48"],"Document_AL":["2.14"],"Document_CASIS-CO_CO":["Originator: Pfizer (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD359471    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"}],"DOCNO":"PH033858","CASIS_COMPOUND":[{"CN":"SUO11248 CCN=SUO11248","SRC_DB":"PHPROJ"},{"CN":"Sutent CCN=SUTENT","SRC_DB":"PHPROJ"},{"CN":"sunitinib malate CCN=SUNITINIBMALATE","SRC_DB":"PHPROJ"},{"CN":"PHA-290940AD CCN=PHA290940AD","SRC_DB":"PHPROJ"},{"CN":"Sutene CCN=SUTENE","SRC_DB":"PHPROJ"},{"CN":"SU-11248 CCN=SU11248","SRC_DB":"PHPROJ"},{"CN":"SU-010398 CCN=SU010398","SRC_DB":"PHPROJ"},{"CN":"SU11248 CCN=SU11248","SRC_DB":"PHPROJ"},{"CN":"sunitinib CCN=SUNITINIB","SRC_DB":"PHPROJ"},{"CN":"SU-011248 CCN=SU011248","SRC_DB":"PHPROJ"},{"CN":"SU011248  CCN=SU011248","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"COLSF-R1-AN","THE_USE":"Colony stimulating factor 1 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, neuroendocrine, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN3-AN","THE_USE":"VEGFR-3 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLB-AN","THE_USE":"Platelet-derived growth factor receptor beta kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-FLT3-AN","THE_USE":"Flt-3 kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN2-AN","THE_USE":"VEGFR-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN1-AN","THE_USE":"VEGFR-1 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-RET-AN","THE_USE":"RET tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN-AN","THE_USE":"VEGFR tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLA-AN","THE_USE":"Platelet-derived growth factor receptor alpha kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[83, 117, 110, 105, 116, 105, 110, 105, 98, 32, 109, 97, 108, 97, 116, 101, 32, 105, 115, 32, 97, 110, 32, 111, 114, 97, 108, 32, 115, 109]...', original message: bytes can be at most 32766 in length; got 36800
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36800
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:52:46,575][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.9gb[5.2%], shards will be relocated away from this node
[2016-06-14 13:52:47,407][DEBUG][action.bulk              ]  B cell activation following BCR stimulation by anti-IgM with an EC50 of 2nM while failing to inhibit T cell activation at concentrations up to 2000nM. (74th ACR (Atlanta), 2010, Abs 286, http://files.shareholder.com/downloads/PCYC/1103738875x0x429590/ C0E5B262-533F-44F2-AF45-9812C7467245/ACR2010_PCI- 45292_Btk_poster_final.pdf).^In human whole blood basophils, both ibrutinib and PCI-45292 inhibited anti-IgE mediated upregulation of CD63 with an EC50 of 20-100nM (74th ACR (Atlanta), 2010, Abs 286, http:// files.shareholder.com/downloads/PCYC/1103738875x0x429590/C0E5B262- 533F-44F2-AF45-9812C7467245/ACR2010_PCI- 45292_Btk_poster_final.pdf).^In human liver microsomes, the half-life of ibrutinib was 2.5min compared to 19.2min for PCI-45292 (74th ACR (Atlanta), 2010, Abs 286, http://files.shareholder.com/downloads/PCYC/ 1103738875x0x429590/C0E5B262-533F-44F2-AF45-9812C7467245/ ACR2010_PCI-45292_Btk_poster_final.pdf).^In human B-cell BCR-expressing lymphoma cell lines, ibrutinib inhibited tumour growth by inhibiting BCR signalling. A 1hr pulse of ibrutinib inhibited B-cell activation for 18hr. It prevented mast cell activation in vitro (Press release, Pharmacyclics, 10 Dec 2007; Form 424-B4, Pharmacyclics, 17 Jul 2009).^In in vitro B-cell lymphoma models, ibrutinib blocked B-cell receptor (BCR)-mediated signalling (Press release, Pharmacyclis, 14 Apr 2008).^Patents^The patent for ibrutinib expires at the end of 2026 in Europe, Japan and the US (Scrip Intelligence, 21 Mar 2013, http:// www.scripintelligence.com/home/STOCKWATCH-Cycles-and-irrational- valuations-341375).^It has issued and pending patents with protection until 2029 (JP Morgan 30th Ann Healthcare Conf (San Francisco), 2012, Slide 33 of 35, http://jpmorgan.metameetings.com/webcasts/healthcare12/ webcast_ow.php?p=8873).^US8088781, covering an inhibited tyrosine kinase comprising an irreversible BTK inhibitor having a covalent bond to a cysteine residue of a Bruton's tyrosine kinase (BTK) has been issued (Press release, Pharmacyclics, 19 Dec 2011, http:// ir.pharmacyclics.com//ReleaseDetail.cfm?ReleaseID=634117).^PCT applications have been filed for methods, uses and composition of ibrutinib. A US patent covering methods, uses and composition of ibrutinib has been issued. It has global patent protection untill Dec 2026 (Form 424-B4, Pharmacyclics, 17 Jul 2009; Invest presentation, Pharmacyclics, Jul 2009).^Licensing^Agreements^________________^Janssen Biotech (Johnson and Johnson (JandJ)).^Worldwide; worldwide collaboration to develop and commercialize ibrutinib. Under the terms of the agreement, Pharmacyclics will receive an upfront payment and will receive additional development and regulatory milestone payments. Pharmacyclics and Janssen will collaborate on the development of ibrutinib for oncology and other indications, excluding inflammation and immune mediated conditions. Each company will lead development for specific indications as stipulated in a global development plan, with development costs shared on a 40/60 basis. The agreement includes plans to launch multiple Phase III trials of ibrutinib over the next several years. Following regulatory approval, both Pharmacyclics and Janssen will book revenue and co-commercialize ibrutinib. In the US, Pharmacyclics will book sales and take a lead role in US commercial strategy development and both Pharmacyclics and Janssen will share in commercialization activities. Outside the US, Janssen will book sales and lead and perform commercialization activities (Press release, Pharmacyclics, 8 Dec 2011, http://ir.pharmacyclics.com/ releasedetail.cfm?ReleaseID=631854).^National Cancer Institute^USA; Pharmacyclics has a 5yr cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI) to develop ibrutinib for the treatment of haematologic malignancies. Under the terms of agreement, NCI plans to sponsor Phase I and Phase II trials of PCI-32765 in various haematologic malignancies, including NHL and multiple myeloma (Press release, Pharmacyclics, 9 Aug 2011, http://ir.pharmacyclics.com// ReleaseDetail.cfm?ReleaseID=598143).^Qualifying Therapeutic Discovery Project^USA; Pharmacyclics received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) for the development of ibrutinib (IRS.gov Web Page, 13 Jan 2011, http:// www.irs.gov/businesses/small/article/0,,id=229024,00.html).^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["Yes"],"Document_RB":["6"],"Document_TF":["695: Enzyme > EC number > 2.7.10.1;","695: Enzyme > Kinase."],"Document_TG":["695: Bruton agammaglobulinaemia tyrosine kinase"],"Document_LCH":["20140314:AD283 : Enrollment completion in Phase II trial (PCYC- 1106-CA) for B-cell lymphoma reported"],"Document_TB":["695: Enzyme > EC number > 2.7.10.1;","695: EC number > 2.7.10.1;","695: Enzyme;","695: 2.7.10.1;","695: Enzyme > EC number.","695: Enzyme > Kinase;","695: Kinase;","695: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-TY-BTK-AN: Bruton's tyrosine kinase inhibitor: Enzyme, Transferase, KITYBTransmitter: Btk kinase inhibitor: E-TR-KI-TY-BT-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["440.51"],"Document_AL":["3.93"],"Document_CASIS-CO_CO":["Originator: Pharmacyclics (US): Launched","Licensee: Johnson & Johnson (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"}],"DOCNO":"PH046621","CASIS_COMPOUND":[{"CN":"PCI-32765 CCN=PCI32765","SRC_DB":"PHPROJ"},{"CN":"PCI32765 CCN=PCI32765","SRC_DB":"PHPROJ"},{"CN":"PCI 32765 CCN=PCI32765","SRC_DB":"PHPROJ"},{"CN":"ibrutinib CCN=IBRUTINIB","SRC_DB":"PHPROJ"},{"CN":"Imbruvica CCN=IMBRUVICA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:44","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Arthritis, rheumatoid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-BTK-AN","THE_USE":"Bruton's tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, B-cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Rhinitis, allergic, seasonal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"I5","THE_USE":"Immunosuppressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lymphoma, non-Hodgkin's","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, myeloma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"M2C","THE_USE":"Antiarthritic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"R8B","THE_USE":"Antiallergic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Lupus erythematosus, systemic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Waldenstrom's hypergammaglobulinaemia","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 98, 114, 117, 116, 105, 110, 105, 98, 32, 40, 80, 67, 73, 45, 51, 50, 55, 54, 53, 41, 32, 105, 115, 32, 97, 110, 32, 111, 114]...', original message: bytes can be at most 32766 in length; got 64870
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 64870
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:52:57,957][DEBUG][action.bulk              ] nconova, 8 Jul 2011, http://www.onconova.com/pdfs/ pressreleases/20110708_Onconova_SymBio%20PressRelease.pdf).^The Leukemia and Lymphoma Society (LLS)^USA; Onconova is collaborating to advance clinical development of ON-01910.Na for MDS (Press release, Onconova, 1 Jun 2010, http:// www.onconova.com/pdfs/pressreleases/ 20100601_LLS_Onconova_PressRelease.pdf)^Availability^________________^Worldwide; Onconova will seek partners after Phase II trials (Company Web Page, Onconova, 2 Jan 2009).^"],"Document_HA":["8"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Rat (10microgram/ml):AUC:290:microgmin/ml","Rat (10microgram/ml):Cl:2.91:ml/min","Rat (10microgram/ml):Cmax:11.3:microg/ml","Rat (100microgram/ml):AUC:4010:microgmin/ml","Rat (100microgram/ml):Cl:2.08:ml/min","Rat (100microgram/ml):Cmax:106:microg/ml","Rat (250microgram/ml):AUC:21100:microgmin/ml","Rat (250microgram/ml):Cl:0.959:ml/min","Rat (250microgram/ml):Cmax:257:microg/ml","Rat (50microgram/ml):AUC:1480:microgmin/ml","Rat (50microgram/ml):Cl:2.71:ml/min","Rat (50microgram/ml):Cmax:56.1:microg/ml","Human (80-4370mg):Vd:58:l","Human (80-4370mg):t1/2:20:hr","Human (80-4370mg):Cl:13:l/hr","Human (80-4370mg):t1/2beta:27:hr","Human (800-1800mg/m2/day):t1/2:1.3:hr"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TF":["5347: Enzyme > EC number > 2.7.11.21;","5347: Enzyme > Kinase."],"Document_TG":["5347: polo-like kinase 1","4170: myeloid cell leukaemia sequence 1 (BCL2-related)"],"Document_LCH":["20140312:PP236 : Pivotal trial plans and details of Phase I/II (09-08) trial for myelodysplastic syndrome reported"],"Document_TB":["5347: Enzyme > EC number > 2.7.11.21;","5347: EC number > 2.7.11.21;","5347: Enzyme;","5347: 2.7.11.21;","5347: Enzyme > EC number.","5347: Enzyme > Kinase;","5347: Kinase;","5347: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-PLK-1-AN: Polo-like kinase 1 inhibitor: Enzyme, Transferase, Pololike kinase 1 inhibitor: PLK1 inhibitor: E-TR-KI-PLK-1-AN|CELL-CY-AN: Cell cycle inhibitor: Physiological, Biochemical, Cell cycle inhibitor: P-B-CELL-CY-AN|KI-PR-AN: Protein kinase inhibitor: Enzyme, Transferase, Protein kinase inhibitor: E-TR-KI-PR-AN|MCL-1-AN: Mcl-1 antagonist: Physiological, Biochemical, M: P-B-MCL1-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["450.49"],"Document_AL":["2.72"],"Document_CASIS-CO_CO":["Originator: Onconova (US): Phase III Clinical Trial","Licensee: Baxter International (US): Phase III Clinical Trial","Licensee: SymBio Pharmaceuticals (JP): Phase I Clinical Trial"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001","MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["3:Speed Rating - Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Preclinical Not Available for Licensing"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Available for Licensing in the Future"}],"DOCNO":"PH034170","CASIS_COMPOUND":[{"CN":"ON 01910.Na (IV) CCN=ON01910.NA(IV)","SRC_DB":"PHPROJ"},{"CN":"rigosertib (IV) CCN=RIGOSERTIB(IV)","SRC_DB":"PHPROJ"},{"CN":"Novonex (IV) CCN=NOVONEX(IV)","SRC_DB":"PHPROJ"},{"CN":"SyB 1101 (IV) CCN=SYB1101(IV)","SRC_DB":"PHPROJ"},{"CN":"Novonex (oral) CCN=NOVONEX(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON-01910 (IV) CCN=ON01910(IV)","SRC_DB":"PHPROJ"},{"CN":"rigosertib sodium CCN=RIGOSERTIBSODIUM","SRC_DB":"PHPROJ"},{"CN":"ON 01910.Na (oral) CCN=ON01910.NA(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON-01910.Na (IV) CCN=ON01910.NA(IV)","SRC_DB":"PHPROJ"},{"CN":"ON-01910 CCN=ON01910","SRC_DB":"PHPROJ"},{"CN":"SyB L-1101 CCN=SYBL1101","SRC_DB":"PHPROJ"},{"CN":"rigosertib CCN=RIGOSERTIB","SRC_DB":"PHPROJ"},{"CN":"SyB 1101 (oral) CCN=SYB1101(ORAL)","SRC_DB":"PHPROJ"},{"CN":"SyB 1101 CCN=SYB1101","SRC_DB":"PHPROJ"},{"CN":"ESTYBON CCN=ESTYBON","SRC_DB":"PHPROJ"},{"CN":"SyB C-1101 CCN=SYBC1101","SRC_DB":"PHPROJ"},{"CN":"ON 01910 (oral) CCN=ON01910(ORAL)","SRC_DB":"PHPROJ"},{"CN":"rigosertib (oral) CCN=RIGOSERTIB(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON 01910 (IV) CCN=ON01910(IV)","SRC_DB":"PHPROJ"},{"CN":"ON-01910 (oral) CCN=ON01910(ORAL)","SRC_DB":"PHPROJ"},{"CN":"ON-01910.Na CCN=ON01910.NA","SRC_DB":"PHPROJ"},{"CN":"ON-01910.NA (oral) CCN=ON01910.NA(ORAL)","SRC_DB":"PHPROJ"},{"CN":"Product A, Onconova CCN=PRODUCTAONCONOVA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C1","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-PR-AN","THE_USE":"Protein kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, leukaemia, chronic myelomonocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, leukaemia, chronic lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-PLK-1-AN","THE_USE":"Polo-like kinase 1 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"MCL-1-AN","THE_USE":"Mcl-1 antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, skin, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, haematological, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, lymphoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, cervical","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute lymphocytic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, leukaemia, chronic myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Myelodysplastic syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"CELL-CY-AN","THE_USE":"Cell cycle inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, sarcoma, leiomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, anal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[82, 105, 103, 111, 115, 101, 114, 116, 105, 98, 32, 40, 79, 78, 45, 48, 49, 57, 49, 48, 59, 32, 69, 83, 84, 89, 66, 79, 78, 41]...', original message: bytes can be at most 32766 in length; got 36383
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36383
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:52:58,218][DEBUG][action.bulk              ] 321: Enzyme > Kinase;","2321: Kinase;","2321: Enzyme.","2321: Receptor;","3791: Enzyme > Kinase;","3791: Kinase;","3791: Enzyme.","3791: Receptor;","2324: Enzyme > EC number > 2.7.10.1;","2324: EC number > 2.7.10.1;","2324: Enzyme;","2324: 2.7.10.1;","2324: Enzyme > EC number.","2324: Enzyme > Kinase;","2324: Kinase;","2324: Enzyme.","2324: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["KI-GFEN-AN: VEGFR tyrosine kinase inhibitor: Enzyme, Transferase, VEGFR tyrosine kinase inhibitor: Vascular endothelial growth factor receptor TK inhibitor: E-TR-KI-GFEN-AN|KI-FLT3-AN: Flt-3 kinase inhibitor: Enzyme, Transferase, Flt3 kinase inhibitor: E-TR-KI-FLT3-AN|KI-TY-KT-AN: C-kit inhibitor: Enzyme, Transferase, Ckit inhibitor: KIT tyrosine kinase inhibitor: Stem cell factor receptor tyrosine kinase inhibitor: E-TR-KI-TY-KT-AN|COLSF-R1-AN: Colony stimulating factor 1 receptor antagonist: Physiological, Hormonal, Colony stimulating factor 1 receptor antagonist: macrophage colony-stimulating factor receptor antagonist: c-FMS antagonist: CSF-1R antagonist: P-H-COLSF-R1-AN|GF-EN-AN: Vascular endothelial growth factor (VEGF)receptor antagonist: Physiological, Hormonal, Vascular endothelial growth factor (VEGF)receptor antagonist: VEGF antagonist: VEGFR antagonist: P-H-GF-EN-AN|KI-TY-RET-AN: RET tyrosine kinase inhibitor: Enzyme, Transferase, KITYREnzyme: E-TR-KI-TY-RE-AN|ANGG-AN: Angiogenesis inhibitor: Physiological, Hormonal, Angiogenesis inhibitor: P-H-ANGG-AN|KI-GFEN1-AN: VEGFR-1 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 1 tyrosine kinase inhibitor: Flt-1 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 1 TK inhibitor: E-TR-KI-GFEN1-AN|KI-GFEN2-AN: VEGFR-2 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 2 tyrosine kinase inhibitor: KDR tyrosine kinase inhibitor: Flk-1 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 2 TK inhibitor: E-TR-KI-GFEN2-AN|KI-GFEN3-AN: VEGFR-3 tyrosine kinase inhibitor: Enzyme, Transferase, VEGFReceptor, 3 tyrosine kinase inhibitor: Flt-4 tyrosine kinase inhibitor: Vascular endothelial growth factor receptor 3 TK inhibitor: E-TR-KI-GFEN3-AN|KI-GFPLB-AN: Platelet-derived growth factor receptor beta kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor beta kinase inhib: PDGF beta kinase inhibitor: PDGF receptor beta kinase inhibitor: Platelet-derived growth factor beta kinase inhibitor: E-TR-KI-GFPLB-AN|KI-GFPLA-AN: Platelet-derived growth factor receptor alpha kinase inhib: Enzyme, Transferase, Plateletderived growth factor receptor alpha kinase inhib: PDGF alpha kinase inhibitor: PDGF receptor alpha kinase inhibitor: Platelet-derived growth factor alpha kinase inhibitor: E-TR-KI-GFPLA-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["398.48"],"Document_AL":["2.14"],"Document_CASIS-CO_CO":["Originator: Pfizer (US): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD359471    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH033858","CASIS_COMPOUND":[{"CN":"SU11248 CCN=SU11248","SRC_DB":"PHPROJ"},{"CN":"SU-010398 CCN=SU010398","SRC_DB":"PHPROJ"},{"CN":"Sutent CCN=SUTENT","SRC_DB":"PHPROJ"},{"CN":"SU011248  CCN=SU011248","SRC_DB":"PHPROJ"},{"CN":"SU-011248 CCN=SU011248","SRC_DB":"PHPROJ"},{"CN":"sunitinib CCN=SUNITINIB","SRC_DB":"PHPROJ"},{"CN":"SU-11248 CCN=SU11248","SRC_DB":"PHPROJ"},{"CN":"SUO11248 CCN=SUO11248","SRC_DB":"PHPROJ"},{"CN":"Sutene CCN=SUTENE","SRC_DB":"PHPROJ"},{"CN":"sunitinib malate CCN=SUNITINIBMALATE","SRC_DB":"PHPROJ"},{"CN":"PHA-290940AD CCN=PHA290940AD","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C2","THE_USE":"Cancer, leukaemia, acute myelogenous","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-KT-AN","THE_USE":"C-kit inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, sarcoma, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLA-AN","THE_USE":"Platelet-derived growth factor receptor alpha kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stromal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN1-AN","THE_USE":"VEGFR-1 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, neuroendocrine, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"ANGG-AN","THE_USE":"Angiogenesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN-AN","THE_USE":"VEGFR tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, liver","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"KI-FLT3-AN","THE_USE":"Flt-3 kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-TY-RET-AN","THE_USE":"RET tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN3-AN","THE_USE":"VEGFR-3 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"KI-GFPLB-AN","THE_USE":"Platelet-derived growth factor receptor beta kinase inhib","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"GF-EN-AN","THE_USE":"Vascular endothelial growth factor (VEGF)receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, pancreatic, neuroendocrine","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"KI-GFEN2-AN","THE_USE":"VEGFR-2 tyrosine kinase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, thyroid","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"D","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"COLSF-R1-AN","THE_USE":"Colony stimulating factor 1 receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[83, 117, 110, 105, 116, 105, 110, 105, 98, 32, 109, 97, 108, 97, 116, 101, 32, 105, 115, 32, 97, 110, 32, 111, 114, 97, 108, 32, 115, 109]...', original message: bytes can be at most 32766 in length; got 36800
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36800
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:52:58,600][DEBUG][action.bulk              ] PP, 15 Nov 2005).^Additional Clinical Information^Phase II^In a US Phase I/II trial in 41 chemotherapy-naive advanced nsclc patients to determine the MTD and DLTs and evaluate safety and antitumour activity of iv 1x/wk administration, preliminary results showed 1CR, 7 confirmed PRs and 4PRs awaiting confirmation. The study was to be expanded into a Phase II efficacy study (Press releases, APP, 25 Feb 2004 and 3 Nov 2005).^In 2 open-label Phase II trials in metastatic breast cancer patients without steroid pretreatment, ABI-007 175 and 300mg/m2 iv q 21 days gave overall response rates of 51 and 61%, respectively. It was well tolerated (38th ASCO (Orlando), 2002, Abs 209).^In a Phase II trial in 106 patients with progressive metastatic breast cancer whose disease had progressed on standard paclitaxel or docetaxel, ABI-007 1x/wk gave a 15% overall response rate. Probability of survival at 12mth was 38%. The proportion of patients free of disease progression was 40 and 30% at 4 and 6mth, respectively. Response rates were 24 and 16% in patients who had failed on paclitaxel and docetaxel alone, respectively (Scrip's Target Daily Online, 7 Jun 2004, W00846222).^It is in an open-label, non-randomized Phase II trial in 70 patients with locally-advanced or metastatic breast cancer, receiving ABI-007 125mg/m2 30min iv infusion q wk x3 in 4wk cycles in combination with trastuzumab (qv). The primary endpoint is response rate and secondary endpoints are TTP, overall survival and toxicities (Press release, APP, 4 Apr 2005).^In an open-label Phase II trial in early-stage breast cancer patients, ABI-007 260mg/m2 q 2wk x4, administered as adjuvant therapy following doxorubicin + cyclophosphamide, was well tolerated (Press releases, APP, 3 May and 9 Dec 2005).^Phase I^In a randomized Phase I trial in 23 patients with de novo lesions in native coronary arteries, ABI-007 10-100mg/m2 iv following stenting resulted in some trends in efficacy, and there were no significant AEs in patients receiving <70mg/m2. Further trials to determine efficacy in coronary restenosis were conducted (Press release, APP, 5 Apr 2005).^"],"Document_HA":["14"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (260mg/m2):Cl:15:l/hr/m2","Human (260mg/m2):Vd:632:l/m2","Human (80-375mg/m2):t1/2:27:hr","Animal (20mg/kg):Cmax:328:ng/ml","Animal (20mg/kg):AUC:656:nCi/hr/ml"],"Document_NC":["No"],"Document_RB":["18"],"Document_TG":["203068: tubulin, beta class I"],"Document_LCH":["20140314:AD283 : Initiation of Phase II trial (PANC-001) for pancreatic cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["TAX-AG: Taxane: Physiological, Biochemical, Taxane: Taxane anticancer drug: Paclitaxel-type anticancer: P-B-TAX-AG|TUBE-B-AN: Beta tubulin antagonist: Physiological, Biochemical, Beta tubulin antagonist: Beta tubulin binding agent: P-B-TUBE-B-AN|MICTUBE-AG: Microtubule stimulant: Physiological, Biochemical, Microtubule stimulant: Antineoplastic e.g. taxol: P-B-MICTUBE-AG|"],"Document_ROUT":["P-IP: Parenteral, intraperitoneal","P-IV: Parenteral, intravenous","P-UN: Parenteral, general","P-VE: Parenteral, intravesical"],"Document_MW":["853.93"],"Document_AL":["3.96"],"Document_CASIS-CO_CO":["Originator: Celgene (US): Launched","Licensee: Biocon (IN): Launched","Licensee: Taiho (JP): Launched","Licensee: Specialised Therapeutics (AU): Launched","Licensee: Green Cross (KR): Registered","Licensee: AstraZeneca (GB): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD087473    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["3:Speed Rating - Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2010 Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2009 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2008 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH033757","CASIS_COMPOUND":[{"CN":"Abraxane (intravesical) CCN=ABRAXANE(INTRAVESICAL)","SRC_DB":"PHPROJ"},{"CN":"albumin-bound paclitaxel (IV) CCN=ALBUMINBOUNDPACLITAXEL(IV)","SRC_DB":"PHPROJ"},{"CN":"paclitaxel, American BioScience (IV) CCN=PACLITAXELAMERICANBIOSCIENCE(IV)","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel (intravesical) CCN=NABPACLITAXEL(INTRAVESICAL)","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel CCN=NABPACLITAXEL","SRC_DB":"PHPROJ"},{"CN":"Abraxane (IV) CCN=ABRAXANE(IV)","SRC_DB":"PHPROJ"},{"CN":"Capxol CCN=CAPXOL","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel (Intraperitoneal) CCN=NABPACLITAXEL(INTRAPERITONEAL)","SRC_DB":"PHPROJ"},{"CN":"Coroxane CCN=COROXANE","SRC_DB":"PHPROJ"},{"CN":"nab-paclitaxel (IV) CCN=NABPACLITAXEL(IV)","SRC_DB":"PHPROJ"},{"CN":"ABI-007 (IV) CCN=ABI007(IV)","SRC_DB":"PHPROJ"},{"CN":"Abraxane CCN=ABRAXANE","SRC_DB":"PHPROJ"},{"CN":"Abraxane (Intraperitoneal) CCN=ABRAXANE(INTRAPERITONEAL)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:42","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, neuroblastoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"TUBE-B-AN","THE_USE":"Beta tubulin antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR","THE_USE":"Cancer, lung, small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, sarcoma, rhabdomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Restenosis","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"TAX-AG","THE_USE":"Taxane","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K6Z","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K5A","THE_USE":"Radio-chemosensitizer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, gastrointestinal, stomach","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"F3A2","THE_USE":"Reformulation","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"MICTUBE-AG","THE_USE":"Microtubule stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, head and neck","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, pancreatic","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C1","THE_USE":"Cancer, oesophageal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C9Z","THE_USE":"Cardiovascular","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, bladder","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 66, 73, 45, 48, 48, 55, 32, 40, 65, 98, 114, 97, 120, 97, 110, 101, 41, 32, 105, 115, 32, 97, 110, 32, 97, 108, 98, 117, 109]...', original message: bytes can be at most 32766 in length; got 38457
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 38457
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:53:16,629][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.7gb[5%], shards will be relocated away from this node
[2016-06-14 13:53:16,629][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:53:46,684][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.9%], shards will be relocated away from this node
[2016-06-14 13:54:08,395][DEBUG][action.bulk              ] 2/show/NCT00964418).^A randomized, double-blind, crossover-assignment Phase I trial in 18 Type 1 diabetics, assessing the number of hypoglycaemic episodes and glycaemic variability of insulin degludec sc 3x/wk, 4x/wk or once-daily x1wk, was completed (ClinicalTrials.gov, 24 Aug and 21 Sep 2009, http://clinicaltrials.gov/ct2/show/ NCT00964964).^Diabetes, Type 2^A randomized, double-blind, placebo-controlled, single-dose, dose- escalation Phase I trial (NN5401-1718; 2005-003974-65) with insulin 454 in 64 healthy male subjects, followed by a two-period cross-over trial with insulin 454 and insulatard in male subjects with type 1 and Type 2 diabetes mellitus was completed (ClinicalTrials.gov, 1 Jun 2013, http://clinicaltrials.gov/show/ NCT01865279).^A Japanese Phase I trial (NN1250-3763; 2011-001850-27; U1111-1120- 7444) in 10 subjects with Type 2 diabetes, to investigate the pharmacodynamic properties of insulin degludec sc once-daily for 6days was terminated due to low recruitment (ClinicalTrials.gov, 11 Nov 2011 and 6 Jan 2012, http://clinicaltrials.gov/ct2/show/ NCT01467414).^A German Phase I (NN1250-1987) trial evaluating the pharmacodynamic response of insulin degludec sc once-daily x6 days at steady state in 49 Type 2 diabetes patients was completed (ClinicalTrials.gov, 28 Oct and 14 Dec 2010, http:// clinicaltrials.gov/ct2/show/NCT01154881).^A US Phase I trial (NN1250-3762) in 63 Type 2 diabetes patients of different race and/or ethnicity, to assess insulin degludec 0.6U/kg body weight sc once-daily x6 days at steady-state conditions compared to insulin detemir 0.6U/kg body weight sc once-daily x6 days on pharmacodynamic and pharmacokinetic properties was completed (ClinicalTrials.gov, 5 Jan and 4 Nov 2010, http://clinicaltrials.gov/ct2/show/NCT01043510).^Preclinical ^In vitro^In albumin-free conditions, the affinity of insulin degludec for human insulin receptor isoforms HIR-A and HIR-B was 13 and 15%, respectively while the affinity for the human IGF-1 receptor was 2% (70th Meet Am Diabetes Assoc (Orlando), 2010, Abs 1406-P, http://professional.diabetes.org/ Abstracts_Display.aspx?TYP=1andCID=80336).^In primary human mammary epithelial, human colon COLO-205, mammary adenocarcinoma MCF-7cell lines and H3 thymidine incoporated L6 myoblasts expressing human insulin receptors, insulin degludec elicited the same metabolic responses and maximal effect as human insulin. The mitogenic potencies determined with no added albumin ranged from 4-14% relative to human insulin. In cellular assays without albumin, the metabolic potency was 8-20% and therefore resulting in a mitogenic/ metabolic potency ratio of < or =1 (70th Meet Am Diabetes Assoc (Orlando), 2010, Abs 1406-P, http://professional.diabetes.org/ Abstracts_Display.aspx?TYP=1andCID=80336).^Patents^It has patent protection until 2024 (Form 20-F, Novo Nordisk, 6 Feb 2013, Page 15, http://www.sec.gov/Archives/edgar/data/353278/ 000120864613000047/c107892.htm).^"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["No"],"Document_TF":["3643: Receptor."],"Document_TG":["3643: insulin receptor"],"Document_LCH":["20140313:PT : Rejection for use in the Scottish NHS for diabetes reported"],"Document_TB":["3643: Receptor;"],"Document_CASIS-USE_CASIS-MA_PHCD":["INS-LO-AG: Long-acting insulin: Receptor, Hormonal, Longacting insulin: Insulin, long-acting: R-H-INS-LO-AG|"],"Document_ROUT":["P-IM: Parenteral, intramuscular","P-IV: Parenteral, intravenous","P-SC: Parenteral, subcutaneous","P-UN: Parenteral, general"],"Document_CASIS-CO_CO":["Originator: Novo Nordisk (DK): Launched"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH046875","CASIS_COMPOUND":[{"CN":"NNC 0100-0454 (SC) CCN=NNC01000454(SC)","SRC_DB":"PHPROJ"},{"CN":"SIBA, Novo Nordisk (IV) CCN=SIBANOVONORDISK(IV)","SRC_DB":"PHPROJ"},{"CN":"IDeg (IV) CCN=IDEG(IV)","SRC_DB":"PHPROJ"},{"CN":"insulin degludec CCN=INSULINDEGLUDEC","SRC_DB":"PHPROJ"},{"CN":"SIBA, Novo Nordisk (IM) CCN=SIBANOVONORDISK(IM)","SRC_DB":"PHPROJ"},{"CN":"NN1250 (IV) CCN=NN1250(IV)","SRC_DB":"PHPROJ"},{"CN":"NNC-0100-0454 (SC) CCN=NNC01000454(SC)","SRC_DB":"PHPROJ"},{"CN":"Degludec (SC) CCN=DEGLUDEC(SC)","SRC_DB":"PHPROJ"},{"CN":"IDeg CCN=IDEG","SRC_DB":"PHPROJ"},{"CN":"NN-1250 (IM) CCN=NN1250(IM)","SRC_DB":"PHPROJ"},{"CN":"NN1250 (IM) CCN=NN1250(IM)","SRC_DB":"PHPROJ"},{"CN":"insulin degludec (IM) CCN=INSULINDEGLUDEC(IM)","SRC_DB":"PHPROJ"},{"CN":"NN1250 (SC) CCN=NN1250(SC)","SRC_DB":"PHPROJ"},{"CN":"NNC-0100-0454 (IM) CCN=NNC01000454(IM)","SRC_DB":"PHPROJ"},{"CN":"Degludec CCN=DEGLUDEC","SRC_DB":"PHPROJ"},{"CN":"insulin 454 CCN=INSULIN454","SRC_DB":"PHPROJ"},{"CN":"NNC 0100-0454 CCN=NNC01000454","SRC_DB":"PHPROJ"},{"CN":"NNC 0100-0454 (IV) CCN=NNC01000454(IV)","SRC_DB":"PHPROJ"},{"CN":"IDeg (SC) CCN=IDEG(SC)","SRC_DB":"PHPROJ"},{"CN":"insulin degludec (IV) CCN=INSULINDEGLUDEC(IV)","SRC_DB":"PHPROJ"},{"CN":"Degludec (IV) CCN=DEGLUDEC(IV)","SRC_DB":"PHPROJ"},{"CN":"Tresiba (IV) CCN=TRESIBA(IV)","SRC_DB":"PHPROJ"},{"CN":"NN1250 CCN=NN1250","SRC_DB":"PHPROJ"},{"CN":"NN-1250 CCN=NN1250","SRC_DB":"PHPROJ"},{"CN":"NN-1250 (IV) CCN=NN1250(IV)","SRC_DB":"PHPROJ"},{"CN":"Degludec (IM) CCN=DEGLUDEC(IM)","SRC_DB":"PHPROJ"},{"CN":"Tresiba (SC) CCN=TRESIBA(SC)","SRC_DB":"PHPROJ"},{"CN":"Tresiba (IM) CCN=TRESIBA(IM)","SRC_DB":"PHPROJ"},{"CN":"NNC-0100-0454 (IV) CCN=NNC01000454(IV)","SRC_DB":"PHPROJ"},{"CN":"insulin degludec (SC) CCN=INSULINDEGLUDEC(SC)","SRC_DB":"PHPROJ"},{"CN":"NNC 0100-0454 (IM) CCN=NNC01000454(IM)","SRC_DB":"PHPROJ"},{"CN":"SIBA, Novo Nordisk CCN=SIBANOVONORDISK","SRC_DB":"PHPROJ"},{"CN":"Tresiba CCN=TRESIBA","SRC_DB":"PHPROJ"},{"CN":"NNC-0100-0454 CCN=NNC01000454","SRC_DB":"PHPROJ"},{"CN":"SIBA, Novo Nordisk (SC) CCN=SIBANOVONORDISK(SC)","SRC_DB":"PHPROJ"},{"CN":"NN-1250 (SC) CCN=NN1250(SC)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:44","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"H4E1","THE_USE":"Insulin","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"T2C","THE_USE":"Recombinant hormone","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"INS-LO-AG","THE_USE":"Long-acting insulin","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[73, 110, 115, 117, 108, 105, 110, 32, 100, 101, 103, 108, 117, 100, 101, 99, 32, 40, 78, 78, 67, 45, 48, 49, 48, 48, 45, 48, 52, 53]...', original message: bytes can be at most 32766 in length; got 47271
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 47271
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:54:08,701][DEBUG][action.bulk              ]  13-15, trabectedin caused complete regression of the ovarian carcinoma HOC 22, nsclc LXFL 529 and melanoma MEXF 989 (in sc human tumour xenografts in nude mice) (87th AACR (Washington, DC), 1996, Abs 2653).^In vitro^In STS cell lines, dose-dependent reduction of clonogenic survival was observed after treatment with trabectedin. Concomitant treatment with trabectedin and hyperthermia increased cytotoxicity. Heat-^mediated BRCA2-degradation and impairment of HR dependent DSB- repair seemed to be related mechanisms for the thermosensitisation of trabectedin-induced lethality (Press release, PharmaMar, 4 Nov 2013, http://www.pharmamar.com/yondelis- trabectedin-spotlight-annual-meeting-connective-tissue-oncology- society-twenty-one-trials.aspx).^Licensing^Agreements^________________^Ortho Biotech and Janssen (Johnson and Johnson)^Worldwide except Europe and Japan; exclusive rights (Press release, PharmaMar, 10 Aug 2001; Direct communication, PharmaMar, 21 Feb 2002).^Swedish Orphan Biovitrum (Swedish Orphan before the acquisition)^Nordic and eastern European countries (Ann Rep, Swedish Orphan, 2007).^Genesis Pharma^Greece and Cyprus (Scrip Daily Online, 18 Oct 2007, S00974016).^Myriad Genetics^Worldwide; Janssen has an agreement with Myriad to use Myriad's BRACAnalysis test in connection with its Phase III trial of trabectedin in the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers (Press release, Myriad, 9 Dec 2013, http://investor.myriad.com/ releasedetail.cfm?ReleaseID=812437).^Taiho^Japan (Press release, Taiho, 31 Mar 2009).^Additional Clinical Information^Phase I^In a Phase I study in 20 patients with advanced solid malignancies given 6-216microg/m2/day, toxicities included nausea and emesis, neutropenia, phlebitis and elevations in hepatic transaminases and creatinine. In 2 patients at 216microg/m2/day, clearance rates, t1/2s and AUCs(0-24hr) were 137 and 589ml/min/m2, 13.7 and 23.1hr and 158 and 367ngmin/ml, respectively (34th ASCO (Los Angeles), 1998, Abs 737, 0).^"],"Document_HA":["15"],"Document_CASIS-UPD_WE":["20140228"],"Document_PK":["Monkey:Cl:1.43 to 3.68:l/hr/kg","Monkey:Cmax:10.6:ng/ml","Monkey:Vd:94.4 to 287:l/kg","Human (300-650microgram/m2):t1/2beta:37 to 47:hr","Human (300-400microgram/m2 iv):AUC:4.8 to 8.5:nghr/ml","Human (50-800microgram/m2 iv):Cmax:1.5 to 2:ng/ml","Human (50-800microgram/m2 iv):Cl:800:ml/min/m2"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TG":["99999998: Not applicable"],"Document_LCH":["20140218:PP249 : Approval in Brazil for ovarian cancer reported"],"Document_CASIS-USE_CASIS-MA_PHCD":["DNA-AN: DNA inhibitor: Physiological, Biochemical, DNA inhibitor: Antineoplastic e.g. actinomycin, bleomycin, anthracyclines: Antineoplastic alkylating agent: Alkylating antineoplastic agent: DNA cross linking agent: P-B-DNA-AN|DNA-REP-AN: DNA repair enzyme inhibitor: Enzyme, Ligase, DNA repair enzyme inhibitor: DNA joinase inhibitor: Polynucleotide ligase inhibitor: Polydeoxyribonucleotide synthase ATP inhibitor: DNA ligase inhibitor: E-LI-DNA-REP-AN|APOP-AG: Apoptosis stimulant: Physiological, Biochemical, Apoptosis stimulant: General apoptosis stimulant: P-B-APOP-AG|CELL-CY-AN: Cell cycle inhibitor: Physiological, Biochemical, Cell cycle inhibitor: P-B-CELL-CY-AN|"],"Document_ROUT":["P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["761.85"],"Document_AL":["3.62"],"Document_CASIS-CO_CO":["Originator: PharmaMar (ES): Launched","Licensee: Swedish Orphan Biovitrum (SE): Launched","Licensee: Genesis Pharma (GR): Registered","Licensee: Johnson & Johnson (US): Registered","Licensee: Taiho (JP): Phase II Clinical Trial"],"Document_MR":["2:Market Rating - US$ 501-2000 million"],"Document_CASIS-MDNUMBER":["MD113062    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2007 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"}],"DOCNO":"PH021798","CASIS_COMPOUND":[{"CN":"ET-729 CCN=ET729","SRC_DB":"PHPROJ"},{"CN":"NSC-648776 CCN=NSC648776","SRC_DB":"PHPROJ"},{"CN":"ecteinascidins CCN=ECTEINASCIDINS","SRC_DB":"PHPROJ"},{"CN":"ET-759B CCN=ET759B","SRC_DB":"PHPROJ"},{"CN":"ET-736 CCN=ET736","SRC_DB":"PHPROJ"},{"CN":"ET-743 CCN=ET743","SRC_DB":"PHPROJ"},{"CN":"ET-770 CCN=ET770","SRC_DB":"PHPROJ"},{"CN":"ET-759A CCN=ET759A","SRC_DB":"PHPROJ"},{"CN":"ET-722 CCN=ET722","SRC_DB":"PHPROJ"},{"CN":"ET-745 CCN=ET745","SRC_DB":"PHPROJ"},{"CN":"trabectedin CCN=TRABECTEDIN","SRC_DB":"PHPROJ"},{"CN":"ecteinascidin-743 CCN=ECTEINASCIDIN743","SRC_DB":"PHPROJ"},{"CN":"Yondelis CCN=YONDELIS","SRC_DB":"PHPROJ"},{"CN":"ecteinascidin 743 CCN=ECTEINASCIDIN743","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-03 11:21:13","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"N","THE_USE":"Cancer, sarcoma, osteo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, fallopian tube","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, renal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, mesothelioma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, brain","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, lung, non-small cell","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, melanoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-AN","THE_USE":"DNA inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, solid, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A5B","THE_USE":"Hepatoprotective","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, endometrial","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, sarcoma, soft tissue","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, colorectal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, lipo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"APOP-AG","THE_USE":"Apoptosis stimulant","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Cancer, neuroblastoma","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, peritoneal","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Cancer, sarcoma, leiomyo","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K1B","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Hepatic dysfunction, unspecified","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"CELL-CY-AN","THE_USE":"Cell cycle inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, ovarian","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"DNA-REP-AN","THE_USE":"DNA repair enzyme inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[84, 114, 97, 98, 101, 99, 116, 101, 100, 105, 110, 32, 40, 69, 84, 45, 55, 52, 51, 41, 32, 105, 115, 32, 116, 104, 101, 32, 108, 101]...', original message: bytes can be at most 32766 in length; got 35007
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 35007
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:54:16,725][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.9%], shards will be relocated away from this node
[2016-06-14 13:54:16,726][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:54:46,753][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:55:03,025][DEBUG][action.bulk              ] 21425934x0x456195/a9983611- 02a0-41a8-aca3-a59a5364f9f2/ EASL%202011%20IR%20event%20FINAL%204411_2.pdf). Results demonstrated that the combination sofosbuvir + PSI-938 lead to the decline in the viral load rapidly in a biphasic manner. The maximum level of effectiveness was achieved by PSI-938 and sofosbuvir were 1 and 2 days, respectively and the mean antiviral effectiveness were similar for both the drugs (48th Annual Meeting of the European Association for the Study of Liver (EASL) 2013, Amsterdam, The Netherlands, April 24-28, 2013, Abs 1196, http://www.abstractserver.com/easl2013/planner/^^Enrollment is complete in a 5-cohort, 2-part, non-randomized, drug-interaction, open-label, single-group assignment Phase I trial (P7977-1910) in Puerto Rico in 80 HIV and HCV co-infected patients, to evaluate the pharmacokinetics between sofosbuvir 200mg bid x7 days + efavirenz 600mg once-daily + tenofovir 300mg once-daily + emtricitabine 200mg once-daily, sofosbuvir + efavirenz 600mg once-daily + zidovudine 300mg bid + lamivudine 150mg bid and sofosbuvir + atazanavir/ritonavir 400/100mg once- daily + tenofovir 300mg once-daily + emtricitabine 200mg once- daily. Part B will evaluate the efficacy and safety of GS-7977 400mg once-daily with peginterferon alpha-2a 180microg/wk sc and ribavirin 1000-1200mg (ClinicalTrials.gov, 31 Mar 2012 and 1 Mar 2013, http://clinicaltrials.gov/show/NCT01565889).^In a Phase Ib in 19 HCV treatment-naive patients with HIV/HCV co- infection, sofosbuvir 400mg once-daily x7 days showed a median change in HCV RNA similar to monoinfected patients, with >1.5log reductions at 24hr and a maximal HCV RNA decline from baseline >4log. Virologic response was similar in the coinfected and monoinfected cohorts independent of HIV status, HCV genotype and baseline HCV viral load. It was well tolerated with no new safety events observed during the dosing or safety follow-up period. No effect was observed on HIV viral load, CD4 count or CD4% (52nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2012, San Francisco, September 9- 12, 2012, Abs H-1921a, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=9d934432-9dec-46cd-abbe- b4f1297b3e75andcKey=221f3f0b-82af-4fff-ac44- d951bbb2df2dandmKey={6B114A1D-85A4-4054-A83B-04D8B9B8749F}).^A Phase I trial in New Zealand in 40 hepatitis-C patients is planned, with trial completion expected in Aug 2011 (Scrip Intelligence, 17 Jan 2011, http://www.scripclinicalresearch.com/ companies/Beltas-recruits-for-Hepatitis-C-study-308722?autnRef=/ contentstore/gcpj/codex/98299765-2252-11e0-92f3-cf1dfcf723f1.xml).^Preclinical ^In vitro^In vitro, sofosbuvir demonstrated in vitro potency cf PSI-7976 (Form 10-Q, Pharmasset, 9 Feb 2010).^Patents^An EU patent expires in 2028 (Form 10-K, Gilead, 27 Feb 2013, Page 17, http://www.sec.gov/Archives/edgar/data/882095/ 000088209513000015/a2012form10-k.htm).^US7964580, covering the composition-of-matter and its diastereomeric mixture for the treatment of HCV has been issued, with expiry in 2029 (Press release, Pharmasset, 22 Jun 2011, http://investor.pharmasset.com/ releasedetail.cfm?ReleaseID=586664).^It has a US patent, which expires in 2025 (Canaccord Genuity 30th Growth Conf (Boston), 2010, Slide 10, http:// files.shareholder.com/downloads/VRUS/966662061x0x394709/39daffe7- 2ded-4e1a-aea4-3ee507ca881f/ VRUS_CorpPres_081010_Cannacord_all.pdf). Patents are pending, with an expiry date in 2028 on patent issuance (Corporate presentation, Pharmasset, 2 May 2011, Slide 6, http:// files.shareholder.com/downloads/VRUS/1210976004x0x464435/32c9a49f- d2d1-4c21-9a91-085d3b323958/Corp%20Presentation_DB_050211.pdf).^Licensing^Agreements^_______________^Bristol-Myers Squibb^Worldwide; Pharmasset has a clinical collaboration agreement with Bristol-Myers Squibb to evaluate the utility of BMS-790052 in combination with sofosbuvir for the treatment of HCV infection (Press release, BMS and Pharmasset, 10 Jan 2011, http:// www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http:// www.businesswire.com/news/bms/20110110005933/ enandt=634302724749654803).^Tibotec (Johnson and Johnson)^Worldwide; Tibotec has a clinical collaboration agreement with Pharmasset to combine PSI-7977 and Tibotec's simeprevir, a protease inhibitor (Press release, Pharmasset, 25 Jul 2011, http:/ /investor.pharmasset.com/releasedetail.cfm?ReleaseID=593884).^Qualifying Therapeutic Discovery Project^USA; Pharmasset received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) for the development of PSI-7977 (IRS.gov Web Page, 7 Jan 2011, http:// www.irs.gov/businesses/small/article/0,,id=229024,00.html).^Availability^________________^Worldwide; Before the acquisition by Gilead Sciences, Pharmasset was seeking development partners (Canaccord Genuity 30th Growth Conf (Boston), 2010, Slide 3, http://files.shareholder.com/ downloads/VRUS/966662061x0x394709/39daffe7-2ded-4e1a-aea4- 3ee507ca881f/VRUS_CorpPres_081010_Cannacord_all.pdf).^"],"Document_HA":["10"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["Yes"],"Document_RB":["11"],"Document_TF":["951475: Enzyme > Polymerase;","951475: Enzyme > Protease/peptidase."],"Document_TG":["951475: polyprotein, hepatitis-C virus"],"Document_LCH":["20140310:PT : Enrollment completion in Phase IIIb trial (GS-US- 334-0153) and completion of Phase II trial (GS-US-334-0114) & Phase III trials (GS-US-334-0123 & GS-US-334-0115) reported"],"Document_TB":["951475: Enzyme > Polymerase;","951475: Polymerase;","951475: Enzyme.","951475: Enzyme > Protease/peptidase;","951475: Protease/peptidase;","951475: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PO-RRNAN-AN: HCV-NS5B polymerase inhibitor: Enzyme, Transferase, HCVNS5B polymerase inhibitor: HCV polymerase inhibitor: E-TR-PO-RRNAN-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["513.47"],"Document_AL":["1.23"],"Document_CASIS-CO_CO":["Originator: Gilead Sciences (US): Launched"],"Document_MR":["0:Market Rating - Not applicable"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"}],"DOCNO":"PH054359","CASIS_COMPOUND":[{"CN":"PSI-7977 CCN=PSI7977","SRC_DB":"PHPROJ"},{"CN":"sofosbuvir CCN=SOFOSBUVIR","SRC_DB":"PHPROJ"},{"CN":"GS7977 CCN=GS7977","SRC_DB":"PHPROJ"},{"CN":"GS-7977 CCN=GS7977","SRC_DB":"PHPROJ"},{"CN":"Sovaldi CCN=SOVALDI","SRC_DB":"PHPROJ"},{"CN":"GS 7977 CCN=GS7977","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:45","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"PO-RRNAN-AN","THE_USE":"HCV-NS5B polymerase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"J5Z","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[71, 105, 108, 101, 97, 100, 32, 83, 99, 105, 101, 110, 99, 101, 115, 32, 40, 112, 114, 101, 118, 105, 111, 117, 115, 108, 121, 32, 80, 104]...', original message: bytes can be at most 32766 in length; got 46417
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 46417
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:55:16,779][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.4gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:55:16,779][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:55:46,827][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.4gb[4.8%], shards will be relocated away from this node
[2016-06-14 13:56:16,853][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.4gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:56:16,853][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:56:46,923][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.3gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:57:16,949][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.3gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:57:16,949][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:57:24,105][DEBUG][action.bulk              ] cs of venlafaxine in 38 healthy subjects was completed (ClinicalTrials.gov, 24 Sep 2011, http://clinicaltrials.gov/ct2/show/NCT00362271).^Preclinical ^Development for acute agitation was planned (Scrip Daily Online, 22 Nov 2004, S00864506).^In vivo^In chloral hydrate-anaesthetized rats, aripiprazole inhibited the antidromic spike of dopaminergic neurones in the ventral segmental area (5th Conf Clin Pharmacol Ther (Yokohama), 1992, Abs O-15-05 and P-102-17; Company communication, Otsuka, Feb 1995).^Patents^Exclusivity in the US is expected to expire in Apr 2015 (Press release, BMS, 6 Apr 2009).^Patent expirations are expected in 2014 (Scrip Daily Online, 11 Oct 2005, S00898476).^Licensing^Agreements^________________^Bristol-Myers Squibb^Worldwide excluding Japan and select Asian and Middle Eastern countries; it is licensed to BMS for co-marketing in the EU and the US, and for exclusive marketing elsewhere except Japan and some Asian and Middle Eastern countries (Press release, BMS, 21 Sep 1999). The US portion of the development and commercialization agreement with BMS has been extended from Nov 2012 to Apr 2015, when exclusivity in the US is expected to expire (Press release, BMS, 6 Apr 2009).^Ligand^Worldwide (Company Pipeline, Ligand, 6 Oct 2011, http:// www.ligand.com/pipeline).^Lundbeck^EU; Lundbeck gained rights for the promotion of product (Scrip Intelligence, 11 Mar 2013, http://www.scripintelligence.com/home/ Otsuka-and-Lundbeck-tout-alliance-benefits-as-they-mull-future- CNS-strategy-340991).^Additional Clinical Information^Additional References^23rd CINP (Montreal) 2002, AbsP4E031.^23rd CINP (Montreal) 2002, AbsP4E026.^10th Biennial Winter Workshop Schizophrenia (Davos) 2000, 1.^CNS Drug Rev 1997, 3, 24^"],"Document_HA":["5"],"Document_CASIS-UPD_WE":["20140117"],"Document_PK":["Human (po):bioavailability:87:%","Human (po):t1/2beta:75:hr","Human (po):Tmax:3 to 5:hr","Human (iv):Vd:404:l"],"Document_NC":["Yes"],"Document_RB":["7"],"Document_TF":["1813: Receptor > GPCR > Dopamine;","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3356: Receptor > GPCR > 5-Hydroxytryptamine."],"Document_TG":["1813: dopamine receptor D2","3350: 5-hydroxytryptamine (serotonin) receptor 1A, G-protein- coupled","3356: 5-hydroxytryptamine (serotonin) receptor 2A, G-protein- coupled"],"Document_LCH":["20140113:AD67 : Completion of Phase III study (CN138-112) for schizophrenia reported"],"Document_TB":["1813: Receptor > GPCR > Dopamine;","1813: GPCR > Dopamine;","1813: Receptor;","1813: Dopamine;","1813: Receptor > GPCR.","3350: Receptor > GPCR > 5-Hydroxytryptamine;","3350: GPCR > 5-Hydroxytryptamine;","3350: Receptor;","3350: 5-Hydroxytryptamine;","3350: Receptor > GPCR.","3356: Receptor > GPCR > 5-Hydroxytryptamine;","3356: GPCR > 5-Hydroxytryptamine;","3356: Receptor;","3356: 5-Hydroxytryptamine;","3356: Receptor > GPCR."],"Document_CASIS-USE_CASIS-MA_PHCD":["DOPA-D2-AG: Dopamine D2 receptor agonist: Receptor, Transmitter, Dopamine D2 receptor agonist: DA D2 receptor agonist: D2 receptor agonist: Dopamine DA2 receptor agonist: DA DA2 receptor agonist: R-T-DOPA-D2-AG|5HT-1-A-AG: 5 Hydroxytryptamine 1A receptor agonist: Receptor, Hormonal, 5 Hydroxytryptamine 1A receptor agonist: 5HT1A receptor agonist: Serotonin 1A receptor agonist: R-H-5HT-1-A-AG|5HT-2-A-AN: 5 Hydroxytryptamine 2A receptor antagonist: Receptor, Hormonal, 5 Hydroxytryptamine 2A receptor antagonist: 5HT2A receptor antagonist: Serotonin 2A receptor antagonist: R-H-5HT-2-A-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IM: Parenteral, intramuscular","P-UN: Parenteral, general"],"Document_MW":["448.40"],"Document_AL":["4.31"],"Document_CASIS-CO_CO":["Originator: Otsuka (JP): Launched","Licensee: Bristol-Myers Squibb (US): Launched","Licensee: Ligand (US): Launched","Licensee: Lundbeck (DK): Launched"],"Document_MR":["4:Market Rating - US$ 5001-10000 million"],"Document_CASIS-MDNUMBER":["MD021321    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Launched 2005 Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Launched 2006 Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Launched 2003 Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2002 Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2004 Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Launched  Licensing Availability Unknown"}],"DOCNO":"PH018937","CASIS_COMPOUND":[{"CN":"Abilitat (tablet) CCN=ABILITAT(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilify IM CCN=ABILIFYIM","SRC_DB":"PHPROJ"},{"CN":"aripiprazole (tablet) CCN=ARIPIPRAZOLE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilify CCN=ABILIFY","SRC_DB":"PHPROJ"},{"CN":"Abilify (tablet) CCN=ABILIFY(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-337039 (tablet) CCN=BMS337039(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Abilify (solution) CCN=ABILIFY(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole (solution) CCN=ARIPIPRAZOLE(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"OPC-14597 (tablet) CCN=OPC14597(TABLET)","SRC_DB":"PHPROJ"},{"CN":"aripiprazole CCN=ARIPIPRAZOLE","SRC_DB":"PHPROJ"},{"CN":"aripiprazole IM CCN=ARIPIPRAZOLEIM","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-01-20 09:32:51","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Depression, major depressive disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Alzheimer's disease","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Schizophrenia","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Autism","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-2-A-AN","THE_USE":"5 Hydroxytryptamine 2A receptor antagonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"N11Z","THE_USE":"Neurological","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N10A","THE_USE":"Antidepressant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N9A","THE_USE":"Dependence treatment","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5C","THE_USE":"Anxiolytic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N6D","THE_USE":"Cognition enhancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"N5D","THE_USE":"Antineurotic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Psychosis, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Post-traumatic stress disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"5HT-1-A-AG","THE_USE":"5 Hydroxytryptamine 1A receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"DOPA-D2-AG","THE_USE":"Dopamine D2 receptor agonist","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Tourette's syndrome","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N5A1","THE_USE":"Neuroleptic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C3","THE_USE":"Depression, bipolar","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N","THE_USE":"Attention deficit hyperactivity disorder","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"N6B","THE_USE":"Psychostimulant","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Addiction, alcohol","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 114, 105, 112, 105, 112, 114, 97, 122, 111, 108, 101, 32, 105, 115, 32, 97, 32, 113, 117, 105, 110, 111, 108, 105, 110, 111, 110, 101, 32]...', original message: bytes can be at most 32766 in length; got 36451
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 36451
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:57:46,976][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.3gb[4.7%], shards will be relocated away from this node
[2016-06-14 13:58:17,002][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.2gb[4.6%], shards will be relocated away from this node
[2016-06-14 13:58:17,003][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:58:21,372][DEBUG][action.bulk              ] te was well tolerated at doses >500mg/day, and no DLTs were observed. Of the 6 patients who completed the initial 28-day treatment cycle, all experienced a decline in PSA, and 5/6 patients (83%) experienced a >50% decline in PSA (Press release, BTG, 27 Feb 2007).^In a Phase I trial in 14 chemotherapy-naive CRPC patients, despite treatment with LHRH analogues, antiandrogens, diethylstilboestrol and dexamethasone, abiraterone acetate once- daily was well-tolerated at doses up to 2000mg, with no DLTs observed. In 13 patients evaluable for antitumour activity, 9 had a decline in PSA levels of >50% and 6 had a decline of >90%. PR (measured by RECIST) was observed in 5/8 evaluable patients. Individual patients treated with abiraterone acetate experienced radiographic regression of bone metastases and pain reduction. 16/ 18 patients continued treatment, with some receiving abiraterone acetate for >11mth (Press releases, Cougar, 8 Oct and 8 Dec 2006).^In a UK Phase I trial in patients with HRPC, abiraterone acetate was safe and well tolerated and inhibited testosterone generation (Press release, Cougar, 14 Dec 2005).^Preclinical ^In vivo^In male WHT mice, abiraterone acetate 5mmol/kg was rapidly converted to CB-7598, with <5% of prodrug being detected. Dosing ip showed a depot effect with CB-7598 levels of 140ng/ml at 8 and 24hr post-dosing, whereas po dosing gave peak plasma levels of 1512.5ng/ml at 1hr with rapid clearance (terminal t1/2 <3hr). In male Wistar rats, 0.5mmol/kg po was rapidly and almost fully converted to CB-7598, with plasma testosterone reduced to undetectable levels (<0.2nM) within 2hr of dosing and for up to 24hr, and LH levels increased up to 8x within 24hr (85th AACR (San Francisco), 1994, Abs 2507).^Patents^US5604213 and US5618807 have been granted until 2014, and other patent applications have been filed worldwide (Company Web Page, BTG, 1 Aug 2001).^Licensing^Agreements^________________^Boehringer Ingelheim^Worldwide; A licence to Boehringer Ingelheim for development and marketing was discontinued (Direct communication, BTG, 10 Feb 1999).^Johnson and Johnson^Worldwide; it is exclusively licensed to Cougar Biotechnology (Johnson and Johnson) for development and commercialization worldwide (Press release, BTG and Cougar, 20 Apr 2004, http:// www.cougarbiotechnology.com/News/pr_042004.htm).^AstraZeneca; Johnson and Johnson^Japan; co-promotion agreement for the treatment of patients with prostate cancer (Press release, AstraZeneca, 11 Oct 2013, http:// www.astrazeneca.com/Media/Press-releases/Article/20131010- astrazeneca-enters-copromotion-agreement-with-janssen).^Additional Clinical Information^Phase I^In 3 open-label Phase I trials, abiraterone acetate was administered in single or multiple doses of 10-800mg. In a pooled analysis of the 3 trials, AUC, Cmax, Tmax, t1/2alpha and t1/2beta were 0.09-11.66microM/hr, 0.001-1.19microM, 0.16-4hr, 0.05-6.5hr and 12-87hr, respectively. (Br J Cancer, 2004, 90, 2317).^In 2 single-dose clinical studies, castrated and non-castrated prostate cancer patients received abiraterone acetate 10-500mg. 6/ 6 castrated patients had suppression of testosterone to <0.14nM at 500mg. In a multiple-dose study in 6 treatment-experienced prostate cancer patients, abiraterone acetate 500 or 800mg once- daily x12 days suppressed testosterone to castrate levels (<2.0nM). 2/3 patients on 800mg/day had testosterone suppression to levels seen with LHRH agonists (<0.7nM). Treatment was well tolerated with no biochemical or haematological effects (Press releases, Cougar, 25 Oct 2004 and 21 Feb 2005).^"],"Document_HA":["3"],"Document_CASIS-UPD_WE":["20140221"],"Document_PK":["Human (10-800mg/m2):AUC:0.09 to 11.66:microMhr","Human (10-800mg/m2):Cmax:0.001 to 1.19:microM","Human (10-800mg/m2):t1/2alpha:0.05 to 6.5:hr","Human (10-800mg/m2):t1/2beta:12 to 87:hr","Human (10-800mg/m2):Tmax:0.16 to 4:hr"],"Document_NC":["Yes"],"Document_RB":["3"],"Document_TF":["1586: Enzyme > EC number > 1.14.99.9;","1586: Enzyme > Hydroxylase;","1586: Enzyme > Oxygenase."],"Document_TG":["1586: cytochrome P450, family 17, subfamily A, polypeptide 1"],"Document_LCH":["20140217:AD151 : Ongoing development of Phase III trial for prostate cancer reported"],"Document_TB":["1586: Enzyme > EC number > 1.14.99.9;","1586: EC number > 1.14.99.9;","1586: Enzyme;","1586: 1.14.99.9;","1586: Enzyme > EC number.","1586: Enzyme > Hydroxylase;","1586: Hydroxylase;","1586: Enzyme.","1586: Enzyme > Oxygenase;","1586: Oxygenase;","1586: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["LY-1720-AN: 17,20 lyase inhibitor: Enzyme, 17,20 lyase inhibitor: Steroid 17alpha-monooxygenase inhibitor: 17alpha hydroxylase inhibitor: 17,20 desmolase inhibitor: CYP17A1 inhibitor: E-LY-1720-AN|SY-STER-AN: Steroid synthesis inhibitor: Physiological, Biochemical, Steroid synthesis inhibitor: P-B-SY-STER-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["391.56"],"Document_AL":["4.13"],"Document_CASIS-CO_CO":["Originator: BTG (GB): Launched","Licensee: Johnson & Johnson (US): Launched","Licensee: AstraZeneca (GB): Pre-registration","Licensee: Boehringer Ingelheim (DE): Discontinued"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD093356    "],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Launched  Not Available for Licensing"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Not Available for Licensing"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Not Available for Licensing"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2011 Not Available for Licensing"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"}],"DOCNO":"PH021287","CASIS_COMPOUND":[{"CN":"CB-7630 (tablet) CCN=CB7630(TABLET)","SRC_DB":"PHPROJ"},{"CN":"abiraterone CCN=ABIRATERONE","SRC_DB":"PHPROJ"},{"CN":"JNJ 212082 CCN=JNJ212082","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate CCN=ABIRATERONEACETATE","SRC_DB":"PHPROJ"},{"CN":"CB-7630 (capsule) CCN=CB7630(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CB7630 CCN=CB7630","SRC_DB":"PHPROJ"},{"CN":"JNJ-589485 CCN=JNJ589485","SRC_DB":"PHPROJ"},{"CN":"abiraterone (oral suspension) CCN=ABIRATERONE(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate (tablet) CCN=ABIRATERONEACETATE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate (oral suspension) CCN=ABIRATERONEACETATE(ORALSUSPENSION)","SRC_DB":"PHPROJ"},{"CN":"abiraterone (capsule) CCN=ABIRATERONE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CB-7630 CCN=CB7630","SRC_DB":"PHPROJ"},{"CN":"abiraterone (tablet) CCN=ABIRATERONE(TABLET)","SRC_DB":"PHPROJ"},{"CN":"abiraterone acetate (capsule) CCN=ABIRATERONEACETATE(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"CB7630 (tablet) CCN=CB7630(TABLET)","SRC_DB":"PHPROJ"},{"CN":"JNJ-212082 CCN=JNJ212082","SRC_DB":"PHPROJ"},{"CN":"CB-7598 CCN=CB7598","SRC_DB":"PHPROJ"},{"CN":"CB7630 (capsule) CCN=CB7630(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Zytiga CCN=ZYTIGA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-02-25 16:28:19","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"C3","THE_USE":"Cancer, breast","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"K2","THE_USE":"Anticancer","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Cancer, prostate","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"SY-STER-AN","THE_USE":"Steroid synthesis inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"LY-1720-AN","THE_USE":"17,20 lyase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[65, 98, 105, 114, 97, 116, 101, 114, 111, 110, 101, 32, 97, 99, 101, 116, 97, 116, 101, 32, 40, 67, 66, 45, 55, 54, 51, 48, 41, 32]...', original message: bytes can be at most 32766 in length; got 43245
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 43245
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:58:21,683][DEBUG][action.bulk              ] virenz 50mg and the multiple dose efavirenz 600mg on Cyp 3A4 and the pharmacokinetics of faldaprevir (ClinicalTrials.gov, 26 Aug 2011, http://clinicaltrials.gov/show/ NCT01371006).^Enrollment is complete in an open-label, non-randomized, single- group assignment US Phase I drug interaction trial (1220.50) in 16 healthy male and female volunteers to assess the effect of multiple dosing with faldaprevir 240mg bid on the steady state pharmacokinetics of tenofovir 300mg once-daily pharmacokinetics (ClinicalTrials.gov, 20 Jun 2011, http://clinicaltrials.gov/show/ NCT01340196).^Infection, hepatitis-C virus^Enrollment is complete in a multicentre, randomized, open-label, parallel-group Phase I trial (1241.27) in Canada, Germany and the US, in 102 treatment-naive patients and treatment relapsed patients with HCV genotype 1 infection, to evaluate the pharmacokinetic interactions between BI-207127 600mg tid and faldaprevir 120mg once-daily in combination with ribavirin x24wk, and their combined effect on the pharmacokinetics of tenofovir, caffeine, tolbutamide and midazolam (ClinicalTrials.gov, 18 Feb and 7 May 2012 and 24 Jan 2014, http://clinicaltrials.gov/show/ NCT01525628). Preliminary bioanalytical results from an addition of deleobuvir increased faldaprevir plasma concentrations and addition of faldaprevir increased deleobuvir plasma concentrations. After 8wk of combined treatment, faldaprevir concentrations approximated to those observed prior to deleobuvir dosing, while DBV concentrations remained elevated. Pharmacokinetic analysis of CYP probe data is limited to CYP2C9 and CYP3A4, and suggests weak induction of CYP2C9 (64th AASLD (Washington), 2013, Abs 1083, http:// aasld2013.abstractcentral.com/s1agxt/com.scholarone.s1agxt.s1agxt/^^A 2-part Phase I trial in 264 patients with chronic genotype 1 HCV, to investigate safety, efficacy and pharmacokinetics has been completed. The 1st part was a double-blind, randomized trial, in which treatment-naive patients received multiple escalating doses of faldaprevir po x14 days followed by faldaprevir + Pegasys (PEG-interferon alpha-2a, Roche; qv) x14 days. The 2nd part was an open-label trial in which treatment-experienced patients received faldaprevir + Pegasys + ribavirin x28 days. Results are expected in Apr 2011 (ClinicalTrials.gov Web Page, 11 Jan 2010, NCT00793793).^A 24wk trial in naive patients with Type 1 HCV to assess the efficacy, safety and pharmacoepidemiology has been approved by the S Korean FDA (Pharma Koreana, 16 Jan 2009).^In a completed Phase I trial in patients receiving 40-240mg once- daily x12-28 days, it was well tolerated and had a steady-state t1/2 of 22.3-30.9hr.^Preclinical ^In vivo^In rat, monkey and dog models, it showed a good ADME profile. In rats, it showed favorable drug distribution to the target organ (Antimicrob Agents Chemother, Nov 2010, 54, 4611, PMID:20823284, http://www.ncbi.nlm.nih.gov/pubmed/20823284).^In vitro^In vitro, BI-201335 showed a good ADME profile and had good permeability in Caco-2 cell assays, with an EC50 of 6.5 and 3.1nM in genotype 1a and 1b replicon assays (Antimicrob Agents Chemother, Nov 2010, 54, 4611, PMID:20823284, http:// www.ncbi.nlm.nih.gov/pubmed/20823284).^Licensing^Agreements^________________^Presidio^Worldwide; Presidio has a non-exclusive collaboration with Boehringer Ingelheim for a Phase IIa trial of an oral interferon- free, direct-acting antiviral (DAA) combination treatment for patients with chronic HCV infection. The trial will evaluate PPI- 668 in combination with faldaprevir and BI-207127 (Press release, Presidio, 12 Mar 2013, http://presidiopharma.files.wordpress.com/ 2013/03/presidio-pharmaceuticals-announces-collaboration-with- boehringer-ingelheim-press-release-march-12-2013.pdf).^"],"Document_HA":["12"],"Document_CASIS-UPD_WE":["20140321"],"Document_PK":["Human (20-240mg/day):t1/2:26.6:hr"],"Document_NC":["Yes"],"Document_RB":["20"],"Document_TF":["951475: Enzyme > Polymerase;","951475: Enzyme > Protease/peptidase."],"Document_TG":["951475: polyprotein, hepatitis-C virus"],"Document_LCH":["20140310:PT : Addtional results of Phase III trial (STARTVerso 4), enrollment completion in Phase II trial (1241.30) and acceptance of US NDA filing reported"],"Document_TB":["951475: Enzyme > Polymerase;","951475: Polymerase;","951475: Enzyme.","951475: Enzyme > Protease/peptidase;","951475: Protease/peptidase;","951475: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PR-NS3-AN: HCV NS3 protease inhibitor: Enzyme, Hydrolase, HCV NS3 protease inhibitor: NS3-4A protease inhibitor: Protease inhibitor, NS3: HCV NS3 serine protease inhibitor: E-HY-PR-NS3-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["870.85"],"Document_AL":["5.12"],"Document_CASIS-CO_CO":["Originator: Boehringer Ingelheim (DE): Pre-registration"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Pre-registration"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Phase I"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH047429","CASIS_COMPOUND":[{"CN":"BI-201335 (capsule) CCN=BI201335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI201335 CCN=BI201335","SRC_DB":"PHPROJ"},{"CN":"BI-1335 (solution) CCN=BI1335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"faldaprevir CCN=FALDAPREVIR","SRC_DB":"PHPROJ"},{"CN":"faldaprevir (capsule) CCN=FALDAPREVIR(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 NA (solution) CCN=BI201335NA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI201335 (solution) CCN=BI201335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 NA (capsule) CCN=BI201335NA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI 1335 (capsule) CCN=BI1335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 (solution) CCN=BI201335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 NA CCN=BI201335NA","SRC_DB":"PHPROJ"},{"CN":"faldaprevir (solution) CCN=FALDAPREVIR(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 NA CCN=BI201335NA","SRC_DB":"PHPROJ"},{"CN":"BI-201335 NA (solution) CCN=BI201335NA(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI201335 (capsule) CCN=BI201335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-201335 CCN=BI201335","SRC_DB":"PHPROJ"},{"CN":"faldaprevir  CCN=FALDAPREVIR","SRC_DB":"PHPROJ"},{"CN":"BI 201335 (solution) CCN=BI201335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 CCN=BI201335","SRC_DB":"PHPROJ"},{"CN":"BI 1335 CCN=BI1335","SRC_DB":"PHPROJ"},{"CN":"BI-1335 (capsule) CCN=BI1335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 (capsule) CCN=BI201335(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BI-1335 CCN=BI1335","SRC_DB":"PHPROJ"},{"CN":"BI 1335 (solution) CCN=BI1335(SOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BI 201335 NA (capsule) CCN=BI201335NA(CAPSULE)","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:44","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"PR","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"PR-NS3-AN","THE_USE":"HCV NS3 protease inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"J5Z","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[70, 97, 108, 100, 97, 112, 114, 101, 118, 105, 114, 32, 40, 66, 73, 45, 50, 48, 49, 51, 51, 53, 41, 32, 105, 115, 32, 97, 32, 115]...', original message: bytes can be at most 32766 in length; got 40744
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 40744
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 13:58:47,098][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.2gb[4.6%], shards will be relocated away from this node
[2016-06-14 13:59:17,148][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.2gb[4.6%], shards will be relocated away from this node
[2016-06-14 13:59:17,149][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 13:59:47,149][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.1gb[4.5%], shards will be relocated away from this node
[2016-06-14 13:59:57,778][DEBUG][action.search            ] [Pixx] [.kibana][0], node[nq0Gv6qzQE6yhenPlA_5nA], [P], v[14], s[STARTED], a[id=DfqASzSrSVCDPUR-QKCZMw]: Failed to execute [org.elasticsearch.action.search.SearchRequest@68dae8ea] lastShard [true]
RemoteTransportException[[Pixx][casis.bayer.vmserver/172.16.56.130:9300][indices:data/read/search[phase/query]]]; nested: SearchParseException[failed to parse search source [{"query":{"bool":{"must":[{}]}},"from":0,"size":5,"sort":[{"UPD":{"order":"asc"}}],"aggregations":{"aggregation1":{"terms":{"field":"CASIS_COMPANY.CO","order":{"_count":"desc"},"size":5}}}}]]; nested: SearchParseException[No mapping found for [UPD] in order to sort on];
Caused by: SearchParseException[failed to parse search source [{"query":{"bool":{"must":[{}]}},"from":0,"size":5,"sort":[{"UPD":{"order":"asc"}}],"aggregations":{"aggregation1":{"terms":{"field":"CASIS_COMPANY.CO","order":{"_count":"desc"},"size":5}}}}]]; nested: SearchParseException[No mapping found for [UPD] in order to sort on];
	at org.elasticsearch.search.SearchService.parseSource(SearchService.java:855)
	at org.elasticsearch.search.SearchService.createContext(SearchService.java:654)
	at org.elasticsearch.search.SearchService.createAndPutContext(SearchService.java:620)
	at org.elasticsearch.search.SearchService.executeQueryPhase(SearchService.java:371)
	at org.elasticsearch.search.action.SearchServiceTransportAction$SearchQueryTransportHandler.messageReceived(SearchServiceTransportAction.java:368)
	at org.elasticsearch.search.action.SearchServiceTransportAction$SearchQueryTransportHandler.messageReceived(SearchServiceTransportAction.java:365)
	at org.elasticsearch.transport.TransportRequestHandler.messageReceived(TransportRequestHandler.java:33)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: SearchParseException[No mapping found for [UPD] in order to sort on]
	at org.elasticsearch.search.sort.SortParseElement.addSortField(SortParseElement.java:213)
	at org.elasticsearch.search.sort.SortParseElement.addCompoundSortField(SortParseElement.java:187)
	at org.elasticsearch.search.sort.SortParseElement.parse(SortParseElement.java:85)
	at org.elasticsearch.search.SearchService.parseSource(SearchService.java:838)
	... 12 more
[2016-06-14 13:59:59,595][DEBUG][action.search            ] [Pixx] [casisvm1][4]: Failed to execute [org.elasticsearch.action.search.SearchRequest@68dae8ea] while moving to second phase
java.lang.ClassCastException
[2016-06-14 14:00:05,371][DEBUG][action.bulk              ]  pharmacokinetics of dapagliflozin po 10mg tablet bid x2 days in healthy subjects was completed (ClinicalTrials.gov 27 May 2010 and 11 Jan 2011, http:// clinicaltrials.gov/ct2/show/NCT01068756).^A randomized, open-label, active-control, crossover assignment Phase I trial in 11 healthy subjects in Argentina, to assess the effect of glimepiride on dapagliflozin and vice versa was completed. The safety and tolerability of dapagliflozin was to be assessed alone and in combination with glimepiride (ClinicalTrials.gov Web Page, 10 Jul 2008, NCT00562250; ClinicalTrials.gov, 2 Sep 2010, http://clinicaltrials.gov/ct2/ show/NCT00562250).^In healthy subjects receiving 2.5-500mg single doses or 2.5-100mg/ day x14 days, t1/2 was 17hr. Cumulative amounts of glucose excreted /day with 2.5-100mg were 18-62g. Doses of 20-50mg produced close-to-maximal SGLT inhibition for at least 24hr (Clin Pharmacol Ther, 2009, 85, 520, PMID:19129748).^A Phase I trial to determine absolute po bioavailability was completed (ClinicalTrials.gov Web Page, 28 Oct 2009, NCT00908271).^In 6 healthy males receiving single oral doses of 50mg, Tmax was 1hr, and elimantion in faeces and urine was 10.4-36.2% and 59.1- 83.6%, respectively (Am Assoc Pharm Sci (Atlanta), 2008). Cmax and AUC were dose-proportional at 5-100mg (Clin Diabetes, 2010, 28, 5).^Diabetes, Type 2^Bristol-Myers Squibb^It is in a US randomized, parallel group, single-dose Phase I trial (MB102-091) in 24 children and adolescents aged 10 to 17 years with Type 2 diabetes mellitus, to assess the pharmacokinetics and pharmacodynamics study of dapagliflozin 2.5, 5 and 10mg po tablet (ClinicalTrials.gov, 10 Oct 2012, http:// clinicaltrials.gov/ct2/show/NCT01525238).^A US Phase I trial (MB102-066) in 48 healthy subjects and those with Type 2 diabetes, to characterize the kinetics of renal glucose reabsorption of dapagliflozin 10mg tablet po once-daily x7 days was completed (ClinicalTrials.gov, 12 Nov 2010 and 27 Jan 2011, http://clinicaltrials.gov/ct2/show/NCT01165268).^Preclinical ^In vivo^In high fat-fed female ZDF rats, it prevented loss of pancreatic function (69th Meet Am Diabetes Assoc (New Orleans), 2009, Abs 1468-P).^In diabetic rats, 0.01-1.0mg/kg induced renal glucose excretion without inducing hypoglycaemia. A single oral dose of 0.1-1.0mg/ kg reduced plasma glucose levels (Press release, BMS, 25 Jun 2007).^Patents^A US patent covering composition of matter expires in Oct 2020 (Form 10-K, BMS, 18 Feb 2011, Page 9, http://www.sec.gov/Archives/ edgar/data/14272/000119312511040120/d10k.htm).^Licensing^Agreements^________________^AstraZeneca; Bristol-Myers Squibb^Worldwide; a licensing agreement with AstraZeneca (excluding Japan) for co-development was extended to include Japan; however, AstraZeneca has acquired the intellectual property and global rights for the development, manufacture and commercialization of dapagliflozin (Press release, AstraZeneca, 8 Dec 2008; Press release, AstraZeneca, 3 Feb 2014, http://www.astrazeneca.com/ Media/Press-releases/Article/20140203-astrazeneca-acquires-bms- share-of-diabetes-alliance).^Ono^AstraZeneca and Ono has an agreement to co-promote dapagliflozin for an once-daily oral therapy to treat Type 2 diabetes mellitus in Japan. AstraZeneca simultaneously entered into an agreement with BMS granting AstraZeneca exclusive rights to commercialize dapagliflozin in Japan once approved. Under the terms of the agreement, Ono will make an up-front payment and further payments relating to the launch and sales-related milestones, which will be shared by BMS and AstraZeneca. Bristol-Myers Squibb and AstraZeneca will supply dapagliflozin and Ono will be responsible for its distribution. AstraZeneca and Ono will jointly detail dapagliflozin to healthcare professionals in Japan (Press release, Ono, 3 Dec 2013, http://www.ono.co.jp/eng/news/pdf/ sm_cn131203.pdf).^"],"Document_HA":["7"],"Document_CASIS-UPD_WE":["20140328"],"Document_PK":["Healthy subjects (2.5-500mg or 2.5-100mg/day x14 days):t1/2:17:hr","Healthy subjects (50mg po):Tmax:1:hr"],"Document_NC":["Yes"],"Document_RB":["10"],"Document_TF":["6524: Transporter > Porters (uni-, sym- and anti-)."],"Document_TG":["6524: solute carrier family 5 (sodium/glucose cotransporter), member 2"],"Document_LCH":["20140325:PP249 : Japanese approval for Type 2 diabetes reported"],"Document_TB":["6524: Transporter > Porters (uni-, sym- and anti-);","6524: Porters (uni-, sym- and anti-);","6524: Transporter."],"Document_CASIS-USE_CASIS-MA_PHCD":["TRN-NAG2-AN: Sodium/glucose cotransporter 2 inhibitor: Physiological, Biochemical, Sodium/glucose cotransporter 2 inhibitor: Sodium glucose transporter 2 inhibitor: SGLT-2 inhibitor: P-B-TRN-NAG2-AN|"],"Document_ROUT":["A-PO: Alimentary, po","P-IV: Parenteral, intravenous","P-UN: Parenteral, general"],"Document_MW":["408.88"],"Document_AL":["2.88"],"Document_CASIS-CO_CO":["Originator: Bristol-Myers Squibb (US): Discontinued","Licensee: AstraZeneca (GB): Launched","Licensee: Ono (JP): Registered"],"Document_MR":["3:Market Rating - US$ 2001-5000 million"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["4:Speed Rating - Faster than Average"]},"CASIS_DEVSTATUS":[{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Pre-registration Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Registered Not Available for Licensing"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"}],"DOCNO":"PH039336","CASIS_COMPOUND":[{"CN":"Farxiga CCN=FARXIGA","SRC_DB":"PHPROJ"},{"CN":"Forxiga (capsule) CCN=FORXIGA(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Forxiga (oral solution) CCN=FORXIGA(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BMS-512148 CCN=BMS512148","SRC_DB":"PHPROJ"},{"CN":"Farxiga (tablet) CCN=FARXIGA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"Forxiga (IV) CCN=FORXIGA(IV)","SRC_DB":"PHPROJ"},{"CN":"dapagliflozin CCN=DAPAGLIFLOZIN","SRC_DB":"PHPROJ"},{"CN":"BMS-512148 (oral solution) CCN=BMS512148(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"BMS-512148 (tablet) CCN=BMS512148(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dapagliflozin (IV) CCN=DAPAGLIFLOZIN(IV)","SRC_DB":"PHPROJ"},{"CN":"dapagliflozin (tablet) CCN=DAPAGLIFLOZIN(TABLET)","SRC_DB":"PHPROJ"},{"CN":"dapagliflozin (capsule) CCN=DAPAGLIFLOZIN(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"BMS-512148 (capsule) CCN=BMS512148(CAPSULE)","SRC_DB":"PHPROJ"},{"CN":"Forxiga (tablet) CCN=FORXIGA(TABLET)","SRC_DB":"PHPROJ"},{"CN":"BMS-512148 (IV) CCN=BMS512148(IV)","SRC_DB":"PHPROJ"},{"CN":"dapagliflozin (oral solution) CCN=DAPAGLIFLOZIN(ORALSOLUTION)","SRC_DB":"PHPROJ"},{"CN":"Forxiga CCN=FORXIGA","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-31 13:37:07","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"L","THE_USE":"Diabetes, Type 2","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"C2","THE_USE":"Diabetes, Type 1","SOURCE":"IND","SRC_DB":"PHPROJ"},{"CODE":"A10B","THE_USE":"Antidiabetic","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"TRN-NAG2-AN","THE_USE":"Sodium/glucose cotransporter 2 inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[68, 97, 112, 97, 103, 108, 105, 102, 108, 111, 122, 105, 110, 32, 40, 66, 77, 83, 45, 53, 49, 50, 49, 52, 56, 41, 32, 105, 115, 32]...', original message: bytes can be at most 32766 in length; got 52845
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 52845
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 14:00:12,704][INFO ][cluster.metadata         ] [Pixx] [casisvm1] update_mapping [documents]
[2016-06-14 14:00:17,176][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5gb[4.4%], shards will be relocated away from this node
[2016-06-14 14:00:17,176][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:00:22,926][DEBUG][action.search            ] [Pixx] [.kibana][0], node[nq0Gv6qzQE6yhenPlA_5nA], [P], v[14], s[STARTED], a[id=DfqASzSrSVCDPUR-QKCZMw]: Failed to execute [org.elasticsearch.action.search.SearchRequest@4e3ba13d] lastShard [true]
RemoteTransportException[[Pixx][casis.bayer.vmserver/172.16.56.130:9300][indices:data/read/search[phase/query]]]; nested: SearchParseException[failed to parse search source [{"from":0,"size":5,"sort":[{"UPD":{"order":"asc"}}],"aggregations":{"aggregation1":{"terms":{"field":"CASIS_COMPANY.CO","order":{"_count":"desc"},"size":5}}}}]]; nested: SearchParseException[No mapping found for [UPD] in order to sort on];
Caused by: SearchParseException[failed to parse search source [{"from":0,"size":5,"sort":[{"UPD":{"order":"asc"}}],"aggregations":{"aggregation1":{"terms":{"field":"CASIS_COMPANY.CO","order":{"_count":"desc"},"size":5}}}}]]; nested: SearchParseException[No mapping found for [UPD] in order to sort on];
	at org.elasticsearch.search.SearchService.parseSource(SearchService.java:855)
	at org.elasticsearch.search.SearchService.createContext(SearchService.java:654)
	at org.elasticsearch.search.SearchService.createAndPutContext(SearchService.java:620)
	at org.elasticsearch.search.SearchService.executeQueryPhase(SearchService.java:371)
	at org.elasticsearch.search.action.SearchServiceTransportAction$SearchQueryTransportHandler.messageReceived(SearchServiceTransportAction.java:368)
	at org.elasticsearch.search.action.SearchServiceTransportAction$SearchQueryTransportHandler.messageReceived(SearchServiceTransportAction.java:365)
	at org.elasticsearch.transport.TransportRequestHandler.messageReceived(TransportRequestHandler.java:33)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: SearchParseException[No mapping found for [UPD] in order to sort on]
	at org.elasticsearch.search.sort.SortParseElement.addSortField(SortParseElement.java:213)
	at org.elasticsearch.search.sort.SortParseElement.addCompoundSortField(SortParseElement.java:187)
	at org.elasticsearch.search.sort.SortParseElement.parse(SortParseElement.java:85)
	at org.elasticsearch.search.SearchService.parseSource(SearchService.java:838)
	... 12 more
[2016-06-14 14:00:23,366][DEBUG][action.search            ] [Pixx] [casisvm1][4]: Failed to execute [org.elasticsearch.action.search.SearchRequest@4e3ba13d] while moving to second phase
java.lang.ClassCastException
[2016-06-14 14:00:47,235][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5gb[4.4%], shards will be relocated away from this node
[2016-06-14 14:00:54,438][DEBUG][action.search            ] [Pixx] [.kibana][0], node[nq0Gv6qzQE6yhenPlA_5nA], [P], v[14], s[STARTED], a[id=DfqASzSrSVCDPUR-QKCZMw]: Failed to execute [org.elasticsearch.action.search.SearchRequest@4a45fff0] lastShard [true]
RemoteTransportException[[Pixx][casis.bayer.vmserver/172.16.56.130:9300][indices:data/read/search[phase/query]]]; nested: SearchParseException[failed to parse search source [{"from":0,"size":5,"sort":[{"UPD":{"order":"asc"}}],"aggregations":{"aggregation1":{"terms":{"field":"CASIS_COMPANY.CO","order":{"_count":"desc"},"size":5}}}}]]; nested: SearchParseException[No mapping found for [UPD] in order to sort on];
Caused by: SearchParseException[failed to parse search source [{"from":0,"size":5,"sort":[{"UPD":{"order":"asc"}}],"aggregations":{"aggregation1":{"terms":{"field":"CASIS_COMPANY.CO","order":{"_count":"desc"},"size":5}}}}]]; nested: SearchParseException[No mapping found for [UPD] in order to sort on];
	at org.elasticsearch.search.SearchService.parseSource(SearchService.java:855)
	at org.elasticsearch.search.SearchService.createContext(SearchService.java:654)
	at org.elasticsearch.search.SearchService.createAndPutContext(SearchService.java:620)
	at org.elasticsearch.search.SearchService.executeQueryPhase(SearchService.java:371)
	at org.elasticsearch.search.action.SearchServiceTransportAction$SearchQueryTransportHandler.messageReceived(SearchServiceTransportAction.java:368)
	at org.elasticsearch.search.action.SearchServiceTransportAction$SearchQueryTransportHandler.messageReceived(SearchServiceTransportAction.java:365)
	at org.elasticsearch.transport.TransportRequestHandler.messageReceived(TransportRequestHandler.java:33)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: SearchParseException[No mapping found for [UPD] in order to sort on]
	at org.elasticsearch.search.sort.SortParseElement.addSortField(SortParseElement.java:213)
	at org.elasticsearch.search.sort.SortParseElement.addCompoundSortField(SortParseElement.java:187)
	at org.elasticsearch.search.sort.SortParseElement.parse(SortParseElement.java:85)
	at org.elasticsearch.search.SearchService.parseSource(SearchService.java:838)
	... 12 more
[2016-06-14 14:00:54,686][DEBUG][action.search            ] [Pixx] [casisvm1][4]: Failed to execute [org.elasticsearch.action.search.SearchRequest@4a45fff0] while moving to second phase
java.lang.ClassCastException
[2016-06-14 14:01:17,311][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.9gb[4.3%], shards will be relocated away from this node
[2016-06-14 14:01:17,311][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:01:47,354][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.8gb[4.3%], shards will be relocated away from this node
[2016-06-14 14:02:17,382][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.9gb[4.3%], shards will be relocated away from this node
[2016-06-14 14:02:17,382][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:02:47,414][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.9gb[4.3%], shards will be relocated away from this node
[2016-06-14 14:03:17,442][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.8gb[4.3%], shards will be relocated away from this node
[2016-06-14 14:03:17,443][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:03:47,515][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.8gb[4.2%], shards will be relocated away from this node
[2016-06-14 14:04:17,573][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.5gb[4%], shards will be relocated away from this node
[2016-06-14 14:04:17,584][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:04:47,611][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.5gb[4%], shards will be relocated away from this node
[2016-06-14 14:05:12,685][DEBUG][action.bulk              ] 21425934x0x456195/a9983611- 02a0-41a8-aca3-a59a5364f9f2/ EASL%202011%20IR%20event%20FINAL%204411_2.pdf). Results demonstrated that the combination sofosbuvir + PSI-938 lead to the decline in the viral load rapidly in a biphasic manner. The maximum level of effectiveness was achieved by PSI-938 and sofosbuvir were 1 and 2 days, respectively and the mean antiviral effectiveness were similar for both the drugs (48th Annual Meeting of the European Association for the Study of Liver (EASL) 2013, Amsterdam, The Netherlands, April 24-28, 2013, Abs 1196, http://www.abstractserver.com/easl2013/planner/^^Enrollment is complete in a 5-cohort, 2-part, non-randomized, drug-interaction, open-label, single-group assignment Phase I trial (P7977-1910) in Puerto Rico in 80 HIV and HCV co-infected patients, to evaluate the pharmacokinetics between sofosbuvir 200mg bid x7 days + efavirenz 600mg once-daily + tenofovir 300mg once-daily + emtricitabine 200mg once-daily, sofosbuvir + efavirenz 600mg once-daily + zidovudine 300mg bid + lamivudine 150mg bid and sofosbuvir + atazanavir/ritonavir 400/100mg once- daily + tenofovir 300mg once-daily + emtricitabine 200mg once- daily. Part B will evaluate the efficacy and safety of GS-7977 400mg once-daily with peginterferon alpha-2a 180microg/wk sc and ribavirin 1000-1200mg (ClinicalTrials.gov, 31 Mar 2012 and 1 Mar 2013, http://clinicaltrials.gov/show/NCT01565889).^In a Phase Ib in 19 HCV treatment-naive patients with HIV/HCV co- infection, sofosbuvir 400mg once-daily x7 days showed a median change in HCV RNA similar to monoinfected patients, with >1.5log reductions at 24hr and a maximal HCV RNA decline from baseline >4log. Virologic response was similar in the coinfected and monoinfected cohorts independent of HIV status, HCV genotype and baseline HCV viral load. It was well tolerated with no new safety events observed during the dosing or safety follow-up period. No effect was observed on HIV viral load, CD4 count or CD4% (52nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2012, San Francisco, September 9- 12, 2012, Abs H-1921a, http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=9d934432-9dec-46cd-abbe- b4f1297b3e75andcKey=221f3f0b-82af-4fff-ac44- d951bbb2df2dandmKey={6B114A1D-85A4-4054-A83B-04D8B9B8749F}).^A Phase I trial in New Zealand in 40 hepatitis-C patients is planned, with trial completion expected in Aug 2011 (Scrip Intelligence, 17 Jan 2011, http://www.scripclinicalresearch.com/ companies/Beltas-recruits-for-Hepatitis-C-study-308722?autnRef=/ contentstore/gcpj/codex/98299765-2252-11e0-92f3-cf1dfcf723f1.xml).^Preclinical ^In vitro^In vitro, sofosbuvir demonstrated in vitro potency cf PSI-7976 (Form 10-Q, Pharmasset, 9 Feb 2010).^Patents^An EU patent expires in 2028 (Form 10-K, Gilead, 27 Feb 2013, Page 17, http://www.sec.gov/Archives/edgar/data/882095/ 000088209513000015/a2012form10-k.htm).^US7964580, covering the composition-of-matter and its diastereomeric mixture for the treatment of HCV has been issued, with expiry in 2029 (Press release, Pharmasset, 22 Jun 2011, http://investor.pharmasset.com/ releasedetail.cfm?ReleaseID=586664).^It has a US patent, which expires in 2025 (Canaccord Genuity 30th Growth Conf (Boston), 2010, Slide 10, http:// files.shareholder.com/downloads/VRUS/966662061x0x394709/39daffe7- 2ded-4e1a-aea4-3ee507ca881f/ VRUS_CorpPres_081010_Cannacord_all.pdf). Patents are pending, with an expiry date in 2028 on patent issuance (Corporate presentation, Pharmasset, 2 May 2011, Slide 6, http:// files.shareholder.com/downloads/VRUS/1210976004x0x464435/32c9a49f- d2d1-4c21-9a91-085d3b323958/Corp%20Presentation_DB_050211.pdf).^Licensing^Agreements^_______________^Bristol-Myers Squibb^Worldwide; Pharmasset has a clinical collaboration agreement with Bristol-Myers Squibb to evaluate the utility of BMS-790052 in combination with sofosbuvir for the treatment of HCV infection (Press release, BMS and Pharmasset, 10 Jan 2011, http:// www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http:// www.businesswire.com/news/bms/20110110005933/ enandt=634302724749654803).^Tibotec (Johnson and Johnson)^Worldwide; Tibotec has a clinical collaboration agreement with Pharmasset to combine PSI-7977 and Tibotec's simeprevir, a protease inhibitor (Press release, Pharmasset, 25 Jul 2011, http:/ /investor.pharmasset.com/releasedetail.cfm?ReleaseID=593884).^Qualifying Therapeutic Discovery Project^USA; Pharmasset received a grant under the US government Qualifying Therapeutic Discovery Project (QTDP) for the development of PSI-7977 (IRS.gov Web Page, 7 Jan 2011, http:// www.irs.gov/businesses/small/article/0,,id=229024,00.html).^Availability^________________^Worldwide; Before the acquisition by Gilead Sciences, Pharmasset was seeking development partners (Canaccord Genuity 30th Growth Conf (Boston), 2010, Slide 3, http://files.shareholder.com/ downloads/VRUS/966662061x0x394709/39daffe7-2ded-4e1a-aea4- 3ee507ca881f/VRUS_CorpPres_081010_Cannacord_all.pdf).^"],"Document_HA":["10"],"Document_CASIS-UPD_WE":["20140321"],"Document_NC":["Yes"],"Document_RB":["11"],"Document_TF":["951475: Enzyme > Polymerase;","951475: Enzyme > Protease/peptidase."],"Document_TG":["951475: polyprotein, hepatitis-C virus"],"Document_LCH":["20140310:PT : Enrollment completion in Phase IIIb trial (GS-US- 334-0153) and completion of Phase II trial (GS-US-334-0114) & Phase III trials (GS-US-334-0123 & GS-US-334-0115) reported"],"Document_TB":["951475: Enzyme > Polymerase;","951475: Polymerase;","951475: Enzyme.","951475: Enzyme > Protease/peptidase;","951475: Protease/peptidase;","951475: Enzyme."],"Document_CASIS-USE_CASIS-MA_PHCD":["PO-RRNAN-AN: HCV-NS5B polymerase inhibitor: Enzyme, Transferase, HCVNS5B polymerase inhibitor: HCV polymerase inhibitor: E-TR-PO-RRNAN-AN|"],"Document_ROUT":["A-PO: Alimentary, po"],"Document_MW":["513.47"],"Document_AL":["1.23"],"Document_CASIS-CO_CO":["Originator: Gilead Sciences (US): Launched"],"Document_MR":["0:Market Rating - Not applicable"],"Document_CASIS-MDNUMBER":["MD000001"],"Document_SO":["Pharmaprojects. PJB Publications, T&F Informa UK Ltd, London"],"Document_SR":["0:Speed Rating - Not available"]},"CASIS_DEVSTATUS":[{"COUNTRY":"VE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"World","SRC_DB":"PHPROJ","DSTA":"Launched"},{"COUNTRY":"SE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"KR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MX","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"MY","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"FI","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"IT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"LU","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"HK","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"NL","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"FR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GB","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"NZ","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"TH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"US","SRC_DB":"PHPROJ","DSTA":"Launched 2013 Licensing Availability Unknown"},{"COUNTRY":"IE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"DK","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"CL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IL","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"AU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"JP","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"ES","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AR","SRC_DB":"PHPROJ","DSTA":"Phase II"},{"COUNTRY":"DE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"AT","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"ZA","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"TR","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PE","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"PH","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"RU","SRC_DB":"PHPROJ","DSTA":"Phase III"},{"COUNTRY":"CA","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"GR","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"},{"COUNTRY":"NO","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"IN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"CN","SRC_DB":"PHPROJ","DSTA":"Licensing Availability Unknown"},{"COUNTRY":"BE","SRC_DB":"PHPROJ","DSTA":"Registered Licensing Availability Unknown"}],"DOCNO":"PH054359","CASIS_COMPOUND":[{"CN":"GS7977 CCN=GS7977","SRC_DB":"PHPROJ"},{"CN":"GS-7977 CCN=GS7977","SRC_DB":"PHPROJ"},{"CN":"sofosbuvir CCN=SOFOSBUVIR","SRC_DB":"PHPROJ"},{"CN":"Sovaldi CCN=SOVALDI","SRC_DB":"PHPROJ"},{"CN":"GS 7977 CCN=GS7977","SRC_DB":"PHPROJ"},{"CN":"PSI-7977 CCN=PSI7977","SRC_DB":"PHPROJ"}],"DATEINSERTED":"2014-03-25 08:59:45","SRC_DB":"PHPROJ","CASIS_USE":[{"CODE":"PO-RRNAN-AN","THE_USE":"HCV-NS5B polymerase inhibitor","SOURCE":"MA","SRC_DB":"PHPROJ"},{"CODE":"J5Z","THE_USE":"Antiviral","SOURCE":"ACT","SRC_DB":"PHPROJ"},{"CODE":"L","THE_USE":"Infection, hepatitis-C virus","SOURCE":"IND","SRC_DB":"PHPROJ"}]}]}
java.lang.IllegalArgumentException: Document contains at least one immense term in field="DOCUMENT.Document_CASIS-TX_TX.raw" (whose UTF8 encoding is longer than the max length 32766), all of which were skipped.  Please correct the analyzer to not produce such terms.  The prefix of the first immense term is: '[71, 105, 108, 101, 97, 100, 32, 83, 99, 105, 101, 110, 99, 101, 115, 32, 40, 112, 114, 101, 118, 105, 111, 117, 115, 108, 121, 32, 80, 104]...', original message: bytes can be at most 32766 in length; got 46417
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:692)
	at org.apache.lucene.index.DefaultIndexingChain.processField(DefaultIndexingChain.java:365)
	at org.apache.lucene.index.DefaultIndexingChain.processDocument(DefaultIndexingChain.java:321)
	at org.apache.lucene.index.DocumentsWriterPerThread.updateDocument(DocumentsWriterPerThread.java:234)
	at org.apache.lucene.index.DocumentsWriter.updateDocument(DocumentsWriter.java:450)
	at org.apache.lucene.index.IndexWriter.updateDocument(IndexWriter.java:1477)
	at org.apache.lucene.index.IndexWriter.addDocument(IndexWriter.java:1256)
	at org.elasticsearch.index.engine.InternalEngine.innerCreateNoLock(InternalEngine.java:437)
	at org.elasticsearch.index.engine.InternalEngine.innerCreate(InternalEngine.java:378)
	at org.elasticsearch.index.engine.InternalEngine.create(InternalEngine.java:349)
	at org.elasticsearch.index.shard.IndexShard.create(IndexShard.java:545)
	at org.elasticsearch.index.engine.Engine$Create.execute(Engine.java:810)
	at org.elasticsearch.action.index.TransportIndexAction.executeIndexRequestOnPrimary(TransportIndexAction.java:237)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardIndexOperation(TransportShardBulkAction.java:326)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:119)
	at org.elasticsearch.action.bulk.TransportShardBulkAction.shardOperationOnPrimary(TransportShardBulkAction.java:68)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryPhase.doRun(TransportReplicationAction.java:639)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:279)
	at org.elasticsearch.action.support.replication.TransportReplicationAction$PrimaryOperationTransportHandler.messageReceived(TransportReplicationAction.java:271)
	at org.elasticsearch.transport.RequestHandlerRegistry.processMessageReceived(RequestHandlerRegistry.java:75)
	at org.elasticsearch.transport.TransportService$4.doRun(TransportService.java:376)
	at org.elasticsearch.common.util.concurrent.AbstractRunnable.run(AbstractRunnable.java:37)
	at java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1142)
	at java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:617)
	at java.lang.Thread.run(Thread.java:745)
Caused by: org.apache.lucene.util.BytesRefHash$MaxBytesLengthExceededException: bytes can be at most 32766 in length; got 46417
	at org.apache.lucene.util.BytesRefHash.add(BytesRefHash.java:284)
	at org.apache.lucene.index.TermsHashPerField.add(TermsHashPerField.java:150)
	at org.apache.lucene.index.DefaultIndexingChain$PerField.invert(DefaultIndexingChain.java:682)
	... 25 more
[2016-06-14 14:05:17,638][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.7gb[4.1%], shards will be relocated away from this node
[2016-06-14 14:05:17,658][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:05:47,685][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.6gb[4.1%], shards will be relocated away from this node
[2016-06-14 14:06:17,736][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.6gb[4%], shards will be relocated away from this node
[2016-06-14 14:06:17,736][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:06:47,794][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.6gb[4%], shards will be relocated away from this node
[2016-06-14 14:07:17,821][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.5gb[4%], shards will be relocated away from this node
[2016-06-14 14:07:17,821][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:07:47,873][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.5gb[3.9%], shards will be relocated away from this node
[2016-06-14 14:08:17,900][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.4gb[3.9%], shards will be relocated away from this node
[2016-06-14 14:08:17,900][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:08:47,927][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.4gb[3.9%], shards will be relocated away from this node
[2016-06-14 14:09:17,983][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.3gb[3.8%], shards will be relocated away from this node
[2016-06-14 14:09:17,983][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:09:48,011][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.3gb[3.8%], shards will be relocated away from this node
[2016-06-14 14:10:18,065][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 4.2gb[3.7%], shards will be relocated away from this node
[2016-06-14 14:10:18,066][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:10:48,103][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.5gb[4.9%], shards will be relocated away from this node
[2016-06-14 14:11:18,146][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6gb[5.3%], shards will be relocated away from this node
[2016-06-14 14:11:18,146][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:11:48,168][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6gb[5.3%], shards will be relocated away from this node
[2016-06-14 14:12:18,169][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 6gb[5.3%], shards will be relocated away from this node
[2016-06-14 14:12:18,169][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:12:48,219][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.8gb[5.1%], shards will be relocated away from this node
[2016-06-14 14:13:18,265][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.6gb[4.9%], shards will be relocated away from this node
[2016-06-14 14:13:18,273][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:13:48,299][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.6gb[5%], shards will be relocated away from this node
[2016-06-14 14:14:18,323][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.6gb[5%], shards will be relocated away from this node
[2016-06-14 14:14:18,323][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
[2016-06-14 14:14:48,347][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.6gb[5%], shards will be relocated away from this node
[2016-06-14 14:15:18,372][WARN ][cluster.routing.allocation.decider] [Pixx] high disk watermark [90%] exceeded on [nq0Gv6qzQE6yhenPlA_5nA][Pixx][/opt/elasticsearch-2.3.3/data/elasticsearch/nodes/0] free: 5.6gb[5%], shards will be relocated away from this node
[2016-06-14 14:15:18,372][INFO ][cluster.routing.allocation.decider] [Pixx] rerouting shards: [high disk watermark exceeded on one or more nodes]
